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The purpose of this study was to examine prevalence rates of 
antipsychotic use in children and adolescents from 1996 to 2001 in three state 
Medicaid programs and one private managed care organization; prescriber types 
and diagnoses associated with antipsychotic prescribing; and, trends in service 
utilization of youths receiving antipsychotic treatment. 
Prescription claims were used to evaluate total, age-specific, and gender-
specific prevalence of antipsychotic use.  Prescription claims from the Texas 
Medicaid system were used to examine prescriber types, and data from the Texas 
Department of Mental Health and Mental Retardation from 1998 to 2001 were 
 vii
used to examine diagnoses and service utilization of children and adolescents 
receiving antipsychotic treatment. 
From 1996 to 2001, the prevalence of total antipsychotic use increased in 
each insurance program (Ohio Medicaid: 4.7 to 14.3 per 1,000; Texas Medicaid: 
6.3 to 15.5; California Medi-Cal: 4.5 to 6.9; and, Managed Care Organization: 1.5 
to 3.4).  The prevalence of atypical antipsychotic use dramatically increased 
(Ohio Medicaid: 1.4 to 13.1 per 1,000; Texas Medicaid: 2.5 to 14.9; California 
Medi-Cal: 0.3 to 6.2; and, Managed Care Organization: 0.4 to 2.7).  Across all 
systems, the use of antipsychotics increased in children and adolescents above the 
age of five years, and in both males and females.   
In the Texas Medicaid system, psychiatrists accounted for the highest 
number of antipsychotic prescriptions for children and adolescents.  Disruptive 
behavioral disorders were most commonly associated with antipsychotic 
prescribing. 
The mean number of inpatient psychiatric hospitalizations per child or 
adolescent receiving antipsychotic treatment and mental health care services from 
TDMHMR increased, as the mean number of hospital days per hospitalized youth 
decreased.   Utilization of assessment services, counseling and psychotherapy, 
medication-related services, service coordination, and skills training increased.  
The mean duration of enrollment in assessment services, medication-related 
services, and skills training decreased, while the mean duration of enrollment in 
crisis intervention and service coordination increased. 
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Given the limited efficacy and safety data with antipsychotics in children 
and adolescents, additional studies of atypical antipsychotics and other treatment 
modalities are needed on what, how, and when the best treatments can be 
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Introduction and Literature Review 
CHAPTER OVERVIEW 
Chapter One provides a thorough review of the literature on 
epidemiological and pharmacoepidemiological studies, the use of antipsychotics, 
and concerns of increased use of atypical antipsychotics in children and 
adolescents.   
A brief discussion regarding the advantages and need for epidemiological 
studies evaluating the prevalence of psychiatric and behavioral disorders in youths 
in the United States is provided.  Large-scale, prevalence studies, such as the 
National Institute of Mental Health (NIMH) Methods for the Epidemiology of 
Child and Adolescent Mental Disorders (MECA) Study and the Great Smoky 
Mountains Study (GSMS), are detailed.  Following a brief introduction of 
pharmacoepidemiological studies of psychotropic medications, a review of 
pivotal studies examining prevalence rates of psychotropic medication use in 
children and adolescents is presented.  With the focus being on the use of 
antipsychotics, a complete presentation of a study evaluating antipsychotic use in 
Texas Medicaid children and adolescents ensues. 
As the studies demonstrate the increased use of antipsychotics, specifically 
atypical antipsychotics, in children and adolescents, discussion regarding the 
current uses of these agents is warranted.  Furthermore, it is important to examine 
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the available evidence from randomized, controlled trials supporting the safety 
and efficacy of atypical antipsychotics in youths.  Finally, arguments for and 
against the use of antipsychotics in children and adolescents, as well as 
recommendations for future research, are presented. 
At the conclusion of Chapter One, the specific aims of the research study 
are discussed.  Hypotheses and supporting rationales are presented, and 
descriptive analyses are listed. 
 
Introduction to Child and Adolescent Psychiatric Epidemiological Studies 
Child psychiatric epidemiological studies aim to provide estimates of the 
number of children and adolescents having a psychiatric or behavioral problem.  
A majority of child psychiatric epidemiological studies report the prevalence of 
mental problems, which refers to both new and existing cases of a condition 
observed during a specific period of time (period prevalence) or at a point in time 
(point prevalence).1  Very few studies have reported the incidence of these 
conditions, which refers to the occurrence of new cases during a designated 
period of time. 1 
It is important to recognize that psychiatric epidemiological studies offer 
more than patterns of mental illness in the population.  These types of studies 
further the knowledge and understanding of the etiology, natural course, and 
treatment of psychiatric and behavioral problems.2,3  The identification of risk and 
protective factors to the onset, maintenance, and remission of mental illness 
allows the opportunity to develop future studies to evaluate treatment strategies 
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that may prevent the onset of illness, alter the course of disease, or improve 
patient outcomes.  Epidemiological studies can provide information regarding 
prevalence rates, and disease severity and characteristics, across specific 
population subgroups, such as gender, ethnicity, age, socioeconomic status, and 
region.4  These types of data are essential for the development of public policy 
relating to mental health services. 2,3,4  Data on patterns of service utilization and 
barriers to service utilization are necessary to appropriately and adequately 
design, fund, and allocate mental health services. 
As early as 1958, large-scale epidemiological studies have been conducted 
in child psychiatry.5  Past studies provided prevalence rates of global impairment 
of adaptive functioning, not specific psychiatric disorders among children.  Gould 
and colleagues reviewed 25 prevalence studies conducted in the United States 
(U.S.) between 1928 and 1975, and estimated the median prevalence of clinical 
maladjustment at 11.8 percent.6  In the studies reviewed by Gould et al., a single 
informant and a single method were employed to identify and characterize 
mentally impaired children and adolescents, which resulted in much variability of 
prevalence estimates.  More recently, Roberts and colleagues reviewed 52 child 
psychiatric epidemiological studies of samples from over 20 different countries 
conducted over a 33-year period (1963 to 1996).7  The overall mean prevalence 
was 15.8 percent, and the median prevalence was estimated at 13.7 percent.  
Prevalence rates varied greatly, ranging from one percent to 51 percent, and 
depended on methods of case ascertainment and definition.  Roberts et al. 
speculated that problems with sampling, case ascertainment and definition, and 
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data analyses and presentation continue to hinder the ability of epidemiological 
studies to provide valuable, informative data. 
Significant advances in sampling methodologies, types of measures, and 
case definitions have improved the reliability and validity of the findings of more 
recent child psychiatric epidemiological studies.2  For example, an improvement 
in the reliability and validity of diagnostic assessment tools for psychiatric 
disorders in children and adolescents is exemplified by the development of the 
NIMH Diagnostic Interview Schedule for Children (DISC).4  Specific for eliciting 
the American Psychiatric Association’s Diagnostic and Statistical Manual of 
Mental Disorders, Third Edition, Revised (DSM-III-R) criteria for childhood 
psychiatric diagnoses, Version 2.3 of the DISC (DISC-2.3) has been used to 
estimate the prevalence rates of psychiatric disorders in the large-scale, multi-site 
MECA Study.7  With increased sophistication of study design and diagnostic 
assessment, newer generation epidemiological studies have been able to produce 
more homogenous results than earlier studies, and more accurately report 
prevalence rates of child and adolescent psychiatric and behavioral disorders. 
Prevalence Studies of Psychiatric and Behavioral Problems in Children and 
Adolescents 
Psychiatric and behavioral problems have been recognized as a common 
and major cause of disability in children and adolescents.8  Community studies of 
children and adolescents in the 1980s reported prevalence rates of moderate to 
severe psychiatric disorders ranging from 14 to 20 percent.2  Newer, 
methodologically sound, epidemiological studies conducted in the 1990s, such as 
the NIMH MECA Study and the GSMS of Youth, have suggested that up to 30 
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percent of children and adolescents may suffer from some form of a mental 
disorder.7,9  Additionally, these studies have identified patterns of mental health 
service utilization, indicating the need for these services among children and 
adolescents who have psychiatric or behavioral problems.10,11 
The National Institute of Mental Health (NIMH) Methods for the Epidemiology 
of Child and Adolescent Mental Disorders (MECA) Study 
In 1989, the NIMH called for “a methodological study to develop feasible, 
reliable, and valid methods for the assessment of mental disorders, risk factors, 
and service utilization in youths aged nine through 17 years in large-scale, 
population-based surveys.”  A multisite collaboration with researchers from 
Columbia University, Emory University, the University of Puerto Rico, and Yale 
University resulted in the NIMH MECA Study. 4 
For the development of acceptable methods for large-scale child 
psychiatric epidemiological studies, the MECA study aimed to address eight 
issues: 
1. To determine the acceptability of lengthy interviews of children and their 
caretakers and to assess adequacy of response rates from heterogeneous 
community samples; 
2. To evaluate the psychometric properties of structured diagnostic 
interviews based upon DSM-III-R criteria (DISC-2.3); 
3. To develop methods to appropriately diagnose a youth using multiple 
informants; 
4. To develop reliable and valid measures of impairment to distinguish 
severity of psychiatric illness; 
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5. To develop measures of service utilization and identify barriers to service 
utilization; 
6. To develop measures used to identify potential risk factors of 
psychopathology that can be employed in large-scale, population-based 
surveys; 
7. To develop the appropriate methodologies necessary to conduct a multisite 
epidemiological study; and, 
8. To estimate the prevalence of psychiatric disorders, to be used for the 
planning of future epidemiological research in children and adolescents. 4 
All children and adolescents between the ages of nine and 17 years living 
in a housing unit were targeted for the MECA study.  The sample was drawn from 
four geographic areas near the collaborative universities: (1) Westchester County, 
New York (Columbia University); (2) DeKalb, Rockdale, and Henry counties, 
Georgia (Emory University); (3) San Juan, Puerto Rico (University of Puerto 
Rico); and, (4) Hamden, East Haven, and West Haven, Connecticut (Yale 
University).  Potential subjects were drawn from housing units, which were 
defined differently according to study site, to avoid potential biases associated 
with other sampling sites, such as schools.  Additionally, subjects were required 
to have lived in the housing unit for at least the previous six months to ensure that 
the caretaker would have adequate knowledge about the child for the six-month 
time frame for the diagnostic interview. 4 
Over 7,000 sampling housing units across the four geographic sites were 
counted, and from these, 1,523 youths were considered eligible.  Of those eligible 
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for the study, 1,285 (84.4%) youths and their adult caretaker were interviewed 
using the DISC-2.3 (Youth version [DISC-C] and Parent version [DISC-P], 
respectively).  The DISC-2.3 was developed and refined to extract DSM-III-R 
criteria for 31 childhood psychiatric diagnoses: overanxious disorder, separation 
anxiety disorder, avoidant disorder, simple phobia, social phobia, agoraphobia, 
panic disorder, generalized anxiety disorder, obsessive-compulsive disorder, 
attention-deficit hyperactivity disorder, oppositional defiant disorder, conduct 
disorder, major depressive disorder, dysthymic disorder, mania, hypomania, tic 
disorders, elimination disorders, anorexia nervosa, bulimia, and substance abuse.  
The DISC-2.3 also screened for possible psychosis.  All diagnoses made by the 
DISC-2.3 were labeled as current, indicating the occurrence of symptoms during a 
six-month period prior to the structured interview.4  Overall severity of 
disturbance was assessed using the Children’s Global Assessment Scale (CGAS).  
Based upon the Global Assessment Scale (GAS) for adults, the CGAS is a 
unidimensional, global measure of social and psychiatric functioning for children 
between the ages of four and 16 years.  CGAS scores between 61 and 70 indicate 
mild impairment, such as difficulty in a single area, but overall functioning is 
good; scores between 51 and 60 suggest moderate impairment, indicating a need 
for frequent or considerable supervision; and, scores less than 50 denote severe 
impairment, requiring constant supervision.7 
Prevalence rates were estimated for four varying case definitions: (1) a 
case meeting DSM-III-R symptom, onset, and duration criteria only; (2) a case 
meeting DSM-III-R criteria and with a CGAS score less than 70, less than 60, or 
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less than 50; (3) a case meeting DSM-III-R criteria and symptoms resulted in 
impairment at school, at home, or among friends; and, (4) a case meeting DSM-
III-R criteria, having a CGAS score less than 70, 60, or 50, and with significant 
impairment due to symptoms.   Prevalence rates for disorders were also reported 
based upon a child’s self-assessment, parental assessment, and a “combined” 
assessment using information from both the DISC-C and DISC-P.7 
The interviewed sample (N=1,285) consisted of 53 percent males.  Fifty-
one percent of the youths were of non-Hispanic white ethnicity and 28 percent 
were Hispanic.4  Non-Hispanic white subjects were drawn only from the U.S. 
mainland sites, while the Hispanic sample was drawn primarily from Puerto Rico.  
Ninety percent of the adult respondents paired with the interviewed youths were 
biological mothers; only three percent of the adults were fathers of the youths.  
Forty-two percent of the sample had household incomes ranging from $25,000 to 
$64,999. 
The six-month combined prevalence rate for any psychiatric disorder 
based upon DSM-III-R criteria with the DISC-2.3 only was 32.8 percent (Table 
1.1, page 9).7  Without diagnoses of simple phobia and elimination disorders, the 
combined prevalence rate for any disorder decreased slightly to 29.9 percent.  The 
highest six-month prevalence was for any anxiety disorder (20.5%), followed by 
any disruptive disorder (11.5%) and any depression (7.2%).  With regard to 
specific DSM-III-R diagnoses, prevalence was highest for overanxious disorder 
(7.7%), followed by social phobia (7.6%) and oppositional defiant disorder 
(6.5%).  As the level of social and psychiatric functioning decreased, prevalence  
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Table 1.1. Methods for the Epidemiology of Child and Adolescent Mental 
Disorders (MECA) Study Prevalence Rates for DSM-III-R 
Diagnoses7 





















        
Parent 21.0 7.7 4.6 2.0 9.8 5.3 3.0 1.2 
Youth 23.7 10.0 4.4 1.9 12.3 7.1 3.3 1.6 
Combined 39.5 18.5 9.6 4.3 20.5 13.0 7.2 3.2 
ANY 
DEPRESSION 
        
Parent 3.9 3.1 2.3 1.2 3.7 3.0 2.2 1.2 
Youth 6.0 4.7 2.3 1.3 4.3 3.4 2.0 1.1 
Combined 8.8 7.5 4.5 2.6 7.2 6.2 4.2 2.3 
ANY 
DISRUPTIVE 
        
Parent 8.1 5.8 3.7 1.7 7.6 5.8 3.7 1.7 
Youth 7.1 5.7 3.0 1.6 4.7 0.4 2.3 1.3 
Combined 14.3 11.8 7.2 3.9 11.5 10.3 6.4 3.7 
ANY 
DISORDER 
        
Parent 30.3 12.1 6.5 3.2 19.2 10.2 5.5 2.7 
Youth 32.2 15.3 7.2 3.4 19.6 12.3 6.1 2.8 
Combined 50.6 24.7 12.8 6.2 32.8 20.9 11.5 5.4 
Note: Values are percentages. 
 
rates of psychiatric disorders decreased expectedly.  Disagreement between 
youth- and parent-derived prevalence rates existed across certain diagnoses, 
including attention-deficit hyperactivity disorder and oppositional defiant 
disorder.  Prevalence rates of disorders based upon DSM-III-R criteria without the 
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DISC-2.3 were consistently higher compared to those based upon DSM-III-R 
criteria with the DISC-2.3. 
 Youths and their parents involved in the NIMH MECA Study were 
interviewed to determine the utilization of mental health and substance abuse 
services.10  The services component of the interview was designed to collect 
information about the youths’ contacts with health, school-based, social services, 
and other service providers due to emotional, behavioral, drug, or alcohol 
problems.  Twenty-five percent of the youths reported some contact for mental 
health services, and among these, only 36.5 percent met criteria for a psychiatric 
diagnosis.  In each of the four communities under study, no more than 29.0 
percent of youths with a psychiatric diagnosis and significant impairment (CGAS 
< 61) received mental health specialty services. 
The findings from the MECA Study significantly furthered the field of 
child and adolescent psychiatric epidemiology along multiple fronts.  First, the 
study provided preliminary prevalence estimates of psychiatric disorders in 
children and adolescents between nine and 17 years of age.  The estimated 
prevalence rate for any psychiatric disorder was approximately 30 percent, 
suggesting that mental health conditions indeed are common among U.S. 
communities.  Second, the study provided evidence suggesting that parental report 
and child report may not have much in common.  Possible factors influencing 
disagreement included situation-specific problems, and differences in perception 
of symptom severity and impairment.7  Third, the MECA Study exposed the need 
to establish an appropriate definition of a case.  Higher levels of global 
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impairment, as indicated by CGAS scores, resulted in lower prevalence rates.  
Although the level of global impairment directly affected prevalence rates, it was 
unclear whether the impairment is associated with the specific disorder.  Finally, 
the MECA study identified a need for mental health services for children and 
adolescents with a psychiatric or behavioral problem.  Youths with a psychiatric 
diagnosis and significant impairment may not be receiving adequate mental health 
services. 
The Great Smoky Mountains Study (GSMS) of Youth 
The GSMS of Youth examined “the development of, the need for, and use 
of mental health services” in children and adolescents in the southeastern U.S.9  
The GSMS was designed with three major objectives: (1) case finding; (2) 
prevalence estimation; and, (3) generalizability. 
A total of 12,000 children aged nine, 11, and 13 years in the southern 
Appalachian mountain region of North Carolina were identified as potential 
subjects using public schools’ databases.  Within age categories, each child had an 
equal probability of being chosen for the initial screening sample of 4,500 
children (1,570 9-year-olds; 1,590 11-year-olds; and, 1,340 13-year-olds).  
Children were screened using the externalizing scale items of the Child Behavior 
Checklist (CBCL) to identify those with psychiatric symptoms and a high 
probability of mental health service use.12  Children scoring in the top 25 percent 
of the sample, and a one in ten sample of those below the cutoff score were 
recruited for the study.  A total of 1,346 children were recruited, including 1,009 
children who scored high on the screening measure and 337 randomly selected 
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children who scored low.  Of these, 1,071 children enrolled, and 1,015 were 
interviewed during the first wave of the study.  This sample of children was 
comprised of 79 African-American, three Asian-American, six Hispanic, 11 
mixed race, and 916 white subjects. 
The Child and Adolescent Psychiatric Assessment (CAPA) was 
administered to the subjects to draw information about diagnoses and 
symptoms.13  Both child and parent versions were used to assess the occurrence of 
symptoms during the preceding three months. Similar to the MECA Study, 
computer algorithms produced diagnoses based upon combined information from 
the child and parent diagnostic interviews.  The CAPA was also used to measure 
functional impairment or incapacities in relationships with family, peers, and 
teachers, in activities at school, at home, and in the community. 
The three-month combined prevalence rates for any DSM-III-R disorder 
was 20.3 percent (Table 1.2, page 13).9  The highest prevalence rate was 
associated with any core disorder (12.1%), which included any emotional or 
behavioral disorder, schizophrenia, obsessive-compulsive disorder, anorexia, 
bulimia, Tourette disorder, trichotillomania, posttraumatic stress disorder, elective 
mutism, and encopresis.  For the total sample, enuresis (5.1%) was the most 
common specific DSM-III-R diagnosis, followed by motor tics (3.5%), separation 
anxiety (3.5%), conduct disorder (3.3%), and oppositional defiant disorder 
(2.8%).  For males, enuresis (7.7%), conduct disorder (5.4%), motor tics (4.3%), 
and oppositional defiant disorder (3.1%) were the most frequent.  For females, 
separation anxiety (4.3%), motor tics (2.7%), enuresis (2.5%), and generalized  
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Table 1.2. The Great Smoky Mountains Study (GSMS) Prevalence Rates of 
Psychiatric Disorders9 
Diagnosis Female Male Total 
Any anxiety disorder 7.0 4.5 5.7 
Any depressive disorder 1.4 1.7 1.5 
Any emotional disorder 8.0 5.7 6.8 
Any behavioral disorder 3.5 9.5 6.6 
Any tic disorder 2.9 5.5 4.2 
Any other disorder (encopresis, enuresis, tics, 
Tourette disorder, obsessive-compulsive disorder, 
bulimia, trichotillomania) 
5.9 15.0 10.5 
Any emotional or behavioral disorder 10.8 13.0 11.9 
Comorbid emotional and behavioral diagnoses 0.8 2.2 1.5 
Any core disorder 10.9 13.3 12.1 
Any disorder 15.5 24.9 20.3 
Note: Values are percentages. 
 
anxiety disorder (2.4%) were most common.  Rare disorders, defined as fewer 
than five cases per the total sample, included agoraphobia, panic disorder, 
avoidant disorder, elective mutism, posttraumatic stress disorder, anorexia 
nervosa, bulimia, major depression, dysthymia, hypomania, manic episode, 
substance abuse/dependence, vocal tics, Tourette disorder, and schizophrenia.  
Comorbidity was quite common, as 100 (32.6%) of the 307 children were 
diagnosed with more than one disorder (Figure 1.1, page 15).  
Males were more likely to have a diagnosis for a psychiatric disorder 
compared to females, predominantly due to behavioral disorders and enuresis.9  
Within age categories, separation anxiety, tics, and enuresis significantly differed 
between nine- and 11-year-olds.  African-American children had higher rates of 
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functional enuresis compared to white children.  Children from households with 
the lowest income were at increased risk for any psychiatric disorder, with the 
highest risk for behavioral disorders.  Additionally, those from low-income 
families were at higher risk for comorbidity, particularly behavioral and 
emotional disorders.  No significant differences in prevalence rates existed 
between income-adjusted urban and rural children. 
Eleven percent of subjects with a DSM-III-R diagnosis had serious 
emotional disturbance.14  The most common diagnoses associated with serious 
emotional disturbance included enuresis or encopresis (3.9%), conduct disorder 
(2.9%), anxiety disorder (2.6%), and oppositional defiant disorder (2.5%).  Two 
percent of subjects with serious emotional disturbance had more than one 
diagnosis. 
The GSMS also examined service utilization patterns of children and 
adolescents across five service sectors: specialty mental health services, 
education, general medicine, juvenile justice, and child welfare.11  Data were 
collected using the Child and Adolescent Services Assessment (CASA), a 
questionnaire designed to gather information from parents and youths about more 
than 30 types of services that youths may use to address emotional, behavioral, or 
substance abuse problems.  Three-year population estimates of service use 
suggested that 33.6 percent of youths used “any service”, with education being the 
sector most often utilized (24.1%).  Specialty mental health services were 
estimated to be used by 14.2 percent of the youth population, followed by general 
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youths receiving any services during the three-year period, 38 percent received 
services for three months or less, 47 percent received services for three to 12 
months, and 14 percent received services for 12 months or more. 
The prevalence rates of psychiatric disorder in the GSMS sample were 
similar to those previous studies, suggesting approximately 20 percent of children 
had mental health problems.  Furthermore, the results indicated that prevalence 
rates in the rural area were comparable with those extracted from urban areas. 
Comorbidity of psychiatric conditions was quite frequent in this study, which 
causes concern about future risk and poorer long-term patient outcomes.  The 
GSMS also furthered the understanding of disease, as it examined those factors 
influencing the prevalence rate of psychiatric disorders, such as gender, race, and 
household income.  Similar to findings of the MECA Study, the GSMS 
demonstrated the need for mental health specialty services for youths with 
psychiatric, behavioral, or substance abuse problems.  Mental health services may 
be equally needed in rural areas as they are in urban areas, as prevalence rates of 
psychiatric conditions in rural versus urban areas were comparable. 
Other Recent Prevalence Studies of Psychiatric and Behavioral Problems in 
Children and Adolescents 
Halfon and Newacheck conducted a study using the National Health 
Interview Survey (NHIS) to estimate the number of children with parent-reported 
psychiatric conditions from 1992 to 1994.15  Conducted annually by the U.S. 
Bureau of Census, the NHIS surveys approximately 45,000 households 
nationwide.16  Information regarding chronic, disabling conditions is collected 
from parents, and diagnoses are assigned by trained staff at the National Center 
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for Health Statistics (NCHS) using the International Classification of Diseases 
(ICD) coding system. 
During 1992 to 1994, an estimated 1,448,000 (2.1%) children between the 
ages of zero and 18 years in the U.S. were reported to suffer from a chronic, 
disabling mental health condition.  Approximately 1,378,000 children were 
considered moderately to severely impaired.  Higher rates of disabling mental 
health conditions were associated with children from the following groups: 
African-Americans (2.6%), males (2.9%), low socioeconomic status (3.3%), one-
parent households (3.1%), and households whose head was less educated (3.1%).  
Regionally, prevalence rates were significantly greater in the Midwest (2.6%) 
compared to the Northeast (1.9%) and West (1.7%); no difference between the 
Midwest and the South (2.3%) existed. 
The most common chronic, disabling mental health condition was mental 
retardation, as parents reported 1,054 cases per 100,000 children (1.0%).  
Attention-deficit hyperactivity disorder (505 per 100,000; 0.5%) and learning 
disability (279 per 100,000; 0.3%) were also frequently reported by parents.  The 
prevalence of mental health conditions, particularly mental retardation and 
attention-deficit hyperactivity disorder, significantly increased as children became 
older.  Among children suffering from mental retardation, high prevalence rates 
were associated with males, children from poor families, and children whose head 
of household was less educated.  Compared to the West, mental retardation was 
more prevalent in the Midwest, South, and Northeast.  Among children with 
attention-deficit hyperactivity disorder, higher prevalence rates were related to 
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males, poor family income, one-parent households, and family sizes less than five 
members. 
Garland and colleagues examined prevalence rates of psychiatric disorders 
in children and adolescents across five public sectors of care in San Diego, 
California: alcohol and drug services, child welfare, juvenile justice, mental 
health, and public school services for serious emotional disturbance.17  Between 
October 1997 and January 1999, 1,618 youths between the ages of six and 18 
years were randomly selected and administered the computer-assisted version of 
the Diagnostic Interview Schedule for Children (C-DISC-IV).18  Similar to its 
predecessor DISC-2.3, the C-DISC-IV was designed to elicit childhood diagnoses 
based upon the Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV). 
A majority of the sample (54.5%) was drawn from the mental health 
sector.  Sixty-six percent of the total sample was males, and the distributions in 
age categories were similar (6-11 years: 25.1%; 12-15 years: 30.0%; 16-18 years: 
44.9%).  Youths were from a variety of racial/ethnic backgrounds: Caucasian 
(39%), Latino (26%), African American (21%), Asian American/Pacific Islander 
(6%), mixed ethnicity (5%), and other/unknown (3%). 
The total prevalence rate of psychiatric disorders among youths in five 
sectors of public care was 54 percent.  The prevalence of attention-deficit 
hyperactivity disorder and disruptive disorders was highest at 49.7 percent.  
Anxiety and mood disorders had prevalence rates of 9.9 percent and seven 
percent, respectively.  Across sectors of care, prevalence rates were highest 
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among youths in public school services for serious emotional disturbance 
(70.2%), followed by mental health (60.8%), alcohol and drug services (60.3%), 
juvenile justice (52.1%), and child welfare (41.8%).  Additionally, attention-
deficit hyperactivity disorder and disruptive disorders were the most common 
diagnoses in each public sector of care.  
Changes in the Prevalence of Child and Adolescent Psychiatric and Behavioral 
Problems 
One of the major questions in child and adolescent psychiatry is whether 
or not the prevalence rates of psychopathology are increasing over time.  Little is 
known about changes in the prevalence rates of mental disorders in children and 
adolescents.  Most epidemiological studies in child psychiatry have examined 
point prevalence, while few studies have examined changes in prevalence rates 
across multiple years.5 
In an attempt to answer this question, Roberts et al. grouped 
epidemiological studies in children and adolescents based upon date, and 
examined prevalence rates for studies.5  The mean prevalence was 15.4 percent 
for studies conducted prior to or in 1970.  The mean prevalence for studies 
conducted between 1971 and 1980 was 14.1 percent, and for studies between 
1981 and 1990, 13.8 percent.   Studies conducted after 1990 had a significantly 
higher mean prevalence rate at 26 percent (range=12.1% to 50.6%).  Due to 
significant variability in methods for case ascertainment and definition across the 
studies, Roberts and colleagues felt it was difficult to draw valid conclusions 
about changes in the prevalence rates over time. 
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Kelleher and colleagues conducted a retrospective, cohort study to 
examine the trends of psychosocial problems in children and adolescents from 
1979 to 1996.19   The first cohort were subjects recruited from the Monroe County 
Study (MCS) of 1979, which consisted of over 18,000 children between the ages 
of zero and 18 years from 30 pediatric offices in and around Rochester, New 
York.  Data on a total of 9,612 children between four and 15 years of age were 
utilized from the MCS.  These data were compared to data from the Child 
Behavior Study (CBS) of 1996.  This cohort was comprised of 21,065 children, 
ages four through 15 years, from 204 practices in 44 states, the Commonwealth of 
Puerto Rico, and four provinces in Canada.  Sixty-six percent of the CBS 
clinicians were pediatricians, and 26 percent were family practice physicians. 
In the MCS, clinicians identified the presence of a psychosocial problem 
by responding “yes” to the following question: “Regardless of the purpose of this 
visit, in your opinion, does this patient have a behavioral, emotional or school 
problem, treated or untreated?”  In the CBS, clinicians indicated a psychosocial 
problem by responding “yes” to the following question: “Is there a new, ongoing, 
or recurrent psychosocial problem?”  Clinicians from these studies also used the 
World Health Organization (WHO) classification scheme to further identify the 
type of psychosocial problem present.20  Kelleher and colleagues defined 
psychosocial problems as “any mental disorders, psychological symptoms or 
social situations warranting clinical attention or intervention.”   
Clinician-identified psychosocial problems among children significantly 
increased over the 17-year period, as 6.8 percent of children in 1979 were 
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identified compared to 18.7 percent in 1996 (Table 1.3, page 22).  The greatest 
absolute percent changes were associated with attention-deficit/hyperactivity 
disorder (7.8%), and behavioral/conduct problems (6.5%).  Modest increases in 
other types of psychosocial problems were reported, with the exception of mental 
retardation which decreased from 1.1 percent in 1979 to 0.4 percent in 1996.  
Increases in the percentages of children and adolescents with psychosocial 
problems paralleled increases in childhood poverty and single-parent households, 
suggesting the role of environmental factors in the development of psychosocial 
problems. 
Summary 
Beyond providing estimates of the number of children and adolescents 
affected by mental illness, psychiatric epidemiological studies are valuable 
sources of information for understanding disease characteristics and progression.  
Moreover, these types of studies inform about current states of mental health care  
service utilization and associated costs.  Subsequently, these data are used to 
formulate service utilization policies.  Earlier psychiatric epidemiological studies 
of children and adolescents were plagued with methodological problems, which 
resulted in much variability in prevalence estimates.  Variations in prevalence 
estimates of mental disorders in children and adolescents may be due to variations 
in case assessment, particularly with regard to the specificity of the measure.  
Improved study designs and assessment tools, as seen with the NIMH MECA 
Study and the GSMS, have produced more accurate prevalence estimates of 
 
 22
Table 1.3. Monroe County Study (MCS) and Child Behavior Study (CBS) 














               
N = 21065 
Clinician-identified problem 6.8 16.1 18.7 
Adaptation/adjustment reaction 2.3 3.9 4.4 
Attention deficit/hyperactivity disorder 1.4 7.6 9.2 
Specific developmental delays (learning 
disabilities, speech, and language delays) 
1.5 3.5 2.1 
Behavioral/conduct problems 1.0 4.4 7.5 
Childhood psychosis 0.0 0.0 0.2 
Physical manifestations (psychosomatic 
disorders, anorexia) 
0.1 2.9 3.9 
Mental retardation 1.1 0.2 0.4 
Emotional problems (anxiety, sadness, 
personality disorder, neurotic disorder) 
0.2 2.0 3.6 
Other (substance abuse, family problems, 
unspecified others) 
0.0 1.9 3.9 
Note: Values are percentages. 
 
mental disorders in this population.  Twenty to thirty percent of U.S. children 
suffer from mental health conditions, suggesting that these conditions are 
commonplace, and increasing numbers of youths are affected.  Attention-deficit 
hyperactivity disorder and disruptive behavioral disorders, such as conduct and 
oppositional defiant disorder, are diagnoses frequently present in children and 
adolescents.  Pharmacological treatment is considered a suitable option for some 
childhood and adolescent psychiatric disorders.  Given the significant, growing 
 23
number of U.S. youths with mental illness, it is important to determine the extent 
and growth of psychotropic medication use in this population. 
 
Pharmacoepidemiological Studies of Psychotropic Medications in Children 
and Adolescents 
In past years, the utilization of psychotropic medications for the treatment 
of psychiatric and behavioral problems in children and adolescents has received 
much attention.  Public concern concerning the use of psychotropic medications 
in youths stems from the lack of safety and efficacy data for these agents in this 
population.  Without such information, it is difficult to make conclusions 
regarding the type of response and possible short-term and long-term effects 
children and adolescents will experience secondary to the administration of 
psychotropic drugs.   
Little data exist regarding national utilization patterns of overall and 
specific classes of psychotropic medications in children and adolescents.  Results 
from earlier studies examining the prevalence rates of psychotropic medication 
use have been limited in their generalizability to national populations of youths, 
mainly because of confinement to geographic settings, and institutional or clinic 
settings.21  Additionally, pharmacoepidemiological studies utilizing national data 
examined prevalence rates of methylphenidate use alone.22,23  More recent studies 
of prevalence rates of psychotropic medication use have improved the 
representativeness of the sampled population, thus increasing the generalizability 
of their findings.21,24,25  These studies have suggested that over the past few 
decades, there has been a substantial increase in the utilization of psychotropic 
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medications for the treatment of psychiatric and behavioral disorders in children 
and adolescents.  The increase in the use of psychotropic medications in youths 
has translated into a significant increase in costs.  In 1998, the use of psychotropic 
medications in this population accounted for nine percent (approximately $1.1 
billion) of all expenditures for mental health.26 
Prevalence Rates of Psychotropic Medication Use in Children and Adolescents 
Kelleher and colleagues reported that in 1985, 1.5 percent of physician 
office visits by children and adolescents less than 18 years of age included the 
prescription of a psychotropic agent.19   Psychostimulants were the most 
frequently prescribed agents, and psychiatrists were associated with the highest 
prescription rates per office visit.  As subsequent evidence from other 
pharmacoepidemiological studies of psychotropic medication use suggested 
increased prevalence rates, the findings from the Kelleher study were limited in 
applicability and did not inform as to the current rates of psychotropic medication 
prescribing in children and adolescents. 
In order to determine more current rates of psychotropic medication 
prescribing in youths, Jensen and colleagues conducted a study in which data 
from the 1995 National Ambulatory Medical Care Survey (NAMCS) and the 
1995 National Disease and Therapeutic Index (NDTI) were used to estimate 
prevalence rates of psychotropic use.21  Data from the NAMCS consisted of 
36,875 patient record forms from a sample of 1,883 physicians across the U.S.  
This sample included nonfederally employed physicians who are primarily 
engaged in office-based, ambulatory, direct patient care, and excluded those 
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physicians in the medical specialties of anesthesiology, radiology, and pathology.  
Since NAMCS data were derived from office visits only, prescribing rates were 
reported as frequency of psychotropic medication prescription per office visit.  
Data from the NDTI included all patient contacts, office, hospital, face-to-face, or 
phone, from 2,940 office-based physicians.  Prescribing rates were reported as 
drug “mentions,” which includes every time a drug was prescribed, refilled, 
recommended, or provided to the patient as a sample.  Based upon estimates of 
the population for July 1995 provided by the U.S. Bureau of Census, it was 
estimated that 697,082,010 physician office visits were made in 1995. 
Prescribing rates for 11 categories of psychotropic medications were 
examined: anticonvulsant mood stabilizers (carbamazepine and valproate), 
antipsychotics, benzodiazepines, bupropion, buspirone, central adrenergic 
agonists (clonidine and guanfacine), lithium, other antidepressants (nefazodone, 
trazodone, and venlafaxine), selective serotonin reuptake inhibitors (SSRIs), 
stimulants (amphetamine compounds, methylphenidate, and pemoline), and 
tricyclic antidepressants (TCAs).  National prescribing rates for the categories of 
psychotropic medications were determined using the total number of visits 
(NAMCS) and mentions (NDTI) from the samples and projecting these numbers 
to the estimated population (697,082,010 visits). 
 From both the NAMCS and NDTI databases, stimulants were the most 
commonly prescribed or mentioned class of psychotropic medication for patients 
less than 18 years of age (Table 1.4, page 27).  Over 2,000,000 physician office 
visits resulted in the prescribing of a stimulant, and nearly 6,000,000 drug 
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mentions for stimulants occurred in 1995.  SSRIs were the second most frequent 
psychotropic medications in both databases, as there were 358,616 visits resulting 
in SSRI prescriptions and 1,083,000 SSRI drug mentions occurring.  Other 
commonly prescribed psychotropic drug classes included anticonvulsant mood 
stabilizers, TCAs, benzodiazepines, and central adrenergic agonists.  Other 
commonly mentioned psychotropic medications included TCAs, central 
adrenergic agonists, antipsychotics, and benzodiazepines. 
Although the NAMCS and NDTI databases did not allow for estimations 
of actual numbers of children and adolescents receiving psychotropic 
medications, the results indirectly indicate that psychotropic medications are 
commonly prescribed for U.S. youths by physicians.  In addition, the extent of 
exposure of these agents exceeded the available scientific evidence supporting 












Table 1.4. National Estimates of Drug Visits and Mentions for Children and 
Adolescents from the 1995 National Ambulatory Medical Care 
Survey (NAMCS) and National Disease Therapeutic Index 
(NDTI)21; a,b,c 
Number of Drug Visits by Youths for 
Psychiatric Diagnoses (1995 NAMCS) 
Number of Drug Mentions for Youths with 
Psychiatric Diagnoses (1995 NDTI) 
Drug Category N Estimated 
Drug 
Visits 
Drug Category N Estimated Drug 
Mentions 
Stimulants 129 2069488 Stimulants 1410 5971000 
SSRIs 43 358616 SSRIs 316 1083000 
Central adrenergic 
agonists 
26 202032 TCAs 298 969000 
Anticonvulsant mood 
stabilizers 
25 318971 Central adrenergic 
agonists 
132 431000 
TCAs 23 268770 Antipsychotics 108 355000 
Benzodiazepines 15 218523 Benzodiazepines 92 280000 
Antipsychotics 9 71863 Anticonvulsant mood 
stabilizers 
55 185000 
Lithium 8 63584 Lithium 51 175000 





3 15345 Buspirone 17 55000 
Buspirone 2 10692 Bupropion 47 42000 
a SSRI = Selective serotonin reuptake inhibitors; TCA = tricyclic antidepressants. 
b Estimates from NAMCS considered unreliable if based on < 30 records from the actual sample. 
c Estimates from NDTI considered unreliable if less than 100000 of the extrapolated estimates. 
 
 To correct for variations in prescription-to-person ratios, Olfson and 
colleagues designed and conducted a database study to provide direct estimations 
of the number of children and adolescents receiving psychotropic medications in 
1987 and 1996.25,27  Data were collected from the 1987 National Medical 
Expenditure Survey (NMES) and the 1996 Medical Expenditure Panel Survey 
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(MEPS), both sponsored by the Agency for Healthcare Research and Quality and 
conducted as national probability samples of the U.S. civilian, 
noninstitutionalized population.  Data from the NMES were derived from 15,590 
dwelling units, which included 10,389 children and adolescents less than 18 years 
old.  The MEPS data were obtained from 9,400 households, including 6,490 
youths under the age of 18 years.  Both surveys asked for “each prescribed 
medicine bought or otherwise obtained” by participants during 1987 (NMES) and 
1996 (MEPS).  Responses to the above question were categorized into one of the 
following groups: stimulants, antidepressants, and other psychotropic 
medications.  Rates of psychotropic medication use per 100 persons were 
determined for each survey year, and further stratified according to demographic 
variables. 
Between 1987 and 1996, the number of children and adolescents who 
received psychotropic medications increased dramatically, from 1.4 to 3.9 per 100 
youths.  Significant increases in overall psychotropic medication use were 
reported in children and adolescents between the ages of six and 18 years; males 
and females; youths of African-American, Hispanic, and Caucasian ethnic 
backgrounds; privately and publicly insured children and adolescents; and, youths 
residing in the Northeast, Midwest, and South.  When examining specific 
therapeutic classes, the largest increase in use was observed with 
psychostimulants, as children were 3.9 times more likely to use a stimulant in 
1996 than in 1987 (0.6 versus 2.4 per 100 children and adolescents).  Rates of 
stimulant use increased most in children and adolescents between 15 and 18 years 
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of age, and of African-American descent.  Antidepressant use also increased 
significantly from 1987 to 1996, as an additional 0.7 per 100 children and 
adolescents were likely to use these agents in 1996.  The increase in 
antidepressant use was most evident in children and adolescents aged 15 to 18 
years.  An increase in the rate of use of other psychotropic medications increased 
from 0.6 (1987) to 1.2 (1996) per 100 youths. 
In a more recent study by Zito and colleagues, changes in the prevalence 
rates of psychotropic medication use in children and adolescents less than 20 
years of age were examined from 1987 to 1996.24  Data were drawn from 
computerized administrative claims and medical records from geographically 
distinct health care systems: a mid-Atlantic Medicaid state (MAM), a midwestern 
Medicaid state (MWM), and a northwestern group-model health maintenance 
organization (HMO).  In 1987, total enrollments for children and adolescents less 
than 20 years of age were as follows: MAM, 138,018; MWM, 627,187; and, 
HMO, 111,686.  In 1996, total enrollments were as follows: MAM, 121,700; 
MWM, 645,356; and, HMO, 130,638. 
Medicaid fee-for-service reimbursement claims for psychotropic 
medications and the HMO computerized psychotropic medication dispensing 
records were organized into medication categories defined by the American 
Hospital Formulary Service (AHFS).28  Major therapeutic classes included 
antidepressants, anxiolytics, hypnotics, lithium, neuroleptics, and stimulants.  
These categories were further stratified into relevant subclasses: alpha-adrenergic 
agonists (clonidine and guanfacine); antianxiety-antihistamine (hydroxyzine); 
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antidepressants (SSRIs, TCAs, and other [trazodone, bupropion, maprotiline, and 
venlafaxine]); anxiolytics and hypnotics (benzodiazepines and 
nonbenzodiazepines); mood stabilizers (valproate, carbamazepine, and 
gabapentin); and, stimulants (methylphenidate, amphetamines, and pemoline).  
Prevalence of use was defined as the number of children and adolescents with a 
prescription claim for any psychotropic medication per 100 (or 1,000) enrolled 
youths.  Period prevalence rates were determined annually from 1987 to 1996 for 
total, class-specific, subclass-specific psychotropic medication use.  In addition, 
prevalence rates of use were determined for age-specific, gender-specific, and 
ethnicity-specific categories. 
Over the ten-year period, there was a significant increase in the prevalence 
of psychotropic medication use in the MAM, MWM, and HMO (Table 1.5, page 
31).  While the MWM experienced a 2.2-fold increase in use, the MAM and 
HMO more than tripled in prevalence of use (3.3-fold and 3.2-fold, respectively).  
The greatest increase in the prevalence of class-specific psychotropic medication 
use was associated with alpha-adrenergic agonists.  In the MAM system, the 
prevalence rate of alpha-adrenergic agonist use increased from 0.04 (1987) to 6.6 
(1996) per 1,000 enrolled.  In the MWM, a 53-fold increase in use was observed, 
as the prevalence rate increased from 0.1 (1987) to 7.3 (1996).  The prevalence 
rate of alpha-adrenergic agonist use increased from 0.1 (1987) to 3.9 (1996) per 
1,000 enrolled youths in the HMO.  Upon closer examination of annual 




































































































































































































































































































































































































































































































































































































































































































In 1996, the most commonly prescribed psychotropic medications across 
the three systems were psychostimulants.  Prevalence rates of stimulant use in 
1996 ranged from 37.2 to 38.4 per 1,000 enrolled Medicaid children and 
adolescents, and 25.4 per 1,000 enrolled HMO youths.  Although 
methylphenidate accounted for a majority of the prescriptions, amphetamines 
were related to the most significant increase in prevalence rates in the MAM 
(seven-fold increase) and HMO (14-fold increase).  Antidepressants were the 
second most commonly prescribed psychotropic medications for youths less than  
20 years of age.  Within this class, SSRI use represented approximately half of the 
total antidepressant use in 1996.  Other antidepressants, namely nefazodone and 
venlafaxine, were also associated with considerable use during the mid-1990s.  
Despite increases in use of SSRIs and other antidepressants, prevalence rates of 
TCA use remained relatively steady during the ten-year study period. 
In the Medicaid healthcare systems (MAM and MWM), children and 
adolescents between the ages of ten and 14 years used the most psychotropic 
medications in 1996 (Table 1.6, page 33).  Within the HMO, adolescents of 15 to  
19 years of age were associated with the highest prevalence rate of psychotropic 
medication use in 1996.  Males were the highest utilizers of psychotropic 
medications in the MAM and MWM, while females had higher prevalence rates 
in the HMO.  White youths had the highest prevalence rates in the MAM and 
MWM (86.6 and 75.2 per 1,000 youths, respectively).  However, African-
American children and adolescents in the MAM experienced the most dramatic 
 33
increase in prevalence of psychotropic medication use (4.8-fold increase from 
1987 to 1996). 
 
Table 1.6. Prevalence Rates of Psychotropic Medication Use for Age-Specific, 
Gender-Specific, and Ethnicity-Specific Categories24; a 























      
0-4 9.8 2.3 15.3 1.1 17.7 1.5 
5-9 95.4 2.5 86.8 2.6 58.5 3.1 
10-14 129.4 4.8 105.1 3.4 72.0 4.0 
15-19 54.5 7.2 81.5 2.0 82.8 3.3 
Gender       
Male 87.9 3.1 83.0 2.6 59.1 3.5 
Female 37.5 4.0 42.7 1.8 68.5 2.8 
Ethnicity       
White 86.6 2.5 75.2 2.2 N/A N/A 
African-
American 
51.3 4.8 34.6 2.2 N/A N/A 
a Prevalence per 1000 enrolled youths. 
 
Prevalence Rates of Antipsychotic Use in Children and Adolescents 
Most pharmacoepidemiological studies of psychotropic medication use in 
children and adolescents have been limited to the late 1980s and early to mid-
1990s.  While these studies are beneficial in characterizing overall psychotropic 
medication use, they have not addressed the impact of newer medications on 
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utilization, particularly atypical antipsychotics.  Clozapine was introduced to the 
market in 1989, but its use has been limited due to the risk of agranulocytosis.29   
Risperidone was the second atypical antipsychotic introduced in 1993, followed 
by olanzapine in 1996, quetiapine in 1997, ziprasidone in 2001, and aripiprazole 
in 2002. 
Antipsychotic use in children and adolescents increased from 1987 to 
1996, ranging from a 1.6-fold (MWM) to 5.5-fold (MAM) increase.24  Closer 
examination of the data from the MWM demonstrated a trend of increased use of 
all antipsychotics starting in 1993.30  The overall increase in use was solely 
attributed to an increase in the use of atypical antipsychotics, as the use of typical 
antipsychotics decreased from 1994 to 1996.  Although prevalence estimates 
during the mid-1990s suggest an increased trend of atypical antipsychotic use 
among children and adolescents, these findings may not fully represent the current 
trends in use, primarily because no safety and efficacy data in youths were 
available at that time. 
To date, the only published study examining more current trends in 
antipsychotic use in children and adolescents was conducted by Patel and 
colleagues.31  Data were collected from paid prescription claims records from the 
Texas Medicaid Vendor Drug database from 1996 to 2000.  Eligibility data were 
provided from the Research and Forecasting Department of the Texas Health and 
Human Services Commission (HHSC), and annual enrollment of children and 
adolescents, less than 20 years of age, was defined as the December enrollment 
for each study year (Table 1.7, page 35). 
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Table 1.7. Texas Medicaid Eligibility Data for Children and Adolescents from 
1996 to 200031; a 
Year Total Male Female <2 y 2-4 y 5-9 y 10-14 y 15-19 y 
1996 1143025 567712 575313 237220 267800 345133 184152 108720 
1997 1046609 520458 526151 218973 232130 313909 184895 96702 
1998 993021 495489 497532 210515 206552 284085 171052 120817 
1999 976291 487737 488554 212276 197366 271776 165967 128906 
2000 1002341 525692 476649 226490 201444 269988 170722 133697 
a y = Years. 
 
A total of 304,402 prescription claims records for 28,540 children and 
adolescents receiving typical and atypical antipsychotics were examined.  
Prevalence was defined as the number of youths with at least one Medicaid 
prescription claim record for an antipsychotic per 1,000 enrolled children and 
adolescents.  Prevalence rates of total, subclass-specific (typical and atypical), and 
specific atypical (clozapine, olanzapine, quetiapine, and risperidone) 
antipsychotic use were determined annually over a five-year period (1996 to 
2000).  Age-specific (<2, 2-4, 5-9, 10-14, and 15-19 years old) and gender-
specific (male and female) prevalence rates were also determined using annual 
descriptive analyses. 
From 1996 to 2000, the prevalence of total antipsychotic use increased 
160 percent, as an additional 12.3 children and adolescents per 1,000 enrollees 
received antipsychotics (Table 1.8, page 36).  This overall increase was due to a 
substantial increase of 494 percent in the prevalence of atypical antipsychotic use 
(2.7 [1996] to 16.0 [2000] per 1,000 enrolled youths).  The use of typical 
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antipsychotics decreased from 4.9 (1996) to 3.9 (2000) per 1,000 children and 
adolescents, representing a 21 percent decrease over the five-year period.  With 
the exception of clozapine, prevalence rates of specific atypical antipsychotics 
steadily increased.  Risperidone was the most frequently used during each study 
year, followed by olanzapine, quetiapine, and clozapine. 
 
Table 1.8. Annual Prevalence Rates of Antipsychotic Use in Children and 
Adolescents, Less Than 20 Years of Age, in the Texas Medicaid 
Program31;a 
Antipsychotics 1996 1997 1998 1999 2000 
Total 7.63 10.76 13.85 16.99 19.88 
Typical 4.94 4.69 4.19 3.87 3.89 
Atypical 2.69 6.07 9.66 13.11 15.98 
Clozapine 0.04 0.03 0.04 0.04 0.05 
Olanzapine 0.07 1.02 2.15 3.31 4.18 
Quetiapine 0 0.05 0.50 1.35 1.96 
Risperidone 2.57 4.95 6.95 8.42 9.78 
a Prevalence per 1000 enrolled youths. 
 
With regard to age, significant increases in total antipsychotic use were 
associated with age categories greater than two years old (Figure 1.2, page 38).  
Prevalence rates increased 354 percent (+16.2 per 1,000 enrollees) for children 
between the ages of five and nine years, and 173 percent (+30.1) for those 
between ten and 14 years old.  Antipsychotic use increased approximately 75 
percent for children aged two to four years (+1.4) and adolescents aged 15 to 19 
years (+18.1).  Male prevalence rates of total antipsychotic use increased 157 
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percent, from 10.0 in 1996 to 25.7 in 2000 (Figure 1.3, page 39).  Similarly, 
female prevalence rates were 5.3 in 1996 and 13.5 in 2000, indicating a 152 
percent increase over the five-year period. 
Total expenditures for antipsychotics in the Texas Medicaid child and 
adolescent population were $2,278,134 in 1996, and increased by 473 percent to 
$13,730,220 in 2000.  The increase in expenditures was related to the increase in 


















Figure 1.2. Age-specific Prevalence Rates of Total Antipsychotic Use in Texas 















































Figure 1.3. Gender-specific Prevalence Rates of Total Antipsychotic Use in 






























Pharmacoepidemiological studies have demonstrated an increased use of 
psychotropic medications in children and adolescents during the early to mid-
1990s.  Much of this increase is attributable to psychostimulants and 
antidepressants, for which evidence from randomized, controlled clinical trials 
supports the short- and long-term safety and efficacy in youths.21  These studies 
have also shown that children and adolescents older than the age of ten, males, 
and Caucasian youths are among the highest users of psychotropic medications.  
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Epidemiological data on medication utilization are necessary to fully understand 
the extent of psychotropic medication use in children and adolescents, but future 
studies are needed to assess the appropriateness of use and effectiveness of these 
agents.  Furthermore, epidemiological studies need to be conducted periodically 
as newer psychotropic medications are introduced to the market and additional 
safety and efficacy data become available.  Such is the case for antipsychotic use 
in children and adolescents.  To date, only one pharmacoepidemiological study 
has exclusively examined current trends of antipsychotic use in youths since the 
introduction of newer atypical antipsychotics.31  Despite the paucity of safety and 
efficacy data supporting atypical antipsychotic use in this population, dramatic 
increases in the use of these agents has been demonstrated from 1996 to 2000. 
 
Antipsychotics for the Treatment of Psychiatric and Behavioral Problems in 
Children and Adolescents 
As many as half of child and adolescent psychiatric inpatients and one-
third of outpatients are prescribed antipsychotics.32  Antipsychotics can be used to 
treat a wide spectrum of psychiatric and behavioral disorders in children and 
adolescents, including schizophrenia, bipolar disorder, Tourette’s syndrome, and 
disruptive behavioral disorders (Table 1.9, page 41).  However, aggression is the 
most common symptom for which antipsychotics are prescribed.33  Typical 
antipsychotics, specifically chlorpromazine and thioridazine, are approved by the 
Food and Drug Administration (FDA) for the treatment of severe behavioral 
problems in children and adolescents.  No FDA-approved indications exist for  
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Table 1.9. Uses for Antipsychotics in Children and Adolescents33 
Common Uses in Child Psychiatry Common Uses in Pediatric Medicine 
Psychoses Sedation; paradoxical response to 
benzodiazepines 
Schizophrenia Drug-induced psychosis 
Brief psychotic disorder Delirium 
Schizoaffective disorder Chorea 
Psychotic disorder not otherwise specified Organic personality disorder 
Mood disorders Agitation 
Treatment-resistant bipolar disorder Self-injurious behavior 
Bipolar disorder with psychotic features Anorexia nervosa 
Major depression with psychotic features Potential Uses in Child Psychiatry 
Movement disorders Disruptive behavior disorders 
Tic disorders or Tourette’s syndrome Conduct disorder 
Stereotypic movement disorder Severe or treatment-resistant attention-
deficit hyperactivity disorder 
Autism and pervasive developmental disorders Schizoid or schizotypal personality traits 
Intermittent explosive disorder Borderline personality traits 
 Severe stuttering 
 
atypical antipsychotics in the treatment of psychiatric and behavioral problems in 
youths. 
Evidence from randomized, controlled trials supporting the use of atypical 
antipsychotics in children and adolescents is growing.  Most available data are for 
risperidone in the treatment of aggression across different, specific psychiatric 
diagnoses.  Other child and adolescent psychiatric and behavioral disorders for 
which atypical antipsychotics have been evaluated in randomized controlled trials 
include schizophrenia, bipolar disorder, pervasive developmental disorders, and 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1.10. Randomized, Controlled Clinical Trials of Atypical Antipsychotics 
in Children and Adolescents (Cont.) 
 
a CLZ = clozapine; OLZ = olanzapine; QUET = quetiapine; RIS = risperidone; ZIP = ziprasidone. 
 
b CLND = clonidine; CO = crossover; DB = double-blind; DVP = divalproex; HLDL = 
haloperidol; OL = open label; P = parallel groups; PC = placebo-controlled; R = randomized. 
 
c AD = autistic disorder; ADHD = attention-deficit/hyperactivity disorder; AGGR = aggression; 
BEHAV = behavioral problems; BP = bipolar disorder; CD = conduct disorder; CTD = chronic tic 
disorder; DBD = disruptive behavioral disorders; MR = mental retardation; ODD = oppositional 
defiant disorder; PDD = pervasive developmental disorders; SA-IQ = subaverage intelligence; 
SCZ = schizophrenia; TS = Tourette’s syndrome. 
 
d ABC = Aberrant Behavior Checklist; BHRS = Bunney-Hamburg Psychosis Rating Scale; BPRS 
= Brief Psychiatric Rating Scale; CGI = Clinical Global Impressions Scale; CGI-I = Clinical 
Global Impressions Scale – Improvement; CGI-TS = Clinical Global Impressions Scale – 
Tourette’s Syndrome; CGI-S = Clinical Global Impressions Scale – Severity; NCBRF = Nisonger 
Child Behavior Rating Form; RAAPP = Rating of Aggression Against People and/or Property 
Scale; VAS = Visual Analogue Scale; YGTSS = Yale Global Tic Severity Scale; YMRS = Young 
Mania Rating Scale. 
 
e NS = not significant; PBO = placebo. 
 
 
Unanswered Questions Regarding the Use of Antipsychotics in Children and 
Adolescents 
The use of antipsychotic medications in children and adolescents has seen 
a dramatic increase over the past decade.  From 1991 to 1996, prevalence rates for 
antipsychotic use in a mid-Atlantic Medicaid state nearly doubled.24  During the 
latter part of the decade and after the introduction of newer atypical antipsychotics 
to market, prevalence rates of overall antipsychotic use and newer atypical 
antipsychotic use increased by 160% and 494%, respectively, in children and 
adolescents enrolled in the Texas Medicaid system.31  Additionally, 
antipsychotics are commonly used for children and adolescents in the inpatient 
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setting.  In a study by Pappadopulos and colleagues, atypical antipsychotics 
accounted for 27.8 percent, and typical antipsychotics accounted for ten percent 
of psychotropic medication prescriptions at discharge from New York child and 
adolescent public inpatient facilities.47 
Several possible explanations exist for the increase in the use of atypical 
antipsychotics in children and adolescents.  First, growing evidence supports the 
efficacy of atypical antipsychotics in the treatment of aggression, for which these 
agents are most commonly prescribed.33  Second, a shift may be occurring in who 
is actually prescribing antipsychotics.  Studies have demonstrated that 
antipsychotics are commonly prescribed by physicians other than child and 
adolescent psychiatrists.21,32,48  Goodwin and colleagues found that pediatricians 
and general practitioners may prescribe antipsychotic medications to children and 
adolescents more frequently than psychiatrists.49  Plausible explanations regarding 
this shift to “primary care mental health” include a shortage of child and 
adolescent psychiatrists in the U.S. and the emphasis on managed care.  Currently, 
approximately 6,300 child and adolescent psychiatrists practice in the U.S.  The 
U.S. Bureau of Health Professions predicts a 30 percent increase in the number of 
practicing child and adolescent psychiatrists to 8,312.  However, these numbers 
fall well short of the estimated 30,000 child and adolescent psychiatrists needed to 
meet the increased prevalence of mental disorders and managed care staffing 
models.50  Furthermore, the growing emphasis on managed care in Medicaid 
systems may encourage parents to seek initial mental health care with primary 
care physicians.51  In an epidemiological study of child and adolescent 
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psychosocial problems in primary care, community-based pediatricians and 
family practitioners reported that 18.7 percent of the children they treated in 1996 
had mental health problems, compared to 6.8 percent in 1979.  Significant 
increases over the 17-year period were seen in children and adolescents with 
attention-deficit hyperactivity disorder (7.8%) and behavioral/conduct problems 
(6.5%).19  Given the growing prevalence of childhood mental disorders and 
problems with continuity of care between primary and specialty mental health 
care providers, primary care physicians may have limited options other than to 
treat these disorders themselves.  Other factors, including reluctance of families to 
seek psychiatric help, stigma associated with psychiatric disorders, and systemic 
barriers to access,  may contribute to the treatment of pediatric psychiatric and 
behavioral disorders by primary care providers, and perhaps to increased 
medication use.52 
Given the increased prevalence of antipsychotic use in children and 
concerns expressed regarding increased use of all psychotropic medications in 
children, it is important to critically evaluate the arguments for and against the use 
of antipsychotics in children and adolescents.  Furthermore, discussion about 
unanswered questions regarding antipsychotic use in youths and 
recommendations for future studies is warranted. 
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Arguments Supporting the Use of Antipsychotics in Children and 
Adolescents   
Favorable side effect profiles of atypical antipsychotics 
Atypical antipsychotics were developed as a result of typical 
antipsychotics having unfavorable side effect profiles, especially the occurrence 
of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), and lacking 
efficacy for some patients, particularly those with negative symptoms.53  Over the 
past 12 years, six atypical antipsychotics, which include clozapine, risperidone, 
olanzapine, quetiapine, ziprasidone, and aripiprazole, have been introduced to the 
market.   
The presence of EPS during the course of treatment in children and 
adolescents can be problematic and debilitating to the patient.  Emergence of such 
symptoms can lead to decreased medication adherence, decreased patient self-
esteem, and poor patient outcomes.54  Prevention and management of EPS may be 
extremely important in youths as they may be more susceptible to the 
development of EPS, especially dystonic reactions.55  Atypical antipsychotics are 
associated with a decreased propensity to cause EPS compared to typical 
antipsychotics.53   
Hyperprolactinemia is another side effect seen less during treatment with 
atypical antipsychotics, with the exception of risperidone, compared to typical 
antipsychotics.  Increased prolactin levels in females can result in breast 
enlargement, galactorrhea, and dysmenorrhea; in males, hyperprolactinemia can 
lead to gynecomastia and sexual dysfunction.56  Although hyperprolactinemia is 
believed to account for less than ten percent of drug discontinuations, this is 
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poorly studied, and more research is necessary to examine the course and impact 
of this side effect.54   
Efficacy of atypical antipsychotics for aggressive behaviors 
Much of the efficacy data for atypical antipsychotics have come from 
randomized, controlled trials in the adult population.  Evidence suggests that these 
agents not only improve the collection of symptoms associated with schizophrenia 
and other psychotic disorders, but also improve patient outcomes, such as relapse, 
rehospitalization, and quality of life.53,57-60  For children and adolescents, evidence 
from controlled clinical trials supporting the efficacy of atypical antipsychotics is 
growing, especially for the treatment of disruptive behavioral disorders and 
aggression.  Of the atypical antipsychotics, the most data suggesting efficacy for 
aggressive behaviors are available for risperidone. 
In a ten-week, randomized, double-blind, placebo-controlled study, 20 
youths, aged six to 14 years, with conduct disorder (CD), aggressive behavior, 
and average intellectual functioning were randomized to receive either risperidone 
or placebo.  As measured by the Rating of Aggression Against People and/or 
Property Scale (RAAPP), low-dose risperidone (mean dose = 0.028 mg/kg per 
day) was more efficacious than placebo in reducing aggression during the last 
four weeks of the study.37 
In children and adolescents with subaverage intellectual functioning, 
risperidone has been shown to be efficacious in reducing aggressive behaviors.  In 
a four-week randomized controlled trial of 13 children and adolescents (6 to 14 
years old) with behavioral problems and borderline intellectual functioning, 
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risperidone (mean dose = 1.2 mg/day) was superior to placebo in reducing scores 
on the Aberrant Behavior Checklist (ABC), Clinical Global Impressions (CGI) 
scale, and the Visual Analogue Scale (VAS).38  In another small sample of 38 
hospitalized adolescents (mean age = 14.0 years) with severe aggression and 
subaverage levels of intelligence, Buitelaar and colleagues demonstrated that 
treatment with risperidone (mean dose = 2.9 mg/day) was associated with 
significant improvements on the CGI-Severity scale (CGI-S), modified Overt 
Aggression Scale (OAS-M), and the ABC.39 
Aman and colleagues conducted a six-week, randomized, double-blind, 
placebo-controlled study of risperidone in 118 children and adolescents, aged five 
to 12 years, with disruptive behavior disorders and subaverage intelligence.40  
Patients receiving risperidone (mean dose = 1.16 mg/day) had significantly 
greater improvements on the conduct problem subscale of the Nisonger Child 
Behavior Rating Form (NCBRF) compared to those receiving placebo.  
Additionally, the risperidone group showed improvements on other behavioral 
measures, including subscales of the ABC and Behavior Problems Inventory 
(BPI), and the VAS.  Similarly, Snyder and colleagues demonstrated risperidone’s 
efficacy for the treatment of disruptive behaviors in 110 children (aged 5 to 12 
years) with subaverage intelligence.41  In a six-week, randomized, double-blind, 
placebo-controlled trial, risperidone (mean dose = 0.98 mg/day) was superior to 
placebo in reducing scores on the conduct subscale of the NCBRF, as well as the 
ABC, BPI, CGI-Improvement (CGI-I), and VAS. 
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In an eight-week, randomized, double-blind, controlled trial, 101 children, 
between the ages of five and 17 years, with autistic disorder and behavioral 
problems were assigned to receive risperidone or placebo.42  Treatment with 
risperidone (mean dose = 1.8 mg/day) resulted in significant improvements in 
behavioral disturbances as indicated by scores on the ABC irritability subscale 
and CGI-I, compared to placebo.  
Several details regarding the evidence suggesting efficacy for aggression 
need further emphasis.  First, consistent measures were used across studies to 
evaluate aggressive behavior.  The ABC, CGI, and NCBRF are widely-used 
instruments, that have been shown to be reliable and valid.61-64  Second, the 
treatment effects associated with risperidone were fairly large compared to 
placebo, suggesting specific pharmacological benefit with this agent.  These 
effects were also consistently seen in children of varying ages, from five to 17 
years old.  Third, the onset of efficacy of risperidone was rapid, with significant 
separation from placebo occurring during the first week and sustaining throughout 
the study duration.  Finally, risperidone administration was well-tolerated.  
Risperidone was comparable to placebo with regard to extrapyramidal symptoms.  
Elevated prolactin levels were seen with low-dose risperidone, but no clinical 
sequelae were reported.40,41  The availability of such evidence is important since 
the prevalence of aggressive behavior is increasing across the spectrum of 
childhood disorders, and aggression may account for most of the antipsychotic 
prescribing in children and adolescents.33,65   
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Because of the lower frequency of side effects when dosed appropriately, 
atypical antipsychotics may be preferred by clinicians for use in children and 
adolescents when antipsychotic treatment is considered appropriate.  In addition, 
ample evidence in adults supports the use for several psychiatric conditions, such 
as schizophrenia and bipolar disorder.  It is under the assumption that these 
benefits will also be seen in children and adolescents that clinicians prescribe 
atypical antipsychotics for childhood psychotic disorders.  Perhaps more 
importantly, since aggression and nonpsychotic disorders account for a large 
percentage of antipsychotic prescribing in children, evidence supporting the 
efficacy of these agents for these conditions is encouraging. 
Arguments Against the Use of Antipsychotics in Children and Adolescents 
Lack of indications in children and adolescents  
Typical antipsychotics are indicated for the treatment of severe behavioral 
problems (chlorpromazine and thioridazine) and for the treatment of tics and 
vocal utterances of Tourette’s syndrome (haloperidol and pimozide).  Currently, 
the FDA has not approved indications for atypical antipsychotics in the treatment 
of psychiatric or behavioral problems in children and adolescents.  Although 
evidence exists to support the efficacy and safety of risperidone for aggressive 
behavior in children, it is unclear whether this is sufficient to receive an indication 
for a specific disorder.  The evidence supporting atypical antipsychotic use for 
aggression also lacks consistency in the patient populations studied.   With the 
exception of studies conducted by Aman and colleagues and Snyder and 
colleagues, data supporting the efficacy of risperidone for aggression originate 
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from controlled trials evaluating different patient populations.37-42  While it may 
be argued that the generalizability of the results may increase due to heterogeneity 
of patient populations, it is difficult to evaluate the reproducibility of these studies 
for specific populations.  Additionally, most data available supporting risperidone 
use for aggression originate from patients of subaverage intelligence.40-42  It is 
unclear how these findings would translate to patients of normal intelligence or 
those seen in routine clinical practice.  Other possibilities explaining why no 
pediatric indications exist for atypical antipsychotics may be the lack of financial 
initiative for drug manufacturers, philosophical concerns from regulatory agencies 
regarding the use of antipsychotics in children, and political pressure from groups 
opposed to the use of medication intervention for the treatment of psychiatric and 
behavioral problems. 
Potential adverse and long-term effects of atypical antipsychotics 
Although low in incidence, serious side effects, such as EPS, tardive 
dyskinesia, and neuroleptic malignant syndrome, have been reported with atypical 
antipsychotic use.66-68  Other side effects of concern associated with these agents 
include weight gain, hyperglycemia, new-onset diabetes, hyperlipidemia, 
cardiovascular abnormalities, and hyperprolactinemia.69  The development of 
metabolic and cardiovascular side effects may increase the risk of morbidity and 
mortality in this population.  Weight gain may be especially problematic in 
children and adolescents as they may be subject to problems with self-esteem, 
social functioning, and medication adherence.  Obese children are also at high risk 
of developing impaired glucose tolerance or type 2 diabetes.70  Given that the 
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overall incidence of type 2 diabetes is increasing in children and adolescents, 
particularly among minorities, treatment with some atypical antipsychotics may 
precipitate or exacerbate abnormal glucose levels and associated clinical 
sequelae.71,72  Among the atypical antipsychotics, risperidone is most frequently 
associated with hyperprolactinemia, particularly at higher doses.68,73  In short-
term studies of risperidone for the treatment of aggressive behaviors, 
hyperprolactinemia was seen with low doses, but no adverse events related to 
prolactin levels were reported.39-41  In a 48-week open-label trial, administration 
of low-dose risperidone in children and adolescents also resulted in asymptomatic 
increases in prolactin levels.74   
Long-term implications of the use of atypical antipsychotics in children 
and adolescents have yet to be thoroughly determined.  Although associated with 
cognitive benefits in adults with schizophrenia, the cognitive effects of these 
agents in children and adolescents have not been reported in the literature.75  A 
six-week trial comparing risperidone and placebo in 118 children and adolescents 
with disruptive behavior disorders evaluated memory using the Modified Verbal 
Learning Test – Children’s Version (MVLT – CV), and attention and vigilance 
using the Continuous Performance Test (CPT).76  Both the risperidone and 
placebo groups showed significant improvements in memory from baseline to 
endpoint, with no significant differences between groups.  No significant within- 
or between-group differences were reported in CPT scores, suggesting risperidone 
treatment did not affect cognitive performance.  Similarly, data regarding atypical 
antipsychotic effects on growth and development have yet to be published.  A 
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study by Dunbar and colleagues analyzed pooled data from five multicenter trials 
of risperidone in children and adolescents with disruptive behavior disorders to 
retrospectively examine the effects on growth and sexual maturation over a 12-
month period.77  Results indicated that patients receiving risperidone had a mean 
increase of 1.2 centimeters (cm) greater than the reference population, but this 
deviation from expected growth was normally distributed.  Sexual maturation 
occurred more rapidly in patients receiving risperidone than in the reference 
population, as described by a mean of 0.12 Tanner Stages.  Additional data are 
necessary to fully elucidate the effects of risperidone on cognition and growth in 
children and adolescents across diagnoses. 
Pharmacological versus nonpharmacological treatments 
One of the most important issues is the question of whether 
pharmacological intervention is the best modality for treatment of behavioral 
problems.  Since antipsychotics are frequently used for nonpsychotic disorders, 
such as aggression, closer scrutiny of this issue is necessary.  
Nonpharmacological treatments, such as behavioral therapy and psychoeducation, 
may provide alternative treatment modalities.78  Substantial evidence supports 
psychotherapeutic approaches for the treatment of aggression, particularly in 
children and adolescents with developmental disorders.79,80  Parent management 
training (PMT), problem-solving skills training (PSST), and multisystemic 
therapy (MST) are psychosocial treatments shown to be efficacious for aggressive 
youth, with parent management training being the most widely evaluated.81  
Studies have addressed the efficacy and effectiveness of parent training in young 
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children, demonstrating medium to large effect sizes.  The effectiveness of parent 
training in children and adolescents between the ages of nine and 18 years has yet 
to be fully determined, although several models for younger children exist.82-84   
Kazdin and colleagues evaluated the relative effects of PMT, PSST, and a 
combination of both treatments in a randomized controlled trial of 97 children, 
between the ages of seven and 13 years, who were referred to an outpatient child 
conduct clinic.85  PMT consisted of 25 weekly sessions, while PSST consisted of 
16 sessions.  All three groups demonstrated improvement, with the combination 
group having the largest percentage of patients who were normalized on the 
CBCL by post-treatment.  At one-year follow-up, the combination group showed 
continued improvement in child behavior and parent stress, and the PSST group 
further improved in child behavior.  Although the combination treatment resulted 
in improved short-term and long-term child behavior, effect sizes related to CBCL 
total scores were modest when compared to the other treatments (combination 
versus PSST = 0.45 and combination versus PMT = 0.39). 
In a 24-week randomized controlled trial of 92 children, aged four to 
seven years, with oppositional defiant disorder (ODD) or CD, Webster-Stratton 
and Hammond examined the effects of adding child training (CT) to parent 
training (PT).83  Children were randomized to receive CT, PT, CT + PT, or 
control.  At post-treatment, 80.8% of the PT group and 70.0% of the CT + PT 
group were normalized according to parent-rated CBCL scores.  Thirty-seven 
percent of the CT group and 27.3% of the controls were considered normal.  
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Effect sizes for CBCL total scores were largest for PT when compared to controls, 
followed by CT + PT and CT (1.27, 1.25, and 0.49, respectively). 
To determine the effectiveness in the typical service setting, Taylor and 
colleagues conducted a randomized controlled trial comparing Webster-Stratton’s 
Parents and Children Series (PACS) with eclectic typical treatment in 110 
families of three to eight year-old children with conduct problems.86  PACS 
consisted of group therapy, and eclectic treatment was comprised of 
individual/family therapy.  Compared to wait-list (WL) controls, PACS and 
eclectic treatment showed greater improvement for total problems as measured by 
the Eyberg Child Behavior Inventory (ECBI), CBCL, and Parent Daily Report 
(PDR).  Medium effect sizes were reported for ECBI scores (PACS versus WL = 
0.57, eclectic versus WL = 0.43, and PACS versus eclectic = 0.49). 
In published studies, effect sizes are often quite large with 
pharmacological treatment, while those related to behavioral management for 
aggression have typically been modest.  In addition, a few long-term follow-up 
studies of up to four years have been conducted on aggressive delinquent youth 
who have received an intensive home-based therapy (MST).87,88  However, no 
evidence is available to suggest whether pharmacological treatment or 
nonpharmacological treatment is superior with this population.  Furthermore, it is 
unclear whether and when children may benefit most from the combination of 
both interventions.  Head-to-head comparisons, using the same 
inclusion/exclusion criteria and standardized measures across both types of 
interventions, are vital in defining the role of both pharmacological and 
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nonpharmacological interventions.  Evidence supporting the long-term efficacy 
and safety of atypical antipsychotics in children and adolescents is also necessary.  
Existing studies need to be replicated to see whether the beneficial effects of 
atypical antipsychotic treatment hold across patient populations and service 
settings.  Although atypical antipsychotics may be superior to typical 
antipsychotics in some ways, these agents still have the potential to cause harmful 
side effects when used inappropriately.  More data are needed on side effects that 
may negatively impact the outcomes of children and adolescents receiving 
antipsychotic treatments. 
Unanswered Questions and Directions for the Future 
Treatment guidelines for childhood and adolescent disorders 
Consensus recommendations such as those by Pappadapulos and 
colleagues are useful in providing clinicians with guidance regarding the use of 
antipsychotics to treat aggression in youth.89  However, the recommendations are 
limited by the amount of available data to support evidence-based 
recommendations.  Therefore, treatment guidelines in this area should be viewed 
cautiously by clinicians.  While atypical antipsychotics may play a role in the 
treatment of childhood and adolescent psychiatric disorders, more information is 
necessary before one can make definitive conclusions about these agents as a 
class.  However, as seen with risperidone, the growing body of evidence may 
allow for specific evidence-based recommendations regarding the use of this 
particular agent for the treatment of aggression. 
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Disorder-targeted versus symptom-targeted treatment  
A question exists regarding whether disorder-targeted pharmacological 
treatment or symptom-targeted pharmacological treatment is more appropriate in 
children and adolescents.  Arguments for disorder-targeted treatment over 
symptom-targeted treatment include greater evidence of efficacy based upon 
diagnosis and possibly less potential for polypharmacy.  The use of polypharmacy 
in children and adolescents is of concern because it leads to greater risk of drug-
drug interactions, a higher probability of adverse events, a potential increase in 
treatment nonadherence, and increased cost.  On the other hand, disorder-targeted 
treatment requires an accurate diagnosis, which can be extremely difficult in 
children.  For example, much debate exists regarding the diagnoses of attention-
deficit hyperactivity disorder (ADHD) and bipolar disorder, as significant overlap 
in symptoms occurs with these disorders, and questions exist regarding the most 
appropriate diagnostic criteria for bipolar disorder in prepubescent children.90  
Symptom-targeted treatment may allow for short-term administration of 
medications until symptom resolution, as may be the case for aggression.  
However, this method of treatment can result in polypharmacy, and place the 
child or adolescent at risk for adverse events.  Additionally, improvement in 
symptoms may be viewed as a justification for long term treatment, and the 
evidence to support a rationale for this decision is frequently limited. 
Given the merits of basing treatment on a particular diagnosis, the field of 
psychopharmacology may be shifting toward disorder-targeted treatment.  
However, this may not be case for the treatment of aggression, which is seen 
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across a number of child and adolescent psychiatric disorders.  Studies evaluating 
the effects of risperidone on aggressive behaviors have utilized diverse patient 
populations, including those with a diagnosis of disruptive behavior disorders, 
subaverage intelligence, or autistic disorder.  In addition, studies of behavioral 
treatments have targeted children with aggressive symptoms, regardless of 
diagnosis.  Since aggressive behaviors are so widespread across diagnoses, it is 
possible that pharmacological and nonpharmacological treatment for these 
children will always focus on symptom resolution. 
To put this in perspective, fever can be examined as an analogy.  Fever 
results from multiple etiologies, infectious and inflammatory processes are 
examples.  Regardless of the cause, antipyretics typically have efficacy in 
lowering body temperature.  However, antipyretics do not address the underlying 
condition creating the hyperthermia.  If antipyretics are used without addressing 
the underlying etiology, then the underlying disease process may progress.  
However, when used in combination with interventions to address the underlying 
disorder, antipyretics are extremely useful pharmacological agents as they reduce 
symptoms and make the patient more comfortable.  When applying this analogy 
to the treatment of aggression, atypical antipsychotics can be useful in patient 
management as they decrease symptoms and assist in minimizing the possibility 
that the patient will harm self or others.   However, it is critical that the underlying 
disorder be identified, treated, and attempts made to improve the individual’s 
adaptive functioning over the long-term.  Unlike many other areas of medicine, 
the pathophysiolgic etiology of most mental disorders is unknown.  From the 
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perspective of discrete biological targets, the current approach to pharmacological 
treatment by diagnosis may or may not be more accurate than using treatment by 
target symptoms such as aggression.  Thus, from a biological perspective, it is 
unclear whether symptom focused or syndromal based treatment approaches are 
more appropriate. 
‘Real-world’ effectiveness of atypical antipsychotics in children and adolescents 
The gap between scientific evidence and clinical practice seems to be 
widening.  Not only is it difficult to implement evidence-based practices in 
routine clinical care, little is actually known about how well atypical 
antipsychotics work in the “real-world” setting.  Although randomized, controlled 
trials are considered the gold standard in establishing treatment efficacy, future 
research should aim at providing evidence of treatment effectiveness.  
Randomized, controlled trials offer strong evidence of efficacy, but the results are 
generated under conditions in which the external validity may be compromised.  
Effectiveness trials are subject to a number of threats to internal validity since 
patients under study are more likely to be heterogeneous, and there is less control 
over extraneous variables such as treatment setting, frequency of visits, 
medication adherence, and evaluation of treatment effects.  Albeit, effectiveness 
trials may provide more complete answers to the question of how well an agent 
works or does not work in the “real-world” setting. 
Mediators and moderators of treatment effects 
Closer examination of moderators of treatment effects would provide a 
better ability to optimize treatment for a child or adolescent, and hopefully 
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improve patient outcomes.  Patient, clinician, or setting characteristics may 
provide plausible explanations for treatment response or nonresponse.  For 
example, in the NIMH Multimodal Treatment of Children with ADHD (the MTA 
Study), only subjects with comorbid anxiety disorder experienced greater 
improvements with behavioral treatment plus methylphenidate compared with 
methylphenidate alone.91  More recently in a study evaluating the effects of 
fluvoxamine in children and adolescents with anxiety disorders, lower baseline 
depression scores were associated with greater improvement while subjects with 
social phobia were less likely to improve.92  Closer examination of mediators of 
treatment effects will provide a better ability to make treatments more efficient 
and effective.  Treatment adherence (or nonadherence) is one of many factors that 
may account for treatment response (or nonresponse), as it did in both of the 
above trials.91,92  Other factors which may determine the effectiveness of atypical 
antipsychotics outside of the ideal research setting include family acceptance, 
concern of stigmatization, provider and/or organizational choice, dosage 
optimization, and frequency of clinic visits. 
The development and deployment of effective interventions 
A conceptual model developed by the Workgroup on Child and 
Adolescent Mental Health Intervention Development and Deployment describes 
the required processes for the development and deployment of effective 
interventions for children and adolescents (Figure 1.4, page 63).93   The first step 
in the model occurs at the basic sciences level.  Evidence-based theories regarding 
etiology and pathophysiology of child and adolescent psychiatric and behavioral 
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problems need to be established and tested, so that clinicians have a better basis 
for what they are actually treating.  Based upon these studies, biological targets 
for drug action are identified, and compounds are subsequently developed that 
modify these biological processes.94  Medications developed in such a manner 
would then be studied for their efficacy in the treatment of child and adolescent 
psychiatric and behavioral disorders.  Identification of factors influencing 
treatment effects is necessary during this step to better tailor treatment strategies 
according to a child’s personal, familial, and environmental/societal 
characteristics.  Third, evidence-based treatment strategies need to be evaluated in 
the clinical setting for their effectiveness.  For example, effectiveness studies 
examining pharmacotherapy versus different psychosocial treatments versus 
multimodal approaches need to be studied in different types of aggression.  These 
strategies are refined and prepared prior to testing at this stage.  Interventions that 
are shown to be effective are then implemented using multidisciplinary 
approaches that have been shown to be effective in implementing and diffusing 
evidence-based practices into routine care.  While it is important to disseminate 
proven interventions to the clinics, schools, and other places where youths and 
their parents can access them, it is also imperative that “real-world” data from 
these interventions be provided back to the organizations and systems of care 
involved in the development and testing.95-97   
 63
Basic Research and 









Review and Synthesis 







Figure 1.4. A Model for Intervention Development and Deployment93,95 
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Currently, biological targets based upon pathophysiological evidence do 
not exist to support the use of atypical antipsychotics in the treatment of 
aggression, or for that matter, in the treatment of any mental disorder.  As 
additional research evidence evolves regarding brain function and the 
pathophysiology of mental disorders, future treatments should be developed based 
upon biological molecular targets.94  In other respects, the remainder of these 
principles can and should be applied to the development and acceptance of 
treatment modalities in psychiatry, including the use of atypical antipsychotics for 
the management of aggression in children.   
Summary 
Concern over the growing use of atypical antipsychotics in children and 
adolescents exists for a number of reasons.  Although both basic and clinical 
research supporting the rationale, efficacy, and safety of these agents in the 
management of aggressive behaviors is limited, the use of atypical antipsychotics 
in children and adolescents is growing.  In many respects, this may be a reflection 
of the need and demand for effective treatments in these complex disorders.  
Clinicians choosing to prescribe atypical antipsychotics should do so after 
considering the issues at hand and carefully evaluating the patient and his or her 
surroundings.  In general, antipsychotics should only be used in combination with 
behavioral and other psychosocial interventions that have proven benefit, and 
attempts should be made to limit duration of antipsychotic treatment. 
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Specific Aims and Related Hypotheses 
Examination of current use of antipsychotics in children and adolescents 
serves as a foundation upon which future studies can be built.  As newer 
psychotropic medications are introduced to the market with relatively little or no 
data in children and adolescents, it is imperative to determine to what extent these 
agents are being used in this population.  Without database studies such as this 
study, the degree of use and effects of psychotropic medications on patient health 
care outcomes remains unclear.  The possession of efficacy and safety data 
usually precedes the clinical use of psychotropic medications in the adult 
population.  Such standards should also be applicable to psychotropic medication 
use in children and adolescents.  The knowledge and insight to be gained from 
this study may hopefully stimulate additional clinical research evaluating the 
efficacy and safety of antipsychotics in children and adolescents. 
Specific Aims 
The ultimate goal of this research project was to evaluate the trends in 
antipsychotic use in children and adolescents (1996 to 2001).  The research 
project was intended to evaluate the overall prevalence of antipsychotic use, 
including subclasses (typical and atypical antipsychotics), documented use of 
antipsychotics, sources of antipsychotic prescribing, and relationships of 
antipsychotic use on health care service utilization.  To increase the 
generalizability of the study, data were collected from a total of four health 
systems: three geographically diverse Medicaid systems (California, Ohio, and 
Texas) and one managed care health care plan operating nationwide as a health 
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maintenance organization (HMO) and preferred provider organization (PPO).  
The inclusion of three different Medicaid populations provided state-level 
perspectives of the trends in use of antipsychotics in children and adolescents, as 
studies have demonstrated geographic variations in the prescribing of 
antipsychotics.32,98  The inclusion of a private managed care organization 
provided valuable information regarding antipsychotic use in children and 
adolescents enrolled in these types of health care systems. 
The research was primarily based upon the recent attention given to the 
use of psychotropic medications in children and adolescents.  Specifically, the 
increased prevalence of antipsychotic use in children and adolescents has been 
attributed to the introduction of atypical antipsychotics.31  Atypical antipsychotics 
have demonstrated efficacy in a number of pediatric psychiatric disorders, 
including aggression.37-42 
The research study was conducted in three distinct phases and 
examined/evaluated:  
• Phase I: Trends in the prevalence of antipsychotic use in children and 
adolescents;  
• Phase II: Prescribing practices for antipsychotic agents;  






Phase I: Trends in the prevalence of antipsychotic use in children and adolescents  
To date, only one study has examined the trends in antipsychotic use in 
children and adolescents since the introduction of atypical antipsychotics.31  
Although the study demonstrated an overall increase in the use of antipsychotics 
since the introduction of atypical agents, the generalizability of the results is 
limited because the sample population consisted only of those children and 
adolescents enrolled in the Texas Medicaid system.  It is unknown whether these 
prevalence rates are predictive of other regions of the U.S.  Several studies have 
demonstrated geographic variation in antipsychotic prescribing in adults.32,98  It is 
also unknown whether these prevalence rates are similar in other types of health 
care systems, namely private managed care organizations. 
Phase I evaluated data from four health care systems (Medicaid: California 
[West], Ohio [Midwest], and Texas [South]; Managed Care: Nationwide) to 
determine the prevalence of antipsychotic use in children and adolescents.  Total 
antipsychotic, typical antipsychotic, and atypical antipsychotic prevalence rates 
were determined. The extent to which geography influences prescribing of 
antipsychotics in children and adolescents and whether or not the differences (if 
present) are significant also were evaluated using data from the Medicaid 
programs. Differences in antipsychotic prevalence rates between public versus 
private health insurance programs were examined.  In addition, daily dose of 
antipsychotic therapy, rates of antipsychotic switching and concomitant 
psychotropic medication therapy in this population were examined.  Annual cost 
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of all antipsychotic prescriptions, as well as antipsychotic subclass and specific 
atypical antipsychotic, were examined for each of the four health care systems. 
 
Phase II: Prescribing practices for antipsychotic agents 
Given the expected increase in antipsychotic use in children and 
adolescents, it is critical to examine these two parameters (provider and diagnosis) 
when evaluating pharmacoepidemiological trends of antipsychotic medications.  
A trend for increased prescribing of psychotropic medications in youths by 
clinicians other than child and adolescent psychiatrists has been suggested.49  This 
shift may be attributed to a lack of child and adolescent psychiatrists, pressure by 
managed care to preferentially utilize primary care providers, and family 
reluctance to seek mental health care.50-52  Behavioral problems, such as 
aggression, are more likely to be treated with antipsychotics.33  This use may 
account for much of the increase in prevalence, as studies have shown that 
antipsychotics are commonly prescribed for nonpsychotic disorders in children 
and adolescents.47,49 
Phase II evaluated data from the Texas Medicaid and Texas Department of 
Mental Health and Mental Retardation (TDMHMR) systems to examine 
prescribing practices related to antipsychotic use in children and adolescents.  
Provider information, focusing upon the specialty of physician (neurology 
[including child neurology], pediatrics, primary care [including family practice 
and general practice], psychiatry [including child and adolescent psychiatry], or 
other) were collected.  Diagnostic data from 1998 to 2001 were collected from the 
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TDMHMR Client Assignment and Registration System (CARE) database to 
determine the documented diagnoses (anxiety, bipolar, depressive, disruptive, 
psychotic, substance abuse, developmental, and other) for which antipsychotics 
were being prescribed. 
 
Phase III: Relationships of antipsychotic use with patient health care service 
utilization 
A study of mental health expenditures for children in 1998 suggest that 
psychotropic medications account for nine percent of the total were for 
psychotropic medications.26  More specifically related to antipsychotic use in 
youths, expenditures in the Texas Medicaid system totaled $13,730,220 in 2000.31  
This represented a 473 percent increase from the $2,278,134 spent on 
antipsychotics in 1996.  Atypical antipsychotics are clearly associated with high 
medication acquisition costs.  The clinical and economic evaluation of the effects 
of atypical antipsychotic therapy becomes imperative to determine whether the 
higher acquisition costs compared to typical antipsychotics are offset by added 
benefits to the patient.   
Since atypical antipsychotics are used to treat a wide variety of pediatric 
psychiatric and behavioral problems, the impact of these agents on other 
components of health care needed to be explored.  Phase III evaluated data from 
the TDMHMR system to examine how the following service utilization 
parameters were related to antipsychotic use from 1998 to 2001: number and total 
days of inpatient psychiatric hospitalizations, and enrollment and duration of 
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different types of outpatient mental health services.  TDMHMR CARE service 
utilization data included enrollment in the following types of outpatient mental 
health services: Assessment Services (TC08), Counseling and Psychotherapy 
(TC13); Crisis Intervention (In-Home [TC01], Inpatient [TC07], Therapeutic 
Foster Care [TC09], Other Residential Services [TC17], and Acute Day 
Treatment [TC20]); Medication-related Services (TC04); Service Coordination 
(TC06); Skills Training (Rehabilitative Day Treatment [TC03], Individual 
[TC10], Family [TC19]); and, Supportive Services (Respite [TC05], Family-
Focused Services [TC23], and Flexible Community Support [TC24]).  Appendix 
A provides descriptions of each type of outpatient mental health service.  It is 
important to examine what types of outpatient mental health services are being 
delivered to mentally ill youths, as these may improve long-term adaptive 
functioning and patient outcomes.   
In addition to evaluating overall trends of service utilization, trends in 
service utilization based upon age, gender, and diagnosis were examined.  It is 
important to evaluate these parameters, as certain populations may account for a 
significant portion of antipsychotic use, service utilization, and associated costs.  
Evaluation of these parameters may indicate which populations may possibly lack 
access to mental health care services.   
Related Hypotheses 
The hypotheses for Phases I (H1 to H16) were tested for each of the four 
health care systems.  For example, H1 is tested for California Medi-Cal (CA), 
Ohio Medicaid (OH), Texas Medicaid (TX), and the Managed Care Organization 
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(MCO).  The second set of hypotheses for Phase I relates to comparisons between 
the four health systems: California (CA), Ohio (OH), Texas (TX), and the 
Managed Care Organization (MCO).  The first three hypotheses (H17 to H19) 
compare prevalence rates of antipsychotic use only in the Medicaid systems.  The 
last three hypotheses (H20 to H22) compare prevalence rates of antipsychotic use in 
public versus private health insurance systems.  The hypotheses for Phases II and 
III were tested only for Texas Medicaid (H23, H24) and Texas Medicaid youths 
receiving mental health care services within the TDMHMR system (H25 to H29). 
 
Phase I: Trends in the prevalence of antipsychotic use in children and adolescents 
(CA, OH, TX, and MCO) 
 
H1: The prevalence rate of total antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
Rationale: Based upon previous pharmacoepidemiological studies examining 
antipsychotic use in children and adolescents, increased use of 
these agents will be demonstrated.24,31  Much of the overall 
increase in overall antipsychotic use in youths will be attributable 
to an increased use of atypical antipsychotics, as these agents have 
more favorable neurological side effect profiles compared to 
typical antipsychotics and increasing evidence supports safety and 
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efficacy for the treatment of psychiatric and behavioral disorders 
in children and adolescents.33,53 
 
H2: The prevalence rate of atypical antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
Rationale: The prevalence rate of atypical antipsychotic use in children and 
adolescents enrolled in the Texas Medicaid system increased 494 
percent from 1996 to 2000.31  Several possible explanations for the 
increased use of these agents include: (1) the body of evidence 
supporting safety and efficacy of atypical antipsychotics for the 
treatment of psychiatric and behavioral disorders in children and 
adolescents is growing; (2) several randomized, controlled clinical 
trials have demonstrated the safety and efficacy of risperidone for 
the treatment of aggression, which is the most common symptom 
for which antipsychotics are prescribed in children and 
adolescents; and, (3) atypical antipsychotics have more favorable 
side effect profiles compared to typical antipsychotics, specifically 






H3: The prevalence rate of typical antipsychotic use in children and 
adolescents decreases from 1996 to 2001. 
 
Rationale: Typical antipsychotic use in children and adolescents in the Texas 
Medicaid system decreased 21 percent from 1996 to 2000.31  
Prevalence rates of typical antipsychotic use have declined since 
the introduction of newer atypical antipsychotics.  As evidence 
builds supporting the use of atypical antipsychotics and clinicians 
become more familiar with specific agents, decrease in the use of 
typical antipsychotics is likely.  Additionally, these agents are 
associated with unwanted side effects, such as extrapyramidal 
symptoms, tardive dyskinesia, and impaired cognition.53 
 
H4: During each study year (1996 – 2001), risperidone is the most 
commonly used atypical antipsychotic in children and adolescents. 
 
Rationale: Rank order of specific atypical antipsychotic use among Texas 
Medicaid enrolled children and adolescents from 1996 to 2000 
demonstrated that risperidone was the most used, followed by 
olanzapine, quetiapine, and clozapine.31   Although clozapine was 
the first atypical antipsychotic introduced to the market in 1989, its 
use in youths is tempered due to the risk of agranulocytosis, 
frequently required hematologic monitoring, and an indication for 
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treatment-resistant schizophrenia.29,99  Due to these factors along 
with the rarity of early-onset schizophrenia, the prevalence rate of 
clozapine use may not increase during the eight-year study 
period.100  The frequent use of risperidone, which was introduced 
in 1993, may be related to the available evidence supporting its 
safety and efficacy in children and adolescents, specifically in 
aggression.37-42  With increased time on the market, clinicians may 
have a greater degree of comfort with risperidone, particularly 
regarding its safety in youths.  Olanzapine and quetiapine were the 
next atypical antipsychotics introduced to the market, in 1996 and 
1997 respectively.  Although few randomized controlled trials of 
either olanzapine or quetiapine in children and adolescents have 
been conducted, it is possible that the perception of “a class 
effect” may be an important factor driving the use of these agents, 
even if only one agent in a class of medications has demonstrated 
efficacy for certain psychiatric and behavioral symptoms.  Thus, 
clinicians may have become more familiar and more comfortable 






H5: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
Rationale: Trends of increased use of psychotropic medications, including 
atypical antipsychotics, have been demonstrated across all age 
categories.  In a Mid-Atlantic Medicaid state, prevalence rates for 
psychotropic medication use at least doubled from 1987 to 1996 
for the following age categories: 0-4 (2.3-fold increase), 5-9 (2.5), 
10-14 (4.8), and 15-19 (7.2) years.24  Children and adolescents 
between the ages of ten and 14 years were the highest utilizers of 
psychotropic medications, followed by children who were five to 
nine years old.24  With regard to total antipsychotic use from 1996 
to 2000, the most substantial increases were associated with 
children ages five to nine years (+354% [+16.2 per 1,000 
enrollees]) and ten to 14 years (+173% [+30.1]).31  Children 
between the ages of two and four years, as well as adolescents 
ages 15 to 19 years, increasingly used antipsychotics (+76% 
[+1.4] and +76% [+30.2], respectively).31  All age groups showed 
significant increases in the prevalence of atypical antipsychotic 
use: age < two years (+172%), two to four years (+556%), five to 
nine years (+609%), ten to 14 years (+490%), and 15 to 19 years 
(+275%).31 
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  For further reasoning to support the hypothesis, please see 
rationales provided for H1, H2, and H3. 
 
H6: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
Rationale: Please see rationale provided for H5.   
 
H7: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across all age categories (<2, 2-4, 5-9, 10-14, and 15-19 
years). 
 
Rationale: Please see rationale provided for H5.   
 
H8: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across gender groups: male and female.   
 
Rationale: Trends of increased use of psychotropic medications, including 
atypical antipsychotics, have been demonstrated across both males 
and females.  In a Mid-Atlantic Medicaid state, prevalence rates 
for psychotropic medication use tripled from 1987 to 1996 for 
males (3.1-fold increase) and females (4.0).24  Males were the 
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highest utilizers of psychotropic medications.24  With regard to 
total antipsychotic use, both males and females showed substantial 
increases in use from 1996 to 2000 (+157% [+15.7] and +152% 
[+8.0], respectively).31  Both gender groups showed significant 
changes in the prevalence of atypical antipsychotic use: males 
(+578%) and females (+547%).  On the other hand, prevalence 
rates of typical antipsychotic use for males and females decreased 
(-28% and -25%, respectively).31 
  For further reasoning to support the hypothesis, please see 
provided rationales for H1, H2, and H3. 
 
H9: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across gender groups: male and female. 
 
Rationale: Please see rationale provided for H8. 
  
H10: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across gender groups: male and female. 
 




H11: The mean daily dose of risperidone treatment in age-specific 
groups of children and adolescents decreases from 1996 to 2001. 
 
Rationale: Anecdotal reports suggest that the average daily risperidone dose 
in adults has decreased, but no evidence exists in children and 
adolescents.101  It is possible that the mean daily dose of 
risperidone in youths will decrease because of the following 
reasons: (1) as the daily dose increases, the occurrence of adverse 
effects related to risperidone therapy increases because mean 
dopamine D(2) receptor occupancy increases102;  (2) randomized 
controlled trials have demonstrated risperidone’s efficacy at low 
doses (usually less than two milligrams per day) in the treatment of 
aggression in children and adolescents37-42; (3) with increased 
time on the market, clinicians have become more comfortable with 
the recommended dosing strategies for risperidone. 
 
H12: The mean daily dose of olanzapine treatment in age-specific 
groups of children and adolescents increases from 1996 to 2001. 
 
Rationale: The recommended olanzapine dosing range for childhood 
psychosis is 2.5 to 20 milligrams per day.33  Although olanzapine 
has been marketed since 1996, a paucity of evidence exists to 
support dosing recommendations in youths.  Only one randomized 
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controlled trial has evaluated olanzapine for the treatment of 
autistic disorder, and in this study, the mean daily dose was 7.9 
(±2.5)  milligrams.33  Other open-label trials in childhood and 
adolescent disorders, such as schizophrenia and bipolar disorder, 
have reported mean daily doses as high as 20 milligrams.103-105  In 
clinical practice, the average daily dose of olanzapine in adults 
has been increasing to as high as 40 milligrams per day.101  
Additionally, plasma concentrations of olanzapine may be 
correlated with therapeutic response.101  It is difficult to predict the 
trend in olanzapine dosing in children and adolescents from 1996 
to 2001.  However, based upon adult data, it is possible that there 
will be an increase in the mean daily dose of olanzapine. 
  The use of higher doses of olanzapine may be due to 
practice pressures associated with prescribing antipsychotics, such 
as protection of the patient, other patients, and staff.  Additionally, 
the use of higher doses of olanzapine may be associated with the 
tolerability of this agent at higher doses, clinician desire to 
improve outcomes in the patient, and to some extent, limited 
treatment alternatives that are highly effective.  Given these 
reasons, it is possible that there will be an increase in the mean 
daily dose of olanzapine during the study period. 
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H13: The mean daily dose of quetiapine treatment in age-specific groups 
of children and adolescents increases from 1996 to 2001. 
 
Rationale: The recommended quetiapine dosing range for children with 
psychosis ranges from 12.5 to 750 milligrams per day.33  Similar to 
olanzapine, only one randomized controlled trial examines 
quetiapine for adjunctive treatment in adolescent mania.36  The 
mean daily quetiapine dose in this study was 432 milligrams per 
day.  In an open-label trial of quetiapine in adolescents with 
psychotic disorders, the average daily doses in 15 subjects ranged 
from 400 to 800 milligrams.106  In adults, the daily quetiapine dose 
has exceeded the manufacturer’s recommended maximum daily 
dose of 800 milligrams.101  Based upon adult prescribing trends of 
quetiapine, it is possible that there will be an increase in the mean 
daily dose of quetiapine in youths. 
The use of higher doses of quetiapine may be due to 
practice pressures associated with prescribing antipsychotics, such 
as protection of the patient, other patients, and staff.  Additionally, 
the use of higher doses of quetiapine may be associated with the 
tolerability of this agent at higher doses, clinician desire to 
improve outcomes in the patient, and to some extent, limited 
treatment alternatives that are highly effective.  Given these 
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reasons, it is possible that the mean daily dose of quetiapine will 
increase during the study period. 
 
H14: Antipsychotic switch rates in children and adolescents increase 
from 1996 to 2001. 
 
Rationale: In adult patients enrolled in the California Medicaid system (Medi-
Cal), the likelihood of switching was lower with atypical 
antipsychotics than typical antipsychotics.107  No such data exist in 
children and adolescents.  Current trends of antipsychotic use 
show that the use of typical antipsychotics is declining, while 
atypical antipsychotic use is increasing.31  As the number of 
available atypical antipsychotics grows, it is more likely that 
clinicians will switch from one atypical antipsychotic to another if 
the treatment trial is deemed a failure or response is less than 
optimal.  Thus, the rates of antipsychotic switching will increase 







H15: The prevalence of concomitant psychotropic medication use, 
including multiple antipsychotic agents, in children and 
adolescents receiving antipsychotic medications increases from 
1996 to 2001. 
 
Rationale: In the early to mid-1990s, studies examining the use of 
concomitant psychotropic medications reported that over 20 
percent of community-treated, outpatient and over 40 percent of 
inpatient children and adolescents with psychiatric conditions 
received multiple psychotropic agents.108  More recent data 
suggest that over 50 percent of children and adolescents with 
psychiatric conditions receive concomitant psychotropic 
medications.108  Higher frequency of concomitant psychotropic 
medication use is strongly related to treatment by psychiatrists, 
and aggressive behavioral disorders.109-111 
  Antipsychotics are commonly used for aggression across a 
spectrum of psychiatric disorders, including schizophrenia, 
externalizing disorders, and pervasive developmental 
disorders.33,111  Combination therapy with antipsychotics and one 
of the following agents is not uncommon for the treatment of 
aggression: alpha agonists, anticonvulsants, antidepressants, 
lithium, and psychostimulants.112  The use of multiple antipsychotic 
is also becoming commonplace in clinical practice, despite no data 
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comparing the effectiveness of combination antipsychotic therapy 
with antipsychotic monotherapy.  Possible reasons for 
antipsychotic polypharmacy include: 1) the availability of more 
newer, atypical antipsychotics; 2) increased clinician comfort with 
these agents as more evidence becomes available; and, 3) clinician 
desire to improve patient outcomes, especially in those patients 
having suboptimal response to a trial of one antipsychotic.  
However, multiple antipsychotic agents can potentially lead to 
increased adverse events and medication costs. 
 
H16: Total cost for antipsychotic prescriptions for children and 
adolescents increases from 1996 to 2001. 
 
Rationale: In a study of children and adolescents enrolled in the Texas 
Medicaid system and receiving an antipsychotic, total 
reimbursement costs increased by 473 percent from $2,278,134 in 
1996 to $13,730,220 in 2000.31  The increase in expenditures was 
related to the increase in total payments for atypical antipsychotics 
(+$11,171,862 during the 5-year period).  It is expected to see the 
same trends in antipsychotic prescription costs for each of the four 
health care systems, as the use of the more expensive, atypical 
antipsychotics increases over time. 
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H17: For each study year, a significant difference in the prevalence rate 
of total antipsychotic use in children and adolescents from 1996 to 
2001 between states exists.  Texas Medicaid has the highest rates 
of total antipsychotic use, followed by Ohio and California. 
 
Rationale: To date, no study has compared prevalence rates of antipsychotic 
use from the states involved in this study.  However, studies have 
shown geographic variation in antipsychotic prescribing.  Using 
data from NAMCS, Hermann and colleagues reported geographic 
variations, as nonfederal physicians in the Northeast (0.9% of 
visits) and South (0.8%) were more inclined to prescribe 
antipsychotics than physicians in the Midwest (0.7%) and West 
(0.5%).98  A similar trend was seen in a study examining the 
prescribing practices of child and adolescent outpatient 
psychiatrists in New York and Ohio.32  Thirty-seven percent of New 
York patients who were medicated received antipsychotic therapy, 







H18: For each study year, a significant difference in the prevalence rate 
of atypical antipsychotic use in children and adolescents from 1996 
to 2001 between states exists.  Texas Medicaid has the highest 
rates of atypical antipsychotic use, followed by Ohio and 
California. 
 
Rationale: Please see rationale provided for H17. 
 
H19: For each study year, a significant difference in the prevalence rate 
of typical antipsychotic use in children and adolescents from 1996 
to 2001 between states exists.  Texas Medicaid has the highest 
rates of typical antipsychotic use, followed by Ohio and California. 
 
Rationale: Please see rationale provided for H17. 
 
H20: For each study year, a significant difference in the prevalence rate 
of total antipsychotic use in children and adolescents from 1996 to 
2001 between public and private insurance systems exists.  
Medicaid states have higher rates of total antipsychotic use 
compared to the Managed Care Organization. 
 
Rationale: In the study by Zito and colleagues, the prevalence of antipsychotic 
use in the mid-Atlantic and midwestern Medicaid states were 
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higher than the prevalence rate of the northwestern group-model 
health maintenance organization (8.0, 5.4, and 1.0 per 1,000 
enrollees, respectively).24 It is possible to see a similar result in 
this study, despite the use of different Medicaid and private 
insurance systems.  
 
H21: For each study year, a significant difference in the prevalence rate 
of atypical antipsychotic use in children and adolescents from 1996 
to 2001 between public and private insurance systems exists.  
Medicaid states have higher rates of atypical antipsychotic use 
compared to the Managed Care Organization. 
 
Rationale: Please see rationale provided for H20. 
 
H22: For each study year, a significant difference in the prevalence rate 
of typical antipsychotic use in children and adolescents from 1996 
to 2001 between public and private insurance systems exists.  
Medicaid states have higher rates of typical antipsychotic use 
compared to the Managed Care Organization. 
 




Phase II: Prescribing practices for antipsychotic agents (TX only) 
 
H23: The number of antipsychotic prescriptions for a child or adolescent 
from primary care physicians (family practice physicians, general 
practice physicians, and pediatricians) increases from 1996 to 
2001. 
 
Rationale: Studies have demonstrated that antipsychotics are commonly 
prescribed by physicians other than child and adolescent 
psychiatrists.21,32,48,49  A shift of provider type may be occurring 
due to a shortage of child and adolescent psychiatrists in the U.S. 
and the emphasis on managed care.  An estimated 30,000 child 
and adolescent psychiatrists are needed to meet the increased 
prevalence of mental disorders and managed care staffing 
models.50  The  emphasis on managed care in Medicaid systems 
may encourage parents to seek initial mental health care from 
primary care physicians.19,51  Given the growing prevalence of 
childhood mental disorders and problems with continuity of care 
between primary and specialty mental health care providers, 
primary care physicians may have limited options other than to 
treat these disorders themselves.  Other factors, including 
reluctance of families to seek psychiatric help, stigma associated 
with mental disorders, and systemic barriers to access,  may 
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contribute to the treatment of pediatric psychiatric and behavioral 
disorders by primary care providers, and perhaps to increased 
medication use.52 
 
H24: The number of antipsychotic prescriptions for a child or adolescent 
from psychiatrists, including child and adolescent psychiatrists, 
increases from 1996 to 2001. 
 
Rationale: Although the number of practicing child and adolescent 
psychiatrists falls short of the demand for services, the prevalence 
of psychiatric and behavioral disorders in youths has increased.  
The rise in the numbers of affected children and adolescents may 
require psychiatrists to manage more patients, especially those 
whose mental illness is severe.  Increased case loads of children 
and adolescents with psychiatric or behavioral problems may 
increase the use of psychotropic medications as compared with 
nonpharmacological interventions.  A study by Pincus and 
colleagues showed an increase in the number of antipsychotic drug 





H25: From 1998 to 2001, antipsychotics are most prescribed for 
disruptive behavioral disorders, such as oppositional defiant 
disorder, conduct disorder, intermittent explosive disorder, and 
attention-deficit hyperactivity disorders. 
 
Rationale: In a study examining current inpatient antipsychotic treatment 
practices, Pappadopulos and colleagues reported that disruptive 
disorders accounted for 33.3 percent of the antipsychotic 
prescribing, followed by depressive (24.0%), bipolar (11.8%), and 
psychotic (11.3%) disorders.47  Antipsychotic prescribing rates 
may be related to the prevalence rates of these psychiatric 
conditions, as disruptive disorders are the most prevalent disorder 
in the pediatric population.7,9  Furthermore, aggressive behaviors 
are common among children and adolescents with disruptive 









Phase III: Relationships of antipsychotic use with patient health care service 
utilization (TX only) 
 
H26: The mean number of inpatient psychiatric hospitalizations per 
child or adolescent receiving antipsychotic treatment decreases 
from 1998 to 2001. 
 
Rationale: The decreased number of psychiatric hospitalizations for children 
and adolescents may be related to the increased use of atypical 
antipsychotics.  Atypical antipsychotics have been shown to reduce 
relapse and rehospitalization rates in adults.57-60  Compared to 
typical antipsychotics, atypical antipsychotics are associated with 
lower risk of rehospitalization over a one-year period.60,114  
Currently, no studies evaluating relapse or rehospitalization in 
children and adolescents are available.  It is unclear whether 
improvements in outcomes in adults treated with atypical 
antipsychotics will be seen in children and adolescents. 
  The number of psychiatric hospitalizations may also be 
affected by the presence of managed care.  From 1988 to 1995, the 
use of psychiatric inpatient care for children and adolescents was 
dramatically affected by the ongoing changes in health insurance 
for youths.  As the role of private insurance decreased and the role 
of Medicaid increased, a 36 percent increase in hospital 
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discharges and a 44 percent decrease in mean length of stay were 
seen during the study period.115  As the penetration of managed 
care continues to increase into state Medicaid systems, it is 
possible to see decreased utilization of inpatient psychiatric 
services to contain health care costs. 
 
H27: The mean number of hospital days per each hospitalized child or 
adolescent receiving antipsychotic treatment decreases from 1998 
to 2001. 
 
Rationale: Treatment with atypical antipsychotics, specifically risperidone 
and olanzapine, has been associated with significant reductions in 
hospital days for admitted adult and elderly patients.116-118  
However, no evidence exists to suggest the same is true in children 
and adolescents.  With regard to this population, several studies 
have demonstrated a decrease in lengths of stay at psychiatric 
inpatient facilities.  Pottick and colleagues reported a 44 percent 
decline in the mean length of stay over an eight-year period, 
translating to a 23 percent decrease in number of bed-days (from 
more than 3 million in 1988 to about 2.5 million in 1995).115  In a 
trend analysis of four-year (1997-2000) service data of privately 
insured children and adolescents, the mean days of inpatient 
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mental health care decreased 20 percent from 14.4 days in 1997 to 
11.5 in 2000.119   
The duration of psychiatric hospitalizations in children and 
adolescents may be affected by severity of illness and 
environmental factors.  Greater severity of psychopathology and 
specific diagnoses, such as post-traumatic stress disorder, have 
been associated with longer lengths of stay.  Living arrangement 
stability, region of hospitalization, and severity of psychosocial 
stressors also affect psychiatric hospitalization length of stay in 
children and adolescents.120-122  For those requiring longer periods 
of inpatient psychiatric care, their lengths of stay may be affected 
by the efforts of managed care to contain costs associated with 
hospitalizations. 
 
H28: The number of children and adolescents receiving assessment 
services, crisis intervention, medication-based services, and service 
coordination increases from 1998 to 2001, while the number of 
children and adolescents receiving counseling and psychotherapy, 
skills training, and supportive mental health services decreases 
from 1998 to 2001. 
 
Rationale: National estimates of mental health care utilization for children in 
1998 suggested that outpatient care accounts for more than 50 
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percent of the service costs.26  Compared to children with other 
types of insurance, children with Medicaid have higher utilization 
rates of outpatient mental health services.26  Furthermore, children 
with disruptive behavioral disorders are perceived by parents as 
having a greater need for mental health care services, and in fact, 
these children are associated with higher rates of service 
utilization.123,124  It is possible, however, that most outpatient 
mental health care visits in Texas Medicaid may be based upon 
pharmacological services, rather than psychosocial services.  This 
shift towards medication-based outpatient treatment modalities 
may result from attempts by managed care organizations to 
contain mental health care costs.  Thus, as antipsychotics are more 
commonly used for children and adolescents with disruptive 
disorders and/or aggression, it is likely that an increase in the use 
of outpatient mental health care due to medication-based 
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H29: The mean duration of enrollment in outpatient services for 
assessment services, crisis intervention, medication-based services, 
and service coordination increases among children and adolescents 
receiving an antipsychotic from 1998 to 2001.  The mean duration 
of enrollment in outpatient services for counseling and 
psychotherapy, skills training, and supportive mental health 
services decreases among children and adolescents receiving an 
antipsychotic from 1998 to 2001. 
 
Rationale: In the NIMH MECA Study, 8.1 percent of the subjects received 
school-based mental health services, which was equivalent to the 
percent of subjects receiving services from a community-based, 
mental health specialist.125  Psychotherapy, including behavioral 
management interventions, has been shown to be effective for 
childhood disorders, including disruptive behaviors.81  Among 
privately insured children and adolescents with psychiatric or 
behavioral disorders, the use of psychotherapy increased from 3.3 
visits in 1997 to 4.0 visits in 2000.119  However, it is difficult to 
assume that these findings by Martin and Leslie would translate to 
the public insurance system.  With the presence of managed care in 
Medicaid systems, it is possible that pharmacological services may 
serve as a substitute for nonpharmacological interventions to save 
health care dollars.   Given the frequent use of antipsychotics for 
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disruptive disorders among Medicaid youths, it is possible that the 
role of school-based and behavioral management interventions 
may decrease as medication-based outpatient treatment services 
become the majority of the types of outpatient services provided. 
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Chapter Two reports the methods used to evaluate trends of antipsychotic 
use in children and adolescents from 1996 to 2001.  The methods and relevant 
statistical analyses are detailed according to the phases: (1) trends in antipsychotic 
use in children and adolescents; (2) prescribing practices for antipsychotic agents; 
and, (3) relationships of antipsychotic use to service utilization. 
Descriptions of the Medicaid and managed care populations are provided, 
with an emphasis on children and adolescents enrolled in the systems.  Sources 
from which data were collected are discussed, as well as the types of data 
collected from the databases.  A complete description of the statistical analyses 
for each phase follows.  Finally, the advantages and disadvantages of database 
research, particularly with regard to Medicaid databases, are discussed. 
 
The Use of Human Subjects and Related Issues 
Inclusion criteria required patients to be less than 20 years of age, enrolled 
in one of three Medicaid systems (California, Ohio, or Texas) or a private 
managed care organization, and have been prescribed an antipsychotic 
medication.  There were no exclusion criteria with regard to diagnoses, gender, 
ethnicity, or other concurrent medications. 
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The use of "human subjects" was necessary to conduct the current study.  
As this research did not involve direct human subject contact, a waiver of 
informed consent was approved by the Institutional Review Boards at The 
University of Texas at Austin (UT IRB) and TDMHMR (TDMHMR IRB).  The 
research represented no more than minimal risk to the subjects, the waiver did not 
affect the rights and welfare of the subjects, and the research could not have 
practicably been carried out without the waiver.  Potential loss of confidentiality 
was the only known potential risk associated with this research, and safeguards 
were taken to minimize this potential risk. 
The only identified potential risk was breech of confidentiality.  No 
potential physical, psychological, social, legal, or other risks existed for the 
subjects.  Data containing patient identifiers were stored on The University of 
Texas at Austin (UT) Center for Pharmacoeconomics server to ensure data 
security.  All patient identifiers included within the collected data were removed 
after the Medicaid pharmacy and service utilization data were merged.  Dummy 
patient codes were assigned in place of patient identifiers.  Dummy codes were 
also assigned for specific states, as well as for type of service provider.  De-
identified data were stored on the UT Center for Pharmacoeconomics server, 
which again served to provide data security and restricted access.  M. Lynn 
Crismon, Pharm.D. and Michael Johnsrud, Ph.D. reviewed and audited the data to 
ensure that patient confidentiality was maintained throughout the duration of the 
study.  The dissertation and manuscripts resulting from the research contain only 
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de-identified data.  No additional analyses will be performed on this data unless 
additional approvals are obtained from the UT IRB or the TDMHMR IRB. 
The protocol for this study received initial approval on August 21, 2002 
from the UT IRB (Protocol #2002-07-0047).  On June 11, 2003, the research 
study was re-approved for another year by the UT IRB.  On March 31, 2004, the 
protocol for this study received initial approval from the TDMHMR IRB 
(Protocol #655-25-0401).  Annual reviews and a final study report were submitted 
to the UT IRB and TDMHMR IRB upon completion. 
 
The Medicaid Program 
The Medicaid program is the largest single source of health insurance in 
the U.S., serving millions of children and adolescents under the age of 21 years.1  
Eligibility for Medicaid assistance is based upon financial and categorical 
eligibility requirements.  First, beneficiaries of Medicaid must be low-income and 
meet certain resource standards, which are established by individual states.  
Additionally, income and resource requirements may differ for specific 
population groups within a state.  Table 2.1 (page 122) details populations for 
which states are required to provide Medicaid assistance and those for which 
states have the option to provide insurance coverage. 
For those populations which are provided insurance coverage, state 
Medicaid programs are required to provide coverage for a number of mandatory 
services, and have the option to provide additional services.1  Furthermore, states 
determine the amount of coverage, such as duration and scope, within specific 
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service categories.  Table 2.2 (page 123) provides a complete listing of the 
mandatory and optional services provided in state Medicaid programs. 
 
Table 2.1. Medicaid Eligibility Criteria (Required and State Optional)1 
Required Coverage  
Aid to Families with Dependent Children 
(AFDC) Eligible individuals as of July 16, 
1996 
Current and some former recipients of 
Supplemental Security Income (SSI) 
Poverty-related groups (all pregnant 
women and children below age 6 with 
incomes up to 133 percent of the federal 
poverty level [FPL]) 
Foster care and adoption assistance 
All children born after September 30, 1983 
with incomes up to 100 percent FPL 
Certain Medicare beneficiaries (Qualified 
Medicare Beneficiaries [QMBs] and 
Specified Low-Income Medicare 
Beneficiaries [SLMBs]) 
Optional Coverage  
Poverty-related groups (certain higher-
income pregnant women and children) 
Long-term care (individuals receiving 
long-term care with incomes less than 300 
percent of the SSI payment level) 
Medically needy (individuals categorically 
meeting eligibility criteria and have income 
and resources within “medically needy” 
limits determined by the state) 
Working disabled (individuals who are 
disabled as defined by the Social Security 
Administration) 








Table 2.2. Medicaid Covered Services (Mandatory and State Optional)1 
Mandatory Services   
Inpatient hospital services Nurse practitioners’ services Physicians’ services 
Outpatient hospital services Nursing facility (NF) 
services and home health 
services for individuals 21 
years or older 
Medical and surgical 
services of a dentist 
Rural health clinic and 
Federally Qualified Health 
Center (FQHC) services 
Early and periodic 
screening, diagnosis, and 
treatment (EPSDT) for 
individuals less than 21 
years old 
Nurse-midwife services 
Laboratory and X-ray 
services 
Family planning services  
Optional Services   
Podiatrists’ services Dentures Personal care services 
Optometrists’ services Prosthetic devices Transportation services 
Chiropractors’ services Eyeglasses Case management services 
Psychologists’ services Diagnostic services Hospice care services 
Medical social worker 
services 
Screening services Respiratory care services 
Nurse anesthetists services Preventive services Tuberculosis-related services 
Private duty nursing Rehabilitative services Inpatient and NF services for 
individuals older than 65 
years in institutions for 
mental diseases (IMD) 




Dental services Inpatient psychiatric services 
for under age 21 
 
Physical therapy Christian Science Nurses  
Occupational therapy Christian Science 
Sanitoriums 
 
Speech, hearing and 
language disorders 
Nursing facility (NF) 
services for under age 21 
 
Prescription drugs Emergency hospital services  
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Medicaid is the largest children’s health program in the U.S., serving over 
20 percent of all children and adolescents annually.  In fiscal year (FY) 1996, 23.1 
million children and adolescents under the age of 21 years were enrolled in state 
Medicaid programs, accounting for 56.6 percent of all Medicaid enrollees.  
Among these youths insured by Medicaid, children less than six years old 
comprised 43.6 percent, and children and adolescents between the ages of six and 
20 years constituted 56.4 percent.  Medicaid coverage in 1996 was most 
prominent for white, non-Hispanic youths (40.9%), followed by black, non-
Hispanic (29.1%) and Hispanic (20.8%).  Per recipient, Medicaid expenditures for 
all services averaged $1,486 during 1996.  The average cost per recipient of 
mental health care in 1996 was $19,300; the percentage of Medicaid children and 
adolescents using mental health care services was less than 0.5 percent.2 
In FY 2000, over 24 million children and adolescents less than 20 years 
old were enrolled in Medicaid, representing 54.6 percent of all enrollees.  Similar 
to 1996, children under the age of six years accounted for a large portion of 
enrollment at 40.3 percent.  Although the average Medicaid expenditures for all 
services increased to $1,766 per recipient, the average cost per recipient of mental 
health care decreased slightly to $18,193.  Among enrolled youths, 0.3 percent 
used mental health care services in 2000.2 
Children and Adolescents Enrolled in the California Medi-Cal Program 
In California, children and adolescents comprise a significant portion of 
all Medi-Cal enrollees each year.  In FY 1996, 3,682,510 youths were enrolled 
under Medi-Cal, representing 55.6 percent of all enrollees.  Children and 
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adolescents between the ages of six and 20 years make up 60.3 percent, and those 
under the age of six years constitute 39.7 percent.  With regard to ethnicity, most 
enrollees were Hispanic (50.7%), followed by white, non-Hispanic (24.4%) and 
black, non-Hispanic (13.5%).  Medi-Cal expenditures for all services averaged 
$622 per enrollee under 21 years of age, while the average mental health care 
expenditures per user of these types of services were $48,324.  Less than 0.5 
percent of the Medi-Cal youth enrollees used mental health care services.2 
In FY 2000, over 3.8 million children and adolescents were enrolled in 
Medi-Cal, which was a 48 percent increase over FY 1996 enrollment.  Despite an 
increase in total enrollment of youths, this population represented 47.7 percent of 
all Medi-Cal enrollees.  Children and adolescents between six and 20 years old 
accounted for 67.5 percent of all enrollees less than 21 years of age.  An increase 
in average Medi-Cal expenditures per recipient from FY 1996 ($622) to FY 2000 
($1,329) was seen.  Less than 0.05 percent of youths used mental health services, 
and the average expenditures for these services per user was $14,289.2 
Children and Adolescents Enrolled in the Ohio Medicaid Program 
Enrollment of children and adolescents in the Ohio Medicaid program 
accounts for a significant portion of total enrollment.  In FY 1996, 877,582 youths 
enrolled in Ohio Medicaid, representing 56.9 percent of all enrollees.  Fifty-six 
percent of enrollees under 21 years old were between the ages of six and 20 years, 
and 44.2 percent were under the age of six.  Most Ohio Medicaid children and 
adolescents were white, non-Hispanic (59.8%), followed by black, non-Hispanic 
(35.5%) and Hispanic (2.9%).  The average Ohio Medicaid expenditures for all 
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services per recipient in 1996 were $1,315.  Ohio Medicaid spent an average of 
$5,719 on mental health care services per user.  Less than 0.5 percent of youths 
enrolled in Ohio Medicaid used mental health services.2 
Enrollment numbers of children and adolescents in FY 2000 saw a 
decrease, as 822,277 youths were enrolled in Ohio Medicaid.  Children and 
adolescents between six and 20 years of age were the majority (62.8%).  The 
average expenditures for all services per recipient increased to $1,818, and the 
expenditures per user of mental health care increased to $5,180.  Like FY 1996, a 
small percentage (0.1%) of Ohio Medicaid enrolled youths used these types of 
services.2 
Children and Adolescents Enrolled in the Texas Medicaid Program 
In FY 1996, more than 1.8 million children and adolescents under the age 
of 21 years were enrolled in Texas Medicaid.  This group accounted for the 
majority of all enrollees (64.3%).  Children younger than six years were most 
prominent (51.7%), followed by youths who were six to 20 years old (48.3%).  
The ethnic stratification was similar to California, as Hispanics represented 53.4 
percent, white non-Hispanic 23.3 percent, and black, non-Hispanic 21.1 percent.  
The average Texas Medicaid expenditures for all services were $1,215 per 
recipient in FY 1996.  No data were reported with regard to expenditures and 
percentage of users of mental health care services.2 
Over 1.7 million youths were enrolled in FY 2000, and represented 63.1 
percent of all Texas Medicaid enrollees.  Children and adolescents between six 
and 20 years old comprised 53.9 percent of enrollees under the age of 21 years.  
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As was seen in California and Ohio, there was an increase in expenditures for all 
services per recipient from FY 1996 ($1,215) to FY 2000 ($1,694).  
Approximately 0.3 percent of Texas Medicaid youths used mental health care, 
and the average expenditures per user were $6,255.2 
 
The Private Managed Care Organization 
The private managed care organization is a large, publicly traded health 
benefits company with over 6.5 million members from 18 states and Puerto Rico.  
The private managed care organization provides health insurance coverage and 
related services through administrative services products, preferred provider 
organizations, consumer-directed plans, health maintenance organizations, 
government-sponsored plans, plans for U.S. military dependents and trainees, and 
individuals. 
In the commercial group health maintenance organization (HMO) plans, 
pre-paid health care services are provided to members either by: 1) primary care 
and specialty physicians employed by the HMO at facilities owned and operated 
by the private managed care organization; or, 2) a network of independent 
primary care and specialty physicians and other health care providers who are 
contracted by the private managed care organization to provide health care 
services.  Access to other health care providers is regulated by the primary care 
physician, who is typically a family practitioner, internist, pediatrician, or 
obstetrician/gynecologist.  Examples of other health care providers in the HMO 
plans include ambulatory surgical centers, dentists, diagnostic centers, durable 
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medical equipment suppliers, home health agencies, hospitals, mental health and 
substance abuse centers, nursing homes, optometrists, pharmacies, and urgent 
care centers. 
In the commercial group preferred provider organizations (PPO), a 
member is encouraged to obtain health care services from preferred health 
providers.  These providers are contracted by the private managed care 
organization to provide services at favorable rates.  Unlike the HMO plans, the 
member has the ability to choose a physician or other health care provider without 
having to get approval from a primary care physician or “gatekeeper”. 
Approximately 72 percent of the members of the private managed care 
organization belong to the commercial HMO or PPO plans.  The remaining 
members belong to Medicare plans (17%) and specialty and administrative 
services (7%). 
No data were accessible to characterize the child and adolescent 
population enrolled in this private managed care organization. 
 
Study Design 
This study retrospectively evaluated prescription and service utilization 
claims records for children and adolescents less than 20 years of age with at least 
one prescription claim for an antipsychotic from 1996 to 2001.  In Phase I of the 
study, enrollee and pharmacy data from three Medicaid states (California, Ohio, 
and Texas) and one private managed care organization were used to determine the 
prevalence of antipsychotic use in youths.  Texas Medicaid pharmacy data and 
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TDMHMR CARE service utilization data were used during Phase II to identify 
provider specialties and diagnoses, respectively, associated with antipsychotic 
prescribing.  In Phase III, relationships between antipsychotic use and the 
utilization of mental health services were evaluated using TDMHMR CARE 
service utilization data. 
Inclusion/Exclusion Criteria 
All children and adolescents under the age of 20 years with at least one 
prescription claim for an antipsychotic from 1996 to 2001 were eligible for this 
study.  Subjects receiving typical and/or atypical antipsychotics were considered 
eligible (Table 2.3, page 130).  Antipsychotics of all dosage forms (oral, liquid, 
short-acting injectable, and depot formulations) were included in the data set.  No 
limits on the duration of antipsychotic treatment or daily dose of antipsychotic 
medication existed.  It must be noted, however, that no data were collected for 
aripiprazole (Abilify™) and ziprasidone (Geodon®), as these agents were 
introduced to the market after the designated study period. 
Subjects with any diagnosis were included, as well as subjects with any 
number of concomitant psychotropic medications.  Childhood and adolescent 
psychiatric and behavioral diagnoses for which antipsychotics are commonly used 
are provided in Chapter One (Table 1.9, page 41).  Concomitant psychotropic 
medications allowed in this study are listed in Table 2.4 (pages 131-133).  Any 
child or adolescent without a Medicaid prescription claim for an antipsychotic 
were not eligible for this study.  No exclusion criteria based upon race/ethnicity, 
gender, or socioeconomic status existed for this study. 
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Table 2.3. Typical and Atypical Antipsychotic Medications 
Typical Antipsychotics Atypical Antipsychotics 
Chlorpromazine (generic, Thorazine®) Aripiprazole (Abilify™) 
Fluphenazine (generic, Permitil®, 
Prolixin®, decanoate) 
Clozapine (generic, Clozaril®) 
Haloperidol (generic, Haldol®, decanoate) Olanzapine (Zyprexa®) 
Loxapine (generic, Loxitane®) Quetiapine (Seroquel®) 
Mesoridazine (Serentil®) Risperidone (Risperdal®) 
Molindone (Moban®) Ziprasidone (Geodon®) 
Perphenazine (generic, Trilafon®)  
Pimozide (Orap®)  
Thioridazine (generic, Mellaril®)  
Thiothixene (generic, Navane®)  
Trifluoperazine (generic, Stelazine®)  










Table 2.4. Concomitant Psychotropic Medications 
Antidepressants Alpha-Agonists 
Amitriptyline (generic, Elavil®, Endep®) Clonidine (generic, Catapres®) 
Amoxapine (generic, Asendin®) Guanabenz (generic) 
Bupropion (generic, Wellbutrin®, 
Wellbutrin® SR) 
Guanfacine (generic, Tenex®) 
Citalopram (Celexa™) Anti-Parkinsonians 
Clomipramine (generic, Anafranil®) Amantadine (generic, Symmetrel®) 
Doxepin (generic, Sinequan®) Benztropine (generic, Cogentin®) 
Desipramine (generic, Norpramin®) Biperiden (Akineton®) 
Fluoxetine (Prozac®, Prozac Weekly®, 
Sarafem®) 
Trihexylphenidyl (generic, Artane®) 
Fluvoxamine (generic, Luvox®) Anxiolytics/Hypnotics, Non-Benzodiazepines 
Imipramine (generic, Tofranil®) Amobarbital/secobarbital (Tuinal®) 
Maprotiline (generic, Ludiomil®) Buspirone (generic, BuSpar®) 
Mirtazapine (Remeron®, Remeron® Sol-
Tab) 
Butabarbital (generic, Butisol Sodium®) 
Nefazodone (Serzone®) Chloral hydrate (generic) 
Nortriptyline (generic, Aventyl® HCl, 
Pamelor®) 
Diphenhydramine (generic, Benadryl®) 
Paroxetine (Paxil®, Paxil® CR™) Hydroxyzine (generic, Atarax®, 
Vistaril®) 
Phenelzine (Nardil®) Meprobamate (generic, Equanil®, 
Miltown®) 
Protriptyline (generic, Vivactil®) Pentobarbital (generic, Nembutal®) 
Sertraline (Zoloft®) Secobarbital (generic, Seconal®) 
Tranylcypromine (Parnate®) Zaleplon (Sonata®) 
Trazodone (generic, Desyrel®) Zolpidem (Ambien®) 
Trimipramine (Surmontil®)  




Table 2.4. Concomitant Psychotropic Medications (Cont.) 
Benzodiazepines Psychostimulants 
Alprazolam (generic, Xanax®) Amphetamine/dextroamphetamine 
(generic, Adderall®, Adderall™ XR) 
Chlordiazepoxide (generic, Librium®) Dexmethylphenidate (Focalin™) 
Clonazepam (generic, Klonopin®) Dextroamphetamine (generic, 
Dexedrine®) 
Clorazepate (generic, Tranxene SD®, 
Tranxene® T-Tab) 
Methylphenidate (generic, Concerta™, 
Metadate® CD, Metadate™ ER, 
Methylin™, Methylin™ ER, Ritalin®, 
Ritalin® LA, Ritalin SR®) 
Diazepam (generic, Dizac®, Valium®) Pemoline (generic, Cylert®) 
Estazolam (generic, ProSom®) Substance Abuse 
Flurazepam (generic, Dalmane®) Buprenorphine (Subutex®) 
Lorazepam (generic, Ativan®) Buprenorphine/naloxone (Suboxone®) 
Midazolam (generic, Versed®) Bupropion (Zyban®) 
Oxazepam (generic, Serax®) Disulfiram (generic, Antabuse®) 
Prazepam (generic, Centrax®) Mecamyline (Inversine®) 
Temazepam (generic, Restoril®) Methadone (generic, Dolophine®) 
Triazolam (generic, Halcion®) Naltrexone (generic, ReVia®) 
Mania/Bipolar Nicotine transdermal (generic, Nicotrol® 
Patch, NicoDerm® CQ) 
Carbamazepine (generic, Carbatrol®, 
Tegretol®, Tegretol® XR) 
 
Divalproex sodium (Depakote®, 
Depakote® ER, Depakote® Sprinkle®) 
 
Gabapentin (Neurontin®)  
Lamotrigene (Lamictal®)  
Lithium (generic, Eskalith®, Eskalith®-CR, 
Lithobid®, Lithonate®) 
 
Oxcarbazepine (Trileptal®)  
Topiramate (Topamax®)  
Valproic acid (generic, Depakene®)  
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Table 2.4. Concomitant Psychotropic Medications (Cont.) 
Other Psychotropics  
Amitriptyline/chlordiazepoxide (generic, 
Limbitrol®, Limbitrol® DS) 
Phenytoin (generic, Dilantin®) 
Amitriptyline/perphenazine (generic, 
Etrafon®, Triavil®) 
Pindolol (generic, Visken®) 
Ethosuxamide (generic, Zarontin®) Propranolol (generic, Inderal®) 
Felbamate (Felbatol®) Tiagabine (Gabatril®) 
Levetiracetam (Keppra®) Zonisamide (Zonegran®) 
Metoprolol (generic, Lopressor®)  
 
Medicaid Data Sources: Enrollee, Pharmacy, and Service Utilization 
Databases 
Medicaid Enrollee Databases 
In Texas, Medicaid enrollee data (1996 to 2001) were collected with the 
assistance of the Research and Forecasting Department of the Texas HHSC.  
Using their comprehensive databases, total enrollment of children and 
adolescents, less than 20 years of age, was defined as the December enrollment 
for each study year.  This assumed a balance between patient additions and 
withdrawals in enrollment in the Texas Medicaid system.  Enrollee data for the 
California Medicaid system were collected from RAND California, and enrollee 
data for the Ohio Medicaid system were licensed from Constella Health 
Strategies.  Enrollee data were collected in the following enrollment categories: 
total, male, female, and age-specific (<2, 2-4, 5-9, 10-14, and 15-19 years) (Table 
2.5, page 134).  The age strata are based upon the U.S. census categories.3   
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Table 2.5. Enrollment Categories for Medicaid Children and Adolescentsa 
 TOTAL Male Female <2 y 2-4 y 5-9 y 10-14 y 15-19 y 
1996         
1997         
1998         
1999         
2000         
2001         
a y = years. 
 
Infants below the age of one year were captured using zero years as the initial age.  
Patient ages provided on prescription claims records were confirmed using those 
provided on service utilization records to ensure age-related data integrity.  Data 
were categorized on a state basis, as differences in the eligibility criteria of 
individual state Medicaid systems limit the ability to pool state data into a 
national sample. 
Medicaid Pharmacy Databases 
Medicaid pharmacy databases provided prescription claims records for 
individuals enrolled in each state system.  Prescription claims records were 
organized according to date, age, gender, and specific antipsychotic prescribed.  
Antipsychotic subclasses included both typical and atypical antipsychotics, and all 
dosage forms, including short-acting injectables and decanoates, were included in 
the data set (Table 2.3, page 130).  Other pertinent information collected from the 
Medicaid pharmacy databases included daily dose of antipsychotic therapy, rates 
of antipsychotic switching, concomitant psychotropic medications (Table 2.4, 
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pages 131-133), reimbursement cost for each prescription claim, prescriber 
identification number, and prescriber specialty.  Pharmacy data for the California 
and Texas Medicaid systems were collected from academic institutions licensed 
to use these data (The University of Southern California [Jeff McCombs, Ph.D.] 
and The University of Texas at Austin [Michael T. Johnsrud, Ph.D.]) with 
permission of the respective state Medicaid agencies.  Pharmacy data for the Ohio 
Medicaid system were licensed from Constella Health Strategies. 
TDMHMR CARE Service Utilization Databases 
The CARE database consists of limited client-specific data for all persons 
receiving services from TDMHMR.  Over the last eight years, approximately 
18,000 children and adolescents per year received public mental health services.  
Youths are from lower income families, more males, and primarily between the 
ages of six and 18 years.  Forty percent of children and adolescents receiving 
public mental health services are Caucasian, followed by Hispanic (35%) and 
African-American (20%).  A percentage of Texas Medicaid youths with 
psychiatric or behavioral problems receive mental health services through the 
TDMHMR system, and therefore, are tracked by CARE. 
CARE collects demographic and diagnostic information, and records of 
treatment services, including inpatient psychiatric hospitalizations at state 
facilities and outpatient mental health services.  CARE service utilization data 
include enrollment in different types of outpatient mental health services: 
Assessment Services (TC08), Counseling and Psychotherapy (TC13); Crisis 
Intervention (In-Home [TC01], Inpatient [TC07], Therapeutic Foster Care 
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[TC09], Other Residential Services [TC17], and Acute Day Treatment [TC20]); 
Medication-related Services (TC04); Service Coordination (TC06); Skills 
Training (Rehabilitative Day Treatment [TC03], Individual [TC10], Family 
[TC19]); and, Supportive Services (Respite [TC05], Family-Focused Services 
[TC23], and Flexible Community Support [TC24]).  The TDMHMR CARE 
service utilization database was obtained through Alan Shafer, Ph.D., and served 
as the data source for Phase II (diagnostic) and III analyses. 
 
Private Managed Care Organization Data Sources: Enrollee and Pharmacy 
Databases 
Enrollee and pharmacy data for the private managed care organization 
were licensed from Constella Health Strategies.  Similar to Medicaid enrollment 
data, the month of December was used to determine enrollment and these counts 
served as a proxy for the entire calendar year.  Enrollee data were collected in the 
following enrollment categories: total, male, female, and age-specific (<2, 2-4, 5-
9, 10-14, and 15-19 years) (Table 2.5, page 134). 
Prescription claims records were organized according to date, age, gender, 
and specific antipsychotic prescribed.  Antipsychotic subclasses included both 
typical and atypical antipsychotics, and all dosage forms, including short-acting 
injectables and decanoates, were included in the data set (Table 2.3, page 130).  
Other pertinent information collected from the private managed care organization 
pharmacy database included daily dose of antipsychotic therapy, rates of 
 137
antipsychotic switching, concomitant psychotropic medications (Table 2.4, pages 
131-133), and allowable charges for the antipsychotic prescription. 
 
Study Measures 
Phase I: Trends in the prevalence of antipsychotic use in children and 
adolescents (1996 to 2001) 
The study measures evaluated in Phase I of this research were similar to 
those evaluated in a previous pharmacoepidemiological studies of psychotropic 
medication use in children and adolescents.3-5  All analyses were conducted for 
each health system (three Medicaid states and one private managed care 
organization). 
Prevalence is defined as the number of children and adolescents with at 
least one prescription claim for an antipsychotic agent, regardless of subclass, per 
1,000 enrolled children and adolescents under the age of 20 years.  Trends in 
prevalence were assessed over a seven-year period (1996 to 2001) using annual 
descriptive analyses.  In addition to total prevalence, rates for typical and atypical 
antipsychotic use were calculated.  Prevalence rates of specific atypical 
antipsychotic (clozapine, olanzapine, quetiapine, and risperidone) use were 
calculated.  Age-specific prevalence was determined using the age strata 
described previously (<2, 2-4, 5-9, 10-14, and 15-19 years of age).  Gender-
specific prevalence rates were determined using male and female stratifications. 
Some children and adolescents may have received more than one 
antipsychotic during the same calendar year.  In determining the prevalence rate 
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for total antipsychotic use during a given year, these youths contributed a single 
case to the numerator.  If a child or adolescent received a typical and an atypical 
antipsychotic during the same calendar year, he or she contributed a single case to 
both numerators of the prevalence rates for typical and atypical antipsychotics.  If 
a youth received two different typical antipsychotics during the same calendar 
year, he or she contributed a single case to the numerator for the determination of 
prevalence of typical antipsychotic use.  If a youth received two different atypical 
antipsychotics during the same calendar year, he or she contributed a single case 
to the numerator for the determination of prevalence of atypical antipsychotic use.  
However, for youths who received multiple atypical antipsychotics, a single case 
was added to all numerators of the prevalence rates for specific atypical 
antipsychotics.   
Daily dose of antipsychotic prescribed was calculated for age-specific 
groups (<2, 2-4, 5-9, 10-14, and 15-19 years of age) using pharmacy data.  To 
determine daily dose for each prescription record, the quantity dispensed was 
multiplied by the drug strength, and this product was divided by the days supply 
field.  Due to potential errors in the ‘days supply’ field, 5 percent of the dosing 
range (2.5% on each end) was recoded as ‘system-missing’.  The missing values 
were replaced with the mean daily dose of that particular individual.  Table 2.6 
(page 139) provides specific atypical antipsychotic dosing ranges which included 
95 percent of the total sample.  Average daily doses were calculated for specific 
atypical antipsychotics and examined for appropriateness based upon established 
efficacy dosing ranges. 
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Table 2.6. Age-Specific Dosing Ranges (95%) of Atypical Antipsychoticsa,b 
Program Age Group (y) Olanzapine Quetiapine Risperidone 
CA <2  2.50 – 40.00 25.00 – 606.06 0.25 – 8.00 
 2-4  2.50 – 30.30 25.00 – 800.00  0.25 – 7.50 
 5-9  2.50 – 20.00 25.00 – 642.86 0.25 – 6.00 
 10-14  2.50 – 20.67 25.00 – 900.00 0.50 – 7.00 
 15-19  2.50 – 30.00 25.00 – 900.00 0.50 – 9.00 
OH <2  0.83 – 20.00 5.83 – 300.00 0.12 – 6.00 
 2-4  1.25 – 15.00 11.67 – 400.00 0.25 – 4.00 
 5-9  1.25 – 15.00 20.83 – 400.00 0.25 – 4.00 
 10-14  0.83 – 20.00 13.33 – 600.00 0.25 – 6.00 
 15-19  0.67 – 20.00 11.67 – 666.67 0.17 – 6.13 
TX <2  1.25 – 15.00 6.25 – 400.00 0.25 – 5.00 
 2-4  1.25 – 15.00 25.00 – 400.00 0.25 – 5.00 
 5-9  2.50 – 20.00 25.00 – 500.00 0.25 – 6.00 
 10-14  2.50 – 25.00 25.00 – 600.00 0.50 – 6.00 
 15-19  2.50 – 30.00 25.00 – 800.00 0.50 – 8.00 
MCO <2  2.50 – 25.00 50.00 – 600.00 0.50 – 8.00 
 2-4  1.25 – 20.00 25.00 – 800.00 0.25 – 6.00 
 5-9  2.50 – 20.00 25.00 – 600.00 0.25 – 4.50 
 10-14  2.50 – 20.00 25.00 – 800.00 0.50 – 6.00 
 15-19  2.50 – 20.00 25.00 – 800.00 0.50 – 8.00 
aAll doses reported in milligrams per day. 
bAbbreviations: CA=California Medi-Cal; MCO=Managed Care Organization; OH=Ohio Medicaid; 
TX=Texas Medicaid; y=years. 
 
Rates of switching antipsychotic therapy were evaluated as markers of 
poor outcome.  A switch in antipsychotic treatment occurred when the patient 
received one prescription for a certain antipsychotic, then received a prescription 
for different antipsychotic within 30 days of the end of the treatment period of the 
previous prescription.  The presence of any further prescriptions for the first 
antipsychotic did not constitute a switch in antipsychotic therapy.  The treatment 
period for each prescription was defined as the dispensing date plus the days 
supply of the prescription.  The percent of patients who switched antipsychotics, 
the number of switches per patient, and types of antipsychotics switches were 
determined for each calendar year. 
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Concomitant psychotropic medication use was examined and included 
alpha agonists, anticonvulsant/ mood stabilizers, antidepressants, 
benzodiazepines, psychostimulants, and others (i.e., sedative-hypnotics, etc.).  
Other psychotropic medications were considered concomitant if their 
administration overlaps with the antipsychotic treatment period.  Prevalence rates 
of multiple antipsychotic use among children and adolescents receiving an 
antipsychotic were also examined.  Antipsychotic polypharmacy was defined as a 
child or adolescent being treated with two different antipsychotics concurrently 
for a period of 30 days or more. 
Expenditures for antipsychotic prescriptions (total and antipsychotic 
subclass) for children and adolescents were calculated and annual trends in cost 
were assessed.  Consumer price indices for medical care services from 1996 to 
2001 were obtained from the U.S. Bureau of Labor Statistics.  Costs associated 
with antipsychotic prescriptions were adjusted to 2001 prices to account for 
increases in medical care inflation (Table 2.7, page 140). 
 
Table 2.7. Cost-adjustments based upon Medical Care Services Consumer Price 
Indicies7 
Year Medical Care Services CPI Percent adjustment to 2001 prices 
1996 232.4 20.0% 
1997 239.1 16.6% 
1998 246.8 13.0% 
1999 255.1 9.3% 
2000 266.0 4.8% 
2001 278.8 - 
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Table 2.8 (pages 141-142) summarizes the study measures, database 
sources, and corresponding data fields used to complete Phase I analyses. 
 
Table 2.8. Study Measures and Corresponding Data for Phase I Analyses 
Study Measure Database Source(s) Specific Data Field(s) Comments 
Prevalence of total, 





Total number of 
enrolled children and 
adolescents 
Specific atypical 





 Pharmacy (Medicaid, 
Managed Care) 
Total number of 
children and 
adolescents with a 




prevalence of total, 





Total number of 
enrolled children and 
adolescents 
Age categories: <2  y, 
2-4 y, 5-9 y, 10-14 y, 
and 15-19 y 
 Pharmacy (Medicaid, 
Managed Care) 
Total number of 
children and 
adolescents with a 
prescription claim for 
any antipsychotic 




prevalence of total, 





Total number of 
enrolled children and 
adolescents 
Gender categories: 
male and female 
 Pharmacy (Medicaid, 
Managed Care) 
Total number of 
children and 
adolescents with a 









Table 2.8. Study Measures and Corresponding Data for Phase I Analyses 
(Cont.) 
 







quantity, and days 
supply 
Age categories: <2  y, 
2-4 y, 5-9 y, 10-14 y, 
and 15-19 y; daily 









records for an 
individual, 
prescription end date, 
and days supply 
Presented as the 
number of children 
and adolescents 













medication use also 













Total number of 
children and 
adolescents with a 
prescription claim for 
any antipsychotic 
Defined as a child or 
adolescent being 
treated with two 
different 
antipsychotics 
concurrently for a 
period of 30 days or 
more 
 Pharmacy (Medicaid, 
Managed Care) 
Total number of 
children and 
adolescents with 




Cost for prescriptions 








Phase II: Prescribing practices for antipsychotic agents 
Diagnostic and provider specialty information were analyzed in Phase II 
of this study using Texas Medicaid pharmacy and TDMHMR CARE service 
utilization data.  Diagnoses were classified according to the following categories, 
modified from those proposed by Pappadopulos and colleagues:  
• Anxiety disorders (adjustment, anxiety disorder not otherwise 
specified [NOS], generalized anxiety, obsessive-compulsive, 
panic, post-traumatic stress, separation anxiety, and social phobia); 
• Bipolar disorders (bipolar I, bipolar II, bipolar with psychosis, and 
cyclothymic disorder); 
• Depressive disorders (dysthymia, major depressive, major 
depressive with psychosis, and mood disorder NOS);  
• Disruptive disorders (attention-deficit hyperactivity [all types], 
conduct, intermittent explosive, and oppositional defiant;  
• Psychotic disorders (psychotic disorder NOS, schizoaffective, and 
schizophrenia, schizophreniform);  
• Substance abuse disorders (alcohol, cannabis, and polysubstance); 
• Developmental disorders (mental retardation and pervasive 
developmental disorders); 
• Other psychiatric disorders (disorders not specific to childhood); 
and, 
• Other childhood psychiatric disorders (communicative disorders, 
encopresis, enuresis, learning disorders).6 
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Children and adolescents diagnosed with more than one disorder falling in 
the same category were assigned one diagnosis.6  Youths with multiple diagnoses 
were assigned one diagnosis for each distinct category.  The principal diagnosis 
assigned with TDMHMR CARE service utilization was used for the purpose of 
diagnostic classification for subanalyses of service utilization.  It was also 
possible that a child or adolescent receiving an antipsychotic may not have an 
associated psychiatric or behavioral diagnosis, and these youths were categorized 
as “no psychiatric or behavioral diagnosis.” 
Physician specialty was classified using the following categories: 
• Neurology (including child neurology); 
• Primary Care (including family practice, general practice, and 
pediatrics); 
• Psychiatry (including child and adolescent psychiatry); 
• Other; or, 
• Unspecified. 
Provider specialty was collected from the Texas Medicaid pharmacy data.  
Each claim provides a field indicating a state-assigned provider identification 
number.  Using the Texas Medicaid Drug Vendor Program’s prescriber 
directories, the specialty of prescribing physician was determined.  Once the 
specialty of prescriber was identified, a dummy code was assigned based upon the 
above specialties. 
Annual analyses of diagnosis were conducted only for Texas Medicaid 
youths receiving mental health services in the TDMHMR system.  Annual 
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analyses of provider type examined all Texas Medicaid youths receiving an 
antipsychotic.  Additional analyses in Phase II evaluated diagnostic and provider 
information according to age strata. 
Table 2.9 (page 145) summarizes the study measures, database sources, 
and corresponding data fields used to complete Phase II analyses. 
 
Table 2.9. Study Measures and Corresponding Data for Phase II Analyses 
Study Measure Database Source(s) Specific Data Field(s) Comments 
Provider specialty 
classification 
associated with any, 








data also evaluated 
for age-specific and 
gender-specific 
groups 








classification for use 




Diagnosis and date of 
service records 





Phase III: Relationships of antipsychotic use with patient health care service 
utilization 
The purpose of Phase III was to examine how the following service 
utilization parameters were related to antipsychotic use from 1998 to 2001: 
number and total days of inpatient psychiatric hospitalizations, and enrollment 
and duration of different types of outpatient mental health services.  TDMHMR 
CARE service utilization data included enrollment in the following types of 
outpatient mental health services: Assessment Services (TC08), Counseling and 
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Psychotherapy (TC13); Crisis Intervention (In-Home [TC01], Inpatient [TC07], 
Therapeutic Foster Care [TC09], Other Residential Services [TC17], and Acute 
Day Treatment [TC20]); Medication-related Services (TC04); Service 
Coordination (TC06); Skills Training (Rehabilitative Day Treatment [TC03], 
Individual [TC10], Family [TC19]); and, Supportive Services (Respite [TC05], 
Family-Focused Services [TC23], and Flexible Community Support [TC24]).  It 
is important to examine what types of outpatient mental health services are being 
delivered to mentally ill youths, as these may improve long-term adaptive 
functioning and patient outcomes.   
In addition to evaluating overall trends of service utilization, trends in 
service utilization based upon age, gender, and diagnosis were examined.  It is 
important to evaluate these parameters, as certain populations may account for a 
significant portion of antipsychotic use, service utilization, and associated costs.  
Evaluation of these parameters may indicate which populations may possibly lack 
access to mental health care services.   
Table 2.10 (pages 147-148) summarizes the study measures, database 






Table 2.10. Study Measures and Corresponding Data for Phase III Analyses 
Study Measure Database Source(s) Specific Data Field(s) Comments 






Total number of 
service utilization 
claims records for 
inpatient psychiatric 
hospitalizations for an 
individual 
All analyses of 
inpatient psychiatric 
hospitalizations will 
also be evaluated 
according to 
demographic 
variables (age and 
gender) and 
diagnoses. 
Number of inpatient 





discharge dates for 
inpatient psychiatric 




Number of youths 
receiving specific 
types of outpatient 
mental health services 
TDMHMR CARE 
service utilization 
Total number of 
children and 
adolescents receiving 
specific types of 
outpatient mental 
services 
All analyses of 
outpatient mental 
health services will 
also be evaluated 
according to 
demographic 









Table 2.10. Study Measures and Corresponding Data for Phase III Analyses 
(Cont.) 
Study Measure Database Source(s) Specific Data Field(s) Comments 
Duration of 
enrollment in specific 
types of outpatient 














Foster Care [TC09], 
Other Residential 
Services [TC17], and 


















Appropriate statistical procedures were used to test the stated hypotheses.  
All statistical measures are two-tailed, and due to the large sample, significance 
defined at an alpha level of 0.01.  For hypotheses that were tested using analysis 
of variance (ANOVA), post hoc analyses were conducted to further investigate 
the significant difference detected in the ANOVA.  The Scheffe test was used 
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when sample sizes were unequal, but group variances were equal.  The Games-
Howell test was used when both sample sizes and group variances were unequal.8 
Phase I: Trends in the prevalence of antipsychotic use in children and 
adolescents (1996 to 2001) 
Prevalence rates of antipsychotic use were reported as X per 1,000 
enrollees and applied to total, age-specific, gender-specific, and drug-specific 
prevalence rates.  The Pearson chi-square test was used to compare annual 
prevalence rates of antipsychotic use (H1 through H3, and H5 through H10).  
Logistic regression analyses were used to determine odds ratios of each 
prevalence rate of antipsychotic use (i.e., the odds that a child or adolescent were 
to receive an antipsychotic with each additional study year).  Rank order was used 
to compare the specific atypical antipsychotic prevalence rates annually (H4).  
Comparisons of annual prevalence rates of antipsychotic use between Medicaid 
states were examined using the Pearson chi-square (H17 through H19).  
Comparisons of annual prevalence rates of antipsychotic use between Medicaid 
states and the Managed Care Organization were examined using the Pearson chi-
square (H20 through H22). 
Descriptive statistics (mean±standard deviation [SD], median, 95% 
confidence intervals [CI]) were used to report average daily dose of specific 
atypical antipsychotic treatment.  ANOVA was used to evaluate the year effect on 
mean daily dose of atypical antipsychotics prescribed in age-specific groups (H11 
through H13).  The prevalence of antipsychotic switching was reported as the 
percentage of children and adolescents having at least one switch in medications.  
The Pearson chi-square test was used to compare prevalence of antipsychotic 
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switching across the calendar years under study.  Logistic regression analyses 
were used to determine odds ratios of antipsychotic switching (i.e., the odds that a 
child or adolescent were to switch antipsychotic medications with each additional 
study year) (H14).  Percentages of the types of antipsychotic switched occurring 
each year were reported, and the mean number of switches per patient during a 
calendar year was evaluated.  The prevalence of concomitant psychotropic 
medication use was reported as the percentage of children and adolescents having 
at least one concomitant psychotropic medication during antipsychotic treatment.  
The Pearson chi-square test was used to compare prevalence of concomitant 
psychotropic medication use across the calendar years under study.  Logistic 
regression analyses were used to determine odds ratios of antipsychotic switching 
(i.e., the odds that a child or adolescent were to receive a psychotropic medication 
during antipsychotic treatment with each additional study year) (H15).  
Percentages of medication class of concomitant psychotropic medications used 
each year were reported. 
Cost of antipsychotic prescriptions in Phase I (H16) was evaluated for any 
trend over the seven-year period.  No state comparisons were performed on 
prescription costs, as states differ in Medicaid prescription reimbursement 






Table 2.11. Medicaid Prescription Reimbursement Formulas (June 2003)9 




California Average Wholesale Price (AWP) – 5% $4.05 $1.00 
Ohio Wholesaler Acquistion Cost (WAC) + 9% or            
AWP – 12.8% 
$3.70 None 
Texas (AWP – 15% or WAC + 12% [lowest]) / 1.02 $5.27 N/A 
 
Phase II: Prescribing practices for antipsychotic agents 
Diagnostic and provider specialty information were presented as 
percentages.  The Pearson chi-square test was utilized to compare annual rates of 
prescribing from different providers (H23 and H24), as well as the diagnoses for 
which an antipsychotic was prescribed (H25).  Rank order was used to determine 
for which diagnoses antipsychotics were most prescribed from 1998 to 2001. 
Phase III: Relationships of antipsychotic use with patient health care service 
utilization 
Descriptive statistics (mean±SD, median, and 95% CI) were used to report 
data on patient health care service utilization.  The ANOVA model was used to 
evaluate the year effect on interval measures of inpatient and outpatient mental 
health service utilization: mean number of inpatient psychiatric hospitalizations, 
mean number of hospital days, and mean duration of enrollment in outpatient 
mental health services (H26, H27, H29).  The Kruskal-Wallis test was also used to 
evaluate the year effect on interval measures of inpatient and outpatient mental 
health service utilization due to non-normal distributions.  To evaluate trends in 
categorical outpatient mental health service utilization data (frequencies of 
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patients receiving different types of outpatient mental health services), the 
Pearson chi-square test was utilized (H28). 
Hypotheses Testing and Associated Statistical Methods 
Table 2.12 (pages 152-158) provides a summary of the hypotheses tested, 
the study measure used for each hypothesis, and the appropriate statistical 
methods used to test the hypotheses. 
 
Table 2.12. Hypotheses Tested, Associated Study Measure(s), and Statistical 
Methods 
Hypothesis Study Measure Statistical Method 
Phase I: Epidemiology (CA, OH, TX, and MCO) 
H1: The prevalence rate of 
total antipsychotic use in 
children and adolescents 
increases from 1996 to 2001. 
Prevalence of total 
antipsychotic use 
Pearson Chi-square (χ2); 
Logistic regression 
H2: The prevalence rate of 
atypical antipsychotic use in 
children and adolescents 
increases from 1996 to 2001. 
Prevalence of atypical 
antipsychotic use 
Pearson Chi-square (χ2); 
Logistic regression 
H3: The prevalence rate of 
typical antipsychotic use in 
children and adolescents 
decreases from 1996 to 2001. 
Prevalence of typical 
antipsychotic use 
Pearson Chi-square (χ2); 
Logistic regression 
H4: During each study year 
(1996-2001), risperidone is the 
most commonly used atypical 
antipsychotic in children and 
adolescents. 
Prevalence of specific atypical 
antipsychotic use 
Rank order 
H5: Prevalence rates of total 
antipsychotic use from 1996 to 
2001 increase across age 
categories greater than two 
years of age (2-4, 5-9, 10-14, 
and 15-19 years). 
Age-specific prevalence of 
total antipsychotic use 




Table 2.12. Hypotheses Tested, Associated Study Measure(s), and Statistical 
Methods (Cont.) 
Hypothesis Study Measure Statistical Method 
Phase I: Epidemiology (Cont.; CA, OH, TX, and MCO) 
H6: Prevalence rates of 
atypical antipsychotic use 
from 1996 to 2001 increase 
across age categories greater 
than two years of age (2-4, 5-
9, 10-14, and 15-19 years). 
Age-specific prevalence of 
atypical antipsychotic use 
Pearson Chi-square (χ2); 
Logistic regression 
H7: Prevalence rates of typical 
antipsychotic use from 1996 to 
2001 decrease across all age 
categories (<2, 2-4, 5-9, 10-14, 
and 15-19 years). 
Age-specific prevalence of 
typical antipsychotic use 
Pearson Chi-square (χ2); 
Logistic regression 
H8: Prevalence rates of total 
antipsychotic use from 1996 to 
2001 increase across gender 
groups: male and female. 
Gender-specific prevalence of 
total antipsychotic use 
Pearson Chi-square (χ2); 
Logistic regression 
H9: Prevalence rates of 
atypical antipsychotic use 
from 1996 to 2001 increase 
across gender groups: male 
and female. 
Gender-specific prevalence of 
atypical antipsychotic use 
Pearson Chi-square (χ2); 
Logistic regression 
H10: Prevalence rates of typical 
antipsychotic use from 1996 to 
2001 decrease across gender 
groups: male and female. 
Gender-specific prevalence of 
typical antipsychotic use 
Pearson Chi-square (χ2); 
Logistic regression 
H11: The mean daily dose of 
risperidone treatment in age-
specific groups of children and 
adolescents decreases from 
1996 to 2001. 
Daily dose of risperidone ANOVA (year effect) 
H12: The mean daily dose of 
olanzapine treatment in age-
specific groups of children and 
adolescents increases from 
1996 to 2001. 
Daily dose of olanzapine ANOVA (year effect) 
H13: The mean daily dose of 
quetiapine treatment in age-
specific groups of children and 
adolescents increases from 
1996 to 2001. 
Daily dose of quetiapine ANOVA (year effect) 
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Table 2.12. Hypotheses Tested, Associated Study Measure(s), and Statistical 
Methods (Cont.) 
Hypothesis Study Measure Statistical Method 
Phase I: Epidemiology (Cont.; CA, OH, TX, and MCO) 
H14: Antipsychotic switch 
rates in children and 
adolescents increase from 
1996 to 2001. 
Antipsychotic switch rates Pearson Chi-square (χ2); 
Logistic regression 
H15: The prevalence of 
concomitant psychotropic 
medication use, including 
multiple antipsychotics, in 
children and adolescents 
receiving antipsychotic 
medications increases from 
1996 to 2001. 
Any concomitant psychotropic 
medication use 
Pearson Chi-square (χ2); 
Logistic regression 
H16: Total cost for 
antipsychotic prescriptions for 
children and adolescents 
increases from 1996 to 2001. 
Cost for prescriptions for any, 
atypical, and typical 
antipsychotics 
Rank order 
H17: For each study year, a 
significant difference in the 
prevalence rate of total 
antipsychotic use in children 
and adolescents from 1996 to 
2001 between states exists.  
Texas Medicaid has the 
highest rates of total 
antipsychotic use, followed by 
Ohio and California. 
Prevalence of total 
antipsychotic use 
Pearson Chi-square (χ2), Rank 
order 
H18: For each study year, a 
significant difference in the 
prevalence rate of atypical 
antipsychotic use in children 
and adolescents from 1996 to 
2001 between states exists.  
Texas Medicaid has the 
highest rates of atypical 
antipsychotic use, followed by 
Ohio and California. 
Prevalence of atypical 
antipsychotic use 







Table 2.12. Hypotheses Tested, Associated Study Measure(s), and Statistical 
Methods (Cont.) 
Hypothesis Study Measure Statistical Method 
Phase I: Epidemiology (Cont.; CA, OH, TX, and MCO) 
H19: For each study year, a 
significant difference in the 
prevalence rate of typical 
antipsychotic use in children 
and adolescents from 1996 to 
2001 between states exists.  
Texas Medicaid has the 
highest rates of typical 
antipsychotic use, followed by 
Ohio and California. 
Prevalence of typical 
antipsychotic use 
Pearson Chi-square (χ2), Rank 
order 
H20: For each study year, a 
significant difference in the 
prevalence rate of total 
antipsychotic use in children 
and adolescents from 1996 to 
2001 between public and 
private insurance systems 
exists.  Medicaid states have 
higher rates of total 
antipsychotic use compared to 
the Managed Care 
Organization. 
Prevalence of total 
antipsychotic use 
Pearson Chi-square (χ2), Rank 
order 
H21: For each study year, a 
significant difference in the 
prevalence rate of atypical 
antipsychotic use in children 
and adolescents from 1996 to 
2001 between public and 
private insurance systems 
exists.  Medicaid states have 
higher rates of atypical 
antipsychotic use compared to 
the Managed Care 
Organization. 
Prevalence of atypical 
antipsychotic use 










Table 2.12. Hypotheses Tested, Associated Study Measure(s), and Statistical 
Methods (Cont.) 
Hypothesis Study Measure Statistical Method 
Phase I: Epidemiology (Cont.; CA, OH, TX, and MCO) 
H22: For each study year, a 
significant difference in the 
prevalence rate of typical 
antipsychotic use in children 
and adolescents from 1996 to 
2001 between public and 
private insurance systems 
exists.  Medicaid states have 
higher rates of typical 
antipsychotic use compared to 
the Managed Care 
Organization. 
Prevalence of typical 
antipsychotic use 
Pearson Chi-square (χ2), Rank 
order 
Phase II: Prescribing Practices (TX only) 
H23: The number of 
prescriptions for an 
antipsychotic for a child or 
adolescent from primary care 
physicians (family practice 
physicians, general practice 
physicians, and pediatricians) 
increases from 1996 to 2001. 
Provider type classification 
associated with any 
antipsychotic prescription 
Pearson Chi-square (χ2) 
H24: The number of 
prescriptions for an 
antipsychotic for a child or 
adolescent from psychiatrists, 
including child and adolescent 
psychiatrists, increases from 
1996 to 2001. 
Provider type classification 
associated with any 
antipsychotic prescription 
Pearson Chi-square (χ2) 
H25: From 1998 to 2001, 
antipsychotics are most 
prescribed for disruptive 
behavioral disorders, such as 
oppositional defiant disorder, 
conduct disorder, intermittent 











Table 2.12. Hypotheses Tested, Associated Study Measure(s), and Statistical 
Methods (Cont.) 
Hypothesis Study Measure Statistical Method 
Phase III: Service utilization (TX only) 
H26: The mean number of 
inpatient psychiatric 
hospitalizations per child or 
adolescent receiving 
antipsychotic treatment 
decreases from 1998 to 2001. 
Number of inpatient 
psychiatric hospitalizations per 
patient 
ANOVA (year effect) 
H27: The mean number of 
hospital days per each 
hospitalized child or 
adolescent receiving 
antipsychotic treatment 
decreases from 1998 to 2001. 
Length of stay of inpatient 
psychiatric hospitalizations per 
patient hospitalized 
ANOVA (year effect) 
H28: The number of children 
and adolescents receiving 
assessment services, crisis 
intervention, medication-based 
services, and service 
coordination increases from 
1998 to 2001, while the 
number of children and 
adolescents receiving 
counseling and psychotherapy, 
skills training, and supportive 
mental health services 
decreases from 1998 to 2001. 
Number of outpatient mental 
health visits per patient 
















Table 2.12. Hypotheses Tested, Associated Study Measure(s), and Statistical 
Methods (Cont.) 
Hypothesis Study Measure Statistical Method 
Phase III: Service utilization (TX only; Cont.) 
H29: The mean duration of 
enrollment of outpatient 
services for assessment 
services, crisis intervention, 
medication-based services, and 
service coordination increases 
among children and 
adolescents receiving an 
antipsychotic from 1998 to 
2001.  The mean duration of 
enrollment of outpatient 
services for counseling and 
psychotherapy, skills training, 
and supportive mental health 
services decreases among 
children and adolescents 
receiving an antipsychotic 
from 1998 to 2001. 
Types of outpatient mental 
health visits per patient 
ANOVA (year effect) 
 
 
Use of Healthcare Claims Data for Pharmacoepidemiological and Outcomes 
Research 
Pharmacoepidemiological research in pediatric populations is essential to 
provide accurate data on real-world use of drugs, to reveal variations in 
prescribing practices, and to learn about the occurrence of adverse events.  
Randomized, controlled clinical trials are necessary to establish the efficacy of a 
drug, and to detect commonly occurring adverse events associated with that drug.  
While clinical trials are useful, the applicability of the findings may be limited in 
actual clinical practice due to lack of generalizability of study population, 
expenses related to drug treatment, and short duration of study time.  Research 
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using healthcare claims databases is more applicable to the naturalistic practice 
situation, as usual community practice settings, actual patient populations, and 
prescribing physicians are represented.  Use of healthcare claims databases for 
research purposes is less expensive compared to clinical trials, and allows for 
greater flexibility in determining the study methodology.10  Furthermore, 
healthcare claims databases are very accessible sources of data for large numbers 
of patients, which provides greater statistical power. 
Research using healthcare claims databases does have its disadvantages.  
First, study populations resulting from these databases are not randomized to 
treatment and are usually more heterogenous than those patients seen in clinical 
trials.  As varying external interventions may occur, less precision and internal 
validity are associated with database research.  Second, physician-defined 
diagnoses may be subject to imprecision.  The lack of severity and chronicity 
classification schemes may result in significant interpatient differences.11  Third, 
the establishment of causality between drug and patient outcome parameters is 
difficult with retrospective data.  External variables, such as psychosocial 
interventions, may affect patient outcome variables, thus limiting the ability to 
infer that changes are solely due to drug treatment.  Fourth, clinical research using 
administrative data is required to use markers of clinical outcome instead of direct 
measurement of symptoms or functioning.  These markers may or may not be 
indicative of actual clinical outcomes.  Finally, a phenomenon known as 
“confounding by indication” may occur in which poor outcomes are attributed to 
failed drug treatment rather than the actual course of the disease.12 
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Medicaid Databases  
With over 20 million children and adolescents enrolled, Medicaid systems 
provide rich sources of data from which questions regarding medication use and 
service utilization patterns can be answered.  Medicaid systems are extensive in 
scope, providing data for an individual in four separate files: eligibility, provider, 
health service utilization, and prescription claims records.  Patient information, 
such as demographics and socioeconomic status, are included in each record.  
Diagnostic information is also provided as International Classification of Disease 
ICD-9 or ICD-10 codes.  Service utilization claims records provide information 
on physician encounters, hospital admissions, diagnosis (ICD-9 or ICD-10), and 
associated reimbursement costs.  Within the pharmacy database, Medicaid data 
available include drugs coded within the National Drug Code (NDC) Directory, 
quantity, days supply, and reimbursement for the costs. 
Large data sets, such as Medicaid claims databases, can be problematic.  
First, the quality of the data may be questionable as the data are collected for 
reasons other than research.  While little is known about the reliability and 
validity of Medicaid data, a study by Hennessy and colleagues suggested that 
there is some question as to the integrity of these data.13  Other studies have 
shown, however, that there is adequate agreement between Medicaid claims and 
medical records.  Walkup et al. examined the reliability of Medicaid claims for 
use in psychiatric diagnostic and service delivery research.  Diagnostic data from 
the Medicaid claims files were reliable, but outpatient mental health services were 
sometimes not captured by the claims file.14  Lurie and colleagues also 
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demonstrated high reliability (86.8%) of diagnostic data in Medicaid databases.15  
It must be noted that possible errors in the medical records may be carried into 
administrative databases as inaccurate information.  Second, large samples 
inevitably produce statistically significant findings that are measurement errors or 
minute differences without clinical significance.  Researchers need to be aware of 
these potential hazards when using large data sets like Medicaid. 
Limitations exist regarding the extent to which results from a study of a 
Medicaid child and adolescent population can be generalized to the entire U.S. 
child and adolescent population. By definition, this sample consisted of children 
and adolescents of low socioeconomic status, a population which has been shown 
to be at risk for the development of aggressive behaviors.16  Furthermore, 
Medicaid children and adolescents may include those receiving foster care or 
those with severe mental disorders.  These factors make it extremely important to 
examine psychotropic pharmacotherapy in this population, the types of disorders 
being treated, and the other types of mental health services being delivered.  With 
the inclusion of a private managed care organization operating nationwide, 
valuable information regarding antipsychotic use in children and adolescents 
covered by an HMO or PPO is provided.  Additionally, inclusion of private 
managed care organization data allows for a better, overall perspective of the use 
of these agents in youths from 1996 to 2001. 
Although it is unclear how results from the this study translate to the entire 
U.S. child and adolescent population, it provides information as to how much 
these medications are being used, who is prescribing them and for what, the types 
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of mental health services being delivered, and the associated costs of the 
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Chapter Three presents the study results describing the current trends of 
antipsychotic use in children and adolescents from 1996 to 2001.  Descriptions of 
the demographic characteristics of children and adolescents receiving an 
antipsychotic during the designated study are provided according to the health 
system.  The findings are detailed according to the phases: (1) trends in 
antipsychotic use in children and adolescents; (2) prescribing practices for 
antipsychotic agents; and, (3) relationships of antipsychotic use to service 
utilization.  Within each section, the hypotheses and associated statistical analyses 
are presented.   
Phase I analyses, which includes Medi-Cal (CA), Ohio Medicaid (OH), 
Texas Medicaid (TX), and one private managed care organization (MCO), are 
separated accordingly.  Eligibility and prescription claims data were collected for 
each calendar year between 1996 and 2001, but data are reported only for 1996, 
1998, and 2001 in some instances.  The year 1998 was chosen because it 
represents the time point when multiple atypical antipsychotics were available on 
the market, and when the growth of antipsychotic use escalated significantly in 
several of the insurance programs under study.  Phase II includes provider 
analyses from the Texas Medicaid (TX) child and adolescent population.  
Diagnostic (Phase II) and service utilization (Phase III) analyses examines only 
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Texas Medicaid youths receiving mental health services from the Texas 
Department of Mental Health and Mental Retardation (TDMHMR) system from 
1998 to 2001. 
 
Number of Children and Adolescents Enrolled in Three Medicaid Programs 
and One Managed Care Organization 
Total, age-specific, and gender-specific enrollments for children and 
adolescents less than 20 years of age were determined using each insurance 
program’s respective eligibility database.  In 1996, the number of enrolled youths 
in CA was 2,895,158.  Children between the ages of five and nine years 
comprised the largest percentage of enrollment (30.6%), and female enrollment 
was roughly equal to that of males.  In 1998, 2,637,323 youths were enrolled in 
CA.  Thirty-one percent of enrollees were between the ages of five and nine years, 
and 50 percent were females.  Over 2.6 million children and adolescents were 
enrolled in 2001.  As seen in previous years, children aged five to nine years were 
the largest age group (29.5%), and the female to male ratio was approximately 
1.0.  Table 3.1 (page 168) provides further detail regarding CA enrollee data 






Table 3.1. Medi-Cal (CA) Youth Enrollment Numbers from 1996 to 2001a 
 1996 1997 1998 1999 2000 2001 
Total 2895158 2845547 2637323 2651983 2653100 2602614 
Male 1455738 1432158 1329412 1337180 1338367 1314618 
Female 1439418 1413388 1307911 1314803 1314733 1287994 
<2 y 253180 236814 206395 201752 201290 208567 
2 - 4 y 648331 612017 541209 517524 497031 476695 
5 - 9 y 886016 884815 825825 823388 809585 766617 
10 - 14 y 624304 625952 604147 623936 648648 653965 
15 - 19 y 483327 485949 459747 485383 496546 496770 
aAbbreviations: y= years. 
 
Over 744,000 children and adolescents were enrolled in OH in 1996.  
Children aged five to nine years were the largest age group (29.1%), and the 
female to male ratio was approximately 1.0.  In 1998, the number of enrolled 
youths was 687,729.  Children between the ages of five and nine years comprised 
the largest percentage of enrollment (28.6%), and female enrollment was roughly 
equal to that of males.  In 2001, 842,735 youths were enrolled in OH.  Twenty-
seven percent of enrollees were between the ages of five and nine years, and 50 
percent were females.  Table 3.2 (page 169) provides further detail regarding OH 






Table 3.2. Ohio Medicaid (OH) Youth Enrollment Numbers from 1996 to 
2001a  
 1996 1997 1998 1999 2000 2001 
Total 744906 704100 687729 696888 724357 843735 
Male 368733 348634 340797 345930 360617 422264 
Female 376173 355466 346932 350958 363740 421471 
<2 y 118466 113357 110542 110205 116679 128600 
2 - 4 y 157779 142053 129062 126606 130848 153579 
5 - 9 y 216489 205334 196906 195461 196680 223267 
10 - 14 y 144026 141274 141025 148185 157857 192854 
15 - 19 y 108146 102082 110194 116431 122293 145435 
aAbbreviations: y= years. 
 
In 1996, 1,143,025 youths were enrolled in TX.  Thirty percent of 
enrollees were between the ages of five and nine years, and females constituted 50 
percent of enrollees.  Over 993,000 children and adolescents were enrolled in TX 
in 1998.  Children aged five to nine years were the largest age group (28.6%), and 
the female to male ratio was approximately 1.0.  In 2001, the number of enrolled 
youths was 1,144,806.  Similar to previous years, children between the ages of 
five and nine years comprised the largest percentage of enrollment (25.5%), and 
female enrollment was roughly equal to that of males.  Table 3.3 (page 170) 
provides further detail regarding TX enrollee data during each calendar year from 





Table 3.3. Texas Medicaid (TX) Youth Enrollment Numbers from 1996 to 
2001a  
 1996 1997 1998 1999 2000 2001 
Total 1143025 1046609 993021 976291 1002341 1144806 
Male 567712 520458 495489 487737 525692 576284 
Female 575313 526151 497532 488554 476649 568511 
<2 y 237220 218973 210515 212276 226490 244170 
2 - 4 y 267800 232130 206552 197366 201444 230088 
5 - 9 y 345133 313909 284085 271776 269988 292110 
10 - 14 y 184152 184895 171052 165967 170722 230187 
15 - 19 y 108720 96702 120817 128906 133697 148251 
aAbbreviations: y= years. 
 
In 1996, the number of enrolled youths in MCO was 905,310.  Children 
between the ages of five and nine years comprised the largest percentage of 
enrollment (25.9%), and female enrollment was roughly equal to that of males.  In 
1998, 906,343 youths were enrolled.  Twenty-seven percent of enrollees were 
between the ages of five and nine years, and female and male enrollees were 
equal.  Compared to previous years, fewer children and adolescents were enrolled 
in MCO in 2001.  Although the female to male ratio remained approximately 1.0, 
children and adolescents aged ten to 14 years became the largest age group 
(26.2%).  Table 3.4 (page 171) provides further detail regarding MCO enrollee 





Table 3.4. Managed Care Organization (MCO) Youth Enrollment Numbers 
from 1996 to 2001a  
 1996 1997 1998 1999 2000 2001 
Total 905310 867935 906343 828952 695862 632439 
Male 461342 442563 461205 422566 354383 322392 
Female 443968 425372 445138 406386 341479 310047 
<2 y 89757 82552 85134 74573 58488 56306 
2 - 4 y 135139 128726 135329 122801 99920 93252 
5 - 9 y 234401 225437 242563 220507 181565 161715 
10 - 14 y 229477 220276 230126 213306 184018 165888 
15 - 19 y 216536 210944 213191 197765 171871 155278 
aAbbreviations: y= years. 
 
Demographic Characteristics of Children and Adolescents Who Received an 
Antipsychotic from 1996 to 2001 
A total of 118,930 unique children and adolescents from all four insurance 
programs were identified as having at least one prescription for an antipsychotic 
between 1996 and 2001 (CA: 48,030; OH: 26,660; TX: 35,288; and MCO: 
8,952).  Table 3.5 (page 175) summarizes the demographic characteristics of the 
youths receiving an antipsychotic from each of the four programs. 
Children and Adolescents in the California Medi-Cal Program 
 Over the six-year period, the number of children and adolescents enrolled 
in CA who received at least one antipsychotic prescription increased from 13,090 
in 1996 to 17,884 in 2001.  The mean (± SD) age of CA youths treated with an 
antipsychotic also increased (1996: 12.12±5.31 years; 1998: 12.79±4.91 years; 
and, 2001: 13.28±4.12 years).  Children and adolescents above the age of five 
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years represented the majority of those receiving treatment with an antipsychotic.  
From 1996 to 1999, the 15- to 19-year-old group constituted the largest age group 
receiving an antipsychotic (range: 35.6% to 40.1%).  In 2000 and 2001, children 
and adolescents between the ages of ten and 14 years comprised the largest group 
(37.7% and 38.2%, respectively).  Males constituted the majority of youths 
receiving an antipsychotic during each calendar year, and a trend towards an 
increased percentage of males existed (1996: 57.8%; 1998: 63.9%; and, 2001: 
66.0%). 
Children and Adolescents in the Ohio Medicaid Program 
In 1996, a total of 3,515 children and adolescents enrolled in OH had at 
least one prescription for an antipsychotic.  During the study period, the number 
of youths receiving an antipsychotic substantially increased.  In 2001, 12,099 
children and adolescents were identified, which represents a 244.2% increase 
from 1996.  The mean (±SD) age of OH youths treated with an antipsychotic 
decreased over the six-year period (1996: 13.77±4.27 years; 1998: 13.31±4.17 
years; and, 2001: 12.69±4.01 years).  Similar to Medi-Cal, children and 
adolescents five years or older were the majority of those receiving an 
antipsychotic from 1996 to 2001.  Adolescents aged 15 to 19 years represented 
the largest age group receiving an antipsychotic in 1996, 1997, and 1998 (44.8%, 
42.4%, and 38.5%, respectively).  The ten- to 14-year-old age group represented 
the highest percentage of users from 1999 to 2001 (range: 37.7% to 40.4%).  
During each calendar year, the majority of OH youths receiving an antipsychotic 
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were males.  From 1996 to 2001, there was a 277.1 percent increase in the number 
of males receiving an antipsychotic (1996: 2,196; 1998: 3,848; and, 2001: 8,282). 
Children and Adolescents in the Texas Medicaid Program 
During the study period, the number of TX youths receiving an 
antipsychotic more than doubled from 1996 to 2001 (1996: 7,240; 1998: 10,656; 
and, 2001: 17,790).  The mean (±SD) age of children and adolescents slightly 
increased from 1996 (11.63±4.28 years) to 2001 (11.79±3.99 years).  In age 
groups at least two years old, a trend showing an increased number of youths 
receiving an antipsychotic existed.  The ten- to 14-year-old age group constituted 
the largest age group during each calendar year (range: 37.4% to 41.5%), 
followed by five to nine-year olds (range: 32.5% to 34.2%) and 15- to 19-year 
olds (range: 18.1% to 20.4%).    Although males comprised the majority of 
children and adolescents treated with an antipsychotic during each study year, 
there was a 159.6 percent increase in the number of females receiving an 
antipsychotic over the six-year period. 
The percentage of TX youths receiving antipsychotic treatment and mental 
health care services from TDMHMR remained fairly consistent from 1998 to 
2001.  In 1998, 2,413 (22.6%) children and adolescents received services from 
TDMHMR.  In 2001, 4,124 (23.2%) youths received TDMHMR services. 
Children and Adolescents in the Private Managed Care Organization 
The number of children and adolescents enrolled in MCO who received at 
least one antipsychotic prescription increased from 1,338 in 1996 to 2,861 in 
2000.  In 2001, the number of youths treated with an antipsychotic decreased 
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compared to 2000 (2,172 versus 2,861, respectively).  During the six-year period, 
the mean (±SD) age of children and adolescents slightly decreased (1996: 
11.63±4.28 years; 1998: 13.21±4.54 years; and 2001: 11.79±3.99 years).    
Adolescents aged 15 to 19 years represented the largest age group receiving an 
antipsychotic in 1996, 1997, and 1998 (47.0%, 43.6%, and 38.8%, respectively).  
The ten- to 14-year-old age group represented the highest percentage of users 
from 1999 to 2001 (range: 35.1% to 37.4%). 
 
Hypothesis Testing: Phase I (Trends in the prevalence of antipsychotic use in 
children and adolescents [1996 to 2001]) 
Phase I evaluated data from four health care systems (Medicaid: California 
[West], Ohio [Midwest], and Texas [South]; Managed Care: Nationwide) to 
determine the prevalence of antipsychotic use in children and adolescents.  Total 
antipsychotic, typical antipsychotic, and atypical antipsychotic prevalence rates 
were determined (H1 to H10). In addition, daily dose of antipsychotic therapy (H11 
to H13), rates of antipsychotic switching (H14), and concomitant psychotropic 
medication therapy (H15) in this population were examined.  Annual cost of all 
antipsychotic prescriptions (H16), as well as antipsychotic subclass and specific 
atypical antipsychotic, were examined for each of the four health care systems. 
Appendix B provides the details of logistic regression analyses examining 
time trends in the prevalence of antipsychotic use.  Appendix C provides details 
of the analyses examining the relationship between year and mean daily doses of 



























































































































































































































































































































































































































































































































































Prevalence of Antipsychotic Use in Children and Adolescents Enrolled in 
California Medi-Cal (1996 to 2001) 
 
H1: The prevalence rate of total antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
 From 1996 to 2001, the prevalence rate of total antipsychotic use 
increased 1.52-fold (Figure 3.1, page 177).  In 1996, 4.52 youths per 1,000 
enrollees had at least one prescription for an antipsychotic.  The prevalence rate of 
total antipsychotic use decreased in 1997, but increased steadily thereafter.  In 
2001, an additional 2.35 youths per 1,000 enrollees received an antipsychotic 
compared to 1996 (prevalence [PREV] in 2001=6.87; % change=51.98%). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of total antipsychotic use (χ2=2611.13, df=5, 
p<0.0001; Table 3.6, page 177).  Logistic regression analysis showed a nine 
percent increase in the odds of receiving any antipsychotic with each additional 
year (odds ratio [OR]=1.0987; 95% confidence interval [CI]=1.0944 to 1.1031). 
 






Table 3.6. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Total Antipsychotic Use in Medi-Cal Youths and Calendar Yeara,b 









13090 11710 13017 13349 15652 17884 
aχ2=2611.13, df=5, p<0.0001. 
bOR=1.0987 (95% CI: 1.0944 – 1.1031). 
 
Figure 3.1. Prevalence Rates of Total Antipsychotic Use in Medi-Cal Youths 


































H2: The prevalence rate of atypical antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
From 1996 to 2001, the prevalence rate of atypical antipsychotic use 
increased almost 20-fold (Figure 3.2, page 179).  In 1996, 0.31 youths per 1,000 
enrollees had at least one prescription for an atypical antipsychotic.  Over the 
study period, there was an increase in the use of atypical antipsychotics, with 
much of the growth occurring after 1997.  In 2001, the prevalence rate of atypical 
antipsychotic use was 6.17 youths per 1,000 enrollees, which represented a 
1873.0 percent increase from 1996 (+5.86 per 1,000). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of atypical antipsychotic use (χ2=23448.56, 
df=5, p<0.0001; Table 3.7, page 179).  Logistic regression analysis showed a 56 
percent increase in the odds of receiving an atypical antipsychotic with each 
additional year (OR=1.5563; 95% CI=1.5469 to 1.5657). 
 







Table 3.7. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Atypical Antipsychotic Use in Medi-Cal Youths and Calendar 
Yeara,b 









905 2649 6789 9655 13029 16051 
aχ2=23448.56, df=5, p<0.0001. 
bOR=1.5563 (95% CI: 1.5469 – 1.5657). 
 
Figure 3.2. Prevalence Rates of Atypical Antipsychotic Use in Medi-Cal Youths 


































H3: The prevalence rate of typical antipsychotic use in children and 
adolescents decreases from 1996 to 2001. 
 
From 1996 to 2001, the use of typical antipsychotics in youths enrolled in 
CA decreased by 71.4 percent (prevalence ratio [PR]=0.29; Figure 3.3, page 181).  
In 1996, 4.38 youths per 1,000 enrollees had at least one prescription for a typical 
antipsychotic.  Over the study period, the prevalence rate of typical antipsychotic 
use steadily decreased.  In 2001, 3.13 fewer youths per 1,000 enrollees received a 
typical antipsychotic (PREV=1.25 per 1,000). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of typical antipsychotic use (χ2=7441.30, df=5, 
p<0.0001; Table 3.8, page 181).  Logistic regression analysis showed a 22 percent 
decrease in the odds of receiving a typical antipsychotic with each additional year 
(OR=0.7797; 95% CI=0.7752 to 0.7842). 
 








Table 3.8. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Typical Antipsychotic Use in Medi-Cal Youths and Calendar Yeara,b 









12685 10168 8113 5544 4363 3263 
aχ2=7441.30, df=5, p<0.0001. 
bOR=0.7797 (95% CI: 0.7752 – 0.7842). 
 
Figure 3.3. Prevalence Rates of Typical Antipsychotic Use in Medi-Cal Youths 


































H4: During each study year (1996 – 2001), risperidone is the most 
commonly used atypical antipsychotic in children and adolescents. 
 
 Rank order of prevalence rates of specific atypical antipsychotic 
demonstrated that risperidone was the most commonly used agent in children and 
adolescents enrolled in CA over the six-year period (Table 3.9, page 182).  In 
1996, the prevalence rate of clozapine use was slightly higher than that of 
olanzapine.  In 1997, the prevalence rate of clozapine use was higher than that of 
quetiapine.  From 1998 to 2001, the prevalence rate of risperidone use was 
highest, followed by olanzapine, quetiapine, and clozapine.  In 2001, risperidone 
use was approximately double the use of olanzapine (PREV: 4.18 versus 1.84), 
and quadruple that of quetiapine (PREV: 4.18 versus 1.02). 
 
Result: H4 accepted. 
 
Table 3.9. Prevalence Rates of Specific Atypical Antipsychotic Use in Medi-
Cal Youths from 1996 to 2001a,b 
Atypical 
Antipsychotic 






CLZ 0.02 0.02 0.03 0.04 0.04 0.04 1.77 76.89 
OLZ 0.01 0.28 0.98 1.29 1.61 1.84 148.29 14728.96 
QUET  0.001 0.11 0.34 0.58 1.02 965.06c 96405.65d 
RIS 0.29 0.70 1.76 2.48 3.39 4.18 14.49 1349.19 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: CLZ=clozapine; OLZ=olanzapine; QUET=quetiapine; RIS=risperidone. 
cPrevalence ratio (2001:market entry). 
dPercent change from market entry to 2001. 
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H5: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
The overall use of antipsychotics decreased in children less than five years 
of age (<2 years: PR=0.09, % change=-91.2%; 2 to 4 years: PR=0.43, % change=-
57.3%).  A trend toward the increased use of antipsychotics was seen in the five- 
to nine-year olds (PR=1.78, % change=78.0%), ten- to 14-year olds (PR=1.75, % 
change=75.5%), and 15- to 19-year olds (PR=1.40, % change=39.9%; Table 3.10, 
page 184).  Adolescents aged 15 to 19 years had the highest prevalence rates 
during each calendar year, but ten- to 14-year olds had the steepest growth (+4.90 
per 1,000; Figure 3.4, page 184).  Children between the ages of five and nine 
years had the greatest percent change in prevalence rates from 1996 to 2001. 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of total antipsychotic use across all age groups 
(p<0.001; Table 3.10, page 184).  Logistic regression analysis showed a 36 
percent and 19 percent decrease in the odds of receiving any antipsychotic in the 
less than 2 years (OR=0.6422; 95% CI=0.6188 to 0.665) and two to four year age 
groups (OR=0.8145; 95% CI=0.7986 to 0.8307), respectively.  Children and 
adolescents aged ten to 14 years had the highest odds of receiving any 
antipsychotic with each calendar year (OR=1.1393; 95% CI=1.1318 to 1.1468), 
followed by five- to nine-year olds (OR=1.1335; 95% CI=1.1240 to 1.1431) and 
15- to 19-year olds (OR=1.0763; 95% CI=1.0696 to 1.0831). 
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Result: H5 rejected. 
 
Table 3.10. Age-Specific Prevalence Rates of Total Antipsychotic Use in Medi-
Cal Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 2.17 1.66 0.19 0.09 -91.16 10660.66 <0.0001 
2 – 4 y 1.83 1.35 0.78 0.43 -57.34 525.51 <0.001 
5 – 9 y 3.17 3.49 5.65 1.78 77.97 1085.42 <0.0001 
10 – 14 y 6.50 7.41 11.40 1.75 75.46 1660.56 <0.0001 
15 – 19 y 10.15 11.46 14.20 1.40 39.87 580.28 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.4. Age-Specific Prevalence Rates of Total Antipsychotic Use in Medi-
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H6: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
The use of atypical antipsychotics increased across all age categories from 
1996 to 2001 (Table 3.11, page 186; Figure 3.5, page 186).  In children less than 
two years of age, there was a 17-fold increase in the prevalence of atypical 
antipsychotic use (+0.132 per 1,000; % change=1660.2%).  Compared to 1996, an 
additional 0.61 and 5.14 youths per 1,000 enrollees received an atypical 
antipsychotic in the two- to four-year old (PR=40.94, % change=3993.8%) and 
five- to nine-year old (PR=48.99, % change=4799.2%) groups, respectively, in 
2001.  Prevalence rates of atypical antipsychotic use also increased 24-fold in the 
ten- to 14-year age group (+10.11 per 1,000), and 10-fold in the 15- to 19-year 
age group (+11.08 per 1,000) over the six-year period. 
 Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of atypical antipsychotic use across all age 
groups (p<0.01; Table 3.11, page 186).  Children between the ages of five and 
nine years had the highest odds (OR=1.7463; 95% CI=1.7222 to 1.7706), 
followed by two- to four-year olds (OR=1.5860; 95% CI=1.5217 to 1.6531), ten- 
to 14-year olds (OR=1.5790; 95% CI=1.5636 to 1.5945), and 15- to 19-year olds 
(OR=1.4170; 95% CI=1.4044 to 1.4298). 
 
Result: H6 accepted. 
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Table 3.11. Age-Specific Prevalence Rates of Atypical Antipsychotic Use in 
Medi-Cal Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.008 0.16 0.14 17.60 1660.16 65.51 <0.01 
2 – 4 y 0.02 0.29 0.63 40.94 3993.76 548.60 <0.001 
5 – 9 y 0.11 1.48 5.25 48.99 4799.15 7601.55 <0.0001 
10 – 14 y 0.43 4.14 10.54 24.56 2355.72 9472.64 <0.0001 
15 – 19 y 1.15 6.99 12.23 10.67 967.25 6411.53 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.5. Age-Specific Prevalence Rates of Atypical Antipsychotic Use in 
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H7: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across all age categories (<2, 2-4, 5-9, 10-14, and 15-19 
years). 
 
The use of typical antipsychotics decreased across all age categories from 
1996 to 2001 (Table 3.12, page 188).  Although prevalence rates of typical 
antipsychotic use in adolescents were higher than those for children, both children 
and adolescents received fewer typical antipsychotics over the six-year period 
(Figure 3.6, page 188).  Compared to 1996, there was a 90 to 97 percent decrease 
in the prevalence rate of typical antipsychotic use in children less than five years 
of age.  In youths above the age of five years, the use of typical antipsychotics 
decreased by 62 to 80 percent. 
 Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of typical antipsychotic use across all age 
groups (p<0.001; Table 3.12, page 188).  Younger children had lower odds of 
receiving a typical antipsychotic with each calendar year compared to their older 
counterparts (<2 years: OR=0.5649; 95% CI=0.5408 to 0.5901).  With increasing 
age, the odds of receiving a typical antipsychotic with each calendar year 
increased (2 to 4 years: OR=0.6271; 5 to 9 years: OR=0.7450; 10 to 14 years: 
OR=0.7707; and, 15 to 19 years: OR=0.8113). 
 
Result: H7 accepted. 
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Table 3.12. Age-Specific Prevalence Rates of Typical Antipsychotic Use in 
Medi-Cal Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 2.16 1.52 0.06 0.03 -97.12 914.50 <0.001 
2 – 4 y 1.82 1.12 0.18 0.10 -90.11 1447.40 <0.0001 
5 – 9 y 3.12 2.34 0.63 0.20 -79.70 2147.74 <0.0001 
10 – 14 y 6.29 4.34 1.54 0.24 -75.51 2662.88 <0.0001 
15 – 19 y 9.62 6.49 3.57 0.37 -62.91 2233.50 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.6. Age-Specific Prevalence Rates of Typical Antipsychotic Use in 
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H8: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across gender groups: male and female.   
 
The use of antipsychotics increased in both male and female groups from 
1996 to 2001 (Table 3.13, page 190).  Compared to 1996, an additional 3.52 
males and 0.8 females per 1,000 enrollees received an antipsychotic in 2001 
(Male: PR=1.71, % change=70.9%; Female: PR=1.22, % change=21.9%).  
During each calendar year, male prevalence rates of total antipsychotic use were 
higher than those of females (Figure 3.7, page 190). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of total antipsychotic use in males and females 
(p<0.001; Table 3.13, page 190).  Males (OR=1.1262, 95% CI=1.1204 to 1.1320) 
had higher odds of receiving any antipsychotic with each calendar year compared 
to females (OR=1.0470, 95% CI=1.0400 to 1.0541). 
 









Table 3.13. Gender-Specific Prevalence Rates of Total Antipsychotic Use in 
Medi-Cal Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 4.97 5.86 8.49 1.71 70.93 2288.49 <0.0001 
Female 3.66 3.36 4.46 1.22 21.89 473.05 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.7. Gender-Specific Prevalence Rates of Total Antipsychotic Use in 

































H9: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across gender groups: male and female. 
 
Prevalence rates of atypical antipsychotic use increased in both male and 
female groups from 1996 to 2001 (Table 3.14, page 192).  Compared to 1996, 
there was a 21-fold increase in atypical antipsychotic use in males in 2001, and a 
18-fold increase in females (Male: +7.44 per 1,000, % change=2037.9%; Female: 
+3.57 per 1,000, % change=1714.6%).  Male prevalence rates of atypical 
antipsychotic use were higher than those of females (Figure 3.8, page 192). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of atypical antipsychotic use in males and 
females (p<0.0001; Table 3.14, page 192).  Males showed a 58 percent increase in 
the odds of receiving an atypical antipsychotic with each additional calendar year 
(OR=1.5782, 95% CI=1.5661 to 1.5903), and females showed a 53 percent 
increase (OR=1.5342, 95% CI=1.5178 to 1.5509). 
 








Table 3.14. Gender-Specific Prevalence Rates of Atypical Antipsychotic Use in 
Medi-Cal Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 0.37 3.08 7.81 21.38 2037.89 15468.95 <0.0001 
Female 0.21 1.68 3.78 18.15 1714.55 6816.09 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.8. Gender-Specific Prevalence Rates of Atypical Antipsychotic Use in 
































H10: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across gender groups: male and female. 
 
The use of typical antipsychotic use decreased by 72 percent in males, and 
71 percent in females from 1996 to 2001 (Table 3.15, page 194).  In 2001, 3.47 
fewer males and 2.54 fewer females per 1,000 received a typical antipsychotic 
compared to 1996 (Male: PR=0.28; Female: PR=0.29).  Male prevalence rates of 
typical antipsychotic use remained higher than those of females (Figure 3.9, page 
194). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of typical antipsychotic use in males and 
females (p<0.0001; Table 3.15, page 194).  Males showed a 22 percent decrease 
in the odds of receiving a typical antipsychotic with each additional calendar year 
(OR=0.7842, 95% CI=0.7782 to 0.7903), and females showed a 24 percent 
decrease (OR=0.7645, 95% CI=0.7572 to 0.7719). 
 








Table 3.15. Gender-Specific Prevalence Rates of Typical Antipsychotic Use in 
Medi-Cal Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 4.80 3.62 1.33 0.28 -72.25 4044.71 <0.0001 
Female 3.56 2.12 1.02 0.29 -71.28 3330.82 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.9. Gender-Specific Prevalence Rates of Typical Antipsychotic Use in 
































H11: The mean daily dose of risperidone treatment in age-specific 
groups of children and adolescents decreases from 1996 to 2001. 
 
A trend toward lower mean daily doses of risperidone over the six-year 
period existed in all age groups.  Analysis of variance (ANOVA) showed 
significant differences in mean risperidone doses between calendar years for age 
categories greater than two years of age (p<0.001).  In children under the age of 
two years, no significant between-year differences existed (p=0.044). 
In the two- to four-year age group, mean risperidone doses in 1998 and 
1999 were significantly higher than those in 2001 (p=0.007 and p=0.006, 
respectively).  Mean risperidone doses in children between the ages of five and 
nine years were significantly higher in 1996 compared to 1998, 1999, 2000, and 
2001 (p<0.001).  In the ten- to 14-year age group, risperidone doses in 1996 and 
1997 were significantly higher than 1998 through 2001 (p<0.001).  Mean 
risperidone doses in 15- to 19-year olds were significantly higher in 1996 
compared to 1997 through 2001. 
 






H12: The mean daily dose of olanzapine treatment in age-specific 
groups of children and adolescents increases from 1996 to 2001. 
 
Mean daily doses of olanzapine increased in children less than two years 
of age from 1996 to 2001, while olanzapine doses decreased over time in ten- to 
14-year olds.  Other age groups (2 to 4, 5 to 9, and 15 to 19 years) showed no 
distinct trends in olanzapine dosing.  ANOVA showed significant differences in 
mean olanzapine doses between calendar years for children and adolescents aged 
ten to 14 years (p<0.001).  In the ten- to 14-year age group, mean olanzapine 
doses in 1997 were significantly higher than those in 2001 (p=0.001).   
 












H13: The mean daily dose of quetiapine treatment in age-specific groups 
of children and adolescents increases from 1996 to 2001. 
 
The 15- to 19-year age groups showed a trend in increased quetiapine 
dosing from 1998 to 2001.  Other age groups showed no distinct trend in mean 
quetiapine dosing over the study period.  ANOVA showed no significant 
differences in mean quetiapine doses between calendar years for children and 
adolescents.   
 














H14: Antipsychotic switch rates in children and adolescents increase 
from 1996 to 2001. 
 
The prevalence of switches in antipsychotic treatment increased from 
114.8 per 1,000 youths receiving an antipsychotic in 1996 to 194.1 per 1,000 in 
2001 (Table 3.16, page 199).  A peak in the prevalence of antipsychotic switches 
occurred in 1999.  With each additional calendar year, a child or adolescent had a 
nine percent increase in the odds that they would experience a switch in 
antipsychotic treatment (OR=1.0968, 95% CI=1.0858 to 1.1080). 
Among children and adolescents having at least one switch in 
antipsychotic treatment, the mean (±SD) number of switches per youth during a 
calendar year remained fairly steady over the six-year period (range: 1.30±0.59 to 
1.38±0.67).  No significant differences in the mean number switches per youth 
between calendar years existed. 
Closer examination of the types of antipsychotic switches revealed a 
decrease in typical to typical antipsychotic switches over time (1996: 69.2%; 
1998: 15.8%; 2001: 3.0%).  Conversely, there was an increase in atypical to 
atypical antipsychotic switches (1996: 1.1%; 1998: 20.5%; 2001: 57.6%).  
Typical to atypical switches peaked in 1998, and atypical to typical switches 
peaked in 1999.  Chi-square analysis demonstrated a significant relationship 
between calendar year and type of antipsychotic switch (χ2=7848.66, df=15, 
p<0.001; Table 3.17, page 199). 
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Result: H14 accepted. 
 
Table 3.16. Prevalence of Antipsychotic Switches in Medi-Cal Youths from 
1996 to 2001 





13090 11710 13017 13349 15652 17884 
Number of 
youths with 










114.8 164.7 205.1 214.2 201.6 194.1 
 
 
Table 3.17. Types of Antipsychotic Switches in Medi-Cal Youths from 1996 to 
2001a 
Type of Switch  1996 1997 1998 1999 2000 2001 
Typical →Typical N 1355 1107 568 339 254 141 
                                                  % 69.2 42.8 15.8 8.6 5.9 3.0 
Typical → Atypical                  N 443 980 1565 1459 1467 1158 
 % 22.6 37.9 43.4 37.0 34.1 24.7 
Atypical → Typical N 139 333 733 883 777 693 
 % 7.1 12.9 20.3 22.4 18.1 14.8 
Atypical → Atypical N 21 168 737 1260 1806 2701 
 % 1.1 6.5 20.5 32.0 42.0 57.6 
aχ2=7848.66, df=15, p<0.001 
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H15: The prevalence of concomitant psychotropic medication use, 
including multiple antipsychotic agents, in children and 
adolescents receiving antipsychotic medications increases from 
1996 to 2001. 
 
The prevalence of concomitant psychotropic medication use increased by 
61 percent from 1996 to 2001 (+285.4 per 1,000 youths receiving an 
antipsychotic; Table 3.18, page 202).  Over the six-year period, the number of 
youths having at least one concomitant psychotropic medication during 
antipsychotic treatment steadily increased (Figure 3.10, page 202).  With each 
calendar year, a child or adolescent had a 25 percent increase in the odds of 
receiving a concomitant psychotropic medication during antipsychotic treatment 
(OR=1.2551; 95% CI=1.2448 to 1.2655). 
Antidepressants (range: 27.0% to 31.0%) were the most commonly used 
agents during each year, followed by antimanic/bipolar agents (range: 20.2% to 
23.6%; Table 3.19, page 203).  The use of psychostimulants increased from 1996 
to 2001, while the use of anti-parkinsonian agents decreased.  Chi-square analysis 
demonstrated a significant relationship between calendar year and the number of 
youths receiving different classes of concomitant psychotropic medications 
(χ2=1668.281, df=40, p<0.001). 
The prevalence of antipsychotic polypharmacy increased by 91 percent 
from 1996 to 2001 (+34.4 per 1,000 youths receiving an antipsychotic; Table 
3.20, page 204).  Over the six-year period, the number of youths receiving 
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treatment with two different antipsychotic medications for at least 30 days 
steadily increased (Figure 3.11, page 204).  With each calendar year, a child or 
adolescent had a 10 percent increase in the odds of receiving two different 
antipsychotic medications for a period of 30 days or more (OR=1.1049; 95% 
CI=1.0876 to 1.1224). 
The use of two typical agents decreased over time (1996: 66.2%; 1998: 
16.3%; 2001: 3.8%), while the use of two atypical agents increased (1996: 0.7%; 
1998: 18.3%; 2001: 53.1%).  The use of a typical and atypical agent 
concomitantly was fairly common during all study years (range: 33.1% to 65.4%), 
and peaked in 1998.  Chi-square analysis demonstrated a significant relationship 
between calendar year and percentage of type of antipsychotic polypharmacy 
(χ2=2284.515, df=10, p<0.001).   
 











Table 3.18. Prevalence of Concomitant Psychotropic Medication Use in Medi-
Cal Youths Receiving an Antipsychotic from 1996 to 2001 


















464.2 575.7 635.7 690.5 690.3 749.6 
 
Figure 3.10. Number of Medi-Cal Youths Receiving a Concomitant Psychotropic 
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Table 3.19. Medication Class of Concomitant Psychotropic Medications with 
Antipsychotic Treatment in Medi-Cal Youths from 1996 to 2001a 
Psychotropic Class  1996 1997 1998 1999 2000 2001 
Alpha-agonists                               N 886 1085 1447 1667 1999 2350 
                                                        % 8.6 8.9 9.3 9.5 9.6 9.2 
Antidepressants                              N 2772 3524 4546 5209 6198 7919 
 % 27.0 29.0 29.3 29.6 29.8 31.0 
Anti-parkinsonian agents N 1696 2054 2077 1950 1921 1943 
 % 16.5 16.9 13.4 11.1 9.3 7.6 
Anxiolytics/sedatives/hypnotics N 1043 1152 1504 1681 1882 2282 
 % 10.2 9.5 9.7 9.6 9.1 8.9 
Benzodiazepines N 513 541 632 686 780 1080 
 % 5.0 4.4 4.1 3.9 3.8 4.2 
Antimanic/bipolar agents N 2075 2518 3418 3974 4894 5935 
 % 20.2 20.7 22.0 22.6 23.6 23.2 
Psychostimulants N 953 992 1536 2069 2712 3568 
 % 9.3 8.1 9.9 11.8 13.1 14.0 
Substance abuse agents N 11 12 15 14 30 57 
 % 0.1 0.1 0.1 0.1 0.1 0.2 
Other psychotropic agents N 315 294 338 340 351 418 
 % 3.1 2.4 2.2 1.9 1.7 1.6 















Table 3.20. Prevalence of Antipsychotic Polypharmacy in Medi-Cal Youths 
Receiving an Antipsychotic from 1996 to 2001 

















37.6 56.4 76.3 81.7 74.6 72.0 
 
Figure 3.11. Number of Medi-Cal Youths with Antipsychotic Polypharmacy and 



























H16: Total cost for antipsychotic prescriptions for children and 
adolescents increases from 1996 to 2001. 
 
 In 1996, a total of $2,072,231 was spent on antipsychotic medications for 
children and adolescents.  Typical antipsychotics cost $948,325, and atypical 
antipsychotics cost $1,123,906.  Over the six-year period, substantial increases in 
the cost of all antipsychotics occurred, primarily due to the cost associated with 
the increased use of atypical antipsychotics (Figure 3.12, page 206).  In 2001, a 
total of $25,705,600 was spent on antipsychotic medications, and 98 percent of 
this total was associated with atypical antipsychotics ($25,235,474). 
 













Figure 3.12. Cost Associated with Antipsychotic Medications for Medi-Cal 


















































Prevalence of Antipsychotic Use in Children and Adolescents Enrolled in Ohio 
Medicaid (1996 to 2001) 
 
H1: The prevalence rate of total antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
 From 1996 to 2001, the prevalence rate of total antipsychotic use 
increased 3-fold (Figure 3.13, page 208).  In 1996, 4.72 youths per 1,000 
enrollees had at least one prescription for an antipsychotic.  The prevalence rate of 
total antipsychotic use increased steadily over the six-year period.  In 2001, an 
additional 9.62 youths per 1,000 enrollees received an antipsychotic compared to 
1996 (PREV in 2001=14.34; % change=203.89%). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of total antipsychotic use (χ2=5683.106, df=5, 
p<0.0001; Table 3.21, page 208).  Logistic regression analysis showed a 24 
percent increase in the odds of receiving any antipsychotic with each additional 
year (OR=1.2424; 95% CI=1.2353 to 1.2496). 
 






Table 3.21. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Total Antipsychotic Use in Ohio Medicaid Youths and Calendar 
Yeara,b 









3515 4430 5865 7265 9496 12099 
aχ2=5683.106, df=5, p<0.0001. 
bOR=1.2424 (95% CI: 1.2353 – 1.2496). 
 
Figure 3.13. Prevalence Rates of Total Antipsychotic Use in Ohio Medicaid 

































H2: The prevalence rate of atypical antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
From 1996 to 2001, the prevalence rate of atypical antipsychotic use 
increased 9-fold (Figure 3.14, page 210).  In 1996, 1.43 youths per 1,000 
enrollees had at least one prescription for an atypical antipsychotic.  Over the 
study period, there was an continual increase in the use of atypical antipsychotics.  
In 2001, the prevalence rate of atypical antipsychotic use was 13.09 youths per 
1,000 enrollees, which represented a 814.1 percent increase from 1996 (+11.66 
per 1,000). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of atypical antipsychotic use (χ2=10714.85, 
df=5, p<0.0001; Table 3.22, page 210).  Logistic regression analysis showed a 43 
percent increase in the odds of receiving an atypical antipsychotic with each 
additional year (OR=1.4335; 95% CI=1.4233 to 1.4437). 
 







Table 3.22. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Atypical Antipsychotic Use in Ohio Medicaid Youths and Calendar 
Yeara,b 









1067 2397 4054 5748 8246 11047 
aχ2=10714.85, df=5, p<0.0001. 
bOR=1.4335 (95% CI: 1.4233 – 1.4437). 
 
Figure 3.14. Prevalence Rates of Atypical Antipsychotic Use in Ohio Medicaid 

































H3: The prevalence rate of typical antipsychotic use in children and 
adolescents decreases from 1996 to 2001. 
 
From 1996 to 2001, the use of typical antipsychotics in youths enrolled in 
OH decreased by 46.9 percent (PR=0.53; Figure 3.15, page 212).  In 1996, 3.69 
youths per 1,000 enrollees had at least one prescription for a typical antipsychotic.  
Over the study period, the prevalence rate of typical antipsychotic use steadily 
decreased.  In 2001, 1.73 fewer youths per 1,000 enrollees received a typical 
antipsychotic (PREV=1.96 per 1,000). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of typical antipsychotic use (χ2=576.03, df=5, 
p<0.001; Table 3.23, page 212).  Logistic regression analysis showed an 11 
percent decrease in the odds of receiving a typical antipsychotic with each 
additional year (OR=0.8919; 95% CI=0.8832 to 0.9007). 
 








Table 3.23. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Typical Antipsychotic Use in Ohio Medicaid Youths and Calendar 
Yeara,b 









2748 2517 2382 2120 1910 1654 
aχ2=576.03, df=5, p<0.001. 
bOR=0.8919 (95% CI: 0.8832 – 0.9007). 
 
Figure 3.15. Prevalence Rates of Typical Antipsychotic Use in Ohio Medicaid 


































H4: During each study year (1996 – 2001), risperidone is the most 
commonly used atypical antipsychotic in children and adolescents. 
 
 Rank order of prevalence rates of specific atypical antipsychotic 
demonstrated that risperidone was the most commonly used agent in children and 
adolescents enrolled in OH over the six-year period (Table 3.24, page 213).  In 
1996, the prevalence rate of clozapine use was slightly lower than that of 
olanzapine.  In 1997, the prevalence rate of clozapine use was higher than that of 
quetiapine.  From 1998 to 2001, the prevalence rate of risperidone use was 
highest, followed by olanzapine, quetiapine, and clozapine.  In 2001, risperidone 
use was approximately double the use of olanzapine (PREV: 8.15 versus 3.68), 
and almost triple that of quetiapine (PREV: 8.15 versus 2.98). 
 
Result: H4 accepted. 
 
Table 3.24. Prevalence Rates of Specific Atypical Antipsychotic Use in Ohio 
Medicaid Youths from 1996 to 2001a,b 
Atypical 
Antipsychotic 






CLZ 0.07 0.08 0.07 0.08 0.09 0.09 1.29 28.90 
OLZ 0.10 1.01 1.74 1.93 2.85 3.68 36.54 3553.89 
QUET  0.01 0.49 1.30 2.20 2.98 233.38c 23238.29d 
RIS 1.32 2.60 4.25 5.93 7.81 8.15 6.20 519.63 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: CLZ=clozapine; OLZ=olanzapine; QUET=quetiapine; RIS=risperidone. 
cPrevalence ratio (2001:market entry). 
dPercent change from market entry to 2001. 
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H5: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
The overall use of antipsychotics decreased in children less than two years 
of age (PR=0.56, % change=-44.1%).  A trend toward the increased use of 
antipsychotics was seen in the two- to four-year olds (PR=2.84, % change=183.6), 
five- to nine-year olds (PR=4.71, % change=370.6%), ten- to 14-year olds 
(PR=3.19, % change=219.36%), and 15- to 19-year olds (PR=1.93, % 
change=93.4%; Table 3.25, page 215).  Adolescents aged 15 to 19 years had the 
highest prevalence rates during each calendar year, but ten- to 14-year olds had 
the steepest growth (+18.69 per 1,000; Figure 3.16, page 215).  Children between 
the ages of five and nine years had the greatest percent change in prevalence rates. 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of total antipsychotic use across all age groups 
(p<0.01; Table 3.25, page 215).  Logistic regression analysis showed an 11 
percent decrease in the odds of receiving any antipsychotic in the less than 2 years 
age group (OR=0.8906; 95% CI=0.8278 to 0.9582).  Children and adolescents 
aged five to nine years had the highest odds of receiving any antipsychotic with 
each calendar year (OR=1.3564; 95% CI=1.3400 to 1.3729), followed by two- to 
four-year olds (OR=1.2510; 95% CI=1.2112 to 1.2922), ten- to 14-year olds 
(OR=1.2500; 95% CI=1.2386 to 1.2615), and 15- to 19-year olds (OR=1.1304; 
95% CI=1.1199 to 1.1410). 
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Result: H5 accepted. 
 
Table 3.25. Age-Specific Prevalence Rates of Total Antipsychotic Use in Ohio 
Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.47 0.22 0.26 0.56 -44.07 27.27 <0.01 
2 – 4 y 0.77 1.53 2.17 2.84 183.58 209.27 <0.001 
5 – 9 y 3.05 6.57 14.35 4.71 370.57 2604.06 <0.0001 
10 – 14 y 8.52 16.22 27.21 3.19 219.36 2366.66 <0.0001 
15 – 19 y 14.55 21.52 28.12 1.93 93.35 694.41 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.16. Age-Specific Prevalence Rates of Total Antipsychotic Use in Ohio 
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H6: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
The use of atypical antipsychotics increased across all age categories 
greater than two years of age from 1996 to 2001 (Table 3.26, page 217; Figure 
3.17, page 217).  In children less than two years of age, there was a decrease in 
the prevalence of atypical antipsychotic use (-0.06 per 1,000; % change=31.9%).  
Compared to 1996, an additional 1.81 and 13.07 youths per 1,000 enrollees 
received an atypical antipsychotic in the two- to four-year old (PR=36.73, % 
change=3572.8%) and five- to nine-year old (PR=20.93, % change=1992.9%) 
groups, respectively, in 2001.  Prevalence rates of atypical antipsychotic use also 
increased 9-fold in the ten- to 14-year age group (+22.80 per 1,000), and 5-fold in 
the 15- to 19-year age group (+19.46 per 1,000) over the six-year period. 
 Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of atypical antipsychotic use across all age 
groups (p<0.01; Table 3.26, page 217).  Children between the ages of two and 
four years had the highest odds (OR=1.6594; 95% CI=1.5788 to 1.7442), 
followed by five- to nine-year olds (OR=1.5842; 95% CI=1.5608 to 1.6080), ten- 
to 14-year olds (OR=1.4183; 95% CI=1.4028 to 1.4339), and 15- to 19-year olds 
(OR=1.3009; 95% CI=1.2857 to 1.3162). 
 
Result: H6 accepted. 
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Table 3.26. Age-Specific Prevalence Rates of Atypical Antipsychotic Use in 
Ohio Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.19 0.08 0.13 0.68 -31.91 25.83 <0.01 
2 – 4 y 0.05 0.72 1.86 36.73 3572.77 484.39 <0.001 
5 – 9 y 0.66 4.72 13.73 20.93 1992.92 4211.95 <0.0001 
10 – 14 y 2.83 12.21 25.63 9.07 806.82 4233.77 <0.0001 
15 – 19 y 4.76 13.97 24.22 5.09 408.68 2031.99 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.17. Age-Specific Prevalence Rates of Atypical Antipsychotic Use in 
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H7: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across all age categories (<2, 2-4, 5-9, 10-14, and 15-19 
years). 
 
The use of typical antipsychotics decreased across all age categories from 
1996 to 2001 (Table 3.27, page 219).  Although prevalence rates of typical 
antipsychotic use in adolescents were higher than those for children, both children 
and adolescents received fewer typical antipsychotics over the six-year period 
(Figure 3.18, page 219).  Compared to 1996, there was a 49 to 59 percent 
decrease in the prevalence rate of typical antipsychotic use in children less than 
five years of age.  In youths above the age of five years, a 47 to 59 percent 
decrease in the use of typical antipsychotics. 
 Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of typical antipsychotic use across all age 
groups (p<0.01; Table 3.27, page 219).  Younger children had lower odds of 
receiving a typical antipsychotic with each calendar year compared to their older 
counterparts (<2 years: OR=0.8315; 95% CI=0.7583 to 0.9118).  Children and 
adolescents above the age of two years were less likely to receive a typical 
antipsychotic with each calendar year (2 to 4 years: OR=0.9214; 5 to 9 years: 
OR=0.8630; 10 to 14 years: OR=0.8555; and, 15 to 19 years: OR=0.8778). 
 
Result: H7 accepted. 
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Table 3.27. Age-Specific Prevalence Rates of Typical Antipsychotic Use in Ohio 
Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.38 0.14 0.16 0.41 -59.06 25.35 <0.01 
2 – 4 y 0.73 0.97 0.37 0.51 -49.08 42.34 <0.01 
5 – 9 y 2.55 2.39 1.04 0.41 -59.00 183.19 <0.001 
10 – 14 y 6.45 5.43 2.72 0.42 -57.80 338.71 <0.001 
15 – 19 y 11.09 9.79 5.83 0.53 -47.41 325.13 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.18. Age-Specific Prevalence Rates of Typical Antipsychotic Use in Ohio 
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H8: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across gender groups: male and female.   
 
The use of antipsychotics increased in both male and female groups from 
1996 to 2001 (Table 3.28, page 221).  Compared to 1996, an additional 13.65 
males and 5.54 females per 1,000 enrollees received an antipsychotic in 2001 
(Male: PR=3.29, % change=229.3%; Female: PR=2.58, % change=158.3%).  
During each calendar year, male prevalence rates of total antipsychotic use were 
higher than those of females (Figure 3.19, page 221). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of total antipsychotic use in males and females 
(p<0.0001; Table 3.28, page 221).  Males (OR=1.2613, 95% CI=1.2524 to 
1.2703) had higher odds of receiving any antipsychotic with each calendar year 
compared to females (OR=1.2038, 95% CI=1.1920 to 1.2157). 
 









Table 3.28. Gender-Specific Prevalence Rates of Total Antipsychotic Use in 
Ohio Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 5.96 11.29 19.61 3.29 229.33 4299.57 <0.0001 
Female 3.50 5.81 9.04 2.58 158.34 1403.02 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.19. Gender-Specific Prevalence Rates of Total Antipsychotic Use in 

































H9: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across gender groups: male and female. 
 
Prevalence rates of atypical antipsychotic use increased in both male and 
female groups from 1996 to 2001 (Table 3.29, page 223).  Compared to 1996, 
there was a 10-fold increase in atypical antipsychotic use in males in 2001, and a 
7-fold increase in females (Male: +16.67 per 1,000, % change=903.6%; Female: 
+6.63 per 1,000, % change=644.2%).  Male prevalence rates of atypical 
antipsychotic use were higher than those of females (Figure 3.20, page 223). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of atypical antipsychotic use in males and 
females (p<0.0001; Table 3.29, page 223).  Males showed a 45 percent increase in 
the odds of receiving an atypical antipsychotic with each additional calendar year 
(OR=1.4473, 95% CI=1.4350 to 1.4598), and females showed a 40 percent 
increase (OR=1.3994, 95% CI=1.3815 to 1.4175). 
 








Table 3.29. Gender-Specific Prevalence Rates of Atypical Antipsychotic Use in 
Ohio Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 1.84 8.26 18.51 10.04 903.57 7848.65 <0.0001 
Female 1.03 3.57 7.66 7.44 644.23 2836.07 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.20. Gender-Specific Prevalence Rates of Atypical Antipsychotic Use in 
































H10: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across gender groups: male and female. 
 
The use of typical antipsychotic use decreased by 55 percent in males, and 
33 percent in females from 1996 to 2001 (Table 3.30, page 225).  In 2001, 2.55 
fewer males and 0.92 fewer females per 1,000 received a typical antipsychotic 
compared to 1996 (Male: PR=0.45; Female: PR=0.67).  Male prevalence rates of 
typical antipsychotic use remained higher than those of females (Figure 3.21, 
page 225). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of typical antipsychotic use in males and 
females (p<0.001; Table 3.30, page 225).  Males showed a 13 percent decrease in 
the odds of receiving a typical antipsychotic with each additional calendar year 
(OR=0.8652, 95% CI=0.8541 to 0.8764), and females showed a seven percent 
decrease (OR=0.9305, 95% CI=0.9164 to 0.9448). 
 








Table 3.30. Gender-Specific Prevalence Rates of Typical Antipsychotic Use in 
Ohio Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 4.62 4.16 2.07 0.45 -55.16 527.38 <0.001 
Female 2.77 2.78 1.85 0.67 -33.36 105.98 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.21. Gender-Specific Prevalence Rates of Typical Antipsychotic Use in 
































H11: The mean daily dose of risperidone treatment in age-specific 
groups of children and adolescents decreases from 1996 to 2001. 
 
ANOVA showed significant differences in mean risperidone doses 
between calendar years for all age categories (p<0.01).  In the two- to four-year, 
ten- to 14-year, and 15- to 19-year age groups, a trend toward lower mean 
risperidone doses existed.  In five- to nine-year-olds, there was an initial increase 
in the mean risperidone dose until 1998, followed by a decrease in mean daily 
dose.  In children aged less than two years, a definitive trend in risperidone dosing 
did not exist over the six-year period.  
In the two- to four-year age group, mean risperidone doses from 1996 to 
2000 were significantly higher than those in 2001 (p≤0.003).  Mean risperidone 
doses in children between the ages of five and nine years were significantly lower 
in 1996 and 1997 compared to 1998 and 1999 (p<0.001).  In the same age group, 
mean risperidone doses in 1997 through 2000 were significantly higher than doses 
in 2001 (p<0.001).  In the ten- to 14-year age group, risperidone doses in 1996 
through 2000 were significantly higher than 2001 (p<0.001).  The same between-
year differences in risperidone dosing were seen in 15- to 19-year olds (1996 
through 2000 > 2001; p<0.001). 
 




H12: The mean daily dose of olanzapine treatment in age-specific 
groups of children and adolescents increases from 1996 to 2001. 
 
All age groups showed no definitive trend in olanzapine dosing from 1996 
to 2001.  ANOVA showed significant differences in mean olanzapine doses 
between calendar years for the less than two years, two- to four-year, ten to 14-
year, and 15- to 19-year age groups (p<0.001).  In the ten- to 14-year age group, 
mean olanzapine doses in 1998 were significantly higher than those in 1999 and 
2000 (p≤0.001).  Olanzapine doses in 1999 and 2000 were significantly lower 
than those in 2001 in ten- to 14-year-olds (p<0.001).  In the 15- to 19-year age 
group, mean olanzapine doses were significantly higher in 1998 and 2000, 
compared to 2001 (p<0.001 and p=0.007, respectively).   
 










H13: The mean daily dose of quetiapine treatment in age-specific groups 
of children and adolescents increases from 1996 to 2001. 
 
From 1998 to 2001, age groups greater than five years of age showed a 
trend of increased mean quetiapine doses.  No distinct time trends in quetiapine 
dosing existed for the younger children.  ANOVA showed significant differences 
in mean quetiapine doses between calendar years for all age groups, except the 
two- to four-year-olds (p<0.001). 
In the five- to nine-year age group, mean quetiapine doses were 
significantly lower in 1998 through 2000, compared to 2001 (p≤0.007).  Mean 
quetiapine doses in ten- to 14-year-olds were significantly lower in 1998 and 1999 
than those in 2000 and 2001 (p<0.001).  Finally, mean daily doses of quetiapine 
in adolescents aged 15 to 19 years were significantly lower in 1998 compared to 
1999, 2000, and 2001 (p<0.001). 
 








H14: Antipsychotic switch rates in children and adolescents increase 
from 1996 to 2001. 
 
The prevalence of switches in antipsychotic treatment increased from 
101.8 per 1,000 youths receiving an antipsychotic in 1996 to 167.0 per 1,000 in 
2001 (Table 3.31, page 230).  From 1997 to 1999, the prevalence of antipsychotic 
switches remained fairly steady, and increased thereafter.  With each additional 
calendar year, a child or adolescent had a nine percent increase in the odds that 
they would experience a switch in antipsychotic treatment (OR=1.0918, 95% 
CI=1.0730 to 1.1109). 
Among children and adolescents having at least one switch in 
antipsychotic treatment, the mean (±SD) number of switches per youth during a 
calendar year remained fairly steady over the six-year period (range: 1.22±0.51 to 
1.29±0.58).  No significant differences in the mean number switches per youth 
between calendar years existed. 
Closer examination of the types of antipsychotic switches revealed a 
decrease in typical to typical antipsychotic switches over time (1996: 32.3%; 
1998: 6.3%; 2001: 1.2%).  Typical to atypical switches and atypical to typical 
switches decreased over the six-year period.  There was an increase in atypical to 
atypical antipsychotic switches (1996: 5.5%; 1998: 36.9%; 2001: 75.8%).  Chi-
square analysis demonstrated a significant relationship between calendar year and 
type of antipsychotic switch (χ2=1820.44, df=15, p<0.001; Table 3.32, page 230). 
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Result: H14 accepted. 
 
Table 3.31. Prevalence of Antipsychotic Switches in Ohio Medicaid Youths 
from 1996 to 2001 





3515 4430 5865 7265 9496 12099 
Number of 











101.8 132.1 135.4 133.8 143.4 167.0 
 
 
Table 3.32. Types of Antipsychotic Switches in Ohio Medicaid Youths from 
1996 to 2001a 
Type of Switch  1996 1997 1998 1999 2000 2001 
Typical →Typical N 141 102 62 54 48 30 
                                                 % 32.3 14.3 6.3 4.3 2.8 1.2 
Typical → Atypical                 N 166 291 348 364 410 358 
 % 38.0 40.7 35.3 29.1 23.5 13.9 
Atypical → Typical N 106 158 212 253 240 237 
 % 24.3 22.1 21.5 20.2 13.8 9.2 
Atypical → Atypical N 24 164 364 582 1043 1959 
 % 5.5 22.9 36.9 46.4 59.9 75.8 
aχ2=1820.44, df=15, p<0.001 
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H15: The prevalence of concomitant psychotropic medication use, 
including multiple antipsychotic agents, in children and 
adolescents receiving antipsychotic medications increases from 
1996 to 2001. 
 
The prevalence of concomitant psychotropic medication use increased by 
46 percent from 1996 to 2001 (+263.3 per 1,000 youths receiving an 
antipsychotic; Table 3.33, page 233).  Over the six-year period, the number of 
youths having at least one concomitant psychotropic medication during 
antipsychotic treatment steadily increased (Figure 3.22, page 233).  With each 
calendar year, a child or adolescent had a 29 percent increase in the odds of 
receiving a concomitant psychotropic medication during antipsychotic treatment 
(OR=1.2896; 95% CI=1.2717 to 1.3077). 
Antidepressants (range: 27.2% to 30.2%) were the most commonly used 
agents from 1996 to 2000 (range: 27.2% to 30.2%; Table 3.34, page 234).  
Antimanic/bipolar agent use remained fairly constant (range: 22.0% to 24.6%), 
while the concomitant use of psychostimulants increased from 1996 to 2001 
substantially (1996: 7.3%; 1998: 17.7%; 2001: 27.5%).  Chi-square analysis 
demonstrated a significant relationship between calendar year and the number of 
youths receiving different classes of concomitant psychotropic medications 
(χ2=1920.42, df=40, p<0.001). 
The prevalence of antipsychotic polypharmacy was unable to be 
determined because of data integrity problems.  Due to a large percentage of 
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prescription records in which the ‘days supply’ field equaled the ‘quantity 
dispensed’ field, a proxy of 30 days was used as ‘days supply’.  This recoding 
affected the ability to determine prevalence rates of antipsychotic polypharmacy. 
 




















Table 3.33. Prevalence of Concomitant Psychotropic Medication Use in Ohio 
Medicaid Youths Receiving an Antipsychotic from 1996 to 2001 


















574.7 680.4 751.6 802.9 822.5 838.0 
 
Figure 3.22. Number of Ohio Medicaid Youths Receiving a Concomitant 
Psychotropic Medication While Receiving an Antipsychotic from 




















Youths receiving any other concomitant
psychotropic medication
Youths receiving an antipsychotic
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Table 3.34. Medication Class of Concomitant Psychotropic Medications with 
Antipsychotic Treatment in Ohio Medicaid Youths from 1996 to 
2001a 
Psychotropic Class  1996 1997 1998 1999 2000 2001 
Alpha-agonists                               N 361 644 970 1292 1612 1890 
                                                        % 10.7 11.8 11.4 11.1 10.3 9.6 
Antidepressants                              N 1013 1579 2280 3230 4264 5350 
 % 30.2 28.9 26.8 27.9 27.2 27.1 
Anti-parkinsonian agents N 363 561 742 749 795 799 
 % 10.8 10.3 8.7 6.5 5.1 4.0 
Anxiolytics/sedatives/hypnotics N 258 395 505 647 844 973 
 % 7.7 7.2 5.9 5.6 5.4 4.9 
Benzodiazepines N 176 225 314 375 463 542 
 % 5.2 4.1 3.7 3.2 3.0 2.7 
Antimanic/bipolar agents N 805 1344 1975 2551 3519 4387 
 % 24.0 24.6 23.2 22.0 22.5 22.2 
Psychostimulants N 246 549 1502 2489 3864 5422 
 % 7.3 10.1 17.7 21.5 24.7 27.5 
Substance abuse agents N 35 29 51 68 101 119 
 % 1.0 0.5 0.6 0.6 0.6 0.6 
Other psychotropic agents N 102 130 169 187 211 265 
 % 3.0 2.4 2.0 1.6 1.3 1.3 












H16: Total cost for antipsychotic prescriptions for children and 
adolescents increases from 1996 to 2001. 
 
 In 1996, a total of $777,425 was spent on antipsychotic medications for 
children and adolescents.  Typical antipsychotics cost $218,582, and atypical 
antipsychotics cost $558,844.  Over the six-year period, substantial increases in 
the cost of all antipsychotics occurred, primarily due to the cost associated with 
the increased use of atypical antipsychotics (Figure 3.23, page 236).  In 2001, a 
total of $10,607,043 was spent on antipsychotic medications, and 99 percent of 
this total was associated with atypical antipsychotics ($10,469,722). 
 













Figure 3.23. Cost Associated with Antipsychotic Medications for Ohio Medicaid 






















































Prevalence of Antipsychotic Use in Children and Adolescents Enrolled in Texas 
Medicaid (1996 to 2001) 
 
H1: The prevalence rate of total antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
 From 1996 to 2001, the prevalence rate of total antipsychotic use 
increased 2.45-fold (Figure 3.24, page 238).  In 1996, 6.33 youths per 1,000 
enrollees had at least one prescription for an antipsychotic.  The prevalence rate of 
total antipsychotic use increased steadily over the six-year period.  In 2001, an 
additional 9.21 youths per 1,000 enrollees received an antipsychotic compared to 
1996 (PREV in 2001=15.54; % change=145.34%). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of total antipsychotic use (χ2=6424.48, df=5, 
p<0.0001; Table 3.35, page 238).  Logistic regression analysis showed a 19 
percent increase in the odds of receiving any antipsychotic with each additional 
year (OR=1.1883; 95% CI=1.1832 to 1.1935). 
 






Table 3.35. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Total Antipsychotic Use in Texas Medicaid Youths and Calendar 
Yeara,b 









7240 8875 10656 12664 14879 17790 
aχ2=6424.48, df=5, p<0.0001. 
bOR=1.1883 (95% CI: 1.1832 – 1.1935). 
 
Figure 3.24. Prevalence Rates of Total Antipsychotic Use in Texas Medicaid 

































H2: The prevalence rate of atypical antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
From 1996 to 2001, the prevalence rate of atypical antipsychotic use 
increased 6-fold (Figure 3.25, page 240).  In 1996, 2.49 youths per 1,000 
enrollees had at least one prescription for an atypical antipsychotic.  Over the 
study period, there was an increase in the use of atypical antipsychotics.  In 2001, 
the prevalence rate of atypical antipsychotic use was 14.88 youths per 1,000 
enrollees, which represented a 498.6 percent increase from 1996 (+12.39 per 
1,000). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of atypical antipsychotic use (χ2=13991.22, 
df=5, p<0.0001; Table 3.36, page 240).  Logistic regression analysis showed a 35 
percent increase in the odds of receiving an atypical antipsychotic with each 
additional year (OR=1.3452; 95% CI=1.3384 to 1.3520). 
 







Table 3.36. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Atypical Antipsychotic Use in Texas Medicaid Youths and Calendar 
Yeara,b 









2841 5522 8064 10558 13493 17034 
aχ2=13991.22, df=5, p<0.0001. 
bOR=1.3452 (95% CI: 1.3384 – 1.3520). 
 
Figure 3.25. Prevalence Rates of Atypical Antipsychotic Use in Texas Medicaid 

































H3: The prevalence rate of typical antipsychotic use in children and 
adolescents decreases from 1996 to 2001. 
 
From 1996 to 2001, the use of typical antipsychotics in youths enrolled in 
TX decreased by 66.3 percent (PR=0.34; Figure 3.26, page 242).  In 1996, 4.55 
youths per 1,000 enrollees had at least one prescription for a typical antipsychotic.  
Over the study period, the prevalence rate of typical antipsychotic use steadily 
decreased.  In 2001, 3.02 fewer youths per 1,000 enrollees received a typical 
antipsychotic (PREV=1.53 per 1,000). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of typical antipsychotic use (χ2=2091.31, df=5, 
p<0.0001; Table 3.37, page 242).  Logistic regression analysis showed a 16 
percent decrease in the odds of receiving a typical antipsychotic with each 
additional year (OR=0.8416; 95% CI=0.8351 to 0.8483). 
 








Table 3.37. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Typical Antipsychotic Use in Texas Medicaid Youths and Calendar 
Yeara,b 









5200 4573 3907 3524 2788 1753 
aχ2=2091.31, df=5, p<0.0001. 
bOR=0.8416 (95% CI: 0.8351 – 0.8483). 
 
Figure 3.26. Prevalence Rates of Typical Antipsychotic Use in Texas Medicaid 
Youths from 1996 to 2001 





























H4: During each study year (1996 – 2001), risperidone is the most 
commonly used atypical antipsychotic in children and adolescents. 
 
 Rank order of prevalence rates of specific atypical antipsychotic 
demonstrated that risperidone was the most commonly used agent in children and 
adolescents enrolled in TX over the six-year period (Table 3.38, page 243).  The 
prevalence rate of clozapine use was lower than that of olanzapine in 1996, and 
lower than that of quetiapine in 1997.  From 1998 to 2001, the prevalence rate of 
risperidone use was highest, followed by olanzapine, quetiapine, and clozapine.  
In 2001, risperidone use was more than double the use of olanzapine (PREV: 
10.07 versus 4.46), and more than triple that of quetiapine (PREV: 10.07 versus 
2.77). 
 
Result: H4 accepted. 
 
Table 3.38. Prevalence Rates of Specific Atypical Antipsychotic Use in Texas 
Medicaid Youths from 1996 to 2001a,b 
Atypical 
Antipsychotic 






CLZ 0.04 0.04 0.04 0.05 0.05 0.05 1.14 13.82 
OLZ 0.07 1.00 2.05 3.12 3.94 4.46 60.73 5972.68 
QUET  0.06 0.49 1.30 1.85 2.77 47.45c 4644.97d 
RIS 2.43 4.64 6.47 7.84 9.60 10.07 4.14 314.04 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: CLZ=clozapine; OLZ=olanzapine; QUET=quetiapine; RIS=risperidone. 
cPrevalence ratio (2001:market entry). 
dPercent change from market entry to 2001. 
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H5: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
From 1996 to 2001, the overall use of antipsychotics increased in all age 
groups (<2 years: PR=1.41, % change=41.4%; 2 to 4 years: PR=2.39, % 
change=138.6%; 5 to 9 years: PR=2.89, % change=189.1%; 10 to 14 years: 
PR=2.23, % change=122.5%; 15 to 19 years: PR=1.69, % change=68.9%; Table 
3.39, page 245).  Children and adolescents aged ten to 14 years had the highest 
prevalence rates from 1998 to 2001, and had the steepest growth (+19.48 per 
1,000; Figure 3.27, page 245).  Children between the ages of five and nine years 
had the greatest percent change in prevalence rates from 1996 to 2001. 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of total antipsychotic use across youths older 
than two years (p<0.001; Table 3.39, page 245).  Children and adolescents aged 
five to nine years had the highest odds of receiving any antipsychotic with each 
calendar year (OR=1.2344; 95% CI=1.2254 to 1.2436), followed by two- to four-
year olds (OR=1.1800; 95% CI=1.1615 to 1.1989) and ten- to 14-year olds 
(OR=1.1743; 95% CI=1.1667 to 1.1819).  Adolescents between the ages of 15 
and 19 years had lower odds of receiving any antipsychotic with each additional 
calendar year (OR=1.0964; 95% CI=1.0862 to 1.1067). 
 
Result: H5 accepted. 
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Table 3.39. Age-Specific Prevalence Rates of Total Antipsychotic Use in Texas 
Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.29 0.38 0.41 1.41 41.44 10.31 0.07 
2 – 4 y 2.30 3.43 5.50 2.39 138.63 429.32 <0.001 
5 – 9 y 7.17 12.90 20.74 2.89 189.08 3269.34 <0.0001 
10 – 14 y 15.90 27.33 35.38 2.23 122.52 2726.24 <0.0001 
15 – 19 y 15.59 19.72 26.33 1.69 68.87 407.16 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.27. Age-Specific Prevalence Rates of Total Antipsychotic Use in Texas 
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H6: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
The use of atypical antipsychotics increased across all ages (Figure 3.28, 
page 247).  In children less than two years of age, a 5.6-fold increase in the 
prevalence of atypical antipsychotic use existed (+0.23 per 1,000; % 
change=458.6%).  Compared to 1996, an additional 4.69 and 17.33 youths per 
1,000 enrollees received an atypical antipsychotic in the two- to four-year old 
(PR=9.37, % change=836.6%) and five- to nine-year old (PR=7.44, % 
change=643.7%) groups, respectively, in 2001.  Atypical antipsychotic use 
increased 5-fold in the ten- to 14-year age group (+27.35 per 1,000), and 3.8-fold 
in the 15- to 19-year age group (+18.26 per 1,000). 
 Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of atypical antipsychotic use across all age 
groups (p<0.01; Table 3.40, page 247).  Children between the ages of two and 
four years had the highest odds (OR=1.4535; 95% CI=1.4235 to 1.4841), 
followed by five- to nine-year olds (OR=1.4091; 95% CI=1.3968 to 1.4214), and 
less than two year olds (OR=1.3196; 95% CI=1.2185 to 1.4291).  Ten- to 14-year 
olds had a 31 percent increase in the odds of receiving an atypical antipsychotic 
with each year (OR=1.3082; 95% CI=1.2985 to 1.3181), while 15- to 19-year olds 
had a 24 percent increase in odds (OR=1.2413; 95% CI=1.2276 to 1.2551). 
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Result: H6 accepted. 
 
Table 3.40. Age-Specific Prevalence Rates of Atypical Antipsychotic Use in 
Texas Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.05 0.15 0.28 5.59 458.63 49.06 <0.01 
2 – 4 y 0.56 2.10 5.25 9.37 836.55 1365.36 <0.0001 
5 – 9 y 2.69 9.70 20.02 7.44 643.76 6447.51 <0.0001 
10 – 14 y 6.69 21.48 34.04 5.09 408.77 5520.13 <0.0001 
15 – 19 y 6.52 14.82 24.78 3.80 280.02 1536.16 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.28. Age-Specific Prevalence Rates of Atypical Antipsychotic Use in 
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H7: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across all age categories (<2, 2-4, 5-9, 10-14, and 15-19 
years). 
 
The use of typical antipsychotics decreased across all age categories from 
1996 to 2001 (Table 3.41, page 249).  Although prevalence rates of typical 
antipsychotic use in adolescents were higher than those for children, both children 
and adolescents received fewer typical antipsychotics over the six-year period 
(Figure 3.29, page 249).  Compared to 1996, there was a 48 to 77 percent 
decrease in the prevalence rate of typical antipsychotic use in children less than 
five years of age.  In youths above the age of five years, a 67 to 70 percent 
decrease occurred in the use of typical antipsychotics. 
 Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of typical antipsychotic use across all age 
groups (p<0.01; Table 3.41, page 249).  Children below the age of two years had 
higher odds of receiving a typical antipsychotic with each calendar year compared 
to their older counterparts (<2 years: OR=0.9119; 95% CI=0.8544 to 0.9731).  
The odds of receiving a typical antipsychotic with each calendar year were similar 
for the two- to four-year and 15- to 19-year age groups (2 to 4 years: OR=0.8053; 
15 to 19 years: OR=0.8045).  Both the five- to nine-year and ten- to 14-year age 
groups showed a 17 percent decrease in odds of receiving a typical antipsychotic. 
 
Result: H7 accepted. 
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Table 3.41. Age-Specific Prevalence Rates of Typical Antipsychotic Use in 
Texas Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.26 0.26 0.14 0.52 -48.29 16.08 <0.01 
2 – 4 y 1.92 1.64 0.43 0.23 -77.31 284.84 <0.001 
5 – 9 y 5.12 4.58 1.54 0.30 -69.93 737.43 <0.001 
10 – 14 y 10.90 8.99 3.19 0.29 -70.72 988.91 <0.001 
15 – 19 y 11.00 7.46 3.67 0.33 -66.64 749.65 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.29. Age-Specific Prevalence Rates of Typical Antipsychotic Use in 
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H8: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across gender groups: male and female.   
 
The use of antipsychotics increased in both male and female groups from 
1996 to 2001 (Table 3.42, page 251).  Compared to 1996, an additional 12.07 
males and 6.19 females per 1,000 enrollees received an antipsychotic in 2001 
(Male: PR=2.37, % change=137.2%; Female: PR=2.63, % change=162.7%).  
During each calendar year, male prevalence rates of total antipsychotic use were 
higher than those of females (Figure 3.30, page 251). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of total antipsychotic use in males and females 
(p<0.0001; Table 3.42, page 251).  Females (OR=1.2057, 95% CI=1.1965 to 
1.2150) had higher odds of receiving any antipsychotic with each calendar year 
compared to males (OR=1.1786, 95% CI=1.1725 to 1.1848). 
 









Table 3.42. Gender-Specific Prevalence Rates of Total Antipsychotic Use in 
Texas Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 8.79 14.66 20.86 2.37 137.24 3918.77 <0.0001 
Female 3.81 6.61 10.00 2.63 162.74 2390.94 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.30. Gender-Specific Prevalence Rates of Total Antipsychotic Use in 

































H9: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across gender groups: male and female. 
 
Prevalence rates of atypical antipsychotic use increased in both male and 
female groups from 1996 to 2001 (Table 3.43, page 253).  Compared to 1996, 
there was a 5.9-fold increase in atypical antipsychotic use in males in 2001, and a 
6.2-fold increase in females (Male: +16.62 per 1,000, % change=488.3%; Female: 
+7.99 per 1,000, % change=517.3%).  Male prevalence rates of atypical 
antipsychotic use were higher than those of females (Figure 3.31, page 253). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of atypical antipsychotic use in males and 
females (p<0.0001; Table 3.43, page 253).  Males showed a 34 percent increase in 
the odds of receiving an atypical antipsychotic with each additional calendar year 
(OR=1.3414, 95% CI=1.3331 to 1.3498), and females showed a 35 percent 
increase (OR=1.3511, 95% CI=1.3390 to 1.3633). 
 








Table 3.43. Gender-Specific Prevalence Rates of Atypical Antipsychotic Use in 
Texas Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 3.40 11.01 20.02 5.88 488.27 9170.99 <0.0001 
Female 1.54 5.09 9.53 6.17 517.32 4611.29 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.31. Gender-Specific Prevalence Rates of Atypical Antipsychotic Use in 
































H10: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across gender groups: male and female. 
 
The use of typical antipsychotics decreased by 69 percent in males, and 61 
percent in females from 1996 to 2001 (Table 3.44, page 255).  In 2001, 4.35 fewer 
males and 1.65 fewer females per 1,000 received a typical antipsychotic 
compared to 1996 (Male: PR=0.31; Female: PR=0.39).  Male prevalence rates of 
typical antipsychotic use remained higher than those of females (Figure 3.32, 
page 255). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of typical antipsychotic use in males and 
females (p<0.001; Table 3.44, page 255).  Males showed a 19 percent decrease in 
the odds of receiving a typical antipsychotic with each additional calendar year 
(OR=0.8256, 95% CI=0.8178 to 0.8336), and females showed a 13 percent 
decrease (OR=0.8715, 95% CI=0.8595 to 0.8837). 
 








Table 3.44. Gender-Specific Prevalence Rates of Typical Antipsychotic Use in 
Texas Medicaid Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 6.33 5.42 1.98 0.31 -68.67 1688.52 <0.0001 
Female 2.71 2.39 1.06 0.39 -60.84 472.11 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.32. Gender-Specific Prevalence Rates of Typical Antipsychotic Use in 
































H11: The mean daily dose of risperidone treatment in age-specific 
groups of children and adolescents decreases from 1996 to 2001. 
 
A trend toward lower mean daily doses of risperidone over the six-year 
period existed in children and adolescents above the age of five years.  A trend 
toward lower risperidone doses existed in children younger than five years after 
1998.  ANOVA showed significant differences in mean risperidone doses 
between calendar years for age categories greater than two years of age (p<0.001).   
In the two- to four-year age group, mean risperidone doses in 1996 
through 1998 were significantly higher than those in 2000 and 2001 (p≤0.002).  
Mean risperidone doses in children aged five and nine years were significantly 
higher from 1996 to 1999 compared to 2000 and 2001 (p<0.001).  In ten- to 14-
year olds, risperidone doses in 1996 were significantly higher than all subsequent 
years (p<0.001).  Risperidone doses in this age group in 1997 and 1998 were 
significantly higher than those in 2000 and 2001 (p<0.001).  Mean risperidone 
doses in 15- to 19-year olds were significantly higher in 1996 compared to 1998 
through 2001.  Risperidone doses in 1997 and 1998 were higher than 2000 and 
2001 (p<0.001). 
 





H12: The mean daily dose of olanzapine treatment in age-specific 
groups of children and adolescents increases from 1996 to 2001. 
 
Mean daily doses of olanzapine showed a decreasing trend in children and 
adolescents between the ages of ten and 14 years.  In 15- to 19-year olds, 
olanzapine doses remained fairly constant from 1997 to 2001.  Other age groups 
(<2, 2 to 4, and 5 to 9 years) showed no distinct trends in olanzapine dosing.  
ANOVA showed significant differences in mean olanzapine doses between 
calendar years for children and adolescents aged five to 14 years (p<0.001).  In 
five- to nine-year olds, post hoc analyses revealed no significant between-year 
differences.  In the ten- to 14-year age group, mean olanzapine doses in 1996 and 
1997 were significantly higher than those in 2000 and 2001 (p≤0.01).   
 











H13: The mean daily dose of quetiapine treatment in age-specific groups 
of children and adolescents increases from 1996 to 2001. 
 
In children and adolescents above the age of two years, a trend in 
increased quetiapine dosing existed from 1998 to 2001.  ANOVA showed 
significant differences in mean quetiapine doses between calendar years for 
children and adolescents above the age of five years (p<0.001). 
In children between the ages of five and nine years, mean quetiapine doses 
in 1998 were significantly lower than those from 1999 to 2001 (p≤0.006).  In ten- 
to 14-year olds, quetiapine doses in 1998 and 1999 were significantly lower than 
2001 doses (p=0.001 and p=0.002, respectively).  Mean quetiapine doses in 
adolescents aged 15 to 19 years were significantly lower in 1998 compared to 
2000 and 2001 (p≤0.002).   
 










H14: Antipsychotic switch rates in children and adolescents increase 
from 1996 to 2001. 
 
The prevalence of switches in antipsychotic treatment increased from 
160.1 per 1,000 youths receiving an antipsychotic in 1996 to 202.3 per 1,000 in 
2001 (Table 3.45, page 260).  With each additional calendar year, a child or 
adolescent had a four percent increase in the odds that they would experience a 
switch in antipsychotic treatment (OR=1.0392, 95% CI=1.0276 to 1.0510). 
Among children and adolescents having at least one switch in 
antipsychotic treatment, the mean (±SD) number of switches per youth during a 
calendar year remained fairly steady over the six-year period (range: 1.24±0.54 to 
1.30±0.63).  No significant differences in the mean number of switches per youth 
between calendar years existed. 
Closer examination of the types of antipsychotic switches revealed a 
decrease in typical to typical antipsychotic switches over time (1996: 34.3%; 
1998: 8.5%; 2001: 1.2%).  Conversely, there was an increase in atypical to 
atypical antipsychotic switches (1996: 4.2%; 1998: 32.2%; 2001: 71.0%).  
Typical to atypical switches peaked in 1997, and then decreased over time.  
Atypical to typical switches also peaked in 1997, and then decreased.  Chi-square 
analysis demonstrated a significant relationship between calendar year and type of 
antipsychotic switch (χ2=4056.84, df=15, p<0.001; Table 3.46, page 260). 
 
Result: H14 accepted. 
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Table 3.45. Prevalence of Antipsychotic Switches in Texas Medicaid Youths 
from 1996 to 2001 





7240 8875 10656 12664 14879 17790 
Number of 











160.1 188.4 192.9 199.5 196.1 202.3 
 
 
Table 3.46. Types of Antipsychotic Switches in Texas Medicaid Youths from 
1996 to 2001a 
Type of Switch  1996 1997 1998 1999 2000 2001 
Typical →Typical N 492 316 222 185 170 58 
                                                 % 34.3 14.8 8.5 5.7 4.5 1.2 
Typical → Atypical                 N 617 932 1006 1105 1176 831 
 % 43.0 43.8 38.7 33.9 31.0 17.9 
Atypical → Typical N 266 462 532 594 567 457 
 % 18.5 21.7 20.5 18.2 14.9 9.8 
Atypical → Atypical N 60 419 837 1379 1883 3296 
 % 4.2 19.7 32.2 42.3 49.6 71.0 




H15: The prevalence of concomitant psychotropic medication use, 
including multiple antipsychotic agents, in children and 
adolescents receiving antipsychotic medications increases from 
1996 to 2001. 
 
The prevalence of concomitant psychotropic medication use increased by 
12 percent from 1996 to 2001 (+107.9 per 1,000 youths receiving an 
antipsychotic; Table 3.47, page 263).  Over the six-year period, the number of 
youths having at least one concomitant psychotropic medication during 
antipsychotic treatment steadily increased (Figure 3.33, page 263).  With each 
calendar year, a child or adolescent had a 46 percent increase in the odds of 
receiving a concomitant psychotropic medication during antipsychotic treatment 
(OR=1.4643; 95% CI=1.4358 to 1.4934). 
Antidepressants (range: 26.1% to 28.8%) were the most commonly used 
agents during each year, followed by psychostimulants (range: 20.7% to 23.7%; 
Table 3.48, page 264).  The use of antimanic/bipolar agents increased from 1996 
to 2001, while the use of anti-parkinsonian agents decreased.  Chi-square analysis 
demonstrated a significant relationship between calendar year and the number of 
youths receiving different classes of concomitant psychotropic medications 
(χ2=1069.30, df=40, p<0.001). 
The prevalence of antipsychotic polypharmacy increased by 58 percent 
from 1996 to 2001 (+23.4 per 1,000 youths receiving an antipsychotic; Table 
3.49, page 265).  Over the six-year period, the number of youths receiving 
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treatment with two different antipsychotic medications for at least 30 days 
steadily increased (Figure 3.34, page 265).  With each calendar year, a child or 
adolescent had an eight percent increase in the odds of receiving two different 
antipsychotic medications for a period of 30 days or more (OR=1.0778; 95% 
CI=1.0572 to 1.0988). 
The use of two typical agents decreased over time (1996: 32.2%; 1998: 
5.5%; 2001: 1.4%), while the use of two atypical agents increased (1996: 2.7%; 
1998: 31.9%; 2001: 63.5%).  The use of a typical and atypical agent 
concomitantly was fairly common during all study years (range: 35.1% to 67.5%), 
and peaked in 1997.  Chi-square analysis demonstrated a significant relationship 
between calendar year and percentage of type of antipsychotic polypharmacy 
(χ2=958.118, df=10, p<0.001).   
 











Table 3.47. Prevalence of Concomitant Psychotropic Medication Use in Texas 
Medicaid Youths Receiving an Antipsychotic from 1996 to 2001 


















868.8 906.1 931.6 951.8 971.5 976.7 
 
Figure 3.33. Number of Texas Medicaid Youths Receiving a Concomitant 
Psychotropic Medication While Receiving an Antipsychotic from 
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Table 3.48. Medication Class of Concomitant Psychotropic Medications with 
Antipsychotic Treatment in Texas Medicaid Youths from 1996 to 
2001a 
Psychotropic Class  1996 1997 1998 1999 2000 2001 
Alpha-agonists                               N 1333 1785 2302 2889 3481 4067 
                                                        % 10.6 10.8 10.9 11.0 11.0 10.7 
Antidepressants                              N 3297 4526 5945 7462 8988 10903 
 % 26.1 27.4 28.0 28.5 28.5 28.8 
Anti-parkinsonian agents N 1155 1146 1303 1350 1400 1557 
 % 9.1 6.9 6.1 5.1 4.4 4.1 
Anxiolytics/sedatives/hypnotics N 1010 1233 1467 1747 1936 2104 
 % 8.0 7.5 6.9 6.7 6.1 5.6 
Benzodiazepines N 662 827 985 1114 1285 1450 
 % 5.2 5.0 4.6 4.2 4.1 3.8 
Antimanic/bipolar agents N 2250 3163 4250 5513 6743 8145 
 % 17.8 19.1 20.1 21.0 21.3 21.5 
Psychostimulants N 2620 3501 4490 5591 7190 8987 
 % 20.7 21.2 21.2 21.3 22.8 23.7 
Substance abuse agents N 54 71 60 70 70 70 
 % 0.4 0.4 0.3 0.3 0.2 0.2 
Other psychotropic agents N 249 279 393 468 492 584 
 % 2.0 1.7 1.9 1.8 1.6 1.5 














Table 3.49. Prevalence of Antipsychotic Polypharmacy in Texas Medicaid 
Youths Receiving an Antipsychotic from 1996 to 2001 
















40.5 51.0 56.5 63.4 62.5 63.9 
 
Figure 3.34. Number of Texas Medicaid Youths with Antipsychotic 



























H16: Total cost for antipsychotic prescriptions for children and 
adolescents increases from 1996 to 2001. 
 
 In 1996, a total of $2,735,845 was spent on antipsychotic medications for 
children and adolescents.  Typical antipsychotics cost $467,522, and atypical 
antipsychotics cost $2,268,323.  Over the six-year period, substantial increases in 
the cost of all antipsychotics occurred, primarily due to the cost associated with 
the increased use of atypical antipsychotics (Figure 3.35, page 267).  In 2001, a 
total of $19,514,011 was spent on antipsychotic medications, and 99 percent of 
this total was associated with atypical antipsychotics ($19,337,017). 
 













Figure 3.35. Cost Associated with Antipsychotic Medications for Texas Medicaid 






















































Prevalence of Antipsychotic Use in Children and Adolescents Enrolled in the 
Private Managed Care Organization (1996 to 2001) 
 
H1: The prevalence rate of total antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
 From 1996 to 2001, the prevalence rate of total antipsychotic use 
increased 2.32-fold (Figure 3.36, page 269).  In 1996, 1.48 youths per 1,000 
enrollees had at least one prescription for an antipsychotic.  The prevalence rate of 
total antipsychotic use increased steadily over the six-year period, with much of 
the growth occurring after 1998.  From 2000 to 2001, there was a decrease in the 
prevalence of total antipsychotic use in MCO youths.  In 2001, an additional 1.95 
youths per 1,000 enrollees received an antipsychotic compared to 1996 (PREV in 
2001=3.43; % change=132.4%). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of total antipsychotic use (χ2=1771.75, df=5, 
p<0.0001; Table 3.50, page 269).  Logistic regression analysis showed a 24 
percent increase in the odds of receiving any antipsychotic with each additional 
year (OR=1.2364; 95% CI=1.2229 to 1.2501). 
 





Table 3.50. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Total Antipsychotic Use in Managed Care Organization Youths and 
Calendar Yeara,b 











1338 1423 1725 2305 2861 2172 
aχ2=1771.75, df=5, p<0.0001. 
bOR=1.2364 (95% CI: 1.2229 – 1.2501). 
 
Figure 3.36. Prevalence Rates of Total Antipsychotic Use in Managed Care 


































H2: The prevalence rate of atypical antipsychotic use in children and 
adolescents increases from 1996 to 2001. 
 
From 1996 to 2001, the prevalence rate of atypical antipsychotic use 
increased 7-fold (Figure 3.37, page 271).  In 1996, 0.37 youths per 1,000 
enrollees had at least one prescription for an atypical antipsychotic.  The use of 
atypical antipsychotics increased from 1996 to 2000, and then decreased in 2001.  
In 2001, the prevalence rate of atypical antipsychotic use was 2.67 youths per 
1,000 enrollees, which represented a 616.2 percent increase from 1996 (+2.30 per 
1,000). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of atypical antipsychotic use (χ2=3060.49, df=5, 
p<0.0001; Table 3.51, page 271).  Logistic regression analysis showed a 48 
percent increase in the odds of receiving an atypical antipsychotic with each 
additional year (OR=1.4779; 95% CI=1.4557 to 1.5005). 
 







Table 3.51. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Atypical Antipsychotic Use in Managed Care Organization Youths 
and Calendar Yeara,b 









338 590 873 1486 2075 1691 
aχ2=3060.49, df=5, p<0.0001. 
bOR=1.4779 (95% CI: 1.4557 – 1.5005). 
 
Figure 3.37. Prevalence Rates of Atypical Antipsychotic Use in Managed Care 


































H3: The prevalence rate of typical antipsychotic use in children and 
adolescents decreases from 1996 to 2001. 
 
From 1996 to 2001, the use of typical antipsychotics in youths enrolled in 
MCO decreased by 27.8 percent (PR=0.72; Figure 3.38, page 273).  In 1996, 1.19 
youths per 1,000 enrollees had at least one prescription for a typical antipsychotic.  
Over the study period, the prevalence rate of typical antipsychotic use slightly 
decreased from 1996 to 1998.  During the next couple of years, the use of typical 
antipsychotics increased until 2000, and then decreased in 2001.  In 2001, 0.33 
fewer youths per 1,000 enrollees received a typical antipsychotic (PREV=0.86 per 
1,000). 
 Chi-square analysis demonstrated a significant relationship between 
calendar year and prevalence rate of typical antipsychotic use (χ2=67.50, df=5, 
p<0.01; Table 3.52, page 273).  Logistic regression analysis showed a two percent 
decrease in the odds of receiving a typical antipsychotic with each additional year 
(OR=0.9801; 95% CI=0.9643 to 0.9962). 
 







Table 3.52. Chi-Square Analysis of the Relationship Between Prevalence Rate of 
Typical Antipsychotic Use in Managed Care Organization Youths 
and Calendar Yeara,b 









1079 903 935 928 890 544 
aχ2=67.50, df=5, p<0.01. 
bOR=0.9801 (95% CI: 0.9643 – 0.9962). 
 
Figure 3.38. Prevalence Rates of Typical Antipsychotic Use in Managed Care 
































H4: During each study year (1996 – 2001), risperidone is the most 
commonly used atypical antipsychotic in children and adolescents. 
 
 Rank order of prevalence rates of specific atypical antipsychotic 
demonstrated that risperidone was the most commonly used agent in children and 
adolescents enrolled in MCO over the six-year period (Table 3.53, page 274).  
The prevalence rate of clozapine use was lower than that of olanzapine in 1996, 
and slightly higher than that of quetiapine in 1997.  From 1998 to 2001, the 
prevalence rate of risperidone use was highest, followed by olanzapine, 
quetiapine, and clozapine.  In 2001, risperidone use was more than double the use 
of olanzapine (PREV: 1.68 versus 0.65), and triple that of quetiapine (PREV: 1.68 
versus 0.56). 
 
Result: H4 accepted. 
 
Table 3.53. Prevalence Rates of Specific Atypical Antipsychotic Use in 
Managed Care Organization Youths from 1996 to 2001a,b 
Atypical 
Antipsychotic 






CLZ 0.004 0.003 0.003 0.01 0.009 0.006 1.43 43.14 
OLZ 0.01 0.13 0.26 0.47 0.75 0.65 44.93 4392.58 
QUET  0.002 0.03 0.14 0.43 0.56 244.28c 24328.04d 
RIS 0.36 0.58 0.73 1.33 2.07 1.68 4.61 360.67 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: CLZ=clozapine; OLZ=olanzapine; QUET=quetiapine; RIS=risperidone. 
cPrevalence ratio (2001:market entry). 
dPercent change from market entry to 2001. 
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H5: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
From 1996 to 2001, the overall use of antipsychotics increased in all age 
groups (<2 years: PR=1.48, % change=48.4%; 2 to 4 years: PR=2.30, % 
change=130.2%; 5 to 9 years: PR=3.51, % change=251.0%; 10 to 14 years: 
PR=2.64, % change=164.3%; 15 to 19 years: PR=1.68, % change=68.1%; Table 
3.54, page 276).  Adolescents aged 15 to 19 years had the highest prevalence rates 
from 1996 to 1999.  Ten- to 14-year olds had the highest prevalence rates in 2000 
and 2001, and had the steepest growth (+3.04 per 1,000; Figure 3.39, page 276).  
Children between the ages of five and nine years had the greatest percent change 
in prevalence rates from 1996 to 2001. 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of total antipsychotic use across all age groups 
(p<0.001; Table 3.54, page 276).  Children and adolescents aged five to nine 
years had the highest odds of receiving any antipsychotic with each calendar year 
(OR=1.3392; 95% CI=1.3066 to 1.3726), followed by ten- to 14-year olds 
(OR=1.2644; 95% CI=1.2411 to 1.2882) and two- to four-year olds (OR=1.2340; 
95% CI=1.1697 to 1.3019).  Children below the age of two years and adolescents 
between the ages of 15 and 19 years had similar odds of receiving any 
antipsychotic with each additional calendar year (OR=1.1590 and OR=1.1523, 
respectively). 
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Result: H5 accepted. 
 
Table 3.54. Age-Specific Prevalence Rates of Total Antipsychotic Use in 
Managed Care Organization Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.32 0.47 0.48 1.48 48.42 24.11 <0.01 
2 – 4 y 0.38 0.65 0.87 2.30 130.16 77.35 <0.01 
5 – 9 y 0.87 1.39 3.05 3.51 251.00 656.53 <0.001 
10 – 14 y 1.85 2.56 4.89 2.64 164.30 742.58 <0.001 
15 – 19 y 2.90 3.14 4.88 1.68 68.05 321.03 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.39. Age-Specific Prevalence Rates of Total Antipsychotic Use in 
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H6: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across age categories greater than two years of age (2-4, 
5-9, 10-14, and 15-19 years). 
 
The use of atypical antipsychotics increased across all age groups (Figure 
3.40, page 278).  In children less than two years of age, a 4-fold increase in the 
prevalence of atypical antipsychotic use existed (+0.07 per 1,000; % 
change=298.5%).  Compared to 1996, an additional 0.48 and 2.35 youths per 
1,000 enrollees received an atypical antipsychotic in the two- to four-year old 
(PR=10.14, % change=914.4%) and five- to nine-year old (PR=11.43, % 
change=1043.2%) groups, respectively, in 2001.  The prevalence of atypical 
antipsychotic use increased 7-fold in the ten- to 14-year age group (+3.56 per 
1,000), and 5.2-fold in the 15- to 19-year age group (+2.77 per 1,000). 
 Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of atypical antipsychotic use across all age 
groups (p<0.01; Table 3.55, page 278).  Children between the ages of five and 
nine years had the highest odds (OR=1.5845; 95% CI=1.5345 to 1.6362), 
followed by two- to four-year olds (OR=1.5043; 95% CI=1.3816 to 1.6378), and 
ten- to 14-year olds (OR=1.4729; 95% CI=1.4379 to 1.5087).  Fifteen- to 19-year 
olds had a 40 percent increase in the odds of receiving an atypical antipsychotic 
with each year (OR=1.3965; 95% CI=1.3604 to 1.4336), while less than two year 
olds had a 29 percent increase in odds (OR=1.2871; 95% CI=1.0932 to 1.5155). 
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Result: H6 accepted. 
 
Table 3.55. Age-Specific Prevalence Rates of Atypical Antipsychotic Use in 
Managed Care Organization Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.02 0.14 0.09 3.99 298.52 22.24 <0.01 
2 – 4 y 0.05 0.25 0.53 10.14 914.43 115.08 <0.001 
5 – 9 y 0.23 0.80 2.58 11.43 1043.17 987.40 <0.001 
10 – 14 y 0.58 1.51 4.14 7.08 608.18 1201.80 <0.0001 
15 – 19 y 0.66 1.34 3.43 5.23 423.43 717.55 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.40. Age-Specific Prevalence Rates of Atypical Antipsychotic Use in 



























2 to 4 Years
5 to 9 Years
10 to 14 Years
15 to 19 Years
 
 279
H7: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across all age categories (<2, 2-4, 5-9, 10-14, and 15-19 
years). 
 
The use of typical antipsychotics decreased from 1996 to 2001 across age 
categories greater than two years of age (Table 3.56, page 280).  Prevalence rates 
of typical antipsychotic use in all age groups remained fairly constant from 1996 
to 2000.  In 2001, there was a decrease in the use of typical antipsychotics in 
youths older than two years of age (Figure 3.41, page 280).  Compared to 1996, 
there was a 30 percent increase in the prevalence rate of typical antipsychotic use 
in children less than two years of age.  In youths above the age of two years, a one 
to 36 percent decrease occurred in the use of typical antipsychotics. 
 Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of typical antipsychotic use in youths above 
the age of ten years (p<0.01; Table 3.56, page 280).  Children below the age of 
two years had a 12 percent increase in odds of receiving a typical antipsychotic 
with each calendar year (OR=1.1198; 95% CI=1.0216 to 1.2274).  The odds of 
receiving a typical antipsychotic with each calendar year were similar for the ten- 
to 14-year and 15- to 19-year age groups (10 to 14 years: OR=0.9574; 15 to 19 
years: OR=0.9675). 
 
Result: H7 rejected. 
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Table 3.56. Age-Specific Prevalence Rates of Typical Antipsychotic Use in 
Managed Care Organization Youths from 1996 to 2001a,b 





χ2 Value p-value 
<2 y 0.30 0.34 0.39 1.30 29.89 10.32 0.07 
2 – 4 y 0.35 0.42 0.34 0.99 -1.33 8.62 0.13 
5 – 9 y 0.70 0.68 0.54 0.77 -22.69 9.14 0.10 
10 – 14 y 1.39 1.17 0.89 0.64 -36.25 24.41 <0.01 
15 – 19 y 2.41 1.95 1.64 0.68 -31.74 35.89 <0.01 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: y=years; χ2=chi-square. 
 
Figure 3.41. Age-Specific Prevalence Rates of Typical Antipsychotic Use in 
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H8: Prevalence rates of total antipsychotic use from 1996 to 2001 
increases across gender groups: male and female.   
 
The use of antipsychotics increased in both male and female groups from 
1996 to 2001 (Table 3.57, page 282).  Compared to 1996, an additional 2.56 
males and 1.32 females per 1,000 enrollees received an antipsychotic in 2001 
(Male: PR=2.61, % change=160.5%; Female: PR=1.98, % change=97.9%).  
During each calendar year, male prevalence rates of total antipsychotic use were 
higher than those of females (Figure 3.42, page 282). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of total antipsychotic use in males and females 
(p<0.0001; Table 3.57, page 282).  Males (OR=1.2654, 95% CI=1.2474 to 
1.2836) had higher odds of receiving any antipsychotic with each calendar year 
compared to females (OR=1.1954, 95% CI=1.1751 to 1.2161). 
 









Table 3.57. Gender-Specific Prevalence Rates of Total Antipsychotic Use in 
Managed Care Organization Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 1.60 2.12 4.16 2.61 160.53 1270.42 <0.0001 
Female 1.36 1.68 2.68 1.98 97.90 535.43 <0.001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.42. Gender-Specific Prevalence Rates of Total Antipsychotic Use in 


































H9: Prevalence rates of atypical antipsychotic use from 1996 to 2001 
increases across gender groups: male and female. 
 
Prevalence rates of atypical antipsychotic use increased in both male and 
female groups from 1996 to 2001 (Table 3.58, page 284).  Compared to 1996, 
there was a 7.6-fold increase in atypical antipsychotic use in males in 2001, and a 
6.5-fold increase in females (Male: +3.01 per 1,000, % change=656.0%; Female: 
+1.56 per 1,000, % change=548.9%).  Male prevalence rates of atypical 
antipsychotic use were higher than those of females (Figure 3.43, page 284). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of atypical antipsychotic use in males and 
females (p<0.001; Table 3.58, page 284).  Males showed a 49 percent increase in 
the odds of receiving an atypical antipsychotic with each additional calendar year 
(OR=1.4867, 95% CI=1.4592 to 1.5147), and females showed a 46 percent 
increase (OR=1.4610, 95% CI=1.4234 to 1.4995). 
 








Table 3.58. Gender-Specific Prevalence Rates of Atypical Antipsychotic Use in 
Managed Care Organization Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 0.46 1.23 3.47 7.56 656.00 2090.69 <0.0001 
Female 0.28 0.69 1.84 6.49 548.92 977.32 <0.0001 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.43. Gender-Specific Prevalence Rates of Atypical Antipsychotic Use in 

































H10: Prevalence rates of typical antipsychotic use from 1996 to 2001 
decreases across gender groups: male and female. 
 
The use of typical antipsychotic use decreased by 69 percent in males, and 
61 percent in females from 1996 to 2001 (Table 3.59, page 286).  In 2001, 0.43 
fewer males and 0.22 fewer females per 1,000 received a typical antipsychotic 
compared to 1996 (Male: PR=0.65; Female: PR=0.80).  Male prevalence rates of 
typical antipsychotic use remained higher than those of females from 1996 to 
1999.  Female use of typical antipsychotics was greater than that of males in 2000 
and 2001 (Figure 3.44, page 286). 
Chi-square analysis demonstrated significant relationships between 
calendar year and prevalence rates of typical antipsychotic use in males and 
females (p<0.01; Table 3.59, page 286).  Males showed a four percent decrease in 
the odds of receiving a typical antipsychotic with each additional calendar year 
(OR=0.9621, 95% CI=0.9404 to 0.9844). 
 








Table 3.59. Gender-Specific Prevalence Rates of Typical Antipsychotic Use in 
Managed Care Organization Youths from 1996 to 2001a,b 





χ2 Value p-value 
Male 1.25 1.00 0.82 0.65 -34.77 44.10 <0.01 
Female 1.13 1.07 0.91 0.80 -19.86 33.56 <0.01 
aPrevalence values reported as X per 1,000 enrollees. 
bAbbreviations: χ2=chi-square. 
 
Figure 3.44. Gender-Specific Prevalence Rates of Typical Antipsychotic Use in 

































H11: The mean daily dose of risperidone treatment in age-specific 
groups of children and adolescents decreases from 1996 to 2001. 
 
A trend toward lower mean daily doses of risperidone over the six-year 
period existed in children and adolescents above the age of two years.  In the ten- 
to 14-year and 15- to 19-year age groups, a peak in the mean daily dose of 
risperidone occurred.  No distinct trend in risperidone dosing existed in children 
below the age of two years.  ANOVA showed significant differences in mean 
risperidone doses between calendar years for the following age categories: two- to 
four-year olds, five- to nine-year olds, and 15- to 19-year olds (p≤0.003).   
In the two- to four-year age group, post hoc analysis showed no significant 
between-year differences in risperidone doses.  Mean risperidone doses in 
children aged five and nine years were significantly higher from 1996 to 1999 
compared to 2001 (p<0.001).  In 15- to 19-year olds, risperidone doses in 1996 
were significantly higher than those in 2001 (p<0.001).   
 







H12: The mean daily dose of olanzapine treatment in age-specific 
groups of children and adolescents increases from 1996 to 2001. 
 
Mean daily doses of olanzapine showed a decreasing trend in children and 
adolescents less than two years, and between the ages of ten and 14 years.  No 
definitive trends in olanzapine dosing existed in the other age groups.  ANOVA 
showed no significant differences in mean olanzapine doses between calendar 
years for all age categories.   
 














H13: The mean daily dose of quetiapine treatment in age-specific groups 
of children and adolescents increases from 1996 to 2001. 
 
In children and adolescents above the age of two years, a trend in 
increased quetiapine dosing existed.  In two- to four-year olds, the trend of 
increasing mean quetiapine doses started in 1999.  In the ten- to 14-year and 15- 
to 19-year age groups, a peak in quetiapine dosing occurred in 2000 and 1999, 
respectively.  ANOVA showed no significant differences in mean quetiapine 
doses between calendar years for children and adolescents enrolled in MCO 
(p<0.001). 
 












H14: Antipsychotic switch rates in children and adolescents increase 
from 1996 to 2001. 
 
The prevalence of switches in antipsychotic treatment increased from 87.4 
per 1,000 youths receiving an antipsychotic in 1996 to 111.0 per 1,000 in 2001 
(Table 3.60, page 291).  With each additional calendar year, a child or adolescent 
had a seven percent increase in the odds that they would experience a switch in 
antipsychotic treatment (OR=1.0676, 95% CI=1.0267 to 1.1100). 
Among children and adolescents having at least one switch in 
antipsychotic treatment, the mean (±SD) number of switches per youth during a 
calendar year remained fairly steady over the six-year period (range: 1.13±0.36 to 
1.26±0.61).  No significant differences in the mean number switches per youth 
between calendar years existed. 
Closer examination of the types of antipsychotic switches revealed a 
decrease in typical to typical antipsychotic switches over time (1996: 33.3%; 
1998: 9.6%; 2001: 0.3%).  Conversely, there was an increase in atypical to 
atypical antipsychotic switches (1996: 5.6%; 1998: 32.2%; 2001: 72.7%).  
Typical to atypical switches peaked in 1997, and then decreased over time.  
Atypical to typical switches decreased initially from 1996 to 1997, peaked in 
1998, and then decreased thereafter.  Chi-square analysis demonstrated a 
significant relationship between calendar year and type of antipsychotic switch 
(χ2=316.92, df=15, p<0.001; Table 3.61, page 291). 
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Result: H14 accepted. 
 
Table 3.60. Prevalence of Antipsychotic Switches in Managed Care 
Organization Youths from 1996 to 2001 
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87.4 78.7 81.2 98.5 95.1 111.0 
 
 
Table 3.61. Types of Antipsychotic Switches in Managed Care Organization 
Youths from 1996 to 2001a 
Type of Switch  1996 1997 1998 1999 2000 2001 
Typical →Typical N 48 19 17 19 13 1 
                                                 % 33.3 15.1 9.6 6.9 4.0 0.3 
Typical → Atypical                 N 53 51 62 72 75 40 
 % 36.8 40.5 35.0 26.3 23.1 13.7 
Atypical → Typical N 35 23 41 57 44 39 
 % 24.3 18.3 23.2 20.8 13.5 13.3 
Atypical → Atypical N 8 33 57 126 193 213 
 % 5.6 26.2 32.2 46.0 59.4 72.7 
aχ2=316.92, df=15, p<0.001 
 
 292
H15: The prevalence of concomitant psychotropic medication use, 
including multiple antipsychotic agents, in children and 
adolescents receiving antipsychotic medications increases from 
1996 to 2001. 
 
The prevalence of concomitant psychotropic medication use increased by 
54 percent from 1996 to 2001 (+255.7 per 1,000 youths receiving an 
antipsychotic; Table 3.62, page 294).  The number of youths having at least one 
concomitant psychotropic medication during antipsychotic treatment steadily 
increased until 2000, and then decreased in 2001 (Figure 3.45, page 294).  With 
each calendar year, a child or adolescent had a 26 percent increase in the odds of 
receiving a concomitant psychotropic medication during antipsychotic treatment 
(OR=1.2553; 95% CI=1.2260 to 1.2853). 
Antidepressants (range: 33.0% to 38.6%) were the most commonly used 
agents during each year (Table 3.63, page 295).  From 1996 to 1999, the 
concomitant use of antimanic/bipolar agents increased by six percent, and was 
second most common.  Over the six-year period, the use of psychostimulants 
increased dramatically, and exceeded that of antimanic/bipolar agents in 2000 and 
2001.  The use of anti-parkinsonian agents decreased.  Chi-square analysis 
demonstrated a significant relationship between calendar year and the number of 
youths receiving different classes of concomitant psychotropic medications 
(χ2=405.29, df=40, p<0.001). 
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The prevalence of antipsychotic polypharmacy increased by 117 percent 
from 1996 to 2001 (+14.9 per 1,000 youths receiving an antipsychotic; Table 
3.64, page 296).  Over the six-year period, the number of youths receiving 
treatment with two different antipsychotic medications for at least 30 days 
steadily increased until 2000 (Figure 3.46, page 296).  With each calendar year, a 
child or adolescent had an 18 percent increase in the odds of receiving two 
different antipsychotic medications for a period of 30 days or more (OR=1.1800; 
95% CI=1.0846 to 1.2839). 
The use of two typical agents peaked in 1997, and then decreased over 
time (1996: 30.0%; 1998: 11.8%; 2001: 1.5%), while the use of two atypical 
agents increased over the study period (1996: 10.0%; 1998: 26.5%; 2001: 64.7%).  
The use of a typical and atypical agent concomitantly was fairly common during 
all study years (range: 33.8% to 61.8%), and peaked in 1998.  Chi-square analysis 
demonstrated a significant relationship between calendar year and percentage of 
type of antipsychotic polypharmacy (χ2=56.00, df=10, p<0.001).   
 








Table 3.62. Prevalence of Concomitant Psychotropic Medication Use in 
Managed Care Organization Youths Receiving an Antipsychotic 
from 1996 to 2001 
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Figure 3.45. Number of Managed Care Organization Youths Receiving a 
Concomitant Psychotropic Medication While Receiving an 
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Table 3.63. Medication Class of Concomitant Psychotropic Medications with 
Antipsychotic Treatment in Managed Care Organization Youths 
from 1996 to 2001a 
Psychotropic Class  1996 1997 1998 1999 2000 2001 
Alpha-agonists                               N 85 108 176 270 281 177 
                                                        % 8.2 8.5 9.6 9.5 7.7 6.2 
Antidepressants                              N 393 490 666 941 1236 989 
 % 38.0 38.6 36.4 33.0 34.1 34.4 
Anti-parkinsonian agents N 116 102 105 148 161 82 
 % 11.2 8.0 5.7 5.2 4.4 2.8 
Anxiolytics/sedatives/hypnotics N 61 70 65 116 144 110 
 % 5.9 5.5 3.5 4.1 4.0 3.8 
Benzodiazepines N 83 104 146 185 187 154 
 % 8.0 8.2 8.0 6.5 5.2 5.4 
Antimanic/bipolar agents N 159 230 380 611 774 644 
 % 15.4 18.1 20.7 21.4 21.3 22.4 
Psychostimulants N 107 145 264 550 799 678 
 % 10.3 11.4 14.4 19.3 22.0 23.6 
Substance abuse agents N 2 3 3 4 5 7 
 % 0.2 0.2 0.2 0.1 0.1 0.2 
Other psychotropic agents N 29 18 27 30 41 37 
 % 2.8 1.4 1.5 1.1 1.1 1.3 














Table 3.64. Prevalence of Antipsychotic Polypharmacy in Managed Care 
Organization Youths Receiving an Antipsychotic from 1996 to 2001 
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Figure 3.46. Number of Managed Care Organization Youths with Antipsychotic 



























H16: Total cost for antipsychotic prescriptions for children and 
adolescents increases from 1996 to 2001. 
 
 In 1996, a total of $172,440 was spent on antipsychotic medications for 
children and adolescents.  Typical antipsychotics cost $31,603, and atypical 
antipsychotics cost $140,837.  Over the six-year period, substantial increases in 
the cost of all antipsychotics occurred, primarily due to the cost associated with 
the increased use of atypical antipsychotics (Figure 3.47, page 298).  In 2001, a 
total of $1,156,289 was spent on antipsychotic medications, and 99 percent of this 
total was associated with atypical antipsychotics ($1,140,700). 
 













Figure 3.47. Cost Associated with Antipsychotic Medications for Managed Care 






























































Hypothesis Testing: Phase I Comparisons of Antipsychotic Prevalence Rates 
Prevalence rates in the Medicaid systems were compared for geographic 
variations in antipsychotic prescribing (H17 to H19).  Prevalence rates of 
antipsychotic use in public versus private health insurance systems were also 
compared (H20 to H22). 
 
Comparative Analyses of Antipsychotic Prevalence Rates 
 
H17: For each study year, a significant difference in the prevalence rate 
of total antipsychotic use in children and adolescents from 1996 to 
2001 between states exists.  Texas Medicaid has the highest rates 
of total antipsychotic use, followed by Ohio and California. 
 
From 1996 to 2001, prevalence rates of total antipsychotic use were 
highest in Texas Medicaid children and adolescents, followed by Ohio and 
California Medicaid programs (Table 3.65, page 300).  In 1996, the prevalence of 
total antipsychotic use in Texas Medicaid was 1.40 and 1.34 times that of 
California and Ohio, respectively.  Over the six-year period, the growth of total 
antipsychotic use in Ohio Medicaid paralleled that of Texas Medicaid (Figure 
3.48, page 300).  Conversely, the growth of total antipsychotic use in California 
Medi-Cal was not as steep as Texas and Ohio Medicaid. 
Chi-square analysis showed a significant relationship between annual 
prevalence rates of total antipsychotic use and state Medicaid program (p<0.001). 
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Result: H17 accepted. 
 
Table 3.65. A Comparison of Total Antipsychotic Prevalence Rates Between 
State Medicaid Programs from 1996 to 2001a 
 Prevalence of Total Antipsychotic Use   
Year CA OH TX Chi-Square p-value 
1996 4.52 4.72 6.33 555.50 <0.001 
1998 4.94 8.53 10.73 3909.05 <0.0001 
2001 6.87 14.34 15.54 7355.53 <0.0001 
aAbbreviations: CA=California Medi-Cal; OH=Ohio Medicaid; TX=Texas Medicaid. 
 
 
Figure 3.48. A Comparison of Total Antipsychotic Prevalence Rates Between 




































H18: For each study year, a significant difference in the prevalence rate 
of atypical antipsychotic use in children and adolescents from 1996 
to 2001 between states exists.  Texas Medicaid has the highest 
rates of atypical antipsychotic use, followed by Ohio and 
California. 
 
From 1996 to 2001, prevalence rates of atypical antipsychotic use were 
highest in Texas Medicaid children and adolescents, followed by Ohio and 
California Medicaid programs (Table 3.66, page 302).  In 1996, the prevalence of 
atypical antipsychotic use in Texas Medicaid was 8.0 and 1.74 times that of 
California and Ohio, respectively.  Over the six-year period, the growth of 
atypical antipsychotic use in Ohio Medicaid was similar to that of Texas Medicaid 
(Figure 3.49, page 302).  In California Medi-Cal, the growth of atypical 
antipsychotic use was not as steep as seen in the other Medicaid states. 
Chi-square analysis showed a significant relationship between annual 
prevalence rates of atypical antipsychotic use and state Medicaid program 
(p<0.001). 
 






Table 3.66. A Comparison of Atypical Antipsychotic Prevalence Rates Between 
State Medicaid Programs from 1996 to 2001a 
 Prevalence of Atypical Antipsychotic Use   
Year CA OH TX Chi-Square p-value 
1996 0.31 1.43 2.49 4008.49 <0.0001 
1998 2.57 5.89 8.12 5522.10 <0.0001 
2001 6.17 13.09 14.88 7654.40 <0.0001 
aAbbreviations: CA=California Medi-Cal; OH=Ohio Medicaid; TX=Texas Medicaid. 
 
 
Figure 3.49. A Comparison of Atypical Antipsychotic Prevalence Rates Between 










































H19: For each study year, a significant difference in the prevalence rate 
of typical antipsychotic use in children and adolescents from 1996 
to 2001 between states exists.  Texas Medicaid has the highest 
rates of typical antipsychotic use, followed by Ohio and California. 
 
In 1996, rank order showed that the use of typical antipsychotics in 
children and adolescents were highest for Texas Medicaid, then California Medi-
Cal and Ohio Medicaid.  From 1997 to 2000, typical antipsychotic use remained 
highest in Texas Medicaid children and adolescents, but use in Ohio Medicaid 
exceeded California Medi-Cal (Table 3.67, page 304).  In 2001, the prevalence 
rate of typical antipsychotic use was highest in Ohio Medicaid, followed by Texas 
and California.  During the study period, prevalence rates of typical antipsychotic 
were similar across all three state Medicaid programs.  The decline in use of 
typical antipsychotics were gradual, and the greatest percent change in use was in 
California Medi-Cal (-71.4%; Figure 3.50, page 304).   
Chi-square analysis showed a significant relationship between annual 
prevalence rates of typical antipsychotic use and state Medicaid program 
(p<0.001). 
 





Table 3.67. A Comparison of Typical Antipsychotic Prevalence Rates Between 
State Medicaid Programs from 1996 to 2001a 
 Prevalence of Typical Antipsychotic Use   
Year CA OH TX Chi-Square  p-value 
1996 4.38 3.69 4.55 85.54 <0.01 
1998 3.08 3.46 3.93 163.90 <0.001 
2001 1.25 1.96 1.53 225.77 <0.001 
aAbbreviations: CA=California Medi-Cal; OH=Ohio Medicaid; TX=Texas Medicaid. 
 
 
Figure 3.50. A Comparison of Typical Antipsychotic Prevalence Rates Between 









































H20: For each study year, a significant difference in the prevalence rate 
of total antipsychotic use in children and adolescents from 1996 to 
2001 between public and private insurance systems exists.  
Medicaid states have higher rates of total antipsychotic use 
compared to the Managed Care Organization. 
 
From 1996 to 2001, prevalence rates of total antipsychotic use were higher 
in the three Medicaid programs compared to the Managed Care Organization 
(Table 3.68, page 305).  In 1996, the prevalence rate of total antipsychotic use 
was at least three-times higher in Medicaid programs than in the Managed Care 
Organization.  In 2001, the use of antipsychotics in Medicaid youths was at least 
double that of Managed Care Organization youths.  Chi-square analysis showed a 
significant relationship between annual prevalence rates of total antipsychotic use 
and health insurance program (p<0.001). 
 
Result: H20 accepted. 
 
Table 3.68. A Comparison of Total Antipsychotic Prevalence Rates Between 
Public and Private Payer Insurance Programs from 1996 to 2001a 
 Prevalence of Total Antipsychotic Use   
Year CA OH TX MCO Chi-
Square  
p-value 
1996 4.52 4.72 6.33 1.48 2749.79 <0.0001 
1998 4.94 8.53 10.73 1.90 7534.72 <0.0001 
2001 6.87 14.34 15.54 3.43 10850.50 <0.00001 
aAbbreviations: CA=California Medi-Cal; OH=Ohio Medicaid; TX=Texas Medicaid; 
MCO=Managed Care Organization. 
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H21: For each study year, a significant difference in the prevalence rate 
of atypical antipsychotic use in children and adolescents from 1996 
to 2001 between public and private insurance systems exists.  
Medicaid states have higher rates of atypical antipsychotic use 
compared to the Managed Care Organization. 
 
In 1996, the prevalence of atypical antipsychotic use in Managed Care 
Organization youths was slightly higher than that of California Medi-Cal youths.  
From 1997 to 2001, prevalence rates of atypical antipsychotic use were higher in 
the three Medicaid programs compared to the Managed Care Organization (Table 
3.69, page 306).  In 2001, the use of atypical antipsychotics in Medicaid youths 
was at least 2.3 times that of Managed Care Organization youths.  Chi-square 
analysis showed a significant relationship between annual prevalence rates of 
atypical antipsychotic use and health insurance program (p<0.001). 
 
Result: H21 rejected. 
 
Table 3.69. A Comparison of Atypical Antipsychotic Prevalence Rates Between 
Public and Private Payer Insurance Programs from 1996 to 2001a 
 Prevalence of Atypical Antipsychotic Use   
Year CA OH TX MCO Chi-
Square  
p-value 
1996 0.31 1.43 2.49 0.37 4790.96 <0.0001 
1998 2.57 5.89 8.12 0.96 8699.23 <0.0001 
2001 6.17 13.09 14.88 2.67 11458.04 <0.00001 
aAbbreviations: CA=California Medi-Cal; OH=Ohio Medicaid; TX=Texas Medicaid; 
MCO=Managed Care Organization. 
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H22: For each study year, a significant difference in the prevalence rate 
of typical antipsychotic use in children and adolescents from 1996 
to 2001 between public and private insurance systems exists.  
Medicaid states have higher rates of typical antipsychotic use 
compared to the Managed Care Organization. 
 
From 1996 to 2001, prevalence rates of typical antipsychotic use were 
higher in the three Medicaid programs compared to the Managed Care 
Organization (Table 3.70, page 307).  In 1996, the prevalence rate of typical 
antipsychotic use was at least three-times higher in Medicaid programs than in the 
Managed Care Organization.  In 2001, typical antipsychotic use in Medicaid 
youths was at least 1.5-times that of Managed Care Organization youths.  Chi-
square analysis showed a significant relationship between annual prevalence rates 
of typical antipsychotic use and health insurance program (p<0.001). 
 
Result: H29 accepted. 
 
Table 3.70. A Comparison of Typical Antipsychotic Prevalence Rates Between 
Public and Private Payer Insurance Programs from 1996 to 2001a 
 Prevalence of Typical Antipsychotic Use   
Year CA OH TX MCO Chi-
Square  
p-value 
1996 4.38 3.69 4.55 1.19 2047.82 <0.0001 
1998 3.08 3.46 3.93 1.03 1544.32 <0.0001 
2001 1.25 1.96 1.53 0.86 379.04 <0.001 
aAbbreviations: CA=California Medi-Cal; OH=Ohio Medicaid; TX=Texas Medicaid; 
MCO=Managed Care Organization. 
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Hypothesis Testing: Phase II (Prescribing Practices for Antipsychotic 
Agents) 
Phase II evaluated data from the Texas Medicaid and TDMHMR systems 
to examine prescribing practices related to antipsychotic use in children and 
adolescents.  The number of antipsychotic prescriptions per year based upon the 
specialty of physician (neurology [including child neurology], pediatrics, primary 
care [including family practice and general practice], psychiatry [including child 
and adolescent psychiatry], other, or unspecified) were determined (H23 and H24).  
Diagnostic data were collected to determine the documented diagnoses (anxiety, 
bipolar, depressive, disruptive, psychotic, substance abuse, developmental, other 
psychiatric, other childhood psychiatric, or no psychiatric or behavioral diagnosis) 

















Prescribing practices for antipsychotic agents in Texas 
 
H23: The number of antipsychotic prescriptions for a child or adolescent 
from primary care physicians (family practice physicians, general 
practice physicians, and pediatricians) increases from 1996 to 
2001. 
 
 Over the six-year period, there was a 69 percent increase in the number of 
antipsychotic prescriptions from primary care physicians.  In 1996, primary care 
physicians wrote 5,961 antipsychotic prescriptions for children and adolescents.  
In 2001, 10,098 antipsychotic prescriptions were written by primary care 
physicians (Table 3.71, page 312; Figure 3.51, page 312).  Chi-square analysis 
showed a significant relationship between physician specialty associated with 
antipsychotic prescribing and calendar year (χ2=5064.56, df=20, p<0.001). 
Within this specialty group, more antipsychotic prescriptions originated 
from pediatricians (n=27,766) compared to family/ general practice physicians 
(n=17,931).  From 1996 to 2001, there was a 38 percent and 130 percent increase 
in the number of antipsychotic prescriptions from pediatricians and family/ 
general practice physicians, respectively. 
 With regard to atypical antipsychotics, a 444 percent increase in the 
number of atypical antipsychotic prescriptions from primary care physicians 
existed (1996: n=1,616; 1998: n=4,450; 2001: n=8,791; Table 3.72, page 313; 
Figure 3.52, page 313).  The number of atypical antipsychotic prescriptions from 
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pediatricians and family/ general practice physicians increased from 1996 to 2001 
(% change: 369.5% and 563.7%, respectively).  The number of typical 
antipsychotic prescriptions from primary care physicians decreased by 70 percent, 
from 4,345 prescriptions in 1996 to 1,307 in 2001 (Table 3.73, page 314; Figure 
3.53, page 314).  The number of typical antipsychotic prescriptions from 
pediatricians and family/ general practice physicians decreased by 74 percent and 
62 percent, respectively. 
 Across all age groups, the number of antipsychotic prescriptions from 
primary care physicians increased from 1996 to 2001.  More specifically, the 
number of antipsychotic prescriptions from primary care physicians nearly 
doubled from 1996 to 2001 for five- to nine-year olds (1996: n=1,689; 2001: 
n=3,225) and ten- to 14-year olds (1996: n=2,117; 2001: n=3,931).  It must be 
noted, however, that over time, primary care physicians accounted for a smaller 
percentage of the total volume of antipsychotic prescriptions for all age groups.  
With regard to atypical antipsychotics, substantial increases in the number of 
prescriptions from primary care physicians existed (<2 years: 36 more 
prescriptions in 2001 compared to 1996 [% change: not calculated since 0 
prescriptions in 1996]; 2- to 4-years: +481 [2091%]; 5- to 9-years: +2,450 
[553%]; 10- to 14-years: +2,793 [449%]; 15- to 19-years: +1,487 [283%]).  The 
number of typical antipsychotic prescriptions decreased across all age groups (<2 
years: 5 fewer prescriptions in 2001 compared to 1996 [% change: -15%]; 2- to 4-
years: -226 [-78%]; 5- to 9-years: -914 [-73%]; 10- to 14-years: -979 [-65%]; 15- 
to 19-years: -950 [-76%]). 
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 The number of antipsychotic prescriptions from primary care physicians 
increased for both males and females over the six-year period.  In 1996, 4,135 and 
1,777 antipsychotic prescriptions were written by primary care physicians for 
males and females, respectively.  In 2001, primary care physicians wrote 7,291 
antipsychotic prescriptions for males (% change: 76%), and 2,767 antipsychotic 
prescriptions for females (56%).  An additional 5,384 prescriptions for atypical 
antipsychotics were written by primary care physicians for male youths in 2001 
(n=6,407), which represented a 526 percent increase from the number of atypical 
antipsychotic prescriptions in 1996 (n=1,023).  Similarly, the number of atypical 
antipsychotic prescriptions from primary care physicians for female youths 
increased by 333 percent (1996: n=571; 2001: n=2,414).  The number of typical 
antipsychotic prescriptions from primary care physicians for males and females 
decreased by 72 percent (1996: n=3,112; 2001: n=884) and 71 percent (1996: 
n=1,206; 2001: n=353), respectively. 
 









Table 3.71. Physician Specialty and the Number of Antipsychotic Prescriptions 
for Texas Medicaid Youths from 1996 to 2001a 
Physician 
Specialty 
1996 1997 1998 1999 2000 2001 Total Percent 
Change 
Psychiatry 24765 33050 43333 54375 69345 85066 309934 243.5% 
  65.5% 69.9% 72.9% 75.8% 78.4% 78.0% 74.9%  
Primary Care 5961 6200 7284 7884 8270 10098 45697 69.4% 
  15.8% 13.1% 12.3% 11.0% 9.3% 9.3% 11.0%  
Neurology 1453 1990 2743 2741 2446 2359 13732 62.4% 
  3.8% 4.2% 4.6% 3.8% 2.8% 2.2% 3.3%  
Other 2209 2007 2338 3097 4027 5343 19021 142.0% 
  5.8% 4.2% 3.9% 4.3% 4.6% 4.9% 4.6%  
Unspecified 3425 4045 3704 3681 4394 6256 25505 82.7% 
  9.1% 8.6% 6.2% 5.1% 5.0% 5.7% 6.2%  
aχ2=5064.56, df=20, p<0.001 
 
Figure 3.51. Physician Specialty and the Percentage of Antipsychotic 




































Table 3.72. Physician Specialty and the Number of Atypical Antipsychotic 
Prescriptions for Texas Medicaid Youths from 1996 to 2001 
Physician 
Specialty 
1996 1997 1998 1999 2000 2001 Total Percent 
Change 
Psychiatry 10066 20241 32344 44733 61447 78801 247632 682.8% 
  71.7% 74.5% 75.6% 78.2% 79.9% 78.6% 77.8%  
Primary Care 1616 2760 4450 5387 6252 8791 29256 444.0% 
  11.5% 10.2% 10.4% 9.4% 8.1% 8.8% 9.2%  
Neurology 418 982 1858 1913 1918 1936 9025 363.2% 
  3.0% 3.6% 4.3% 3.3% 2.5% 1.9% 2.8%  
Other 933 1110 1636 2264 3454 4866 14263 421.5% 
  6.6% 4.1% 3.8% 4.0% 4.5% 4.9% 4.5%  
Unspecified 1010 2073 2507 2884 3846 5801 18121 474.4% 
  7.2% 7.6% 5.9% 5.0% 5.0% 5.8% 5.7%  
 
Figure 3.52. Physician Specialty and the Percentage of Atypical Antipsychotic 




































Table 3.73. Physician Specialty and the Number of Typical Antipsychotic 
Prescriptions for Texas Medicaid Youths from 1996 to 2001 
Physician 
Specialty 
1996 1997 1998 1999 2000 2001 Total Percent 
Change 
Psychiatry 14699 12809 10989 9642 7898 6265 62302 -57.4% 
  61.8% 63.6% 66.2% 66.1% 68.3% 70.2% 65.2%  
Primary Care 4345 3440 2834 2497 2018 1307 16441 -69.9% 
  18.3% 17.1% 17.1% 17.1% 17.4% 14.6% 17.2%  
Neurology 1035 1008 885 828 528 423 4707 -59.1% 
  4.4% 5.0% 5.3% 5.7% 4.6% 4.7% 4.9%  
Other 1276 897 702 833 573 477 4758 -62.6% 
  5.4% 4.5% 4.2% 5.7% 5.0% 5.3% 5.0%  
Unspecified 2415 1972 1197 797 548 455 7384 -81.2% 
  10.2% 9.8% 7.2% 5.5% 4.7% 5.1% 7.7%  
 
Figure 3.53. Physician Specialty and the Percentage of Typical Antipsychotic 




































H24: The number of antipsychotic prescriptions for a child or adolescent 
from psychiatrists, including child and adolescent psychiatrists, 
increases from 1996 to 2001. 
 
Over the six-year period, there was a 244 percent increase in the number 
of antipsychotic prescriptions from psychiatrists, including child and adolescent 
psychiatrists.  In 1996, psychiatrists wrote 24,765 antipsychotic prescriptions for 
children and adolescents.  In 2001, 85,066 antipsychotic prescriptions were 
written by psychiatrists (Table 3.71, page 312; Figure 3.51, page 312).  Chi-
square analysis showed a significant relationship between physician specialty 
associated with antipsychotic prescribing and calendar year (χ2=5064.56, df=20, 
p<0.001). 
Within this specialty group, more antipsychotic prescriptions originated 
from psychiatrists (n=213,636) compared to child and adolescent psychiatrists 
(n=96,298).  From 1996 to 2001, there was a 240 percent and 252 percent 
increase in the number of antipsychotic prescriptions from psychiatrists and child 
and adolescent psychiatrists, respectively. 
 With regard to atypical antipsychotics, a 683 percent increase in the 
number of atypical antipsychotic prescriptions from psychiatrists existed (1996: 
10,066; 1998: 32,344; 2001: 78,801; Table 3.72, page 313; Figure 3.52, page 
313).  The number of atypical antipsychotic prescriptions from psychiatrists and 
child and adolescent psychiatrists increased from 1996 to 2001 (% change: 
695.6% and 656.2%, respectively).  The number of typical antipsychotic 
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prescriptions from psychiatrists decreased by 57 percent, from 14,699 
prescriptions in 1996 to 6,265 in 2001 (Table 3.73, page 314; Figure 3.53, page 
314).  The number of typical antipsychotic prescriptions from psychiatrists and 
child and adolescent psychiatrists decreased by 59 percent and 54 percent, 
respectively. 
 Across all age groups, the number of antipsychotic prescriptions from 
psychiatrists increased from 1996 to 2001.  More specifically, the number of 
antipsychotic prescriptions from psychiatrists nearly quadrupled from 1996 to 
2001 for five- to nine-year olds (1996: n=7,072; 2001: n=26,946) and ten- to 14-
year olds (1996: n=10,255; 2001: n=37,371).  The number of antipsychotic 
prescriptions from psychiatrists nearly tripled over the six-year period for two- to 
four-year olds (1996: n=1,427; 2001: n=4,020) and 15- to 19-year olds (1996: 
n=5,901; 2001: n=16,597).  Furthermore, psychiatrists accounted for a larger 
percentage of the total volume of antipsychotic prescriptions for all age groups 
over the six-year period.  With regard to atypical antipsychotics, substantial 
increases in the number of prescriptions from psychiatrists existed (<2 years: 93 
more prescriptions in 2001 compared to 1996 [% change: 372%]; 2- to 4-years: 
+3,505 [920%]; 5- to 9-years: +23,085 [827%]; 10- to 14-years: +31,031 [735%]; 
15- to 19-years: +12,474 [472%]).  The number of typical antipsychotic 
prescriptions decreased across all age groups (<2 years: 64 fewer prescriptions in 
2001 compared to 1996 [% change: -64%]; 2- to 4-years: -912 [-87%]; 5- to 9-
years: -3,211 [-75%]; 10- to 14-years: -3,915 [-65%]; 15- to 19-years: -1,778 [-
55%]). 
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 The number of antipsychotic prescriptions from psychiatrists increased for 
both males and females over the six-year period.  In 1996, 16,923 and 7,587 
antipsychotic prescriptions were written by psychiatrists for males and females, 
respectively.  In 2001, psychiatrists wrote 57,099 antipsychotic prescriptions for 
males (% change: 237%), and 27,456 antipsychotic prescriptions for females 
(262%).  An additional 47,220 prescriptions for atypical antipsychotics were 
written by psychiatrists for male youths in 2001 (n=53,906), which represented a 
706 percent increase from the number of atypical antipsychotic prescriptions in 
1996 (n=6,686).  Similarly, the number of atypical antipsychotic prescriptions 
from psychiatrists for female youths increased by 689 percent (1996: n=3,278; 
2001: n=25,862).  The number of typical antipsychotic prescriptions from 
psychiatrists for males and females decreased by 69 percent (1996: n=10,237; 
2001: n=3,193) and 63 percent (1996: n=4,309; 2001: n=1,594), respectively. 
 










H25: From 1998 to 2001, antipsychotics are most prescribed for 
disruptive behavioral disorders, such as oppositional defiant 
disorder, conduct disorder, intermittent explosive disorder, and 
attention-deficit hyperactivity disorders. 
 
 Diagnostic data from the TDMHMR CARE database were available for 
97.6 percent (2,355/2,413) of matched youths in 1998, 98.1 percent (2,902/2,957) 
in 1999, 85.2 percent (2,892/3,394) in 2000, and 60.8 percent (2,506/4,124) in 
2001.  Chi-square analysis showed a significant relationship between diagnostic 
category associated with antipsychotic prescribing and calendar year (χ2=93.067, 
df=27, p<0.001; Table 3.74, page 322). 
 Disruptive behavioral disorders accounted for the highest percentage of 
diagnoses associated with children and adolescents receiving antipsychotic 
treatment and mental health care services from TDMHMR over the four-year 
period (Figure 3.54, page 323).  In 1998, 35.9 percent (1,400/3,897) of the 
diagnoses were categorized as a disruptive behavioral disorder.  In 2001, 35.1 
percent (1,234/3,512) of the diagnoses were categorized as a disruptive behavioral 
disorder.  Closer examination of disruptive behavioral disorder diagnoses showed 
that attention-deficit hyperactivity disorder was the most common diagnosis in 
this category (47.8% to 52.6%), followed by oppositional defiant disorder and 
conduct disorder (38.3% to 42.2%; Table 3.75, page 324).  
Depressive disorders were the second most common diagnosis in children 
and adolescents receiving antipsychotic treatment and services from TDMHMR.  
The percentage of depressive diagnoses remained consistent over the four-year 
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period (1998: 17.4%; 1999: 19.1%; 2000: 17.9%; and, 2001: 18.1%).  Bipolar 
disorders accounted for roughly 12 percent of all diagnoses, and a trend toward 
more children and adolescents diagnosed with bipolar disorder existed.  In 1998, 
9.5 percent of youths (371/3,897) had a bipolar disorder diagnosis.  In 2001, 14.5 
percent (508/3,512) had a bipolar disorder diagnosis, representing a significant 
increase over the four-year period. 
Among children and adolescents with a diagnosis associated with a 
thought disorder (bipolar disorder with psychosis, major depressive disorder with 
psychosis, and psychotic disorders [schizophrenia, schizophreniform disorder, 
schizoaffective disorder]) and receiving an antipsychotic and TDMHMR mental 
health services, the majority had a diagnosis of a psychotic disorder (Table 3.75, 
page 324).  In 1998, 57.0 percent (437/766) of youths with a thought disorder 
were diagnosed with a psychotic disorder, followed by 33.0 percent (253/766) 
diagnosed with major depressive disorder with psychosis.  In 2001, psychotic 
disorder remained the most common diagnosis (51.0%), followed by major 
depressive disorder with psychosis (32.3%).  Over the four-year period, trends 
toward fewer children and adolescents diagnosed with a psychotic disorder, and 
more diagnosed with bipolar disorder with psychosis existed. 
The percentage of youths with a diagnosis of mental retardation or a 
pervasive developmental disorder was fairly steady (1998: 6.1%; 1999: 5.2%; 
2000: 5.9%; and, 2001: 5.4%).  Of these, the majority had mental retardation 
(69.0% to 71.5%), compared to a pervasive developmental disorder (28.5% to 
31.0%; Table 3.75, page 324). 
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Approximately three percent of children and adolescents receiving 
antipsychotic treatment and mental health care services from TDMHMR did not 
have a psychiatric or behavioral diagnosis.  In 1998, 133 youths (3.4%) were not 
diagnosed with a psychiatric or behavioral disorder.  In 2001, 91 youths (2.6%) 
did not receive a psychiatric or behavioral diagnosis. 
In the 5- to 9-year age group, disruptive behavioral disorders were the 
most common diagnoses during each year (Table 3.76, page 325).  Depressive 
disorders were the second most common from 1998 to 2000, followed by bipolar 
disorders.  In 2001, a slightly higher percentage of 5- to 9-year olds had bipolar 
disorder diagnoses compared to depressive disorders.  In 10- to 14-year olds, 
disruptive behavioral disorders were most common over the four-year period, 
followed by depressive disorders.  The percentage of 10- to 14-year olds 
diagnosed with a bipolar disorder increased over time (1998: 9.9%; 2001: 15.2%).  
Additionally, a higher percentage of the 10- to 14-year age group had a psychotic 
disorder during each year compared to younger children and adolescents.  In 15- 
to 19-year olds, depressive disorders were the most common diagnoses, as 
approximately 23 percent of the age group received such a diagnosis.  Compared 
to 10- to 14-year olds, a higher percentage of 15- to 19-year olds had a psychotic 
disorder diagnosis and a lower percentage had a disruptive behavioral disorder 
diagnosis.  Similar to younger aged children and adolescents, the percentage of 
15- to 19-year olds diagnosed with bipolar disorder increased over time (1998: 
10.2%; 2001: 17.7%). 
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From 1998 to 2001, a higher percentage of male youths had disruptive 
behavioral disorders than females (Table 3.77, page 326).  Depressive and anxiety 
disorders were more common in females during each year.  Both males and 
females showed comparable percentages of psychotic disorders, and a trend 




















Table 3.74. Diagnostic Categories for Texas Medicaid Youths Receiving an 
Antipsychotic and Mental Health Services from TDMHMR from 
1998 to 2001a 
Diagnostic Category 1998 1999 2000 2001 Total 
Anxiety disorders 320 358 349 259 1286 
 8.2% 7.7% 7.7% 7.4% 7.8% 
Bipolar disorders 371 511 551 508 1941 
 9.5% 10.9% 12.2% 14.5% 11.7% 
Depressive disorders 677 891 809 635 3012 
 17.4% 19.1% 17.9% 18.1% 18.2% 
Disruptive behavioral 
disorder 
1400 1573 1563 1234 5770 
 35.9% 33.7% 34.7% 35.1% 34.8% 
Psychotic disorders 336 427 376 289 1428 
 8.6% 9.1% 8.3% 8.2% 8.6% 
Substance abuse disorders 102 112 106 70 390 
 2.6% 2.4% 2.4% 2.0% 2.4% 
Mental retardation/ 
developmental disorders 
238 244 265 190 937 
 6.1% 5.2% 5.9% 5.4% 5.6% 
Other mental health disorders 75 102 75 47 299 
 1.9% 2.2% 1.7% 1.3% 1.8% 
Other childhood mental 
health disorders 
245 274 303 189 1011 
 6.3% 5.9% 6.7% 5.4% 6.1% 
No psychiatric or behavioral 
disorder 
133 178 111 91 513 
 3.4% 3.8% 2.5% 2.6% 3.1% 





Figure 3.54. Diagnostic Categories for Texas Medicaid Youths Receiving an 
Antipsychotic and Mental Health Services from TDMHMR from 









































Table 3.75. Diagnostic Subgroups for Texas Medicaid Youths Receiving an 
Antipsychotic and Mental Health Services from TDMHMR from 
1998 to 2001a 
Diagnostic Category Subgroup 1998 1999 2000 2001 Total 
Disruptive behavioral 
disorders 
ADHD 1315 1683 1757 1333 6088 
  47.8% 47.9% 50.2% 52.6% 49.5% 
 ODD, CD 1155 1482 1413 969 5019 
  42.0% 42.2% 40.4% 38.3% 40.8% 
 ICD 279 350 331 231 1191 
  10.1% 10.0% 9.5% 9.1% 9.7% 
Thought disorders BP + Psy 76 133 177 116 502 
  9.9% 12.8% 18.0% 16.7% 14.4% 
 MDD + Psy 253 365 321 225 1164 
  33.0% 35.0% 32.7% 32.3% 33.4% 
 Psy 437 545 483 355 1820 
  57.0% 52.3% 49.2% 51.0% 52.2% 
Mental retardation/ 
developmental disorders 
MR 327 373 383 243 1326 
  71.4% 71.5% 71.2% 69.0% 70.9% 
 PDD 131 149 155 109 544 
  28.6% 28.5% 28.8% 31.0% 29.1% 
aAbbreviations: ADHD = attention-deficit hyperactivity disorder, BP + Psy = bipolar disorder with 
psychosis, CD = conduct disorder, ICD = impulse control disorders, MDD + Psy = major 
depressive disorder with psychosis, MR = mental retardation, PDD = pervasive developmental 









Table 3.76. Diagnostic Categories for Age-Specific Groups of Texas Medicaid 
Youths Receiving an Antipsychotic and Mental Health Services 
from TDMHMR from 1998 to 2001a 
Age Diagnostic Category 1998 1999 2000 2001 Total 
5 to 9 years Anxiety disorders 8.5 9.6 9.6 7.3 8.9 
 Bipolar disorders 8.7 9.7 11.8 12.7 10.7 
 Depressive disorders 11.6 12.0 11.9 12.4 12.0 
 Disruptive behavioral 
disorders 
48.1 45.1 45.0 45.8 45.9 
 Psychotic disorders 5.9 6.2 4.8 5.8 5.7 
 Mental retardation/ 
developmental disorders 
5.0 5.2 5.9 5.1 5.3 
10 to 14 years Anxiety disorders 7.8 7.2 6.7 7.6 7.3 
 Bipolar disorders 9.9 11.1 12.5 15.2 12.1 
 Depressive disorders 20.2 22.6 20.7 21.3 21.3 
 Disruptive behavioral 
disorders 
33.4 30.8 32.3 31.9 32.0 
 Psychotic disorders 8.0 8.3 8.0 7.7 8.0 
 Mental retardation/ 
developmental disorders 
5.8 4.4 4.8 5.1 5.0 
15 to 19 years Anxiety disorders 8.4 5.6 7.1 6.1 6.8 
 Bipolar disorders 10.2 13.4 12.6 17.7 13.2 
 Depressive disorders 21.4 23.6 23.4 23.4 23.0 
 Disruptive behavioral 
disorders 
19.8 18.3 19.1 15.9 18.5 
 Psychotic disorders 16.2 17.5 16.0 16.9 16.7 
 Mental retardation/ 
developmental disorders 
8.7 7.0 8.5 6.7 7.8 







Table 3.77. Diagnostic Categories for Gender-Specific Groups of Texas 
Medicaid Youths Receiving an Antipsychotic and Mental Health 
Services from TDMHMR from 1998 to 2001a 
Gender Group Diagnostic Category 1998 1999 2000 2001 Total 
Male Anxiety disorders 7.2 6.3 6.9 6.4 6.7 
 Bipolar disorders 8.9 10.6 11.7 13.9 11.2 
 Depressive disorders 14.9 16.4 15.0 15.0 15.4 
 Disruptive behavioral 
disorders 
39.0 37.6 38.8 39.7 38.7 
 Psychotic disorders 8.5 9.3 8.2 8.1 8.6 
 Mental retardation/ 
developmental disorders 
6.4 5.4 6.1 5.3 5.8 
Female Anxiety disorders 10.9 10.7 9.9 9.7 10.3 
 Bipolar disorders 11.1 11.8 13.5 15.9 13.0 
 Depressive disorders 23.9 25.2 25.0 25.5 24.9 
 Disruptive behavioral 
disorders 
27.7 24.9 24.6 24.1 25.3 
 Psychotic disorders 8.8 8.8 8.7 8.5 8.7 
 Mental retardation/ 
developmental disorders 
5.2 4.7 5.3 5.7 5.2 














Hypothesis Testing: Phase III (Relationships of Antipsychotic Use with 
Patient Health Care Service Utilization) 
Phase III evaluated data from the TDMHMR system to examine how the 
following service utilization parameters were related to antipsychotic use from 
1998 to 2001: number and total days of inpatient psychiatric hospitalizations (H26 
and H27), and enrollment and duration of different types of outpatient mental 
health services (H28 and H29).  TDMHMR CARE service utilization data included 
enrollment in the following types of outpatient mental health services: 
Assessment Services (TC08), Counseling and Psychotherapy (TC13); Crisis 
Intervention (In-Home [TC01], Inpatient [TC07], Therapeutic Foster Care 
[TC09], Other Residential Services [TC17], and Acute Day Treatment [TC20]); 
Medication-related Services (TC04); Service Coordination (TC06); Skills 
Training (Rehabilitative Day Treatment [TC03], Individual [TC10], Family 
[TC19]); and, Supportive Services (Respite [TC05], Family-Focused Services 
[TC23], and Flexible Community Support [TC24]). 
Appendix A provides descriptions of each type of outpatient mental health 
service.  Appendix D provides the details of parametric and nonparametric 
analyses examining time trends in the number and total days of inpatient 
hospitalizations.  Appendix E provides details of parametric and nonparametric 
analyses examining the year effect on duration of enrollment in different types of 






Relationships of antipsychotic use with patient health care service utilization in 
Texas 
 
H26: The mean number of inpatient psychiatric hospitalizations per 
child or adolescent receiving antipsychotic treatment decreases 
from 1998 to 2001. 
 
Analysis of inpatient hospitalization data for all matched youths revealed 
that a trend toward a greater number of inpatient psychiatric hospitalizations per 
child or adolescent receiving antipsychotic treatment and mental health services 
from TDMHMR existed from 1998 to 2001 (Table 3.78, page 330; p<0.001 for 
ANOVA and Kruskal-Wallis test).  In 1998, the mean (±SD) number of inpatient 
psychiatric hospitalizations per matched youth was 0.13±0.44.  In 2001, the mean 
(±SD) number of inpatient psychiatric hospitalizations per matched youth was 
0.17±0.49.  Over the four-year period, the mean (±SD) number of inpatient 
psychiatric hospitalizations peaked at 0.19±0.54 during the year 2000.  Post-hoc 
analyses revealed significant differences in the number of inpatient psychiatric 
hospitalizations per matched youth between 1998 and 2000 (p<0.001), and 1998 
and 2001 (p=0.003).  The median number of inpatient psychiatric hospitalizations 
per matched youth was zero for all four years. 
Analysis of inpatient hospitalization data for only those youths who were 
hospitalized did not reveal a significant year effect on the mean number of 
inpatient psychiatric hospitalizations (Table 3.78, page 330).  The mean (±SD) 
number of inpatient psychiatric hospitalizations per child or adolescent was 
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1.28±0.62 in 1998, 1.38±0.87 in 1999, 1.31±0.72 in 2000, and 1.25±0.62 in 2001.  
The median number of inpatient psychiatric hospitalizations per hospitalized 
youth was one for all four years. 
Age-specific analyses of inpatient hospitalization data for only those 
youths who were hospitalized showed no significant year effect on the mean 
number of inpatient psychiatric hospitalizations in the five- to nine-year, ten- to 
14-year, and 15- to 19-year age groups.  Gender-specific analyses showed no 
significant year effect on the mean number of inpatient psychiatric 
hospitalizations in male and female groups.  Diagnosis-specific analyses showed 
no significant year effect on the mean number of inpatient psychiatric 
hospitalizations in the following diagnostic categories: anxiety disorders, bipolar 
disorders, depressive disorders, disruptive behavorial disorders, psychotic 
disorders, mental retardation/developmental disorders, comorbid psychiatric 











Table 3.78. Number of Inpatient Psychiatric Hospitalizations Per Child or 
Adolescent Receiving an Antipsychotic and Mental Health Care 
Services from TDMHMR from 1998 to 2001 
Sample Year N Mean 
(±SD) 
95% CI Median p-value 
All matched youths 1998 2413 0.13±0.44 0.12 – 0.15 0.0 
 1999 2957 0.16±0.53 0.14 – 0.18 0.0 
 2000 3394 0.19±0.54 0.17 – 0.21 0.0 
 2001 4124 0.17±0.49 0.16 – 0.19 0.0 
<0.001* 
Hospitalized youths 1998 251 1.28±0.62 1.20 – 1.36 1.0 
 1999 341 1.38±0.87 1.28 – 1.47 1.0 
 2000 487 1.31±0.72 1.25 – 1.37 1.0 
 2001 573 1.25±0.62 1.20 – 1.31 1.0 
0.09†, 
0.178‡ 
*p-value for both ANOVA and Kruskal-Wallis test. 
†p-value for ANOVA. 














H27: The mean number of hospital days per each hospitalized child or 
adolescent receiving antipsychotic treatment decreases from 1998 
to 2001. 
  
Over the four-year period, the mean number of hospital days per each 
hospitalized child or adolescent receiving antipsychotic treatment decreased 
(Table 3.79, page 333; p<0.001 for ANOVA and Kruskal Wallis test).  In 1998, 
the mean (±SD) number of hospital days per hospitalized youth was 83.20±80.42.  
In 2001, the mean (±SD) number of hospital days per hospitalized youth was 
56.93±60.64.  Post hoc analyses revealed a significant difference in the mean 
number of hospital days between 1998 and 2001 (p<0.001), and 1999 and 2001 
(p<0.001).  The median number of hospital days per hospitalized child or 
adolescent for 1998, 1999, 2000, and 2001 was 59, 57, 48, and 36, respectively. 
Age-specific analyses of the mean number of hospital days per 
hospitalized youth showed significant year effects for the ten- to 14-year (p<0.001 
for ANOVA and Kruskal Wallis test; Figure 3.55, page 334) and 15- to 19-year 
age groups (p=0.002 for ANOVA; p<0.001 for Kruskal Wallis test; Figure 3.56, 
page 334).  In ten- to 14-year olds, the mean number of hospital days increased 
slightly in 1999 compared to 1998, but then decreased steadily in 2000 and 2001.  
A significant difference in the mean number of hospital days for hospitalized ten- 
to 14-year olds existed between 1998 and 2001 (p=0.005), and 1999 and 2001 
(p<0.001).  The median number of hospital days per hospitalized ten- to 14-year 
old for 1998 and 2001 was 71 and 30, respectively.  Similar trends in the mean 
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number of hospital days were seen in the 15- to 19-year age group.  The mean 
number of hospital days in 2001 were significantly lower than that in 1999 
(p=0.005).  The median number of hospital days per hospitalized 15- to 19-year 
old for 1998 and 2001 was 45 and 29, respectively. 
A trend toward fewer hospital days per hospitalized male existed from 
1998 to 2001 (p<0.001 for ANOVA and Kruskal Wallis test; Figure 3.57, page 
335).  Over the four-year period, the mean number of hospital days per male 
declined continually (1998: 89.44±85.74 days; 2001: 54.68±60.83 days).  
Compared to 1998, the mean number of hospital days per male was significantly 
lower in 2000 (p=0.008) and 2001 (p<0.001).  Additionally, the mean number of 
hospital days per male was significantly lower in 2001 compared to 1999 
(p=0.001).  The median number of hospital days per hospitalized male for 1998 
and 2001 was 60 and 33, respectively.  Analysis of the mean number of hospital 
days per hospitalized female did not exhibit the same trend as that seen in males 
(p=0.005 for ANOVA; p=0.014 for Kruskal Wallis test; Figure 3.58, page 335).  
An initial increase was observed in the mean number of hospital days per female, 
followed by a decrease over the next two years.  The mean number of hospital 
days per female was significantly lower in 2001 compared to 1999 (p=0.004).  
The median number of hospital days per hospitalized female for 1998 and 2001 
was 48.5 and 40, respectively. 
Diagnosis-specific analyses showed no significant year effect on the mean 
number of hospital days per hospitalized youth in the following diagnostic 
categories: anxiety disorders, bipolar disorders, depressive disorders, disruptive 
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behavorial disorders, psychotic disorders, mental retardation/developmental 




Table 3.79. Number of Hospital Days Per Hospitalized Child or Adolescent 
Receiving an Antipsychotic and Mental Health Care Services from 
TDMHMR from 1998 to 2001 
Sample Year N Mean (±SD) 95% CI Median p-value 
Hospitalized youths 1998 251 83.20±80.42 73.20 – 93.19 59.0 
 1999 341 82.64±78.45 74.29 – 91.00 57.0 
 2000 487 67.80±66.28 61.90 – 73.70 48.0 
 2001 573 56.93±60.64 51.96 – 61.91 36.0 
<0.001* 












Figure 3.55. Mean and Median Number of Hospital Days Per Hospitalized Ten- 
to Fourteen-Year Old Receiving an Antipsychotic and Mental Health 














































Figure 3.56. Mean and Median Number of Hospital Days Per Hospitalized 15- to 
19-Year Old Receiving an Antipsychotic and Mental Health Care 














































Figure 3.57. Mean and Median Number of Hospital Days Per Hospitalized Male 
Receiving an Antipsychotic and Mental Health Care Services from 










































Figure 3.58. Mean and Median Number of Hospital Days Per Hospitalized 
Female Receiving an Antipsychotic and Mental Health Care 












































H28: The number of children and adolescents receiving assessment 
services, crisis intervention, medication-based services, and service 
coordination increases from 1998 to 2001, while the number of 
children and adolescents receiving counseling and psychotherapy, 
skills training, and supportive mental health services decreases 
from 1998 to 2001. 
 
 Over the four-year period, the number of children and adolescents enrolled 
in assessment services, counseling and psychotherapy, medication-related 
services, service coordination, and skills training increased (Table 3.80, page 
339).  The number of youths enrolled in crisis intervention and supportive 
services decreased from 1998 to 2001.  Chi-square analysis revealed a significant 
relationship between frequencies of children and adolescents enrolled in different 
types of outpatient mental health care services and calendar year (χ2=389.389, 
df=18, p<0.001). 
 During each year, medication-related services accounted for the highest 
percentage of outpatient service enrollment (79.7% to 83.0%), and a trend toward 
a higher number of enrolled youths in these services existed.  Similar trends were 
seen with service coordination and skills training.  Percent enrollment in 
assessment services, and counseling and psychotherapy remained consistent over 
the study period.  Percent enrollment in crisis intervention and supportive services 
decreased from 1998 to 2001. 
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 In five- to nine-year olds, enrollment in medication-related services was 
most common, followed by service coordination and skills training (Table 3.81, 
page 340).  In 2001, approximately 80 percent of children between the ages of 
five and nine years were enrolled in medication-related services.  Sixty-nine 
percent of five- to nine-year olds were enrolled in service coordination in 2001, 
and 51 percent were enrolled in skills training.  Trends of decreased enrollment in 
crisis intervention and supportive services existed in this age group.  Similar 
results regarding enrollment in different outpatient mental health services were 
seen in the ten- to 14-year and 15- to 19-year age groups.  Chi-square analyses for 
these age groups showed a significant relationship between frequencies of 
children and adolescents enrolled in different types of outpatient mental health 
care services and calendar year (5- to 9-years: χ2=81.581, df=18, p<0.001; 10- to 
14-years: χ2=239.155, df=18, p<0.001; 15- to 19-years: χ2=106.196, df=18, 
p<0.001). 
 Gender-specific analyses of outpatient mental health services revealed 
higher enrollment in medication-related services, service coordination, and skills 
training for both males and females (Table 3.82, page 341).  Over the four-year 
period, fewer males and females were enrolled in crisis intervention and 
supportive services.  Chi-square analyses for males and females showed a 
significant relationship between frequencies of children and adolescents enrolled 
in different types of outpatient mental health care services and calendar year 
(males: χ2=276.37, df=18, p<0.001; females: χ2=125.846, df=18, p<0.001). 
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 Diagnosis-specific analyses showed similar trends of enrollment in 
outpatient mental health services (Table 3.83, pages 342-344).  Across all 
diagnostic groups, enrollment was highest in medication-related services, 
followed by service coordination and skills training.  Additionally, youths in each 
diagnostic group enrolled in crisis intervention and supportive services less 
frequently from 1998 to 2001.  Chi-square analyses showed a significant 
relationship between frequencies of children and adolescents enrolled in different 
types of outpatient mental health care services and calendar year for the following 
diagnostic groups: bipolar disorders (χ2=42.759, df=18, p<0.001); depressive 
disorders (χ2=66.089, df=18, p<0.001); disruptive disorders (χ2=132.853, df=18, 
p<0.001); other psychiatric disorders (χ2=45.353, df=18, p<0.001); and, comorbid 













Table 3.80. Enrollment of Texas Medicaid Youths Receiving an Antipsychotic 
and Mental Health Services from TDMHMR in Different Types of 
Outpatient Mental Health Services from 1998 to 2001a 
Type of Outpatient Service 1998 1999 2000 2001 
Assessment services 1093 1257 1153 1574 
 46.9% 44.2% 36.0% 40.5% 
Counseling and psychotherapy 875 973 971 1307 
 37.5% 34.2% 30.3% 33.7% 
Crisis intervention 397 386 311 327 
 17.0% 13.6% 9.7% 8.4% 
Medication-related services 1858 2310 2655 3202 
 79.7% 81.2% 83.0% 82.5% 
Service coordination 1391 2074 2140 2613 
 59.7% 72.9% 66.9% 67.3% 
Skills training 1136 1424 1704 1983 
 48.7% 50.0% 53.3% 51.1% 
Supportive services 177 155 55 62 
 7.6% 5.4% 1.7% 1.6% 




















Table 3.81. Age-Specific Enrollment of Texas Medicaid Youths Receiving an 
Antipsychotic and Mental Health Services from TDMHMR in 
Different Types of Outpatient Mental Health Services from 1998 to 
2001a,b 
Age Type of Outpatient 
Service 
1998 1999 2000 2001 
5 to 9 years Assessment services 41.8 42.4 35.5 36.7 
 Counseling and 
psychotherapy 
40.9 31.6 27.5 31.5 
 Crisis intervention 14.6 9.9 8.5 7.1 
 Medication-related 
services 
79.8 82.7 81.2 84.1 
 Service coordination 61.4 73.3 66.6 69.4 
 Skills training 51.5 50.3 52.5 50.9 
 Supportive services 5.9 3.9 1.7 2.0 
10 to 14 years Assessment services 46.7 41.3 31.3 38.5 
 Counseling and 
psychotherapy 
35.3 32.6 30.1 32.1 
 Crisis intervention 16.8 12.8 9.3 7.4 
 Medication-related 
services 
75.0 77.5 80.8 79.0 
 Service coordination 58.5 72.6 64.7 66.2 
 Skills training 49.7 49.9 53.6 51.7 
 Supportive services 8.2 5.8 2.0 1.4 
15 to 19 years Assessment services 42.8 44.5 37.9 40.0 
 Counseling and 
psychotherapy 
31.1 34.8 28.2 32.8 
 Crisis intervention 15.7 16.0 9.6 9.6 
 Medication-related 
services 
74.7 75.2 75.8 76.6 
 Service coordination 53.0 64.9 59.9 57.1 
 Skills training 39.1 44.1 48.5 45.1 
 Supportive services 6.7 5.3 0.8 1.3 
aAll values reported as percentages. 
b5 to 9 years: χ2=81.581, df=18, p<0.001; 10 to 14 years: χ2=239.155, df=18, p<0.001; 15 to 19 
years: χ2=106.196, df=18, p<0.001. 
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Table 3.82. Gender-Specific Enrollment of Texas Medicaid Youths Receiving an 
Antipsychotic and Mental Health Services from TDMHMR in 
Different Types of Outpatient Mental Health Services from 1998 to 
2001a,b 
Gender Type of Outpatient 
Service 
1998 1999 2000 2001 
Male Assessment services 46.4 42.0 36.4 39.8 
 Counseling and 
psychotherapy 
37.5 33.0 29.0 32.6 
 Crisis intervention 16.0 12.8 8.9 8.4 
 Medication-related 
services 
81.4 82.7 84.2 83.8 
 Service coordination 60.0 73.6 66.8 67.8 
 Skills training 49.9 51.3 53.9 52.5 
 Supportive services 8.0 5.4 1.7 1.6 
Female Assessment services 48.1 49.4 35.2 42.3 
 Counseling and 
psychotherapy 
37.6 36.9 33.6 36.3 
 Crisis intervention 19.8 15.3 11.8 8.4 
 Medication-related 
services 
75.3 77.6 80.0 79.3 
 Service coordination 58.8 71.2 67.1 66.2 
 Skills training 45.8 47.0 51.7 47.5 
 Supportive services 6.6 5.6 1.7 1.5 
aAll values reported as percentages. 








Table 3.83. Diagnosis-Specific Enrollment of Texas Medicaid Youths Receiving 
an Antipsychotic and Mental Health Services from TDMHMR in 
Different Types of Outpatient Mental Health Services from 1998 to 
2001a,b 
Diagnostic Group Type of Outpatient 
Service 
1998 1999 2000 2001 
Anxiety Assessment services 47.0 41.0 36.1 49.2 
 Counseling and 
psychotherapy 
48.5 37.7 25.0 42.4 
 Crisis intervention 15.2 14.8 4.2 3.4 
 Medication-related 
services 
72.7 72.1 76.4 88.1 
 Service coordination 59.1 72.1 70.8 86.4 
 Skills training 54.5 39.3 54.2 62.7 
 Supportive services 3.0 0.0 5.6 3.4 
Bipolar Assessment services 41.7 34.9 36.5 44.6 
 Counseling and 
psychotherapy 
43.4 37.6 34.4 41.7 
 Crisis intervention 21.7 13.5 8.9 9.7 
 Medication-related 
services 
81.1 81.2 86.9 90.0 
 Service coordination 57.1 75.1 70.6 78.5 
 Skills training 56.0 54.1 60.3 66.1 
 Supportive services 7.4 3.1 1.4 3.4 
Depressive Assessment services 55.6 51.4 38.9 50.5 
 Counseling and 
psychotherapy 
36.6 40.4 34.2 48.2 
 Crisis intervention 17.6 14.6 13.5 13.2 
 Medication-related 
services 
78.6 80.2 85.9 88.2 
 Service coordination 54.0 71.6 72.4 75.7 
 Skills training 46.3 48.6 51.9 57.9 
 Supportive services 6.4 5.2 1.1 2.1 
aAll values reported as percentages. 
bAnxiety: χ2=21.834, df=18, p=0.239; Bipolar: χ2=42.759, df=18, p<0.001; Depressive: 
χ2=66.089, df=18, p<0.001. 
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Table 3.83. Diagnosis-Specific Enrollment of Texas Medicaid Youths Receiving 
an Antipsychotic and Mental Health Services from TDMHMR in 
Different Types of Outpatient Mental Health Services from 1998 to 
2001c,d (Cont.) 
Diagnostic Group Type of Outpatient 
Service 
1998 1999 2000 2001 
Disruptive Assessment services 44.5 43.2 30.4 39.1 
 Counseling and 
psychotherapy 
37.0 30.8 30.9 40.2 
 Crisis intervention 13.3 10.4 7.2 7.6 
 Medication-related 
services 
76.5 79.5 83.0 87.3 
 Service coordination 64.0 73.0 69.8 75.5 
 Skills training 50.1 51.1 59.2 63.0 
 Supportive services 7.2 5.5 2.0 1.7 
Psychotic Assessment services 48.8 41.6 32.1 45.1 
 Counseling and 
psychotherapy 
25.9 36.9 31.0 30.6 
 Crisis intervention 16.3 14.0 9.6 11.4 
 Medication-related 
services 
81.3 86.0 90.4 91.2 
 Service coordination 61.4 70.6 73.8 77.7 
 Skills training 47.6 49.1 49.7 62.2 
 Supportive services 8.4 6.5 1.6 3.6 
MR/Developmental Assessment services 24.6 26.7 21.1 34.1 
 Counseling and 
psychotherapy 
21.9 16.8 10.9 31.9 
 Crisis intervention 8.8 8.4 6.8 5.9 
 Medication-related 
services 
86.0 86.3 83.7 85.2 
 Service coordination 36.0 42.7 36.1 45.9 
 Skills training 25.4 24.4 31.3 35.6 
 Supportive services 6.1 1.5 1.4 1.5 
cAll values reported as percentages. 
dDisruptive: χ2=132.853, df=18, p<0.001; Psychotic: χ2=29.83, df=18, p=0.039; 
MR/Developmental: χ2=27.475, df=18, p=0.071. 
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Table 3.83. Diagnosis-Specific Enrollment of Texas Medicaid Youths Receiving 
an Antipsychotic and Mental Health Services from TDMHMR in 
Different Types of Outpatient Mental Health Services from 1998 to 
2001e,f (Cont.) 
Diagnostic Group Type of Outpatient 
Service 
1998 1999 2000 2001 
Other psychiatric Assessment services 50.8 43.7 29.4 49.2 
 Counseling and 
psychotherapy 
38.5 25.8 22.4 37.9 
 Crisis intervention 18.5 6.6 5.6 9.7 
 Medication-related 
services 
65.4 66.2 77.6 75.0 
 Service coordination 57.7 75.5 67.1 71.8 
 Skills training 36.9 49.0 53.8 62.9 
 Supportive services 3.1 4.6 2.1 0.8 
Comorbid psychiatric Assessment services 54.5 51.8 47.0 62.4 
 Counseling and 
psychotherapy 
45.7 40.7 37.6 47.5 
 Crisis intervention 26.5 21.9 14.6 17.7 
 Medication-related 
services 
89.8 89.2 91.6 88.7 
 Service coordination 67.2 82.8 80.2 79.4 
 Skills training 60.1 59.6 66.9 69.5 
 Supportive services 13.1 8.8 3.2 2.8 
eAll values reported as percentages. 








H29: The mean duration of enrollment in outpatient services for 
assessment services, crisis intervention, medication-based services, 
and service coordination increases among children and adolescents 
receiving an antipsychotic from 1998 to 2001.  The mean duration 
of enrollment in outpatient services for counseling and 
psychotherapy, skills training, and supportive mental health 
services decreases among children and adolescents receiving an 
antipsychotic from 1998 to 2001. 
 
Assessment services 
 The duration of enrollment in assessment services decreased from 1998 to 
2001 (Table 3.84, page 349; Figure 3.59, page 350; p<0.001 for ANOVA and 
Kruskal Wallis test).  In 1998, the mean (±SD) duration of enrollment in 
assessment services was 5.01±13.99 days.  Enrollment in assessment services 
continually declined over the four-year period.  In 2001, the mean (±SD) duration 
of enrollment in assessment services was 2.29±4.20 days.  Post hoc analyses 
revealed significant differences in mean duration of enrollment in assessment 
services between 1998 and 1999, 2000, and 2001 (p<0.001).  Additionally, the 
mean duration of enrollment in assessment services in 1999 was significantly 
higher than those in 2000 (p=0.001) and 2001 (p<0.001).  The median duration of 
enrollment in assessment services for all four years was one day. 
 In five- to nine-year olds, the duration of enrollment in assessment 
services decreased from 1998 to 2001 (p<0.001 for ANOVA and Kruskal Wallis 
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test).  Mean durations of enrollment in assessment services in 1998 and 1999 were 
significantly higher than in 2000 and 2001 (p≤0.001).  The median duration of 
enrollment in assessment services for the five- to nine-year age group for all four 
years was one day.  In ten- to 14-year olds, a trend of decreased duration of 
enrollment in assessment services existed over the four-year period (p<0.001 for 
ANOVA and Kruskal Wallis test).  Post hoc analyses revealed significant 
differences in mean duration of enrollment in assessment services between 1998 
and 1999, 2000, and 2001 (p≤0.003).  Additionally, the mean duration of 
enrollment in assessment services was significantly higher in 1999 compared to 
2001 (p<0.001).  The median duration of enrollment in assessment services for 
the ten- to 14-year age group for all four years was one day.  In 15- to 19-year 
olds, the duration of enrollment in assessment services decreased from 1998 to 
2000, and then increased slightly in 2001 (p<0.001 for ANOVA and Kruskal 
Wallis test).  The mean duration of enrollment in assessment services for the 15- 
to 19-year age group was significantly higher in 1999 compared to 2000 
(p=0.008).  The median duration of enrollment in assessment services for 15- to 
19-year olds for all four years was one day.  In two- to four-year olds, no 
significant year effect existed in the duration of enrollment in assessment services. 
 In both males and females, the duration of enrollment in assessment 
services decreased from 1998 to 2001 (p<0.001 for ANOVA and Kruskal Wallis 
test).  In males, the mean duration of enrollment in assessment services in 1998 
was significantly higher compared to those in 1999, 2000, and 2001 (p≤0.003).  
Additionally, a significant difference in mean duration of enrollment in 
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assessment services existed between 1999 and 2000, and 1999 and 2001 
(p<0.001).  In females, mean durations of enrollment in assessment services in 
1998 and 1999 were significantly higher than that in 2001 (p=0.004 and p=0.001, 
respectively).  Also, a significant difference in mean duration of enrollment in 
assessment services in females existed between 1998 and 2000 (p=0.009).  The 
median duration of enrollment in assessment services for both males and females 
for all four years was one day. 
 A significant year effect on the duration of enrollment in assessment 
services existed for children and adolescents with bipolar disorders, depressive 
disorders, disruptive behavioral disorders, psychotic disorders, other psychiatric 
disorders, comorbid psychiatric disorders, and no psychiatric disorder.  In the 
bipolar disorder group, the duration of enrollment in assessment services 
decreased over the four-year period (p<0.001 for ANOVA and Kruskal Wallis 
test).  The mean duration of enrollment in assessment services for bipolar youths 
was significantly higher in 1999 compared to 2001 (p<0.001).  The median 
duration of enrollment in assessment services for the bipolar group was one day 
for all four years.  In youths with depressive disorders, the duration of enrollment 
in assessment services decreased.  ANOVA did not show a significant year effect, 
but the Kruskal Wallis test did (p<0.001).  The median duration of enrollment for 
all four years in this diagnostic group was one day.  In the disruptive behavioral 
disorder group, the duration of enrollment in assessment services decreased from 
1998 to 2000, and then increased slightly in 2001 (p<0.001 for ANOVA and 
Kruskal Wallis test).  Post hoc analyses revealed significant differences in the 
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mean duration of enrollment in assessment services for the following: 1998 and 
2000 (p<0.001); 1998 and 2001 (p<0.001); and, 1999 and 2000 (p=0.005).  The 
median duration of enrollment for each year was one day in the disruptive 
behavioral disorder group.  In youths with psychotic disorders, the duration of 
enrollment in assessment services decreased from 1998 to 2001 (p<0.001 for 
ANOVA and Kruskal Wallis test).  The mean duration of enrollment in 
assessment services for the psychotic disorder group was significantly higher in 
1998 compared to 2001 (p<0.001), and the median duration of enrollment was 
one day for all four years.  In the other psychiatric disorder group, the duration of 
enrollment in assessment services decreased from 1998 to 2000, and then 
increased in 2001 (p=0.008 for ANOVA and p<0.001 for Kruskal Wallis test).  A 
significant difference in the mean duration of enrollment for youths with other 
psychiatric disorders existed between 1998 and 2000 (p<0.001).  The median 
duration of enrollment in assessment services for this diagnostic group was one 
day for all years.  In children and adolescents with comorbid psychiatric 
diagnoses, the duration of enrollment in assessment services decreased for the 
first three years, and then increased slightly (p<0.001 for ANOVA and Kruskal 
Wallis test).  The mean duration of enrollment for the comorbid psychiatric group 
in 1998 was significantly higher than those in 1999 (p=0.003), 2000 (p<0.001), 
and 2001 (p=0.001).  The median duration of enrollment in assessment services 
for all four years was one day.  In youths with no psychiatric disorder, the 
duration of enrollment decreased from 1998 to 2000, and increased thereafter 
(p<0.001 for ANOVA and Kruskal Wallis test).  The mean duration of enrollment 
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in assessment services for this group was significantly higher in 1998 than in 
2000 (p=0.005).  The median duration of enrollment in 1998 was 15 days, and 
one day for the other years.  No significant year effect on the duration of 
enrollment in assessment services existed for children and adolescents with 
anxiety disorders or mental retardation/developmental disorders. 
 
Table 3.84. Duration of Enrollment (Days) in Assessment Services Per Child or 
Adolescent Receiving an Antipsychotic and Mental Health Care 
Services from TDMHMR from 1998 to 2001 
Outpatient Service Year N Mean (±SD) 95% CI Median p-value 
Assessment services 1998 1557 5.01±13.99 4.31 – 5.70 1.0 
 1999 2013 3.39±7.25 3.07 – 3.71 1.0 
 2000 1825 2.35±5.43 2.10 – 2.60 1.0 
 2001 2322 2.29±4.20 2.12 – 2.47 1.0 
<0.001* 












Figure 3.59. Mean and Median Duration of Enrollment (Days) in Assessment 
Services Per Child or Adolescent Receiving an Antipsychotic and 

































Counseling and psychotherapy 
 The duration of enrollment in counseling and psychotherapy decreased 
from 1998 to 1999, but then remained steady for the following three years (Table 
3.85, page 352; Figure 3.60, page 353).  ANOVA did not show a significant year 
effect, but the Kruskal Wallis test did (p=0.001).  Median durations of enrollment 
in counseling and psychotherapy for 1998, 1999, 2000, and 2001 were 31, 29, 31, 
and 26 days, respectively. 
 In five- to nine-year olds, the duration of enrollment in counseling and 
psychotherapy decreased from 1998 to 1999, and remained steady thereafter 
(p=0.004 for ANOVA and p=0.01 for Kruskal Wallis test).  Post hoc analyses did 
not reveal any significant differences between years.  Median durations of 
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enrollment in counseling and psychotherapy for five- to nine-year olds for 1998, 
1999, 2000, and 2001 were 31, 26, 31, and 27 days, respectively.  Age-specific 
analyses of the duration of enrollment in counseling and psychotherapy revealed 
no significant year effect for the two- to four-year, ten- to 14-year, and 15- to 19-
year age groups. 
 In males, the mean duration of enrollment in counseling and 
psychotherapy decreased from 1998 to 2001 (p=0.006 for ANOVA and p=0.002 
for Kruskal Wallis test).  The mean duration of enrollment in counseling and 
psychotherapy for males was significantly higher in 1998 compared to 2001 
(p=0.006).  Median durations of enrollment in counseling and psychotherapy for 
males in 1998, 1999, 2000, and 2001 were 31, 27, 31, and 24 days, respectively.  
No significant year effect on duration of enrollment in counseling and 
psychotherapy in females was present. 
 The duration of enrollment in counseling and psychotherapy for children 
and adolescents with disruptive behavioral disorders decreased over the four-year 
period.  The Kruskal Wallis test revealed a significant year effect (p=0.003), but 
ANOVA did not.  The median duration of enrollment in counseling and 
psychotherapy was 31 days for 1998, 1999, and 2000; the median duration in 
2001 was 22.5 days.  Similarly, the Kruskal Wallis test detected a significant year 
effect on duration of enrollment in counseling and psychotherapy for youths with 
comorbid psychiatric disorders (p=0.005).  In this diagnostic group, median 
durations of enrollment in 1998, 1999, 2000, and 2001 were 31, 26, 29, and 12 
days, respectively.  No significant year effect on the duration of enrollment in 
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counseling and psychotherapy existed for children and adolescents with anxiety 
disorders, bipolar disorders, depressive disorders, psychotic disorders, mental 
retardation/developmental disorders, other psychiatric disorders, and no 
psychiatric disorder. 
 
Table 3.85. Duration of Enrollment (Days) in Counseling and Psychotherapy Per 
Child or Adolescent Receiving an Antipsychotic and Mental Health 
Care Services from TDMHMR from 1998 to 2001 
Outpatient Service Year N Mean (±SD) 95% CI Median p-value 
Counseling and 
psychotherapy 
1998 1294 58.57±78.48 54.29 – 62.85 31.0 
 1999 1515 51.99±73.40 48.29 – 55.69 29.0 
 2000 1377 52.70±68.39 49.08 – 56.31 31.0 
 2001 1892 50.11±70.59 46.92 – 53.29 26.0 
0.012* 
0.001† 
*p-value for ANOVA. 












Figure 3.60. Mean and Median Duration of Enrollment (Days) in Counseling and 
Psychotherapy Per Child or Adolescent Receiving an Antipsychotic 




































 The duration of enrollment in crisis intervention decreased slightly from 
1998 to 1999, and then increased thereafter (Table 3.86, page 355; Figure 3.61, 
page 356; p=0.002 for ANOVA and p=0.001 for Kruskal Wallis test).  In 1998, 
the mean (±SD) duration of enrollment in crisis intervention was 37.93±63.67 
days.  In 2001, the mean (±SD) duration of enrollment in crisis intervention was 
50.20±79.27 days.  Post hoc analyses did not reveal significant differences in 
mean duration of enrollment in crisis intervention between years.  Median 
durations of enrollment in crisis intervention for 1998, 1999, 2000, and 2001 were 
12, 9, 13, and 10 days, respectively. 
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 In ten- to 14-year olds, ANOVA showed a significant year effect on the 
mean duration of enrollment in crisis intervention, as duration increased from 
1998 to 2001 (p<0.001).  Mean durations of enrollment in crisis intervention were 
significantly lower in 1998 and 1999 compared to 2001 (p=0.006 and p=0.01, 
respectively).  No significant year effect on duration of enrollment in crisis 
intervention for this age group was detected using the Kruskal Wallis test.  No 
significant year effect existed in the duration of enrollment in crisis intervention 
for the following age groups: two- to four-years, five- to nine-years, and 15- to 
19-years. 
 In males, the mean duration of enrollment in crisis intervention increased 
in 2000 and 2001, after remaining steady for 1998 and 1999 (p=0.002).  The mean 
duration of enrollment in crisis intervention in 1998 was significantly lower than 
that in 2001 (p=0.01).  No significant year effect on duration of enrollment in 
crisis intervention for males was detected using the Kruskal Wallis test.  In 
females, no significant year effect on duration of enrollment in crisis intervention 
existed. 
 The duration of enrollment in crisis intervention in youths with disruptive 
behavioral disorders increased from 1998 to 2001 (p<0.001 for ANOVA and 
Kruskal Wallis test).  The mean duration of enrollment in crisis intervention for 
this diagnostic group was significantly lower in 1998 and 1999 compared to 2001 
(p=0.002 and p=0.004, respectively).  The median duration of enrollment also 
increased after 1999 (1998: 14 days; 1999: 10 days; 2000: 30 days; and, 2001: 
52.5 days).  In youths with comorbid psychiatric disorders, a significant year 
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effect on the duration of enrollment in crisis intervention existed (p=0.007 for 
ANOVA and p<0.001 for Kruskal Wallis test).  Post hoc analyses revealed no 
significant differences between years.  The median duration of enrollment did not 
show any definitive trend as well (1998: 11 days; 1999: 9 days; 2000: 16 days; 
and, 2001: 6 days).  No significant year effect on the duration of enrollment in 
crisis intervention existed for children and adolescents with anxiety disorders, 
bipolar disorders, depressive disorders, psychotic disorders, mental 
retardation/developmental disorders, other psychiatric disorders, and no 
psychiatric disorder.   
 
Table 3.86. Duration of Enrollment (Days) in Crisis Intervention Per Child or 
Adolescent Receiving an Antipsychotic and Mental Health Care 
Services from TDMHMR from 1998 to 2001 
Outpatient Service Year N Mean (±SD) 95% CI Median p-value 
Crisis intervention 1998 532 37.93±63.67 32.51 – 43.35 12.0 
 1999 543 35.71±65.59 30.18 – 41.24 9.0 
 2000 387 49.06±78.39 41.23 – 56.89 13.0 
 2001 420 50.20±79.27 42.60 -57.80 10.0 
0.002* 
0.001† 
*p-value for ANOVA. 







Figure 3.61. Mean and Median Duration of Enrollment (Days) in Crisis 
Intervention Per Child or Adolescent Receiving an Antipsychotic 





































 The duration of enrollment in medication-related services initially 
remained stable in 1998 and 1999, and declined for 2000 and 2001 (Table 3.87, 
page 358; Figure 3.62, page 359; p<0.001 for ANOVA and p=0.004 for Kruskal 
Wallis test).  In 1998, the mean (±SD) duration of enrollment in medication-
related services was 148.42±118.61 days.  In 2001, the mean (±SD) duration of 
enrollment in medication-related services was 139.21±116.85 days.  Mean 
durations of enrollment in medication-related services were significantly higher in 
1998 and 1999 compared to that in 2000 (p=0.002 and p=0.001, respectively).  
Furthermore, a significant difference in the mean duration of enrollment in 
 357
medication-related services existed between 1999 and 2001 (p=0.005).  Median 
durations of enrollment in medication-related services for 1998, 1999, 2000, and 
2001 was 119, 110, 100, and 102 days, respectively. 
 In ten- to 14-year olds, ANOVA showed a significant year effect on the 
mean duration of enrollment in medication-related services, but no definitive 
pattern was observed over time (p<0.001).  The mean duration of enrollment in 
medication-related services was significantly higher in 1999 compared to 2000 
(p<0.001).  No significant year effect on median duration of enrollment in 
medication-related services in ten- to 14-year olds was detected using the Kruskal 
Wallis test.  In 15- to 19-year olds, a significant year effect on median duration of 
enrollment in medication-related services existed over the four-year period 
(p=0.001).  No significant year effect on mean duration of enrollment in 
medication-related services in this age group was detected using ANOVA.  No 
significant year effect on the duration of enrollment in medication-related services 
existed for the following age groups: two- to four-years and five- to nine-years. 
 Males showed a significant year effect, as the duration of enrollment in 
medication-related services decreased from 1998 to 2001 (p<0.001 for ANOVA 
and p=0.001 for Kruskal Wallis test).  The mean duration of enrollment in 
medication-related services for males in 1998 was significantly higher than those 
in 2000 (p=0.009) and 2001 (p=0.001).  In addition, a significant difference in the 
mean duration of enrollment in medication-related services existed between 1999 
and 2001 (p=0.001).  Median durations of enrollment in medication-related 
services for males in 1998, 1999, 2000, and 2001 were 122, 113, 105, and 102 
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days.  In females, no significant year effect on the duration of enrollment in 
medication-related services existed. 
 As detected by the Kruskal Wallis test, a significant year effect on the 
duration of enrollment in medication-related services existed in youths with 
comorbid psychiatric disorders (p=0.002).  Over time, the median duration of 
enrollment in medication-related services in the comorbid psychiatric disorder 
group did not show any definitive trend (1998: 113 days; 1999: 92 days; 2000: 
110 days; and, 2001: 91 days).  No significant year effect on the duration of 
enrollment in medication-related services existed for children and adolescents 
with anxiety disorders, bipolar disorders, depressive disorders, disruptive 
behavioral disorders, psychotic disorders, mental retardation/developmental 
disorders, other psychiatric disorders, and no psychiatric disorder. 
 
Table 3.87. Duration of Enrollment (Days) in Medication-related Services Per 
Child or Adolescent Receiving an Antipsychotic and Mental Health 
Care Services from TDMHMR from 1998 to 2001 
Outpatient Service Year N Mean (±SD) 95% CI Median p-value 
Medication-related 
services 
1998 2314 148.42±118.61 143.58 – 153.25 119.0 
 1999 3011 148.77±125.47 144.29 – 153.26 110.0 
 2000 3609 137.26±115.68 133.48 – 141.03 100.0 
 2001 4559 139.21±116.85 135.82 – 142.60 102.0 
<0.001* 
0.004† 
*p-value for ANOVA. 
†p-value for Kruskal-Wallis test. 
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Figure 3.62. Mean and Median Duration of Enrollment (Days) in Medication-
related Services Per Child or Adolescent Receiving an Antipsychotic 






































 The duration of enrollment in service coordination increased from 1998 to 
2001 (Table 3.88, page 363; Figure 3.63, page 364; p<0.001 for ANOVA and 
Kruskal Wallis test).  In 1998, the mean (±SD) duration of enrollment in service 
coordination was 82.23±97.35 days.  Enrollment in service coordination 
continually increased over the four-year period.  In 2001, the mean (±SD) 
duration of enrollment in service coordination was 118.43±111.84 days.  Post hoc 
analyses revealed significant differences in mean duration of enrollment in service 
coordination between 1998 and 1999 (p=0.009), 2000, and 2001 (p<0.001).  
Additionally, the mean duration of enrollment in service coordination in 1999 was 
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significantly lower than those in 2000 and 2001 (p<0.001).  Median durations of 
enrollment in service coordination for 1998, 1999, 2000, and 2001 were 45, 58, 
81, and 91 days, respectively. 
 In five- to nine-year olds, the duration of enrollment in service 
coordination increased from 1998 to 2001 (p<0.001 for ANOVA and Kruskal 
Wallis test).  Mean durations of enrollment in service coordination in 1998 and 
1999 were significantly lower than in 2000 and 2001 (p<0.001).  Median 
durations of enrollment in service coordination for 1998, 1999, 2000, and 2001 in 
the five- to nine-year age group were 50, 64, 83.5, and 92 days, respectively.  In 
ten- to 14-year olds, a trend of increased duration of enrollment in service 
coordination existed over the four-year period (p<0.001 for ANOVA and Kruskal 
Wallis test).  Post hoc analyses revealed significant differences in mean duration 
of enrollment in service coordination between 1998 and 1999, 2000, and 2001 
(p≤0.002).  Additionally, the mean duration of enrollment in service coordination 
was significantly lower in 1999 compared to 2000 and 2001 (p<0.001).  The 
median duration of enrollment in service coordination for the ten- to 14-year age 
group also increased (1998: 40 days; 1999: 57 days; 2000: 82 days; and, 2001: 89 
days).  In 15- to 19-year olds, the duration of enrollment in service coordination 
decreased from 1998 to 1999, and increased thereafter (p<0.001 for ANOVA and 
Kruskal Wallis test).  The mean duration of enrollment in service coordination for 
the 15- to 19-year age group was significantly lower in 1999 compared to 2000 
and 2001 (p<0.001).  Median durations of enrollment in service coordination for 
1998, 1999, 2000, and 2001 for 15- to 19-year olds were 53, 53, 75.5, and 71 
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days, respectively.  In two- to four-year olds, no significant year effect existed in 
the duration of enrollment in service coordination. 
 A significant year effect on duration of enrollment in service coordination 
existed in both males and females.  In males, a trend of increased durations of 
enrollment in service coordination existed from 1998 to 2001 (p<0.001 for 
ANOVA and Kruskal Wallis test).  Mean durations of enrollment in service 
coordination in 1998 and 1999 were significantly lower than those in 2000 and 
2001 (p<0.001).  The median duration of enrollment in service coordination for 
males also increased (1998: 47 days; 1999: 59 days; 2000: 84 days; and, 2001: 91 
days).  In females, the same trend over time existed (p<0.001 for ANOVA and 
Kruskal Wallis test).  Post hoc analyses revealed significant differences in the 
mean duration of enrollment in service coordination for females between the 
following years: 1998 and 2000; 1998 and 2001; 1999 and 2000; and, 1999 and 
2001 (p<0.001).  Median durations of enrollment in service coordination for 
females in 1998, 1999, 2000, and 2001 were 38, 54, 74, and 85 days, respectively. 
 The duration of enrollment in service coordination for youths with anxiety 
disorders increased from 1998 to 2000, and then decreased in 2001 (p<0.001 for 
ANOVA and Kruskal Wallis test).  The mean duration of enrollment in the 
anxiety disorder group was significantly lower in 1998 compared to 2000 
(p<0.001).  Median durations of enrollment in service coordination in 1998, 1999, 
2000, and 2001 were 31, 59, 81.5, and 37.5 days.  In youths with bipolar disorder, 
a significant year effect on the duration of enrollment in service coordination 
existed (p<0.001 for ANOVA and Kruskal Wallis test).  The mean duration of 
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enrollment in this diagnostic group was significantly lower in 1998 and 1999 
compared to 2000 and 2001 (p≤0.003).  The median duration of enrollment in 
service coordination for bipolar youths decreased initially, and then increased 
(1998: 67 days; 1999: 53.5 days; 2000: 85 days; and, 2001: 91 days).  In the 
depressive disorder group, the duration of enrollment in service coordination 
increased from 1998 to 2000, and then decreased in 2001 (p<0.001 for ANOVA 
and Kruskal Wallis test).  The mean duration of enrollment in youths with 
depressive disorders was significantly lower in 1998 and 1999 compared to 2000 
and 2001 (p≤0.001).  Median durations of enrollment in service coordination for 
this diagnostic group in 1998, 1999, 2000, and 2001 were 40.5, 59, 90, and 81 
days.  A significant year effect on the duration of enrollment in service 
coordination existed for youths with disruptive behavioral disorders, showing a 
trend of increasing duration (p<0.001 for ANOVA and Kruskal Wallis test).  The 
mean duration of enrollment in this diagnostic group was significantly lower in 
1998 and 1999 compared to 2000 and 2001 (p<0.001).  The median duration of 
enrollment in service coordination for disruptive behavioral youths steadily 
increased (1998: 44 days; 1999: 57 days; 2000: 88 days; and, 2001: 96 days).  
Similarly, the duration of enrollment in service coordination increased from 1998 
to 2001 for children and adolescents with mental retardation/developmental 
disorders (p=0.001 for ANOVA and Kruskal Wallis test).  Compared to 2001, the 
mean duration of enrollment in 1998 was significantly lower for this diagnostic 
group (p=0.004).  The median duration of enrollment in service coordination also 
increased from 31 days in 1998 to 108 days in 2001.  In youths with comorbid 
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psychiatric disorders, a significant year effect on duration of enrollment in service 
coordination existed (p<0.001 for ANOVA and Kruskal Wallis test).  The mean 
duration of enrollment for the comorbid psychiatric disorder group in 1998 was 
significantly lower than those in 2000 (p<0.001) and 2001 (p=0.009).  
Additionally, the mean duration of enrollment in 1999 was significantly lower 
than that in 2000 (p<0.001).  The median duration of enrollment in service 
coordination for youths with comorbid psychiatric disorders increased over time 
(1998: 43 days; 1999: 57 days; 2000: 81 days; and, 2001: 86 days).  No 
significant year effect on duration of enrollment in service coordination existed 
for children and adolescents with psychotic disorders, other psychiatric disorders, 
and no psychiatric disorder. 
 
Table 3.88. Duration of Enrollment (Days) in Service Coordination Per Child or 
Adolescent Receiving an Antipsychotic and Mental Health Care 
Services from TDMHMR from 1998 to 2001 
Outpatient Service Year N Mean (±SD) 95% CI Median p-value 
Service 
coordination 
1998 2355 82.23±97.35 78.29 – 86.16 45.0 
 1999 3300 90.49±97.41 87.17 – 93.82 58.0 
 2000 3073 116.69±109.41 112.82 – 120.56 81.0 
 2001 3964 118.43±111.84 114.95 – 121.91 91.0 
<0.001* 





Figure 3.63. Mean and Median Duration of Enrollment (Days) in Service 
Coordination Per Child or Adolescent Receiving an Antipsychotic 







































 The mean duration of enrollment in skills training initially remained stable 
from 1998 to 2000, and declined in 2001 (Table 3.89, page 366; Figure 3.64, page 
367; p<0.001 for ANOVA and Kruskal Wallis test).  In 1998, the mean (±SD) 
duration of enrollment in skills training was 66.55±78.65 days.  In 2001, the mean 
(±SD) duration of enrollment in skills training was 59.44±78.13 days.  The mean 
duration of enrollment in skills training was significantly higher in 1999 
compared to that in 2001 (p=0.006).  Median durations of enrollment in skills 
training for 1998, 1999, 2000, and 2001 were 38, 35, 34, and 31 days, 
respectively. 
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 In ten- to 14-year olds, the duration of enrollment in skills training 
increased slightly between 1998 and 2000, and then decreased in 2001 (p=0.001 
for ANOVA and p<0.001 for Kruskal Wallis test).  Mean durations of enrollment 
in skills training in 1999 and 2000 in ten- to 14-year olds were significantly 
greater than that in 2001 (p=0.004).  The median duration of enrollment in skills 
training for 1998 was 36 days; for 1999, 36 days; for 2000, 37 days; and, for 
2001, 30 days.  In 15- to 19-year olds, the median duration of enrollment in skills 
training decreased from 1998 to 2001 (31 days and 28 days, respectively; 
p=0.005).  No significant year effect on mean duration of enrollment in skills 
training in this age group was detected using ANOVA.  No significant year effect 
on the duration of enrollment in skills training existed for two- to four-year olds 
and five- to nine-year olds. 
 A significant year effect on the duration of enrollment in skills training 
existed for males (p<0.001 for ANOVA and Kruskal Wallis test).  The mean 
duration of enrollment in skills training for males gradually declined over the 
four-year period, with significant differences between 1998 and 2001 (p=0.001), 
and 2000 and 2001 (p=0.007).  The median duration of enrollment in skills 
training also decreased for males (1998: 39 days; 1999: 32 days; 2000: 35 days; 
and, 2001: 30 days).  No significant year effect on the duration of enrollment in 
skills training existed for females. 
 As detected by the Kruskal Wallis test, a significant year effect on the 
duration of enrollment in skills training existed in youths with disruptive 
behavioral disorders (p=0.009).  Over time, the median duration of enrollment in 
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skills training in this diagnostic group did not show any definitive trend (1998: 39 
days; 1999: 36.5 days; 2000: 39 days; and, 2001: 31 days).  Similarly, the median 
duration of enrollment in skills training decreased over time for youths with 
comorbid psychiatric disorders (p<0.001 for Kruskal Wallis test).  Median 
durations of enrollment in this diagnostic group for 1998, 1999, 2000, and 2001 
were 41, 31, 33, and 22 days, respectively.  No significant year effect on the 
duration of enrollment in skills training existed for children and adolescents with 
anxiety disorders, bipolar disorders, depressive disorders, psychotic disorders, 
mental retardation/developmental disorders, other psychiatric disorders, and no 
psychiatric disorder. 
 
Table 3.89. Duration of Enrollment (Days) in Skills Training Per Child or 
Adolescent Receiving an Antipsychotic and Mental Health Care 
Services from TDMHMR from 1998 to 2001 
Outpatient Service Year N Mean (±SD) 95% CI Median p-value 
Skills training 1998 1885 66.55±78.65 63.00 – 70.10 38.0 
 1999 2587 66.52±82.64 63.33 – 69.70 35.0 
 2000 3294 65.03±79.51 62.32 – 67.75 34.0 
 2001 4180 59.44±78.13 57.07 – 61.81 31.0 
<0.001* 






Figure 3.64. Mean and Median Duration of Enrollment (Days) in Skills Training 
Per Child or Adolescent Receiving an Antipsychotic and Mental 




































 The mean duration of enrollment in supportive services decreased initially 
from 1998 to 1999, but then increased over 2000 and 2001 (Table 3.90, page 368; 
Figure 3.65, page 369).  ANOVA did not show a significant year effect, but the 
Kruskal Wallis test did (p=0.008).  Median durations of enrollment in counseling 
and psychotherapy for 1998, 1999, 2000, and 2001 were 17, 8, 11, and 27 days, 
respectively. 
 Age-specific analyses of the duration of enrollment in supportive services 
showed no significant year effect in the following age groups: two- to four-years, 
five- to nine-years, ten- to 14-years, and 15- to 19-years. 
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 Gender-specific analyses of the duration of enrollment in supportive 
services showed no significant year effect in males and females. 
 Diagnosis-specific analyses of the duration of enrollment in supportive 
services showed no significant year effect in the following diagnostic groups: 
anxiety disorders, bipolar disorders, depressive disorders, disruptive behavioral 
disorders, psychotic disorders, mental retardation/developmental disorders, other 
psychiatric disorders, and comorbid psychiatric disorders.  No child or adolescent 
without a psychiatric disorder received supportive services during the four-year 
period. 
 
Table 3.90. Duration of Enrollment (Days) in Supportive Services Per Child or 
Adolescent Receiving an Antipsychotic and Mental Health Care 
Services from TDMHMR from 1998 to 2001 
Outpatient Service Year N Mean (±SD) 95% CI Median p-value 
Supportive services 1998 217 44.77±68.82 35.56 – 53.98 17.0 
 1999 196 27.36±51.72 20.08 – 34.65 8.0 
 2000 72 34.10±53.58 21.51 – 46.69 11.0 
 2001 72 47.56±85.14 27.55 – 67.56 27.0 
0.022* 
0.008† 
*p-value for ANOVA. 








Figure 3.65. Mean and Median Duration of Enrollment (Days) in Supportive 
Services Per Child or Adolescent Receiving an Antipsychotic and 
























































Chapter Four provides a thorough discussion of the study results 
describing the current trends of antipsychotic use in children and adolescents from 
1996 to 2001.  The results are reviewed according to the phases: (1) trends in 
antipsychotic use in children and adolescents; (2) prescribing practices for 
antipsychotic agents; and, (3) relationships of antipsychotic use to service 
utilization and associated costs.  Possible explanations of the findings are 
proposed, and the potential implications of the study are reported.  Following a 
discussion of the limitations of the study, directions for future research are 
suggested. 
 
Reviews of the Study Results 
Phase I: Trends in the prevalence of antipsychotic use in children and 
adolescents (1996 to 2001) 
Children and adolescents above the age of five years represented the 
majority of those receiving treatment with an antipsychotic.  In 1996, 15- to 19-
year olds in California Medi-Cal, Ohio Medicaid, and the Managed Care 
Organization represented the largest percentage of youths receiving an 
antipsychotic.  In Texas Medicaid, youths aged ten to 14 years represented the 
largest age group treated with antipsychotics.  Over the study period, a trend 
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towards younger-aged children and adolescents receiving an antipsychotic was 
present across all four insurance programs.  In 2001, ten- to 14-year olds 
represented the largest proportion of youths receiving an antipsychotic.  Males 
constituted a majority in each of the four programs during the entire study period, 
and a trend towards increased number of males receiving an antipsychotic existed 
in California Medi-Cal, Ohio Medicaid, and the Managed Care Organization. 
Prevalence of antipsychotic use 
From 1996 to 2001, the prevalence of total antipsychotic use in children 
and adolescents increased two- to three-fold in the insurance programs under 
study.  In Ohio and Texas Medicaid, there was a continual growth in 
antipsychotic use during the six-year period.  In California Medi-Cal and the 
Managed Care Organization, much of the growth occurred after 1997.  Youths 
enrolled in Ohio Medicaid and the Managed Care Organization were more likely 
to receive an antipsychotic with each additional study year, compared to youths in 
California Medi-Cal and Texas Medicaid.   
A pronounced increase in the prevalence of atypical antipsychotic use 
occurred across all programs, as increases ranged from six- to 20-fold.   Over the 
six-year period, an additional 12 children and adolescents per 1,000 Texas 
Medicaid and Ohio Medicaid enrollees received an atypical antipsychotic, 
followed by California Medi-Cal (+6), and the Managed Care Organization (+2).  
Youths in California Medi-Cal had significantly higher odds of receiving an 
atypical antipsychotic with each additional year, compared to youths enrolled in 
the other programs. 
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 With the exception of clozapine, the prevalence of specific atypical 
antipsychotics (olanzapine, quetiapine, and risperidone) increased from 1996 to 
2001 in each health insurance program.  The rank order of specific atypical 
antipsychotic prevalence in 2001 for Texas Medicaid showed risperidone to be 
the most frequently used agent, followed by olanzapine and quetiapine.  This 
finding was consistent from 1996 to 2000, as well as with the other three 
programs. 
The rate of typical antipsychotic prescribing for children and adolescents 
decreased across the four systems, with the largest decreases in use occurring in 
the state Medicaid programs.  There was a continual decrease in the prevalence of 
typical antipsychotic use in the Medicaid programs over the study period.  In the 
Managed Care Organization, there was a gradual increase in the prevalence of 
typical antipsychotic use in Managed Care Organization youths from 1998 to 
2000, before a decrease in 2001.  Children and adolescents in California Medi-Cal 
were less likely to receive a typical antipsychotic with each additional year, 
compared to the other three programs.   
Age-specific prevalence of antipsychotic use 
Antipsychotic use according to age stratifications was most prominent in 
children and adolescents between the ages of ten and 19 years across the four 
programs.  The prevalence of total antipsychotic use in the ten- to 14-year age 
group roughly doubled for California Medi-Cal, Texas Medicaid, and the 
Managed Care Organization, and tripled for Ohio Medicaid.  For youths aged 15 
to 19 years, the prevalence of total antipsychotic use increased approximately 1.5-
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fold.  The growth in prevalence of total antipsychotic use in these particular age 
groups was attributed to the increased use of atypical antipsychotics.  In 
California Medi-Cal ten- to 14-year olds and 15- to 19-years olds, the use of 
atypical antipsychotics increased 25- and 11-fold, respectively, over the six-year 
period.  Although less dramatic, similar increases in atypical antipsychotic use 
occurred in these age groups in the other three programs.  The trend toward 
increased use of atypical antipsychotics in youths aged ten to 19 years enrolled in 
the Medicaid programs was steady from 1996 to 2001, whereas much of the 
growth in atypical antipsychotic use in Managed Care Organization youths 
occurred after 1998.   
 Children between the ages of five and nine years experienced the largest 
increase in the overall use of antipsychotic agents.  Like their older counterparts, 
this age group experienced an increase in the use of atypical antipsychotics.  Over 
the six-year period, an additional 17 five- to nine-year olds per 1,000 Texas 
Medicaid enrollees received an atypical antipsychotic, followed by Ohio 
Medicaid (+13), California Medi-Cal (+5), and the Managed Care Organization 
(+2). 
 In children between the ages of two and four years, the prevalence of total 
and atypical antipsychotic use increased in Ohio Medicaid, Texas Medicaid, and 
the Managed Care Organization.  In California Medi-Cal, the overall use of 
antipsychotics decreased in these youths, while atypical antipsychotic use 
increased 40-fold. 
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 In all age groups across all four health programs, the use of typical 
antipsychotics either remained steady or continually declined during the study 
period. 
Gender-specific prevalence of antipsychotic use 
Female and male prevalence rates of total and atypical antipsychotic use 
increased from 1996 to 2001 in each program.  A greater percent increase in the 
use of antipsychotics was observed in males compared to females in Ohio 
Medicaid, California Medi-Cal, and the Managed Care Organization.  In Texas 
Medicaid, the six-year growth in antipsychotic use was greater in females than in 
males. 
 While the prevalence of typical antipsychotics decreased for both gender 
groups, increases in the use of atypical antipsychotics were seen.  Prevalence rates 
of atypical antipsychotic use in California Medi-Cal females and males increased 
18- and 21-fold, respectively.  An additional four females and eight males per 
1,000 enrollees received an atypical antipsychotic in 2001 compared to 1996.  
Similar, but less dramatic increases in female and male prevalence rates of 
atypical antipsychotic use were evident in Ohio Medicaid (+7 females, +17 
males), California Medi-Cal (+8 females, +17 males), and the Managed Care 
Organization (+2 females, +3 males). 
Geographic and payer system variations in the prevalence of antipsychotic use 
Antipsychotic prescribing in Medicaid children and adolescents was 
strongly associated with geographic region, as Texas Medicaid youths 
consistently had the highest prevalence rates of total antipsychotic use, followed 
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by Ohio Medicaid and California Medi-Cal.  In 2001, prevalence rates of total 
antipsychotic use in Ohio and Texas Medicaid youths were more than double that 
of California Medi-Cal youths.  The same geographic variation was found in 
prevalence rates of atypical antipsychotic use, as rank order showed that Texas 
Medicaid youths had the highest utilization per 1,000 enrollees, followed by Ohio 
Medicaid and California Medi-Cal.  With regard to typical antipsychotic use in 
2001, prevalence rates were highest in Ohio Medicaid and lowest in California 
Medi-Cal. 
 Antipsychotic prescribing was also related to type of payer system, as 
prevalence rates of total antipsychotic use in Medicaid programs significantly 
exceeded those in the Managed Care Organization.  In 2001, total antipsychotic 
use in Medicaid youths doubled that of Managed Care Organization youths.  
Atypical antipsychotic prevalence was two- to six-times greater in Medicaid 
programs, and typical antipsychotic prevalence was approximately two-times 
greater. 
Mean daily doses of specific atypical antipsychotics 
A trend toward lower mean daily risperidone doses over time existed in 
California Medi-Cal, Texas Medicaid, and the Managed Care Organization.  In 
these three programs, the trend of lower risperidone doses over time was apparent 
in youths greater than five years of age.  In Ohio Medicaid youths, no distinct 
trend in risperidone dosing existed over the six-year period.  With regard to mean 
daily olanzapine doses, no definitive trend over time existed in any of the four 
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programs under study.  Similarly, no consistent trend in quetiapine dosing was 
observed across age categories in the four health insurance programs. 
Antipsychotic switch rates 
Antipsychotic switch rates increased from 1996 to 2001 in all programs.  
Youths enrolled in California Medi-Cal and Ohio Medicaid had higher odds of 
switching antipsychotic treatment regimens, compared to Texas Medicaid and 
Managed Care Organization youths.  Atypical to atypical antipsychotic switches 
increased over time, while typical to typical antipsychotic switches decreased.  
Typical to atypical and atypical to typical antipsychotic switches either remained 
fairly constant, or declined over the study period. 
Concomitant psychotropic medications 
The use of concomitant psychotropic medications increased substantially 
from 1996 to 2001 in the four programs.  Children and adolescents in Texas 
Medicaid were more likely to receive concomitant treatment with another 
psychotropic medication during antipsychotic treatment, followed by youths in 
Ohio Medicaid, California Medi-Cal, and the Managed Care Organization.  
Antidepressants were the most commonly used concomitant psychotropic 
medication.  Antimanic/bipolar agents and psychostimulants were also frequently 
used as concomitant agents in youths receiving an antipsychotic. 
Prevalence rates of antipsychotic polypharmacy increased as well over the 
six-year period in three of the four programs.  Youths enrolled in California Medi-
Cal had higher odds of receiving two different antipsychotics for a minimum of 
30 days, compared to Texas Medicaid and Managed Care Organization youths.  
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From 1996 to 2001, the use of two atypical antipsychotics increased, while the 
use of two typical antipsychotics decreased.  The concomitant use of an atypical 
antipsychotic and a typical antipsychotic remained fairly steady. 
Cost of antipsychotic prescriptions 
In all four programs, the cost of all antipsychotics increased dramatically 
from 1996 to 2001.  This was directly attributed to the increased use of atypical 
antipsychotics, which are associated with increased medication cost.  Cost 
associated with typical antipsychotic use decreased over time, as these agents 
were being less utilized. 
Table 4.1 (pages 378-380) summarizes the results of Phase I hypothesis 
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Phase II: Prescribing practices for antipsychotic agents 
Prescriber type of antipsychotic prescriptions 
In Texas Medicaid, psychiatrists, including child and adolescent 
psychiatrists, had the greatest number of prescriptions for any antipsychotic 
during each calendar year, followed by primary care physicians and unspecified 
physicians.  More antipsychotic prescriptions originated from psychiatrists than 
child and adolescent psychiatrists during each year.  Within primary care, 
pediatricians had a larger number of antipsychotic prescriptions than 
family/general practice physicians.  Neurologists had the lowest number of 
prescriptions for antipsychotics, compared to the other prescriber groups.  In all 
groups, there was an increase in the number of antipsychotic prescriptions over 
the six-year period. 
There was an increase in the number of atypical antipsychotic 
prescriptions and a decrease in the number of typical antipsychotic prescriptions 
over time in all prescriber groups.  Among psychiatry specialists, psychiatrists 
had more atypical and typical antipsychotic prescriptions compared to child and 
adolescent psychiatrists.  Within primary care, the number of atypical and typical 
antipsychotic prescriptions from pediatricians exceeded that of family/general 
practice physicians. 
Diagnoses associated with antipsychotic prescribing 
Disruptive behavioral disorders were the most common diagnoses 
associated with children and adolescents receiving antipsychotic treatment and 
mental health care services from the Texas Department of Mental Health and 
 382
Mental Retardation (TDMHMR).  This diagnostic category accounted for 
approximately one-third of all diagnoses associated with these youths.  Within the 
disruptive behavioral disorder category, attention-deficit hyperactivity disorder 
accounted for the highest percentage of diagnoses, followed by conduct disorder 
and oppositional defiant disorder.  Depressive disorders were the second most 
common diagnoses, followed by bipolar disorders.  Among children and 
adolescents with a thought disorder, a diagnosis of a psychotic disorder 
represented the majority each year.  A small percentage of youths receiving 
antipsychotic treatment and mental health care services from TDMHMR had a 
diagnosis of mental retardation or a pervasive developmental disorder.  Three 
percent of youths did not have a psychiatric diagnosis. 





















































































































































































































































































































































































         
 384
Phase III: Relationships of antipsychotic use with patient health care service 
utilization 
Inpatient psychiatric hospitalizations 
From 1998 to 2001, the mean number of inpatient psychiatric 
hospitalizations per child or adolescent receiving antipsychotic treatment and 
mental health care services from TDMHMR increased.  Among those youths who 
were hospitalized, no significant year effect existed regarding the mean number of 
inpatient psychiatric hospitalizations.  The mean number of hospital days per 
hospitalized child or adolescent decreased over the four-year period.  Similarly, 
the median number of hospital days per hospitalized youth decreased. 
Outpatient mental health care services 
From 1998 to 2001, the number of children and adolescents receiving 
assessment services, counseling and psychotherapy, medication-related services, 
service coordination, and skills training increased.  The number of youths 
receiving crisis intervention and supportive services decreased.  Medication-
related services accounted for the highest percentage of outpatient mental health 
care service use, followed by service coordination and skills training.  The 
percentage of children and adolescents using these types of outpatient services 
increased over time. 
The mean duration of enrollment in assessment services, medication-
related services, and skills training decreased over the four-year period, while the 
mean duration of enrollment in crisis intervention and service coordination 
increased.  No significant year effect on the mean duration of enrollment existed 
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in counseling and psychotherapy, and supportive services.  Significant year 
effects on the median duration of enrollment existed across all types of outpatient 
mental health services. 



































































































































































































































































































































































































































































































































































































































































Discussion of the Study Results 
Phase I: Trends in the prevalence of antipsychotic use in children and 
adolescents (1996 to 2001) 
Antipsychotic prevalence rates 
Previous pharmacoepidemiological studies of psychotropic medication use 
in children and adolescents have suggested increased prevalence of antipsychotic 
use during the 1990s.1-3  The findings from this study not only corroborate the 
increased use of antipsychotics in children and adolescents, but also further 
demonstrate that this trend is occurring across various geographic and payer 
systems. 
The increased use of antipsychotics in four health insurance programs is 
directly associated with the use of atypical antipsychotics.  As olanzapine, 
quetiapine, and risperidone were introduced to the market in the 1990s, the trend 
of total antipsychotic use paralleled the increased use of this subclass of 
antipsychotic medications.  Although risperidone was the most commonly used 
atypical antipsychotic, the prevalence of olanzapine and quetiapine use increased 
with time.   
There are ample data supporting the safety and efficacy of atypical 
antipsychotics in adult psychiatric disorders, such as schizophrenia and bipolar 
disorder.  However, the use of these medications in children and adolescents is 
off-label and remains divisive.  Clinicians may be inclined to use atypical 
antipsychotics over typical antipsychotics because of their decreased propensity to 
cause extrapyramidal symptoms and tardive dyskinesia.4  Emergence of 
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antipsychotic-induced movement disorders may severely affect the course of 
treatment in a child and adolescent, as these symptoms may lead to decreased 
medication adherence, decreased patient self-esteem, and poor patient prognosis.5   
Moreover, a growing body of evidence supports the safety and efficacy of 
atypical antipsychotics, especially risperidone, for the treatment of aggression, the 
most common use for antipsychotics among youths.6-11  In the Texas Medicaid 
program, disruptive behavioral disorders, such as attention-deficit hyperactivity 
disorder, conduct disorder, and oppositional defiant disorder, were the most 
common diagnoses in children and adolescents receiving antipsychotic treatment 
and mental health care services from TDMHMR.  These diagnoses often present 
concurrently and are associated with aggressive behaviors, possibly warranting 
treatment with an antipsychotic.12  In a recent international consensus statement 
on disruptive behavioral disorders, experts recommend the use of risperidone as a 
first-line agent in the treatment of aggression and impulsivity in children and 
adolescents.12  
Children and adolescents in most age groups, specifically older than five 
years of age, are increasingly being prescribed atypical antipsychotics.  Although 
more youths between the ages of ten and 19 years received treatment with 
atypical antipsychotics, children aged five to nine years had the most significant 
gains in prevalence of use.  While psychotic disorders were diagnosed in younger 
aged children, the most likely explanation for this particular trend may be related 
to the use of atypical antipsychotics for the treatment of aggressive behaviors 
occurring in the context of neuropsychiatric disorders.  Disruptive behavioral 
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disorders accounted for nearly half of the psychiatric diagnoses in this age group 
in the Texas Medicaid and TDMHMR sample, thus reflecting the growing use of 
atypical antipsychotics.  In children and adolescents of increasing age, the use of 
atypical antipsychotics may have shifted toward the treatment of thought 
disorders, such as schizophrenia, bipolar disorder with psychosis, and depression 
with psychosis.  Late adolescence marks the time period when symptoms related 
to psychosis usually emerge, indicating the onset of the illness and necessitating 
treatment with antipsychotic medications.13,14   
With regard to trends in gender-specific atypical antipsychotic use, the 
higher use of atypical antipsychotics in males is most likely explained by the fact 
that males are more likely to be physically aggressive compared to girls.15  
Aggressive behaviors in males tend to correlate more with hyperactivity and 
impulsivity, which may respond better with pharmacological interventions.16  
Girls tend to exhibit relational and verbal aggression, which may not require 
pharmacological treatment and may be better suited for psychosocial 
interventions.15,17  In this study, disruptive behavioral disorders accounted for a 
higher percentage of the diagnoses in Texas Medicaid males receiving 
antipsychotic treatment and services from TDMHMR, compared to females.  As 
mentioned previously, these disorders are often associated with aggression, which 
is commonly treated with antipsychotics.18 
Mean daily doses of specific atypical antipsychotics 
 From 1996 to 2001, the mean daily dose of risperidone decreased in 
children and adolescents aged five years or older in all four insurance programs.  
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The decrease in mean daily risperidone dose may be explained by time on market 
and the growing body of evidence supporting the safety and efficacy of 
risperidone in childhood and adolescent psychiatric and behavioral disorders, 
namely aggression.  Risperidone was introduced to the market in 1993, thus 
allowing three years for clinicians to become familiar with dosing strategies for 
specific psychiatric and behavioral disorders.  Clinicians not only are able to 
recognize dosing ranges that tend to produce response for symptomatology, but 
also recognize dosing ranges that are associated with a lower occurrence of 
risperidone-related adverse effects.  A study by Lane and colleagues evaluating 
risperidone dosing in adult patients with acutely exacerbated schizophrenia 
showed that lower daily risperidone doses (mean ± standard deviation: 3.4 ± 0.9 
milligrams) were as effective as higher doses (6 milligrams), and were associated 
with a lower incidence of adverse effects.19  Although no such study has been 
conducted in children and adolescents, it is possible that clinicians have become 
accustomed to using lower risperidone doses without compromise of response and 
with low rates of adverse effects. 
 Six randomized, controlled trials evaluating risperidone for the treatment 
of aggressive behaviors across a variety of psychiatric and behavioral conditions 
in children and adolescents demonstrated large effect sizes with relatively low 
doses of risperidone.6-11  In five of the six randomized, controlled trials, the mean 
daily dose of risperidone was less than two milligrams.6,7,9-11  In the study by 
Buitelaar and colleagues, the mean daily dose of risperidone was 2.9 milligrams.8  
These studies collectively suggest that aggressive behaviors in children and 
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adolescents may be successfully treated with low doses of risperidone.  These 
dosing data are also reflected in the international consensus statement on 
attention-deficit hyperactivity disorder and disruptive behavioral disorders.12  The 
recommended maximum daily doses of risperidone for children and adolescents 
are 0.75 milligrams per day (<50 kilograms body weight) and 1.5 milligrams per 
day (≥50 kilograms body weight).12  It is possible that the availability of these 
data may have influenced risperidone dosing over time. 
 No definitive trends in olanzapine or quetiapine dosing existed across age 
groups and insurance programs.  These agents have been studied in children and 
adolescents, but not to the extent of risperidone.20,21  Much of the available 
olanzapine and quetiapine dosing data have been related to the treatment of 
psychotic disorders and mood disorders.  Treatment of these types of psychiatric 
disorders usually requires higher doses than does treatment of aggression.22,23  As 
additional dosing data for olanzapine and quetiapine use in children and 
adolescents become available, it is likely that a more distinct trend in dosing will 
become apparent. 
Antipsychotic switch rates 
 The escalation of switch rates corresponds to several time-dependent 
trends in the use of antipsychotics in children and adolescents: number of atypical 
antipsychotics available, increased utilization of atypical antipsychotics, and 
decreased utilization of typical antipsychotics.  It should be noted, however, that 
the mean number of antipsychotic switches per youth per year did not increase 
over time.  This particular finding is encouraging because antipsychotic switching 
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is generally associated with lack of efficacy, potentially manifested as relapse, or 
the presence of adverse events.24 
During the 1990s, the newer atypical antipsychotics were introduced to the 
market (risperidone in 1993, olanzapine in 1996, and quetiapine in 1997).  With 
the availability of these agents, the likelihood of switching from a typical 
antipsychotic was high due to the favorable side effect profiles and comparable 
efficacy.4  During the study period in all four programs, there was a brief increase 
in the number of typical to atypical antipsychotic switches, followed by a gradual 
decline.  This indicates that youths receiving typical antipsychotics were being 
switched to atypical agents during the early study years.  Studies have shown that 
switching from a typical antipsychotic to an atypical antipsychotic may result in 
improved medication adherence and better patient outcomes.25-27  Since fewer 
children and adolescents were receiving typical antipsychotics over time, the rate 
of switching from a typical to an atypical antipsychotic decreased. 
In all four insurance programs, atypical to atypical antipsychotic switching 
increased from 1996 to 2001.  This trend is most likely attributed to the increased 
number of atypical antipsychotics available on the market.  Other potential 
explanations include medication-related adverse effects and switching behavior.  
Although the atypical antipsychotics are associated with a low incidence of 
extrapyramidal symptoms and tardive dyskinesia, these agents are not free from 
side effects that can be debilitating to a child or adolescent.  Most notable is the 
associated weight gain.28-30  Weight gain can lead to other immediate and long-
term health risks, such as obesity, glucose dysregulation, and dyslipidemia.29,30  
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Perhaps equally as important in children and adolescents is the impact of weight 
gain on the patient’s self-esteem and quality of life.31  Recent data suggest that 
patients receiving atypical antipsychotics may be more likely to switch.  In a 
study by Rothbard and colleagues, the highest switching behavior was found in 
users of atypical antipsychotics compared to those using typical antipsychotics.32  
Similarly, in a Veterans Affairs study of schizophrenia, patients receiving 
olanzapine, quetiapine, or risperidone were equally or more likely to switch 
antipsychotic medications compared to those patients receiving typical 
antipsychotics.33  This notion contradicts other published studies reporting higher 
switch rates and shorter treatment durations for patients receiving typical 
antipsychotics compared to those receiving atypical antipsychotics.34,35  
Differences in patterns of antipsychotic switching may be explained by several 
factors, such as time/date of study and the type of health care system evaluated. 
Rates of switching from an atypical antipsychotic to a typical 
antipsychotic showed varying patterns across insurance programs.  A reduction in 
this type of antipsychotic switching was seen in Ohio Medicaid, Texas Medicaid, 
and the Managed Care Organization over time, and is most likely explained by the 
decreased utilization of typical antipsychotics.  The increase of atypical to typical 
antipsychotic switching seen in California Medi-Cal over time may be explained 
by exacerbations of psychiatric symptoms while on an atypical agent.  It is 
possible that a child or adolescent was stable on a typical antipsychotic, switched 
to an atypical agent, experienced relapse, and then was switched to the original 
typical antipsychotic.  In a Veterans Affairs study of patients with schizophrenia, 
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most patients with stable antipsychotic therapy who switched antipsychotics 
ultimately switched back to their original antipsychotic.33  Alternatively, cost-
related issues may be related to switches from an atypical to a typical 
antipsychotic.   
Concomitant psychotropic medications 
 In all four insurance programs, the prevalence of concomitant 
psychotropic medication use in children and adolescents receiving antipsychotic 
treatment increased over time.  The highest prevalence rate of concomitant 
psychotropic medication use was seen in Texas Medicaid.  Although other studies 
have shown an increase in the rate of concomitant psychotropic medication use in 
children and adolescents over time, the prevalence of such use in this study’s 
samples were relatively higher.36,37  This may be explained by the intrinsic nature 
of the population under study.  Inclusion criteria required children and adolescents 
to have at least one prescription claim record for an antipsychotic.  This may have 
resulted in selection bias, as children and adolescents receiving antipsychotic 
treatment may represent a more severely ill population compared to those 
evaluated in other studies, and this may be associated with more psychotropic 
polypharmacy.  Another potential reason for the high prevalence rates of 
concomitant psychotropic medication use in this study may be the liberal 
definition used to determine concurrent use of two agents.  Other psychotropic 
medications were considered concomitant if their administration overlapped by at 
least one day with the antipsychotic treatment period.  This definition of 
concomitant use of psychotropic agents was chosen because certain psychotropic 
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agents, such as sedative-hypnotics, are commonly used short-term.  If a longer 
period of time was used to determine concurrent use, all concomitant 
psychotropic medication use would not have been captured and prevalence rates 
would have been underestimated. 
Among the psychotropic drug classes, antidepressants, antimanic/bipolar 
agents, and psychostimulants were the most commonly used concomitant 
psychotropic agents with antipsychotics.  Antipsychotic plus antidepressant 
combination treatment occurred in 26 to 38 percent of youths; antipsychotic plus 
antimanic/bipolar agent treatment occurred in 15 to 24 percent; and, antipsychotic 
plus psychostimulant treatment occurred in seven to 28 percent.  These findings 
are consistent with a recent study by Martin and colleagues that examined 
multiple psychotropic pharmacotherapy among youths enrolled in Connecticut 
Medicaid Managed Care.38  The most common drug combination in Connecticut 
children and adolescents was an antipsychotic plus an antidepressant, which 
occurred in 22 percent of the participants.  Eight percent received an antipsychotic 
plus a mood stabilizer, and six percent received an antipsychotic plus a 
psychostimulant. 
The high prevalence rates of concomitant psychotropic medication may be 
best explained by the estimated distribution of specific psychiatric and behavioral 
disorders.  In the sample of youths receiving antipsychotics and mental health 
care services from TDMHMR, disruptive behavioral disorders were the most 
frequent diagnoses assigned by clinicians.  Concomitant use of antipsychotics and 
other psychotropic agents has been found to be widespread in youths with 
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aggression.39-41  Antimanic/bipolar agents, such as lithium and divalproex, have 
been shown to be effective in reducing aggression and may have been used 
primarily for this reason.42-44  Other uses of concomitant antimanic/bipolar agents 
in this study may have included augmentation in depressive disorders and mood 
stabilization in bipolar disorders.45-47  Concomitant use of psychostimulants may 
also have been used to reduce aggressive behaviors, but a more probable 
explanation lies with the high percentage of youths with a diagnosis of attention-
deficit hyperactivity disorder.48-50  The use of psychostimulants for the treatment 
of attention-deficit hyperactivity disorder is well-documented, as this class of 
psychotropic medications is considered first-line.51,52 
The use of antidepressants has increased dramatically in children and 
adolescents since the introduction of selective serotonin reuptake inhibitors 
(SSRIs).2,53,54  SSRIs are considered first-line treatment for childhood depression, 
primarily due to their established safety and efficacy in adults.  Fluoxetine is the 
only SSRI indicated for adolescent depression.55  Clinicians, including those in 
the primary care setting, may be inclined to pharmacologically treat youths with 
depressive symptoms.  The proportion of youths with a depressive disorder was 
fairly significant, thus possibly explaining the high rate of concomitant use of an 
antidepressant with an antipsychotic.  Other potential uses for concomitant 
antidepressant and antipsychotic use may include bipolar depression and 
aggression.17,56-58 
Of the three insurance programs that were evaluated for prevalence rates 
of antipsychotic polypharmacy, all showed a trend of increasing use among 
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children and adolescents.  From 1996 to 2001, the percentage of youths receiving 
treatment with two atypical antipsychotics increased, while those receiving 
treatment with two typical antipsychotics decreased.  The prevalence of 
combination treatment with an atypical and typical antipsychotic did not show 
definitive trends over the six-year period.  The increased utilization and 
availability of atypical antipsychotics, coupled with the decreased use of typical 
antipsychotics, help to explain these trends in antipsychotic polypharmacy.  The 
30-day interval used to define antipsychotic polypharmacy in this study may have 
produced more false positives, as clinicians may have used longer titration and 
tapering schedules for antipsychotics in children and adolescents.12,22,59  
To date, no study evaluating antipsychotic polypharmacy in children and 
adolescents has been published.  Numerous recent studies of adults with 
psychiatric disorders treated in inpatient and outpatient settings have documented 
the increased use of multiple antipsychotic agents.60-65  However, most data 
supporting the safety and efficacy of antipsychotic polypharmacy in adults are 
limited to case reports, case series, and one randomized, controlled trial of two 
atypical agents.66  In an Israeli trial of 28 patients with schizophrenia, the addition 
of sulpiride to clozapine resulted in greater reduction of positive and negative 
symptoms compared to clozapine plus placebo.67  Preliminary data from case 
reports and case series of combination treatment with atypical antipsychotics 
available in the United States suggest that atypical antipsychotic polypharmacy 
may reduce symptoms of schizophrenia without an increase in significant adverse 
effects compared with monotherapy.66  The increased use of antipsychotic 
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polypharmacy in children and adolescents causes significant concern, as a paucity 
of safety and efficacy data support atypical antipsychotic monotherapy in this 
population, and virtually no systematic data in any population support 
polypharmacy with multiple antipsychotics.  
Cost of antipsychotic prescriptions 
The increased cost of antipsychotic treatment in all four insurance 
programs was driven by increased cost and utilization of atypical antipsychotics.  
Compared to typical antipsychotics which are available in generic formulations, 
treatment with atypical antipsychotics incurs significantly greater costs.  For 
example, based upon 2003 average wholesale prices (AWP), treatment with 
risperidone two milligrams per day results in monthly prescription costs of 
$152.10, and annual costs of $1,825.20.  Treatment with haloperidol five 
milligrams per day costs $21.00 each month, and $252.00 each year.68  Higher 
prescription costs coupled with increases in utilization of atypical antipsychotics 
led to significant growth in antipsychotic prescription expenditures.  These 
findings are similar to those recently reported in a nationwide study of 
psychotropic medication costs for privately insured children and adolescents by 
Martin and Leslie.69  From 1997 to 2000, the largest increases in utilization were 
seen with the atypical antipsychotics.  Olanzapine, quetiapine, and risperidone 
accounted for approximately 21 percent of an additional $2.7 million spent in 
2000 for psychotropic medications in children and adolescents by private 
insurance companies.69  Typical antipsychotics accounted for less than one 
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percent of the additional psychotropic drug expenditures in children and 
adolescents in 2000.69 
Geographic and Payer System Variation Findings 
 Geographic variations in antipsychotic prescribing have been 
demonstrated in a previous study of National Ambulatory Medical Care Survey 
data.70  Nonfederal office-based physicians in the Northeast and South had higher 
rates of antipsychotic prescribing to patients of all ages than physicians in the 
Midwest and West.  Additionally, anecdotal reports of antipsychotic use in 
nursing homes have suggested higher rates of use in Texas compared with 
California.  The present study demonstrates similar geographic variations in 
antipsychotic prescribing to children and adolescents, as youths enrolled in Texas 
Medicaid had higher rates of antipsychotic utilization compared to Ohio Medicaid 
and California Medi-Cal youths.   
Philosophical differences in treatment approaches related to physician 
training backgrounds and regional culture, and state-specific policies on 
antipsychotic medication usage may explain at least some of these geographic 
variations in antipsychotic prescribing.71-74  Clinicians receiving training from 
newly established medical schools or those graduating recently are more inclined 
to use newer medications available on the market, such as the atypical 
antipsychotics.71  State-based policies may differ in terms of applied restrictions 
on the use of psychotropic medications for the treatment of psychiatric and 
behavioral disorders in children and adolescents.  Regional culture may be 
reflected in clinicians’ attitudes toward the use of psychotropic medications in 
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youths, and possibly in clinical practice facilities.  Geographic differences in 
provider availability and provider access to information about advances in 
pharmacological treatments may also be reflected in differences in prevalence 
rates of antipsychotic use in these three Medicaid systems.75,76 
Antipsychotic prescribing in the 3 Medicaid state programs was 
substantially greater than that in the Managed Care Organization.  Medicaid state 
programs may have a greater number of children and adolescents with mental and 
behavioral disorders, as the Medicaid population is of lower socioeconomic status 
and includes those with more severe mental disorders.77  More specifically, lower 
socioeconomic status has been shown to be a predictor of aggression.78  It is also 
possible that Medicaid-enrolled youths may be treated more aggressively than 
youths enrolled in private insurance programs.79  This difference in treatment 
approach may be associated with more severe psychopathology or psychosocial 
adversity in Medicaid-enrolled children and adolescents.77,79  Insurance system-
specific factors (i.e., referral systems and criteria for services) may also contribute 
to these differences, and require further evaluation.79  It is important to note the 
decrease in prevalence of antipsychotic use in the Managed Care Organization in 
2001, compared to 2000.  Changes in policy regarding antipsychotic utilization 
within the Managed Care Organization may have resulted in the decreased 
prevalence.  Attempts to obtain further information about potential explanations 
for this finding were unsuccessful. 
 In all four insurance programs, managed behavioral health care may have 
influenced antipsychotic prescribing practices.  The use of medications has 
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increased with the emerging presence of managed behavioral health care, and 
incentives for clinicians to treat with medications rather than psychotherapy.80  
The use of psychotherapy is restricted in many managed care plans, primarily by 
required authorizations or a limited number of therapists.  The use of 
pharmacotherapy is encouraged, as less clinical time is needed for a medication 
visit that is reimbursed at twice or more the rate per minute than psychotherapy.80  
Furthermore, parents of affected children and adolescents may seek initial mental 
health care through a primary care physician.81  In 1995, 75.4 percent of office-
based visits for attention-deficit hyperactivity disorder were to primary care 
physicians; 12.4 percent were to psychiatrists.82  This phenomenon may not be 
applicable to all psychiatric and behavioral disorders, as patients who are more 
complex and more severely ill may need to seek treatment from psychiatrists.83  
Primary care physicians may be more likely to treat children or adolescents with 
pharmacotherapy, compared to psychiatrists.  This may be an artifact of the large 
volume of visits to primary care physicians by children and adolescents needing 
mental health care.84  Eighty-five percent of office-based visits resulting in a 
prescription for a psychotropic medication for a child and adolescent below the 
age of 19 years were to general practitioners or pediatricians.  Similarly, of all 
office-based visits during which an antipsychotic was prescribed to a youth, 85 




Phase II: Prescribing practices for antipsychotic agents 
Prescriber type of antipsychotic prescriptions 
The majority of antipsychotic prescribing to youths in the Texas Medicaid 
program is associated with psychiatrists and child and adolescent psychiatrists.  
Published studies examining prescribing trends of psychotropic medication use 
have shown that psychiatrists are more likely to prescribe antipsychotics 
compared to other physician specialities.70,85,86  In a recent study by Van Brunt 
and colleagues examining outpatient use of antipsychotic medications in 
ambulatory care settings from 1997 to 2000, psychiatrists accounted for 70 
percent of prescribing.86  In this study, the percent of antipsychotics prescribed by 
psychiatrists was slightly higher, at approximately 75 percent.  This may be 
explained by the nature of study population, as Texas Medicaid youths receiving 
antipsychotic treatment may represent a select population who are more ill and 
require health care from a specialist. 
As psychiatrists’ training includes diagnosis and management of 
psychiatric and behavioral problems in children and adolescents, these findings 
are encouraging.  However, this does not necessarily imply that these agents, 
namely atypical antipsychotics, are being used either appropriately or 
inappropriately.  Most of the prescribing was associated with psychiatrists, who 
may be initiating treatment with antipsychotics based upon adult efficacy and 
safety data for certain disorders that occur during childhood and adolescence.  
Without additional information, it is premature to draw conclusions about the 
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appropriateness of treatment, or whether pharmacological intervention is the most 
optimal treatment modality. 
Primary care physicians accounted for roughly one-tenth of the total 
number of antipsychotic prescriptions, which suggests that children and 
adolescents may often receive treatment within this practice setting.  Similar 
findings have been reported regarding antipsychotic prescribing in ambulatory 
settings across age groups, and antidepressant prescribing by primary care 
physicians for children and adolescents.53,86  It has been estimated that 13 percent 
of children and adolescents who use mental health services seek care through the 
general medicine sector.87  It is also possible that youths are initially evaluated by 
a psychiatrist, and then referred to a primary care physician for follow-up 
treatment when the child or adolescent is stabilized.  In addition to the emphasis 
on managed care, reluctance of parents to seek psychiatric help, stigma related to 
psychiatric disorders, and systemic barriers to access, may affect the decision to 
obtain mental health care from a specialized physician.88-90   
Given the expanding role of primary care physicians into the realm of 
mental health care for children and adolescents, it is important to highlight the 
need for specialized training in this area because without it, the ability to improve 
patient outcomes may become relatively poor.84,91  Accuracy of diagnosis or 
symptom identification is imperative in determining, providing, and managing 
clinical treatment.  Efforts to train primary care physicians in these aspects, 
particularly with regard to pharmacological treatments, are necessary to improve 
the psychological well-being and psychosocial functioning of youths affected 
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with mental illnesses.91  In addition, systematic evaluation of patient outcomes are 
needed to ascertain whether mental health care provided by primary care 
physicians is adequate, and to determine areas in which further training may 
improve patient outcomes.  
Diagnoses associated with antipsychotic prescribing 
 In children and adolescents receiving antipsychotic treatment and mental 
health care services, disruptive behavioral disorders were the most common 
diagnoses, followed by depressive disorders.  Pappadopulos and colleagues 
reported comparable proportions of diagnoses in their analysis of “real-world” 
atypical antipsychotic use in inpatient children and adolescents.92   
Disruptive behavioral disorders are often associated with aggressive 
behaviors, the most frequent reason for using antipsychotic treatment.18  Data 
from six randomized, controlled trials suggest that risperidone is effective in 
reducing aggression in children and adolescents with a variety of psychiatric 
disorders.6-11  Expert consensus statements on the treatment of disruptive 
behavioral disorders and aggression in youths recommend the use of 
antipsychotics.12,22,59  Although the use of atypical antipsychotics for disruptive 
behavioral disorders and aggression remains off-label, the availability of 
supporting data represents an evidence-based treatment approach. 
Depressive disorders were the second most frequent diagnoses in children 
and adolescents receiving antipsychotics.  No systematic study examining the use 
of atypical antipsychotics in childhood or adolescent depression exists.  However, 
the Texas Children’s Medication Algorithm Project algorithm for the treatment of 
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childhood major depressive disorder recommends the use of a SSRI for youths 
with depression, with the addition of an antipsychotic medication for those with 
psychotic features.55  The choice of antipsychotic medication is that of the 
clinicians, but the expert consensus panel recommended the use of an atypical 
antipsychotic.  While the diagnosis of major depressive disorder with psychotic 
features was common in the study sample, it is unlikely that this diagnostic 
subtype accounted for all the use of atypical antipsychotics for children and 
adolescents with depressive disorders. 
Depressive disorders in children and adolescents often coincide with 
comorbid disruptive behavioral disorders.93,94  The presence of both disorders in a 
child or adolescent leads to serious maladjustment, and subsequently poorer 
prognosis.95  Additionally, symptoms associated with a disruptive behavioral 
disorder in a child or adolescent with depression often results in psychiatric 
hospitalization.94,96  Treatment of comorbid depressive and disruptive behavioral 
disorders may require the use of atypical antipsychotics.  This may be especially 
true in those youths who are aggressive, and treatment with antidepressants or 
psychosocial intervention have been unsuccessful in reducing these behaviors. 
The proportion of children and adolescents with a diagnosis of bipolar 
disorder and receiving antipsychotic treatment increased from 1998 to 2001.  
Although controversial, it has been suggested that the prevalence of bipolar 
disorder in children has increased.  The prevalence of bipolar disorder in 
adolescence has also increased, and currently is approximately one percent.97,98  
Recent advances in the treatment of bipolar disorder have focused on the atypical 
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antipsychotics.  Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone 
have been assessed as treatments for acute mania in randomized, double-blind, 
placebo-controlled trials.99-108  Both olanzapine and quetiapine have received 
indications for the treatment of acute mania in adults.  In adolescents, only 
quetiapine has been studied in a randomized, controlled trial as adjunctive 
treatment for mania.20  Over a six-week period, quetiapine plus divalproex 
significantly reduced manic symptoms compared to divalproex plus placebo.   
Although data for atypical antipsychotics in the treatment of childhood or 
adolescent bipolar disorder are limited, clinicians are most likely using these 
agents based upon the availability of adult safety and efficacy data and few other 
treatment options for pediatric and adolescent bipolar disorder that have been 
extensively and systematically studied.  Although this practice approach may be 
of concern, atypical antipsychotics do provide clinicians with additional treatment 
options in circumstances where the benefits of initiating antipsychotic treatment 
appear to outweigh the potential risks.97  For example, the use of an atypical 
antipsychotic is appropriate in a child or adolescent with bipolar disorder with 
psychotic features, as both manic and psychotic symptoms may be reduced with 
one agent. 
Similar to depressive disorders in youths, bipolar disorder in children and 
adolescents often co-occurs with disruptive behavioral disorders.  The 
comorbidity between pediatric bipolar disorder and attention-deficit hyperactivity 
disorder has been estimated to range from 60 to 90 percent.109-112  Symptoms 
commonly associated with both disorders include psychomotor agitation, 
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distractibility, restless sleep, poor school performance, and aggression.113,114  
Similarly, bipolar disorder and conduct disorder often present concurrently in 
youths, with the prevalence ranging from 17 to 64 percent.115,116  Comorbidity of 
bipolar disorder with a disruptive behavioral disorder may warrant treatment with 
an antipsychotic, especially if severe aggressive behavior is present.  The use of 
an atypical antipsychotic in such patients may be appropriate, as symptoms 
associated with both bipolar disorder and a disruptive behavioral disorder may be 
reduced. 
 
Phase III: Relationships of antipsychotic use with patient health care service 
utilization 
Inpatient psychiatric hospitalizations 
The number of inpatient hospitalizations per child or adolescent receiving 
antipsychotic treatment and mental health care services from TDMHMR 
increased from 1998 to 2001.  Among those who were hospitalized, the number of 
psychiatric hospitalizations per youth per year did not increase, suggesting that 
recidivism rates did not increase.  The number of hospital days per hospitalized 
child or adolescent decreased significantly from 1998 to 2001. 
In the literature, studies examining trends in psychiatric inpatient 
hospitalizations of children and adolescents are conflicting.  In a study by Pottick 
and colleagues, a 4-fold increase in child and adolescent admissions for 
psychiatric and behavioral problems to the Menninger Clinic was reported.117  
Similarly, an increase of children and adolescents requiring inpatient psychiatric 
admissions was reported in an urban general hospital from 1998 to 2002.118  On 
 408
the contrary, Martin and Leslie reported a decrease in the use of inpatient 
psychiatric hospitalizations among privately insured children and adolescents.119   
Differences in the populations under study may explain the conflicting 
results, as certain risk factors have been identified as strong predictors of inpatient 
psychiatric hospitalization.  Children and adolescents from a lower socioeconomic 
status are at a higher risk for inpatient psychiatric hospitalizations, particularly 
given the severity of psychopathology.120,121  Youths with a history of any mental 
health care services, including prior hospitalizations, are likely to be admitted to 
an inpatient psychiatric facility.122  A diagnosis of a disruptive behavioral disorder 
has also been associated with high use of inpatient psychiatric services.123  
Children and adolescents under examination in this particular study had each of 
the risk factors for psychiatric hospitalization discussed above.  The nature of the 
population may best explain the trend of an increased number of hospitalizations 
over time.  It must be noted, though, that diagnostic-specific analyses of inpatient 
psychiatric hospitalization data did not reveal any significant findings.  Other 
demographic and clinical variables, such as adolescence (13 to 18 years), male 
gender, and prior psychiatric hospitalizations, have been identified as potential 
risk factors for psychiatric hospitalization.120,122  Age- and gender-specific 
analyses of the number of inpatient psychiatric hospitalizations did not show any 
significant results.  Inpatient psychiatric hospitalization data prior to 1998 were 
not available to evaluate the influence of prior psychiatric hospitalizations. 
The number of inpatient psychiatric hospitalizations per hospitalized youth 
per year remained fairly steady over time.  This finding is interesting, given that 
 409
the youths receiving antipsychotic treatment and mental health care services from 
TDMHMR had diagnostic predictors of rehospitalization.  Children and 
adolescents with affective disorders or comorbid psychiatric disorders have been 
shown to have high rehospitalization rates.124  A large percentage of youths under 
study had bipolar disorder or depression, or comorbid psychiatric disorders.  
Children and adolescents with comorbid psychiatric disorders were often 
diagnosed with a disruptive behavioral disorder, which has been shown to be a 
predictor of rehospitalization.123 
A potential explanation for this result may be that reduced 
rehospitalization rates are associated with the increased use of atypical 
antipsychotics.  In adults, newer atypical antipsychotics have been associated with 
decreased rehospitalization rates in schizophrenia.  Several studies have 
demonstrated lower one-year rehospitalization rates in patients with schizophrenia 
receiving clozapine, olanzapine, or risperidone in comparison to those receiving 
typical antipsychotics.125-128  It is possible that the use of atypical antipsychotics 
in hospitalized children and adolescents reduced subsequent rehospitalizations. 
The number of hospital days per hospitalized child or adolescent 
decreased from 1998 to 2001.  Recent studies of child and adolescent inpatient 
service utilization have shown a trend of decreased number of bed days over 
time.119,129  Pottick and colleagues reported a 44 percent decline in the mean 
length of stay over an eight-year period, translating to a 23 percent decrease in 
number of bed-days.129  In a trend analysis of four-year service data of privately 
insured children and adolescents, the mean length of inpatient mental health care 
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decreased 20 percent from 14.4 days in 1997 to 11.5 in 2000.119  The trend of 
decreased hospital days may be explained by the influence of managed care, as 
well as the beneficial effects of atypical antipsychotics. 
As a mechanism to contain health care costs, managed care organizations 
may substitute more costly services, such as inpatient psychiatric hospital days, 
with less costly alternatives.130  Decreased number of hospital days per 
hospitalized youth may represent the penetration of managed care policies into the 
public mental health care system.  Another possible explanation is the increased 
use of atypical antipsychotics.  Although no published study has examined the 
effects of treatment with atypical antipsychotics on hospital days in children and 
adolescents, data from adult and geriatric populations have suggested that 
treatment with atypical antipsychotics is associated with reductions in hospital 
days.131-133  It is possible that such reductions in the number of hospital days due 
to treatment with atypical antipsychotics may be seen in the child and adolescent 
population. 
Other factors, such as severity of illness and environmental factors, may 
influence length of stay.  Greater severity of psychopathology and specific 
diagnoses, such as post-traumatic stress disorder, have been associated with 
longer lengths of stay.  Living arrangement stability, region of hospitalization, and 
severity of psychosocial stressors also affect psychiatric hospitalization length of 
stay in children and adolescents.134-136  These types of data were not available for 
analysis of inpatient hospital days. 
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Outpatient mental health care services 
 Medication-related services, service coordination, and skills training 
constituted a significant percentage of outpatient mental health care services in 
children and adolescents receiving antipsychotic treatment.  With regard to 
enrollment, a trend of more youths receiving these services, in addition to 
assessment services and counseling and psychotherapy, existed.  The number of 
youths receiving crisis intervention and supportive services decreased over the 
four-year period.  These findings are consistent with a recent study by Saunders 
and Heflinger which showed an increase in the use of medication-related services 
and case management by children and adolescents in TennCare.137  Martin and 
Leslie reported an increase in the use of psychotherapy among privately insured 
children and adolescents.119 
 The increased use of medication-related services is expected given the 
nature of the study population and the rising prevalence of psychotropic 
medication use in children and adolescents.  Youths under study were required to 
have received antipsychotic treatment, and therefore, were highly likely to receive 
medication-related services.  The increased use of psychotropic medications in 
children and adolescents has been well-documented.2,3,53  As more and more 
youths are treated pharmacologically, the need for medication-related services 
becomes greater.  Medication-related services are essential for the improvement 
of patient outcomes, as these services are designed to facilitate medication 
adherence and evaluate drug response and side effects.138  Approximately 80 
percent of youths receiving pharmacological treatment were enrolled in 
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medication-related services.  Children and adolescents receiving antipsychotic 
treatment may be receiving similar medication-related services outside the 
TDMHMR system, perhaps from a local psychiatrist, other specialist, or primary 
care physician. 
Interestingly, the duration of enrollment in medication-related services 
decreased by nine days from 1998 to 2001.  The increase in the number of youths 
receiving medication-related services may have affected duration of enrollment, 
as the amount of resources and staff to provide these services may not have been 
sufficient.  It is also possible that once the youth is stabilized on his or her 
medications, he or she is referred to a primary care physician outside the 
TDMHMR system who then manages the youth’s medications.  Adherence to 
psychotropic medication regimens and its relationship to duration of enrollment in 
medication-related services were not assessed.  It is possible that poor medication 
adherence led to the decrease in duration of enrollment in these services, or vice 
versa.  In addition, it is unclear what effects the nine-day decrease in duration has 
on clinical outcomes. 
 Increased enrollment in service coordination may be best explained by the 
study population itself as well as the initiatives to contain mental health care 
costs.  Youths receiving antipsychotic treatment and mental health care services 
from TDMHMR may be severely ill, thus requiring intensive service 
coordination.  As integration of these children and adolescents into the 
community is a central goal to service coordination in the TDMHMR system, the 
need for service coordination for the severely mentally ill is great.  In addition, 
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service coordination is a mechanism by which mental health care costs can be 
reduced by decreasing inpatient hospitalizations.  The impact of intensive service 
coordination on patient outcomes in psychiatry has been examined.  In New York 
State, enrollment in the Children and Youth Intensive Case Management resulted 
in decreased symptomatology, improved psychosocial functioning, and reductions 
in inpatient admissions.139  Although costs associated with inpatient psychiatric 
hospitalizations may decrease, the cost-effectiveness of intensive case 
management has yet to be determined.140,141  The duration of enrollment in service 
coordination increased by 36 days over the four-year period.  This finding may be 
associated with the goal of cost containment, as monies spent to provide service 
coordination are intended to produce cost offsets via decreased inpatient 
psychiatric hospitalizations.  It is also possible that children and adolescents 
receiving antipsychotic treatment and mental health care services from 
TDMHMR represent a population with more intensive needs.  For example, 
children with disruptive behavioral disorders are perceived by parents as having a 
greater need for mental health care services, and in fact, these children are 
associated with higher rates of service utilization.142,143 
 Skills training is designed to improve a child or adolescent’s skills 
necessary to function in society independently, and thus, to maintain or improve 
one’s quality of life.138  The increased use of skills training may be a reflection of 
the growing emphasis on improved patient outcomes and psychosocial 
functioning.  Furthermore, increased enrollment in skills training may be related 
to the diagnostic profile of the population under study.  Skills training has been 
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shown to be effective in reducing symptoms associated with disruptive behavioral 
disorders.144-150  The duration of enrollment in skills training remained stable from 
1998 to 2000, and then declined in 2001.  Similar to medication-related services, 
the duration of enrollment in skills training may have been affected by the 
increased number of youths requiring this type of service, compounded by 
deficiencies in staff and resources.  Furthermore, clinicians may be more inclined 
to use pharmacological interventions, as reimbursement rates for medication-
related visits are higher compared to psychosocial interventions.80  The 
recommended duration of skills training for children and adolescents with 
disruptive behavioral disorders has not been established.  In the case of youths 
with “pure” conduct disorder, experts suggest that the duration of the 
psychosocial intervention be at least eight to ten weeks before response is 
assessed.12  In children and adolescents receiving pharmacological treatment 
along with psychosocial interventions, symptoms should be assessed as early as 
two weeks.12  In this study, the average duration of enrollment in skills training 
was approximately nine weeks, which may have been sufficient.  However, the 
median duration of enrollment was approximately five weeks, which may not 
have been sufficient.  Visit level data were not available, and therefore, the 
frequency or intensity of visits for skills training was not evaluated. 
 The number of children and adolescents enrolled in assessment services 
increased over the four-year period, while the duration of enrollment in these 
services decreased.  Assessment services serve as the first step into TDMHMR 
mental health care services, during which eligibility for services is determined.138  
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The prevalence of psychiatric and behavioral disorders in children and 
adolescents has increased during the past few decades.151  As more youths are 
affected with mental disorders, the need for mental health care services has 
increased correspondingly.  It is possible that the increased demand for mental 
health care services has resulted in decreased time spent to assess children and 
adolescents for psychiatric or behavioral symptomatolgy, functional status, and 
school-related performance. 
 The number of youths enrolled in counseling and psychotherapy 
increased, and the duration of enrollment decreased from 1998 to 2001.  With the 
increase in prevalence of psychiatric and behavioral disorders in children and 
adolescents, the need for counseling and psychotherapy to resolve issues resulting 
from the child or adolescent’s mental illness most likely has also increased.  
Given limited resources for counseling and psychotherapy, these services may be 
focused on more severely ill youths and included as part of their treatment plans.  
Psychotherapy, including behavioral management interventions, has been shown 
to be effective for childhood disorders, including disruptive behaviors.145  The 
duration of enrollment in counseling and psychotherapy may have been affected 
by the increased number of youths requiring this type of service, deficiencies in 
staff and resources, and incentives for clinicians to use pharmacological 
interventions.80 
 Frequency of enrollment in crisis intervention and supportive services 
decreased, while duration of enrollment in these services increased after an initial 
decrease.  Increased use of other types of outpatient mental health care services, 
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namely medication-related services and service coordination, may have resulted 
in a reduction in use of crisis intervention and supportive services.  With 
medication-related services, children and adolescents receiving antipsychotic 
treatment may have been routinely monitored by mental health care professionals.  
Timely detection of treatment failure and subsequent adjustments in medication 
regimens may have limited symptom exacerbations, and the need for crisis 
intervention.  Similarly, intense service coordination may have resulted in 
symptom reduction and improved functioning.  This, in turn, may have reduced 
the need for crisis intervention.  It is also possible that the use of newer atypical 
antipsychotics may have led to a decreased need for these types of services.152  
The finding of increased duration of enrollment in crisis intervention and 
supportive services may be related to severity of psychopathology.  As the 
number of enrolled youths decreased over time, those youths who received crisis 
intervention or supportive may have been more severely ill.  They may have been 
more difficult to treat, thus requiring additional services to prevent inpatient 
psychiatric hospitalizations and maintain psychosocial functioning.  Alternatively, 
the increased duration of enrollment may be an artifact of sample size.  With the 
substantial decrease in the number of youths receiving these services, variability 
in the data may have resulted in inaccurate estimates of the mean and median 




The findings from this study should be viewed in the context of its 
limitations. 
Phase I: Trends in the prevalence of antipsychotic use in children and 
adolescents (1996 to 2001) 
Several limitations to Phase I exist.  First, the generalizability of 
prevalence findings may be limited to other comparable state Medicaid programs 
and private managed care organizations.  It is unknown whether similar trends in 
antipsychotic use are occurring in other insurance programs, such as private fee-
for-service programs.  Second, the study analyzed annual cross-sectional data, 
which does not allow for an evaluation of an individual’s course of treatment over 
the six-year period.  Third, the integrity of the pharmacy database from Ohio 
Medicaid was compromised with regard to the ‘days supply’ field.  Due to a large 
percentage of prescription records in which the ‘days supply’ field equaled the 
‘quantity dispensed’ field, a proxy of 30 days was used as ‘days supply’.  Fourth, 
physician specialty and diagnostic data associated with antipsychotic prescribing 
were not available for three of the four programs.  Physician specialty and 
diagnostic data were available for Texas Medicaid and a subset of youths 
receiving mental health care services from TDMHMR, respectively.  To 
determine the appropriateness of use, it is important to discern the treatment 
setting and the diagnosis for which antipsychotics are being prescribed.  Although 
the geographic variation in antipsychotic prescribing raises important questions, it 
does not indicate whether or not this variance is appropriate.  Fifth, service 
utilization data were not available for California Medi-Cal, Ohio Medicaid, and 
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the Managed Care Organization to determine the percentage of antipsychotic-
treated youths who were receiving psychosocial services, possibly prior to the 
initiation of an antipsychotic.  Service utilization data were available for a subset 
of Texas Medicaid youths receiving mental health care services from TDMHMR.  
Sixth, since this study was based upon administrative data, it cannot be assured 
that each child or adolescent prescribed an antipsychotic actually took the 
medication.  Finally, the absence of clinical outcomes data does not allow one to 
determine the extent to which these children and adolescents benefited from 
antipsychotic treatment. 
Phase II: Prescribing practices for antipsychotic agents 
Prescriber data were collected only from Texas Medicaid.  The 
generalizability of results pertaining to physician specialty may be limited as 
other regions or states may not have similar specialty distributions as Texas.  For 
example, it is possible that the number of practicing psychiatrists, including child 
and adolescent specialists, is greater in other states compared to Texas.  Initiation 
and continuity of care with the same prescriber was not assessed in this phase.  It 
is important to examine which type of physician started a child or adolescent on 
antipsychotic treatment, and whether care is continued with that type of prescriber 
or a referral to different type of specialist is made.  Prescriber data may not have 
been totally reliable, as specialities not likely to be associated with antipsychotic 
prescribing were identified.  Diagnostic data were limited to a subset of Texas 
Medicaid youths receiving antipsychotics and mental health care services from 
TDMHMR.  Results pertaining to diagnosis associated with antipsychotic use 
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may not be generalizable to all Texas Medicaid youths, as well as other children 
and adolescents in other states.  Diagnostic data may not have been reliable as in 
some circumstances, “qualified mental health professionals” are the source of 
diagnostic information.  These individuals may not have adequate training to 
appropriately diagnose psychiatric or behavioral disorders in children and 
adolescents. 
Phase III: Relationships of antipsychotic use with patient health care service 
utilization 
Similar to the limitation of diagnostic analyses in Phase II, service 
utilization data were limited to a subset of Texas Medicaid youths receiving 
antipsychotics and mental health care services from TDMHMR.  Results 
pertaining to service utilization may not be generalizable to all Texas Medicaid 
youths, as well as other children and adolescents in other states.  Service 
utilization data did not include visit level data.  Thus, the frequency, intensity, and 
specifics (e.g., type of therapy) of outpatient mental health care services were not 
evaluated. 
Despite these limitations, this study provides a snapshot of the trends in 
antipsychotic use among children and adolescents since the introduction of 
atypical antipsychotics, prescriber types and diagnoses associated with 




Study Implications and Future Research 
Phase I: Trends in the prevalence of antipsychotic use in children and 
adolescents (1996 to 2001) 
The increased use of atypical antipsychotics further validates the growing 
trend of increased use of psychotropic medications in children and adolescents.  
Although limited systematic data supporting the safety and efficacy of atypical 
antipsychotics in this population exist, these agents may represent advances in the 
treatment of childhood and adolescent psychiatric and behavioral disorders that 
necessitate antipsychotic treatment.  The role of atypical antipsychotics in child 
and adolescent psychiatry is expanding, given their favorable side effect profiles 
compared to typical antipsychotics.  The use of atypical antipsychotics is also 
expanding toward younger aged children.  Early identification and treatment of 
certain psychiatric and behavioral disorders, such as early-onset schizophrenia, 
pediatric bipolar disorder, and disruptive behavioral disorders, may result in better 
long-term prognoses for afflicted children. 
Most published data examining the safety and efficacy of atypical 
antipsychotics in children and adolescents come from anecdotal case reports and 
small open-label trials.  Evidence from controlled clinical trials supporting the 
efficacy of risperidone is available, specifically for the treatment of disruptive 
behavioral disorders and aggression.  More controlled clinical studies in children 
and adolescents are needed to evaluate the short-term and long-term safety and 
efficacy of atypical antipsychotics.  Much attention has been given to the atypical 
antipsychotics and their propensity to induce weight gain, glucose dysregulation, 
lipid abnormalities, and cardiovascular effects.59,153  However, most of these data 
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have been limited to the adult population.  Systematic studies of these metabolic 
and cardiovascular effects in children and adolescents have yet to be conducted.  
Additionally, the long-term safety profiles of atypical antipsychotics have yet to 
be fully determined.  Preliminary evidence on risperidone suggests that the effects 
on cognitive development and physical growth may be negligible, but additional 
data are needed to further validate risperidone’s effects and examine the long-
term effects of the other atypical antipsychotics.154,155   
Future research of child and adolescent aggression should aim to compare 
the relative efficacies of atypical antipsychotic treatment with 
nonpharmacological treatment methods, such as behavioral therapy and 
psychoeducation.  A study with a design similar to that of the National Institute of 
Mental Health Collaborative Multimodal Treatment Study of Children with 
Attention-Deficit Hyperactivity Disorder would provide valuable information 
about short-term and long-term treatment effect sizes associated with the different 
modalities of treatment, mediators and moderators of treatment, and which 
treatment modality is the most cost-effective.156-160  
All these data should be used in turn, to establish evidence-based 
recommendations or guidelines for appropriate use.  For example, Treatment 
Recommendations for the Use of Antipsychotics for Aggressive Youths 
(TRAAY) were developed to provide practicing clinicians evidence-based and 
consensus-based (in areas where evidence was lacking) recommendations for the 
treatment of aggression in youths in inpatient and day treatment settings.22,59  It is 
important to note that TRAAY are recommendations and not guidelines, because 
 422
data were thought to be inadequate to develop evidence-based guidelines.  Similar 
recommendations or guidelines are needed for general outpatient management, as 
well as recommendations or guidelines explaining the role of combined 
pharmacologic and psychosocial interventions. 
Phase II: Prescribing practices for antipsychotic agents 
 Although psychiatrists account for the majority of antipsychotic 
prescriptions for children and adolescents, the primary care setting plays a major 
role in the identification and treatment of mental health problems.  Given this, 
pediatricians, general practice physicians, and family physicians need sufficient 
training to adequately assess and treat children and adolescents presenting with 
psychiatric and behavioral symptomatology.91  Adequate clinic time is also 
necessary, which may require changes in current reimbursement rates.  Additional 
training in child and adolescent psychiatry and clinic time will be even more 
imperative with the ongoing integration of nonphysician prescribing, such as 
mental health nurse practitioners and physician assistants.  Future studies of 
provider specialty associated with antipsychotic medications need to examine 
differences in patient outcomes, as well as costs associated with specific provider 
types.  Policy makers, in turn, need to use these data to develop health care 
systems in which children and adolescents needing mental health treatment do not 
face access to care issues and are provided the most optimal treatments to reduce 
debilitating symptoms and to improve psychosocial functioning. 
 Aggressive behaviors, particularly those associated with disruptive 
behavioral disorders, remain the main reason for antipsychotic use in children and 
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adolescents.  Although risperidone has been systematically evaluated for the 
treatment of aggression and shows reasonable effect sizes, other atypical 
antipsychotics have yet to be studied as such.6-11  Future research studies are 
needed to determine the relative safety and efficacy of other atypical agents with 
different pharmacological profiles compared to risperidone.  Adult data 
supporting the safety and efficacy of atypical antipsychotics are available for 
other psychiatric disorders, such as schizophrenia and bipolar disorder.  However, 
it is unclear how these data are generalizable to the child and adolescent 
population.  The assumption that adult safety and efficacy data are applicable to 
children and adolescents is not sufficient, as seen recently with the controversy 
surrounding SSRIs.161  Researchers from academia, the federal government, and 
the pharmaceutical industry need to collaborate to bridge the widening gap 
between science and clinical practice.  As mentioned previously, studies such as 
the National Institute of Mental Health Collaborative Multimodal Treatment 
Study of Children with Attention-Deficit Hyperactivity Disorder would provide 
valuable information regarding the treatment of childhood and adolescent 
psychiatric and behavioral disorders. 
Phase III: Relationships of antipsychotic use with patient health care service 
utilization 
With the increased use of atypical antipsychotics in children and 
adolescents, the use of inpatient mental health care services has declined and the 
use of outpatient services has increased.  Pharmacological treatment interventions 
have not only become commonplace in child and adolescent psychiatry, but in 
psychiatry as a whole.  Services to promote and maintain children and adolescents 
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on appropriate and beneficial medication regimens are likely to be encouraged.  
This paradigm shift in treatment may be attributed primarily to the emphasis on 
reducing health care costs.  Other reasons for this shift may include a lack of 
resources and qualified staff.   
One should remember that nonpharmacological interventions, such as 
psychotherapy and skills training, are effective treatment modalities that are 
recommended by experts.12  The role of nonpharmacological treatments in 
aggressive children and adolescents has yet to be established, as no evidence is 
available to suggest whether pharmacological treatment or nonpharmacological 
treatment is superior with this population.  It is unclear whether youths with 
aggression will benefit from a combination of both treatment modalities.   
Head-to-head comparisons, using the same inclusion/exclusion criteria and 
standardized measures across both types of interventions, are vital in defining the 
role of both pharmacological and nonpharmacological interventions.  
Additionally, long-term studies are needed to evaluate whether or not the effects 
of pharmacological versus nonpharmacological treatments are sustained.  
Researchers need to evaluate the effects of “real-world” psychosocial 
interventions on psychiatric and behavioral symptoms in children and adolescents.  
The quality of psychosocial interventions in a naturalistic setting may not be 
adequate to produce similar effect sizes as randomized, controlled trials. 
As the focus of mental health care service utilization has turned toward the 
outpatient sector, it is imperative that future studies address which specific types 
of services, alone or in combination, result in high symptom response rates and 
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improved psychosocial functioning.  Policy makers, in turn, should use this 
evidence to create cost-effective treatment plans that produce significant 
improvement and re-integrate afflicted children and adolescents into society as 
independent, productive members. 
 
Conclusions 
The pressures of the health care system may be reflected in the increased 
use of antipsychotics for the treatment of children and adolescents.  The 
appropriateness of atypical antipsychotic use should be evaluated as limited data 
supporting safety and efficacy are available in children and adolescents.  The 
growing body of evidence supporting the safety and efficacy of atypical 
antipsychotics for the treatment of aggressive behaviors is encouraging.  
However, more controlled, clinical studies and long-term effectiveness studies in 
several childhood and adolescent psychiatric and behavioral disorders are 
necessary to fully determine the role of these agents in the treatment of mental 
and behavioral disorders in youths.  Head-to-head comparisons between 
antipsychotic medications, psychosocial treatments, or a combination of both 
treatment modalities are warranted.  Additional treatment guidelines based on 
these studies are needed. 
Physicians of all specialties, perhaps especially primary care, should 
carefully evaluate the patient and his or her surroundings to determine the 
potential benefits and harms of treatment with an antipsychotic.  Routine 
diagnostic assessments with reliable and valid instruments are necessary to ensure 
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that accurate diagnoses have been made and the appropriate pharmacotherapy 
regimen has been initiated.  Scheduled assessments of symptoms and medication 
side effects are also required during the clinical management of these youths.  
Future research should address effectivness of antipsychotic medications across 
treatment settings, which may provide valuable information as to which setting 
provides the best possible improvement in patient outcomes. 
Mental health care services play an important role in the treatment plan of 
a child or adolescent with psychiatric or behavioral problems.  Current studies of 
mental health care service utilization among youths have primarily examined 
patterns of use.  It is important not only to evaluate what different types of 
services are being utilized, but also how these services affect patient outcomes.  
Furthermore, future studies need to examine the quality of services provided to 
children and adolescents, especially those tailored to improving psychosocial 
function. 
As the prevalence of psychiatric and behavioral disorders in children and 
adolescents continues to grow, the need for effective models of psychiatric 
treatment in all sectors will undoubtedly increase.  However, the reality is that 
research efforts in child and adolescent psychiatry lag well behind the current and 
projected needs.  Researchers from academia, government, and the 
pharmaceutical industry need to collaborate and begin gaining ground.  Studies 
should be conducted to determine what types of treatments, pharmacological and 
nonpharmacological, are safe and effective in this population, and how these 
treatments can best be delivered.  These types of data should help decrease the 
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current gap that exists between science and clinical practice, and hopefully 
improve treatment outcomes and psychosocial functioning for children and 






















Chapter Four References 
 
1. Malone RP, Sheikh R, Zito JM.  Novel antipsychotic medications in 
the treatment of children and adolescents.  Psychiatr Serv 1999; 
50:171-174. 
2. Zito JM, Safer DJ, dosReis S, Gardner JF, Magder L, Soeken K, Boles 
M, Lynch F, Riddle MA.  Psychotropic practice patterns for youth: a 
10-year perspective.  Arch Pediatr Adolesc Med 2003; 157:17-25. 
3. Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML.  Trends in 
antipsychotic use in a Texas Medicaid population of children and 
adolescents: 1996 to 2000.  J Child Adolesc Psychopharmacol 2002; 
12: 221-229. 
4. Worrel JA, Marken PA, Beckman SE, Ruehter VL.  Atypical 
antipsychotic agents: a critical review.  Am J Health-Syst Pharm 2000; 
57:238-258. 
5. Findling RL, Schulz C, Reed MD, Blumer JL.  The antipsychotics: a 
pediatric perspective.  Pediatr Clin North Am 1998; 45:1205-1232. 
6. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, 
Blumer JL.  A double-blind pilot study of risperidone in the treatment 
of conduct disorder.  J Am Acad Child Adolesc Psychiatry 2000; 
39:509-516. 
 429
7. Van Bellinghen M, De Troch C.  Risperidone in the treatment of 
behavioral disturbances in children and adolescents with borderline 
intellectual functioning: a double-blind, placebo-controlled pilot trial.  
J Child Adolesc Psychopharmacol 2001; 11:5-13. 
8. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT.  A 
randomized controlled trial of risperidone in the treatment of 
aggression in hospitalized adolescents with subaverage cognitive 
abilities.  J Clin Psychiatry 2001; 62:239-248. 
9. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL.  Double-
blind, placebo-controlled study of risperidone for the treatment of 
disruptive behaviors in children with subaverage intelligence.  Am J 
Psychiatry 2002; 159:1337-1346. 
10. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A.  Effects 
of risperidone on conduct and disruptive behavioral disorders in 
children with subaverage IQs.  J Am Acad Child Adolesc Psychiatry 
2002; 41:1026-1036. 
11. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, 
Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, 
Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, 
Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, 
Vitiello B, Ritz L, Davies M, Robinson J, McMahon D; Research 
 430
Units on Pediatric Psychopharmacology Autism Network.  
Risperidone in children with autism and serious behavioral problems.  
N Engl J Med 2002; 347:314-321. 
12. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, 
Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, 
Taylor E, Tyano S.  International consensus statement on attention-
deficit/hyperactivity disorder (ADHD) and disruptive behaviour 
disorders (DBDs): clinical implications and treatment practice 
suggestions.  Eur Neuropsychopharmacol 2004; 14:11-28. 
13. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 
Text Revision: DSM-IV-TR.  Washington, DC: American Psychiatric 
Association, 2000. 
14. Bryden KE, Gardner DM, Kopala LC.  First episode psychosis: early 
intervention strategies with second-generation antipsychotic 
medications.  Int J Clin Pract 2003; 57:513-518. 
15. Archer J, Pearson NA, Westeman KE.  Aggressive behaviour of 
children aged 6-11: gender differences and their magnitude.  Br J Soc 
Psychol 1988; 27:371-384. 
16. Connor DF, Steingard RJ, Anderson JJ, Melloni RH Jr.  Gender 
differences in reactive and proactive aggression.  Child Psychiatry 
Hum Dev 2003; 33:279-294. 
 431
17. Weller EB, Rowan A, Elia J, Weller RA.  Aggressive behavior in 
patients with attention-deficit/hyperactivity disorder, conduct disorder, 
and pervasive developmental disorders.  J Clin Psychiatry 1999; 
60(suppl 15):5-11. 
18. Gracious BL, Findling RL.  Antipsychotic medications for children 
and adolescents.  Pediatr Ann 2001; 30:138-144. 
19. Lane HY, Chang YC, Chiu CC, Lee SH, Lin CY, Chang WH.  Fine-
tuning risperidone dosage for acutely exacerbated schizophrenia: 
clinical determinants.  Psychopharmacology (Berl) 2004; 172:393-
399. 
20. DelBello MP, Schwiers ML, Rosenberg HL, Strakowski SM.  A 
double-blind, randomized, placebo-controlled study of quetiapine as 
adjunctive treatment for adolescent mania.  J Am Acad Child Adolesc 
Psychiatry 2002; 41:1216-1223. 
21. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA.  A 
pilot study of risperidone, olanzapine, and haloperidol in psychotic 
youth: a double-blind, randomized, 8-week trial.  
Neuropsychopharmacology 2004; 29:133-145. 
22. Pappadopulos E, MacIntyre JC, Crismon ML, Findling RL, Malone 
RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton 
CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick 
 432
SE, Jensen PS.  Treatment recommendations for the use of 
antipsychotics for aggressive Youth (TRAAY): Part II.  J Am Acad 
Child Adolesc Psychiatry 2003; 42:145-61. 
23. Findling RL, McNamara NK, Gracious BL.  Paediatric uses of atypical 
antipsychotics.  Expert Opin Pharmacother 2000;1:935-945. 
24. Ganguli R.  Rationale and strategies for switching antipsychotics.  Am 
J Health Syst Pharm 2002; 59(suppl 8):S22-S26. 
25. Hugenholtz GW, Heerdink ER, Nolen WA, Egberts AC.  Less 
medication switching after initial start with atypical antipsychotics.  
Eur Neuropsychopharmacol 2004; 14:1-5. 
26. Cook PE, Goldberg JO, Van Lieshout RJ.  Benefits of switching from 
typical to atypical antipsychotic medications: a longitudinal study in a 
community-based setting.  Can J Psychiatry 2002; 47:870-874. 
27. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR.  Treatment 
adherence associated with conventional and atypical antipsychotics in 
a large state Medicaid program.  Psychiatr Serv 2003; 54:719-723. 
28. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante 
MC, Weiden PJ.  Antipsychotic-induced weight gain: a comprehensive 
research synthesis.  Am J Psychiatry 1999; 156:1686-1696. 
29. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, 
Hernandez L.  Drug induced weight gain, an impediment to successful 
 433
pharmacotherapy: focus on antipsychotics.  Curr Drug Targets 2004; 
5:279-299. 
30. Stigler KA, Potenza MN, Posey DJ, McDougle CJ.  Weight gain 
associated with atypical antipsychotic use in children and adolescents: 
prevalence, clinical relevance, and management.  Paediatr Drugs 
2004; 6:33-44. 
31. Allison DB, Mackell JA, McDonnell DD.  The impact of weight gain 
on quality of life among persons with schizophrenia.  Psychiatr Serv 
2003; 54:565-567. 
32. Rothbard AB, Kuno E, Foley K.  Trends in the rate and type of 
antipsychotic medications prescribed to persons with schizophrenia.  
Schizophr Bull 2003; 29:531-540. 
33. Leslie DL, Rosenheck RA.  From conventional to atypical 
antipsychotics and back: dynamic processes in the diffusion of new 
medications.  Am J Psychiatry 2002; 159:1534-1540. 
34. Al-Zakwani IS, Barron JJ, Bullano MF, Arcona S, Drury CJ, 
Cockerham TR.  Analysis of healthcare utilization patterns and 
adherence in patients receiving typical and atypical antipsychotic 
medications.  Curr Med Res Opin 2003; 19:619-626. 
 434
35. Dolder CR, Lacro JP, Dunn LB, Jeste DV.  Antipsychotic medication 
adherence: is there a difference between typical and atypical agents?  
Am J Psychiatry 2002; 159:103-108. 
36. Bhatara VS, Feil M, Hoagwood K, Vitiello B, Zima B.  Datapoints: 
trends in combined pharmacotherapy with stimulants for children.  
Psychiatr Serv 2002; 53:244. 
37. Olfson M, Marcus SC, Weissman MM, Jensen PS.  National trends in 
the use of psychotropic medications by children.  J Am Acad Child 
Adolesc Psychiatry 2002; 41:514-521. 
38. Martin A, Van Hoof T, Stubbe D, Sherwin T, Scahill L.  Multiple 
psychotropic pharmacotherapy among child and adolescent enrollees 
in Connecticut Medicaid managed care.  Psychiatr Serv 2003; 54:72-
77. 
39. Kaplan SL, Simms RM, Busner J.  Prescribing practices of outpatient 
child psychiatrists.  J Am Acad Child Adolesc Psychiatry 1994; 33: 35-
44. 
40. Ahsanuddin KM, Ivey JA, Schlotzhauer D, Hall K, Prosen H.  
Psychotropic medication prescription patterns in 100 hospitalized 
children and adolescents.  J Am Acad Child Psychiatry 1983; 22:361-
364. 
 435
41. Connor DF, Ozbayrak KR, Harrison RJ, Melloni RH Jr.  Prevalence 
and patterns of psychotropic and anticonvulsant medication use in 
children and adolescents referred to residential treatment.  J Child 
Adolesc Psychopharmacol 1998; 8:27-38. 
42. Campbell M, Adams PB, Small AM, Kafantaris V, Silva RR, Shell J, 
Perry R, Overall JE.  Lithium in hospitalized aggressive children with 
conduct disorder: a double-blind and placebo-controlled study.  J Am 
Acad Child Adolesc Psychiatry 1995; 34:445-453. 
43. Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M.  A 
double-blind placebo-controlled study of lithium in hospitalized 
aggressive children and adolescents with conduct disorder.  Arch Gen 
Psychiatry 2000; 57:649-654. 
44. Donovan SJ, Stewart JW, Nunes EV, Quitkin FM, Parides M, Daniel 
W, Susser E, Klein DF.  Divalproex treatment for youth with explosive 
temper and mood lability: a double-blind, placebo-controlled crossover 
design.  Am J Psychiatry 2000; 157:818-820. 
45. Shelton RC.  The use of antidepressants in novel combination 
therapies. J Clin Psychiatry 2003; 64(suppl 2):14-18. 
46. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, 
Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, 
Moller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M.  Partial 
 436
response and nonresponse to antidepressant therapy: current 
approaches and treatment options.   J Clin Psychiatry 2002; 63:826-
837. 
47. Evins AE.  Efficacy of newer anticonvulsant medications in bipolar 
spectrum mood disorders.  J Clin Psychiatry 2003; 64(suppl 8):9-14. 
48. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S.  
Clinical efficacy of methylphenidate in conduct disorder with and 
without attention deficit hyperactivity disorder.  Arch Gen Psychiatry 
1997; 54:1073-1080. 
49. Kaplan SL, Busner J, Kupietz S, Wassermann E, Segal B.  Effects of 
methylphenidate on adolescents with aggressive conduct disorder and 
ADDH: a preliminary report.  J Am Acad Child Adolesc Psychiatry 
1990; 29:719-723. 
50. Connor DF, Barkley RA, Davis HT.  A pilot study of methylphenidate, 
clonidine, or the combination in ADHD comorbid with aggressive 
oppositional defiant or conduct disorder.  Clin Pediatr (Phila) 2000; 
39:15-25. 
51. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners 
CK, McCracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, 
Toprac MG.  The Texas Children's Medication Algorithm Project: 
Report of the Texas Consensus Conference Panel on Medication 
 437
Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part 
I. Attention-Deficit/Hyperactivity Disorder.  J Am Acad Child Adolesc 
Psychiatry 2000; 39:908-919. 
52. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners 
CK, McCracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, 
Toprac MG.  The Texas Children's Medication Algorithm Project: 
Report of the Texas Consensus Conference Panel on Medication 
Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part 
II: Tactics. Attention-Deficit/Hyperactivity Disorder.  J Am Acad 
Child Adolesc Psychiatry 2000; 39:920-927. 
53. Delate T, Gelenberg AJ, Simmons VA, Motheral BR.  Trends in the 
use of antidepressants in a national sample of commercially insured 
pediatric patients, 1998 to 2002.  Psychiatr Serv 2004; 55:387-391. 
54. Zito JM, Safer DJ, dosReis S, Gardner JF, Soeken K, Boles M, Lynch 
F.  Rising prevalence of antidepressants among US youths.  Pediatrics 
2002; 109:721-727. 
55. Hughes CW, Emslie GJ, Crismon ML, Wagner KD, Birmaher B, 
Geller B, Pliszka SR, Ryan ND, Strober M, Trivedi MH, Toprac MG, 
Sedillo A, Llana ME, Lopez M, Rush AJ.  The Texas Children's 
Medication Algorithm Project: report of the Texas Consensus 
Conference Panel on Medication Treatment of Childhood Major 
 438
Depressive Disorder.  J Am Acad Child Adolesc Psychiatry 1999; 
38:1442-1454. 
56. Compton MT, Nemeroff CB.  The treatment of bipolar depression.  J 
Clin Psychiatry 2000; 61(suppl 9):57-67. 
57. Cherek DR, Lane SD, Pietras CJ, Steinberg JL.  Effects of chronic 
paroxetine administration on measures of aggressive and impulsive 
responses of adult males with a history of conduct disorder.  
Psychopharmacology (Berl) 2002; 159:266-274. 
58. Armenteros JL, Lewis JE.  Citalopram treatment for impulsive 
aggression in children and adolescents: an open pilot study.  J Am 
Acad Child Adolesc Psychiatry 2002; 41:522-529. 
59. Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan 
A, MacIntyre JC, Pappadopulos E, Greenhill L, Schooler N, Van 
Orden K, Jensen PS.  Treatment recommendations for the use of 
antipsychotics for aggressive youth (TRAAY). Part I: a review.  J Am 
Acad Child Adolesc Psychiatry 2003; 42:132-144. 
60. Stahl SM, Grady MM.  A critical review of atypical antipsychotic 
utilization: comparing monotherapy with polypharmacy and 
augmentation.  Curr Med Chem 2004; 11:313-327. 
61. Botts S, Hines H, Littrell R.  Antipsychotic polypharmacy in the 
ambulatory care setting, 1993-2000.  Psychiatr Serv 2003; 54:1086. 
 439
62. Tempier RP, Pawliuk NH.  Conventional, atypical, and combination 
antipsychotic prescriptions: a 2-year comparison.  J Clin Psychiatry 
2003; 64:673-679. 
63. Jaffe AB, Levine J.  Antipsychotic medication coprescribing in a large 
state hospital system.  Pharmacoepidemiol Drug Saf 2003; 12:41-48. 
64. Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N.  
Combination antipsychotic therapy in clinical practice.  Psychiatr Serv 
2003; 54:55-59. 
65. McCue RE, Waheed R, Urcuyo L.  Polypharmacy in patients with 
schizophrenia.  J Clin Psychiatry 2003; 64:984-989. 
66. Lerner V, Libov I, Kotler M, Strous RD.  Combination of "atypical" 
antipsychotic medication in the management of treatment-resistant 
schizophrenia and schizoaffective disorder.  Prog 
Neuropsychopharmacol Biol Psychiatry 2004; 28:89-98. 
67. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, 
Dorfman-Etrog P, Modai I, Khaikin M, Weizman A.  Sulpiride 
augmentation in people with schizophrenia partially responsive to 
clozapine. A double-blind, placebo-controlled study.  Br J Psychiatry 
1997; 171:569-573. 
 440
68. Medical Economics Staff, Medical Economics, H.E. Cohen (eds).  
Drug Topics Red Book 2003, 106th Edition.  Montvale, NJ: Medical 
Economics, 2003. 
69. Martin A, Leslie D.  Trends in psychotropic medication costs for 
children and adolescents, 1997-2000.  Arch Pediatr Adolesc Med 
2003; 157:997-1004. 
70. Hermann RC, Yang D, Ettner SL, Marcus SC, Yoon C, Abraham M.  
Prescription of antipsychotic drugs by office-based physicians in the 
United States, 1989-1997.  Psychiatr Serv 2002; 53:425-430.  
71. Tamblyn R, McLeod P, Hanley JA, Girard N, Hurley J.  Physician and 
practice characteristics associated with the early utilization of new 
prescription drugs.  Med Care 2003; 41:895-908. 
72. Owen RR, Feng W, Thrush CR, Hudson TJ, Austen MA.  Variations 
in prescribing practices for novel antipsychotic medications among 
Veterans Affairs hospitals.  Psychiatr Serv 2001; 52:1523-1525. 
73. Sheppard C, Beyel V, Moan E, Fracchia J, Merlis S.  Comparative 
survey of psychiatrists' prescription preferences: New York and Texas.  
South Med J 1975; 68:876-880. 
74. Olfson M, Pincus HA, Sabshin M.  Pharmacotherapy in outpatient 
psychiatric practice.  Am J Psychiatry 2001; 151:580-585. 
 441
75. Sturm R, Ringel JS, Andreyeva T.  Geographic disparities in children's 
mental health care.  Pediatrics 2003; 112:e308. 
76. Mark TL, Dirani R, Slade E, Russo PA.  Access to new medications to 
treat schizophrenia.  J Behav Health Serv Res 2002; 29:15-29. 
77. Glied S, Hoven CW, Moore RE, Garrett AB, Regier DA.  Children's 
access to mental health care: does insurance matter?  Health Aff 
(Millwood) 1997; 16:167-174. 
78. Farrington DP. Early predictors of adolescent aggression and adult 
violence. Violence Vict 1989; 4:79-100. 
79. Martin A, Sherwin T, Stubbe D, Van Hoof T, Scahill L, Leslie D. 
Datapoints: use of multiple psychotropic drugs by Medicaid-insured 
and privately insured children. Psychiatr Serv 2002; 53:1508.  
80. Jellinek MS. Mirror, mirror on the wall: are we prescribing the right 
psychotropic medications to the right children using the right treatment 
plan?  Arch Pediatr Adolesc Med 2003; 157:14-16. 
81. Rohland BM, Rohrer JE, Culica D. Substitution of psychiatric care by 
primary care physicians: impact of the Iowa Medicaid managed mental 
health care plan. Adm Policy Ment Health 1999; 26:369-371. 
82. Zarin DA, Suarez AP, Pincus HA, Kupersanin E, Zito JM. Clinical and 
treatment characteristics of children with attention-
 442
deficit/hyperactivity disorder in psychiatric practice. J Am Acad Child 
Adolesc Psychiatry 1998; 37:1262-1270. 
83. Epstein MA, Shaywitz SE, Shaywitz BA, Woolston JL.  The 
boundaries of attention deficit disorder. J Learn Disabil 1991; 24:78-
86. 
84. Goodwin R, Gould MS, Blanco C, Olfson M.  Prescription of 
psychotropic medications to youths in office-based practice.  Psychiatr 
Serv 2001; 52:1081-1087. 
85. Pincus HA, Tanielian TL, Marcus SC, Olfson M, Zarin DA, 
Thompson J, Zito JM.  Prescribing trends in psychotropic medications: 
primary care, psychiatry, and other medical specialties.  JAMA 1998; 
279:526-531. 
86. Van Brunt DL, Gibson PJ, Ramsey JL, Obenchain R. Outpatient use of 
major antipsychotic drugs in ambulatory settings in the United States, 
1997-2000.  MedGenMed 2003; 5:16. 
87. Farmer EM, Burns BJ, Phillips SD, Angold A, Costello EJ.  Pathways 
into and through mental health services for children and adolescents.  
Psychiatr Serv 2003; 54:60-66. 
88. Mitka M.  Alliance anxious about children’s mental health.  JAMA 
2000; 284:31-32. 
 443
89. Horwitz SM, Kelleher K, Boyce T, Jensen P, Murphy M, Perrin E, 
Stein RE, Weitzman M.  Barriers to health care research for children 
and youth with psychosocial problems.  JAMA 2002; 288:1508-1512. 
90. Rushton J, Bruckman D, Kelleher K.  Primary care referral of children 
with psychosocial problems.  Arch Pediatr Adolesc Med 2002; 
156:592-598. 
91. Ringeisen H, Oliver KA, Menvielle E.  Recognition and treatment of 
mental disorders in children: considerations for pediatric health 
systems.  Paediatr Drugs 2002; 4:697-703. 
92. Pappadopulos E, Jensen PS, Schur SB, MacIntyre JC, Ketner S, Van 
Orden K, Sverd J, Sardana S, Woodlock D, Schweitzer R, Rube D.  
“Real world” atypical antipsychotic prescribing practices in public 
child and adolescent inpatient settings.  Schizophr Bull 2002; 28:111-
121. 
93. Emslie GJ, Mayes TL.  Mood disorders in children and adolescents: 
psychopharmacological treatment.  Biol Psychiatry 2001; 49:1082-
1090. 
94. Emslie GJ, Mayes TL, Hughes CW.  Updates in the pharmacologic 
treatment of childhood depression.  Psychiatr Clin North Am 2000; 
23:813-835. 
 444
95. Marmorstein NR, Iacono WG.  Major depression and conduct disorder 
in youth: associations with parental psychopathology and parent-child 
conflict.  J Child Psychol Psychiatry 2004; 45:377-386. 
96. Renouf AG, Kovacs M, Mukerji P.  Relationship of depressive, 
conduct, and comorbid disorders and social functioning in childhood.  
J Am Acad Child Adolesc Psychiatry 1997; 36:998-1004. 
97. DelBello M, Grcevich S.  Phenomenology and epidemiology of 
childhood psychiatric disorders that may necessitate treatment with 
atypical antipsychotics.  J Clin Psychiatry 2004; 65(suppl 6):12-19. 
98. Wolf DV, Wagner KD.  Bipolar disorder in children and adolescents.  
CNS Spectr 2003; 8:954-959. 
99. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha 
A, Ingenito G; Aripiprazole Study Group.  A placebo-controlled, 
double-blind study of the efficacy and safety of aripiprazole in patients 
with acute bipolar mania.  Am J Psychiatry 2003; 160:1651-1658. 
100. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, 
Vieta E, Hardy-Bayle MC, Lawson WB, Emsley RA, Zhang F, Baker 
RW, Risser RC, Namjoshi MA, Evans AR, Breier A.  A 12-week, 
double-blind comparison of olanzapine vs haloperidol in the treatment 
of acute mania.  Arch Gen Psychiatry 2003; 60:1218-1226. 
 445
101. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter 
TA, Milton DR, Risser R, Gilmore JA, Breier A, Tollefson GD.  
Olanzapine versus divalproex in the treatment of acute mania.  Am J 
Psychiatry 2002; 159:1011-1017. 
102. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, 
Janicak PG, Sanger T, Risser R, Zhang F, Toma V, Francis J, 
Tollefson GD, Breier A.  Efficacy of olanzapine in acute bipolar 
mania: a double-blind, placebo-controlled study.  The Olanzapine 
HGGW Study Group.  Arch Gen Psychiatry 2000; 57:841-849. 
103. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa 
KN, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney 
MG, Jacobs TG, David SR, Toma V.  Olanzapine versus placebo in 
the treatment of acute mania.  Olanzapine HGEH Study Group.  Am J 
Psychiatry 1999; 156:702-709. 
104. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A.  
Mood stabilizers plus risperidone or placebo in the treatment of acute 
mania.  International double-blind, randomised controlled trial.  Br J 
Psychiatry 2003; 182:141-147. 
105. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL.  
Combination of a mood stabilizer with risperidone or haloperidol for 
the treatment of acute mania: a double-blind, placebo-controlled 
 446
comparison of efficacy and safety.  Am J Psychiatry 2002; 159:1146-
1154. 
106. Segal J, Berk M, Brook S.  Risperidone compared with both 
lithium and haloperidol in mania: a double-blind randomized 
controlled trial.  Clin Neuropharmacol 1998; 21:176-180. 
107. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K; 
Ziprasidone in Mania Study Group.  Ziprasidone in the treatment of 
acute bipolar mania: a three-week, placebo-controlled, double-blind, 
randomized trial.  Am J Psychiatry 2003; 160:741-748. 
108. Jones MW, Huizar K.  Quetiapine monotherapy for acute mania 
associated with bipolar disorder (STAMP 1 and STAMP 2) [poster].  
Presented at the Annual Meeting of the American Psychiatric 
Association, San Francisco, CA, May 17-22, 2003. 
109. Borchardt CM, Bernstein GA.  Comorbid disorders in hospitalized 
bipolar adolescents compared with unipolar depressed adolescents.  
Child Psychiatry Hum Dev 1995; 26:11-18. 
110. Geller B, Sun K, Zimerman B, Luby J, Frazier J, Williams M.  
Complex and rapid-cycling in bipolar children and adolescents: a 
preliminary study.  J Affect Disord 1995; 34:259-268. 
 447
111. West SA, McElroy SL, Stratkowski SM, Keck PE Jr, McConville 
BJ.  Attention deficit hyperactivity disorder in adolescent mania.  Am J 
Psychiatry 1995; 152:271-273. 
112. Wozniak J, Biederman J, Mundy E, Mennin D, Faraone SV.  A 
pilot family study of childhood-onset mania.  J Am Acad Child 
Adolesc Psychiatry 1995; 34:1577-1583. 
113. Carlson GA.  Mania and ADHD: comorbidity or confusion.  J 
Affect Disord 1998; 51:177-187. 
114. Mick E, Biederman J, Pandina G, Faraone SV.  A preliminary 
meta-analysis of the child behavior checklist in pediatric bipolar 
disorder.  Biol Psychiatry 2003; 53:1021-1027. 
115. Masi G, Toni C, Perugi C, Travierso MC, Millepiedi S, Mucci M, 
Akiskal HS.  Externalizing disorders in consecutively referred children 
and adolescents with bipolar disorder.  Compr Psychiatry 2003; 
44:184-189. 
116. Kovacs M, Pollock M.  Bipolar disorder and comorbid conduct 
disorder in childhood and adolescence.  J Am Acad Child Adolesc 
Psychiatry 1995; 34:715-723. 
117. Pottick KJ, Barber CC, Hansell S, Coyne L.  Changing patterns of 
inpatient care for children and adolescents at the Menninger Clinic, 
1988-1994.  J Consult Clin Psychol 2001; 69:573-577. 
 448
118. Meunier-Sham J.  Increased volume/length of stay for pediatric 
mental health patients: one ED’s response.  J Emerg Nurs 2003; 
29:229-239. 
119. Martin A, Leslie D.  Psychiatric inpatient, outpatient, and 
medication utilization and costs among privately insured youths, 1997-
2000.  Am J Psychiatry 2003; 160:757-764. 
120. Chabra A, Chavez GF, Harris ES, Shah R.  Hospitalization for 
mental illness in adolescents: risk groups and impact on the health care 
system.  J Adolesc Health 1999; 24:349-356. 
121. McDermott BM, McKelvey R, Roberts L, Davies L.  Severity of 
children’s psychopathology and impairment and its relationship to 
treatment setting.  Psychiatr Serv 2002; 53:57-62. 
122. Pottick K, Hansell S, Gutterman E, White HR.  Factors associated 
with inpatient and outpatient treatment for children and adolescents 
with serious mental illness.  J Am Acad Child Adolesc Psychiatry 
1995; 34:425-433. 
123. Lock J, Strauss GD.  Psychiatric hospitalization of adolescents for 
conduct disorder.  Hosp Community Psychiatry 1994; 45:925-928. 
124. Arnold EM, Goldston DB, Ruggiero A, Reboussin BA, Daniel SS, 
Hickman EA.  Rates and predictors of rehospitalization among 
formerly hospitalized adolescents.  Psychiatr Serv 2003; 54:994-998. 
 449
125. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR.  
Rehospitalization rates for depot antipsychotics and 
pharmacoeconomic implications: comparison with risperidone.  Am J 
Health Syst Pharm 1998; 55(suppl 4):17-19. 
126. Conley RR, Kelly DL, Love RC, McMahon RP.  Rehospitalization 
risk with second-generation and depot antipsychotics.  Ann Clin 
Psychiatry 2003; 15:23-31. 
127. Conley RR, Love RC, Kelly DL, Bartko JJ.  Rehospitalization 
rates of patients recently discharged on a regimen of risperidone or 
clozapine.  Am J Psychiatry 1999; 156:863-868. 
128. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, 
Davidson M.  Rehospitalization rates of chronically ill schizophrenic 
patients discharged on a regimen of risperidone, olanzapine, or 
conventional antipsychotics.  Am J Psychiatry 2001; 158:266-269. 
129. Pottick KJ, McAlpine DD, Andelman RB.  Changing patterns of 
psychiatric inpatient care for children and adolescents in general 
hospitals, 1988-1995.  Am J Psychiatry 2000; 157:1267-1273. 
130. Goldman W, McCulloch J, Sturm R.  Costs and use of mental 
health services before and after managed care.  Health Aff (Millwood) 
1998; 17:40-52. 
 450
131. Delgado L, McKoy Y, Rey JA, Troy T.  A comparison of clinical 
outcomes in patients receiving depot vs. atypical antipsychotics 
(poster).  Presented at the 40th Annual National Institute of Mental 
Health New Clinical Drug Evaluation Unit Meeting, Boca Raton, FL, 
May 30-June 2, 2000. 
132. Edell WS, Rupnow MF.  Inpatient length of stay and atypical 
antipsychotic use among elderly patients with psychiatric disorders 
and Alzheimer’s disease.  Manag Care Interface 2003; 16:64-67. 
133. Gianfrancesco F, Durkin MB, Mahmoud R, Wang RH.  Use of 
healthcare services by patients treated with risperidone versus 
conventional antipsychotic agents.  Pharmacoeconomics 2002; 
20:413-427. 
134. Gold J, Shera D, Clarkson B Jr.  Private psychiatric hospitalization 
of children: predictors of length of stay.  J Am Acad Child Adolesc 
Psychiatry 1993; 32:135-143. 
135. Leon SC, Uziel-Miller ND, Lyons JS, Tracy P.  Psychiatric 
hospital service utilization of children and adolescents in state custody.  
J Am Acad Child Adolesc Psychiatry 1999; 38:305-310. 
136. Mossman D, Songer DA, Baker DG.  Predicting length of 
children's psychiatric hospitalizations: an "ecologic" approach.  QRB 
Qual Rev Bull 1991; 17:269-274. 
 451
137. Saunders RC, Heflinger CA.  Access to and patterns of use 
behavioral health services among children and adolescents in 
TennCare.  Psychiatr Serv 2003; 54:1364-1371. 
138. Texas Department of Mental Health and Mental Retardation: 
Children’s Mental Health Services.  Available at: 
http://www.mhmr.state.tx.us/MentalHealthServices/MHChildrensServi
ces.html.  Accessed April 27, 2004. 
139. Evans ME, Huz S, McNulty T, Banks SM.  Child, family, and 
system outcomes of intensive case management in New York State.  
Psychiatr Q 1996; 67:273-286. 
140. Cost-effectiveness of intensive v. standard case management for 
severe psychotic illness.  UK700 case management trial.  UK700 
Group.  Br J Psychiatry 2000; 176:537-543. 
141. Johnston S, Salkeld G, Sanderson K, Issakidis C, Teesson M, 
Buhrich N.  Intensive case management: a cost-effectiveness analysis.  
Aust N Z J Psychiatry 1998; 32:551-559. 
142. Wu P, Hoven CW, Bird HR, Moore RE, Cohen P, Alegria M, 
Dulcan MK, Goodman SH, Horwitz SM, Lichtman JH, Narrow WE, 
Rae DS, Regier DA, Roper MT.  Depressive and disruptive disorders 
and mental health service utilization in children and adolescents.  J Am 
Acad Child Adolesc Psychiatry 1999; 38:1081-1090. 
 452
143. Mandell DS, Guevara JP, Rostain AL, Hadley TR.  Medical 
expenditures among children with psychiatric disorders in a Medicaid 
population.  Psychiatr Serv 2003; 54:465-467. 
144. Antshel KM, Remer R.  Social skills training in children with 
attention deficit hyperactivity disorder: a randomized-controlled 
clinical trial.  J Clin Child Adolesc Psychol 2003; 32:153-165. 
145. Kazdin AE.  Treatments for aggressive and antisocial children.  
Child Adolesc Psychiatr Clin North Am 2000; 9:841-858. 
146. Webster-Stratton C, Herbert M.  Strategies for helping parents of 
children with conduct disorders.  Prog Behav Modif 1994; 29:121-142. 
147. Webster-Stratton C, Hammond M.  Treating children with early-
onset conduct problems: a comparison of child and parent training 
interventions.  J Consult Clin Psychol 1997; 65:93-109. 
148. Webster-Stratton C, Hammond M.  Marital conflict management 
skills, parenting style, and early-onset conduct problems: processes 
and pathways.  J Child Psychol Psychiatry 1999; 40:917-927. 
149. Kazdin AE, Siegel TC, Bass D.  Cognitive problem-solving skills 
training and parent management training in the treatment of antisocial 
behavior in children.  J Consult Clin Psychol 1992; 60:733-747. 
150. Taylor TK, Schmidt F, Pepler D, Hodgins C.  A comparison of 
eclectic treatment with Webster-Stratton’s Parent and Child Series in a 
 453
children’s mental health center: a randomized controlled trial.  Behav 
Ther 1998; 29:221-240. 
151. Kelleher KJ, McInerny TK, Gardner WP, Childs GE, Wasserman 
RC.  Increasing identification of psychosocial problems: 1979-1996.  
Pediatrics 2000; 105:1313-1321. 
152. Viale G, Mechling L, Maislin G, Durkin M, Engelhart L, 
Lawrence BJ.  Impact of risperidone on the use of mental health care 
resources.  Psychiatr Serv 1997; 48:1153-1159. 
153. Serretti A, De Ronchi D, Lorenzi C, Berardi D.  New 
antipsychotics and schizophrenia: a review on efficacy and side 
effects.  Curr Med Chem 2004; 11:343-358. 
154. Pandina G, Bilder R, Keefe R, Simpson G, Gharabawi G.  
Risperidone and cognitive function in children with disruptive 
behavior disorders (poster).  Presented at the Janssen Pharmaceutica 
CNS Advisory Summit, Scottsdale, AZ, February 23 – 26, 2003. 
155. Dunbar F, Kusumakar V, Daneman D, Schulz M.  Growth and 
sexual maturation in children are unaffected by long term treatment 
with risperidone (poster).  Presented at the Janssen Pharmaceutica 
CNS Advisory Summit, Scottsdale, AZ, February 23 – 26, 2003. 
156. MTA Cooperative Group.  National Institute of Mental Health 
Multimodal Treatment Study of ADHD follow-up: changes in 
 454
effectiveness and growth after the end of treatment.  Pediatrics 2004; 
113:762-769. 
157. MTA Cooperative Group.  National Institute of Mental Health 
Multimodal Treatment Study of ADHD follow-up: 24-month 
outcomes of treatment strategies for attention-deficit/hyperactivity 
disorder.  Pediatrics 2004; 113:754-761. 
158. Moderators and mediators of treatment response for children with 
attention-deficit/hyperactivity disorder: the Multimodal Treatment 
Study of children with Attention-deficit/hyperactivity disorder.  Arch 
Gen Psychiatry 1999; 56:1088-1096. 
159. A 14-month randomized controlled trial of treatment strategies for 
attention-deficit/hyperactivity disorder.  The MTA Cooperative Group.  
Multimodal Treatment Study of Children with ADHD.  Arch Gen 
Psychiatry 1999; 56:1073-1086. 
160. Jensen PS; The MTA Cooperative Group.  Cost-effectiveness of 
treatment options for attention-deficit/hyperactivity disorder 
(symposium).  Presented at the 50th Anniversary Meeting of the 
American Academy of Child and Adolescent Psychiatry, Miami, FL, 
October 14 – 19, 2003. 
161. Vitiello B, Swedo S.  Antidepressant medications in children.  N 




Appendix A: Descriptions of Outpatient Mental Health Services Provided by the 
Texas Department of Mental Health and Mental Retardation (Pages 456-463). 
 
Appendix B: Logistic Regression Analyses of Prevalence Data Regarding 
Antipsychotic Use (Pages 464-499). 
 
Appendix C: Analyses of Mean Daily Doses of Atypical Antipsychotics in Age 
Categories (Pages 500-559). 
 
Appendix D: Analyses of Inpatient Hospitalization Data for Texas Medicaid 
Children and Adolescents Receiving Antipsychotic Treatment and Mental Health 
Care Services from TDMHMR (Pages 560-591). 
 
Appendix E: Analyses of Outpatient Mental Health Care Service Utilization Data 
for Texas Medicaid Children and Adolescents Receiving Antipsychotic Treatment 







Descriptions of Outpatient Mental Health Services Provided by 
the Texas Department of Mental Health and Mental Retardation 
 
The following descriptions of outpatient mental health services provided by the 
Texas Department of Mental Health and Mental Retardation are available at 
http://www.mhmr.state.tx.us/MentalHealthServices/MHChildrensServices.html. 
 
Assessment Services (TC08) 
There are several steps to completing an assessment.  The first part is to determine 
whether or not your child is eligible for services from the local mental health 
authority.  In order to be eligible, your child must meet the definition of “priority 
population.”  To be in the priority population, your child must be between the 
ages of three and 17 with a diagnosis of mental illness who exhibit serious 
emotional, behavioral or mental disorders and who: 
• Have a serious functional impairment; 
• Are at risk of disruption of a preferred living or child care environment 
due to psychiatric symptoms; or 
• Are enrolled in a school system’s special education program because 
of a serious emotional disturbance. 
 
A licensed professional will meet with you and your child face-to-face to ask you 
questions about your child’s mental health, emotional and behavioral issues, their 
 457
relationships at home and with friends, their health, their development, their 
schoolwork, and other information needed to complete the assessment. 
 
Counseling and Psychotherapy (TC13) 
Individual, group and/or family counseling designed to resolve problems that 
result from the child’s mental, emotional or behavioral disorder.  An appropriately 
licensed professional will provide this service. 
 
Crisis Intervention (TC01, TC07, TC09, TC17, and TC20) 
In-Home Crisis (TC01) 
Crisis intervention and supports provided in the home to assist children and their 
families manage an identified crisis and keep the child with the family or primary 
caregiver.  This service is provided to a child who is at risk of being placed 
outside the home.  In-home crisis intervention may also be provided in other 
community settings. 
 
Inpatient Services (TC07) 
Hospital services provide 24-hour care to children who cannot be stabilized in a 
less restrictive environment.  Services are designed to provide safety and security 
during an acute psychiatric crisis.  The staff provides intensive interventions 




Therapeutic Foster Care (TC09) 
Therapeutic Foster Care is when trained foster parents provide 24-hour care in 
their home for children who are temporarily unable to live with their parents or 
primary caregivers.  Services and supports include family skills training for the 
natural parents/primary caregivers; training and support for the foster parents; 
crisis management; skills training and individual, group and family counseling. 
 
Other Residential Services (TC17) 
If a child is experiencing a psychiatric crisis that cannot be stabilized in a 
community setting, then short-term (usually 24 hours) residential services are 
provided.  Intensive crisis residential services may be located in a variety of 
settings, including hospitals, therapeutic foster care homes, group homes, and 
crisis stabilization units or crisis beds in residential treatment centers. 
 
Acute Day Treatment (TC20) 
An intensive, short-term program provided during the day for children who need a 
team of professionals to help stabilize their acute and severe psychiatric 
symptoms.  The environment is highly structured and provides constant 
supervision.  Services and supports may include medication-related services, 





Medication-Related Services (TC04) 
If your child is prescribed medication, there are several services that are provided 
as a part of your child’s care: 
• If he or she takes the medicine at the community center, a licensed 
nurse or other qualified and trained staff supervised by a doctor or 
registered nurse will provide or administer it. 
• This person will also be responsible for monitoring your child’s 
medication, by assessing the impact of the medicine, including how 
well the medicine is working, if there are any side effects or adverse 
effects or if your child is experiencing any possible toxic reactions to 
the medicine. 
• Appropriately trained staff will also teach your child and/or family 
member the knowledge and skills needed to be able to administer and 
monitor the medication at home. 
• The doctor will be responsible for managing your child’s medication 
to determine if his/her symptoms are staying the same, getting worse, 
getting better or clearing up completely.  The doctor will evaluate the 
effectiveness of the prescribed medication, the dose (how much), the 
frequency (how often) and whether or not a different medication 
should be tried, and when. 
• Your local mental health authority is responsible for ensuring that your 
child receives his/her prescribed psychoactive medication, under 
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certain circumstances.  Your child’s medication will be provided to 
you if: 
 You have no other means of paying for this medicine; 
 The medicine has been determined to be medically 
necessary; 
 It is prescribed by an authorized representative of the local 
mental health authority; and, 
 Your child is receiving services and registered in the Texas 
Department of Mental Health and Mental Retardation’s 
management information system, called the Client 
Assignment and Registration system. 
 
Service Coordination (TC06) 
Your local mental health authority provides services that help your child access 
needed resources and services.  For children with less intensive needs, this service 
is called case coordination.  The case coordinator will also coordinate your child’s 
treatment, provide continuity of services, and plan for the services needed by your 
child when he/she completes their treatment. 
 
For children with more intensive needs, the local mental health 
authority/community mental health center provides service coordination to help 
your child access needed medical, social, educational and other appropriate 
services that will help your child achieve a quality of life and community 
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participation acceptable to you and your child.  Service coordinators also 
coordinate your child’s treatment, provide continuity of care and develop a plan 
for the services needed by your child when he/she completes his/her treatment. 
 
Your service coordinator also: 
• Helps you when there is a need for crisis prevention and management, 
by locating and coordinating emergency services in order to prevent 
the crisis from getting worse. 
• Is responsible for monitoring the services your child receives to see if 
the services are effective, or if your child needs additional or different 
services. 
• Is responsible for identifying and arranging for the delivery of the 
services and supports that you have discussed with them and that you 
believe will address the child’s needs and desires. 
 
Skills Training (TC03, TC10, and TC19) 
Rehabilitative Day Treatment (TC03) 
A community-based program that operates during the daytime and provides an 
integrated set of services and supports that focuses on improving the functioning 
and behavior of the child.  Day treatment may include counseling, family training, 




Individual Skills Training (TC10) 
Skills training provides your child the opportunity to learn and improve the skills 
that they need to function as appropriately and independently as possible in the 
community.  Skills training is designed to maintain the child’s quality of life.  
This service includes, but is not limited to activities and training to address their 
mental illness or the problems that result when their symptoms interfere with 
functioning in their living and learning environment.  As much as possible, skills 
training should be done within a natural setting, such as home or school, rather 
than in the center’s offices. 
 
Family Skills Training (TC19) 
Families may also receive skills training.  Family training is provided face-to-face 
to the family of a child to help the family understand the effects and treatment of 
emotional, behavioral and mental disorders.  The training is designed to improve 
the symptoms of the child’s disorder. 
 
Supportive Services (TC05, TC23, and TC24) 
Respite (TC05) 
Respite care is designed to provide a break from the stress that results when 
families are taking care of a child with mental illness every day.  Respite care can 
be either provided in the home by respite staff (called community-based respite 
care) or it can be provided at a temporary residential placement outside the child’s 
 463
usual living situation (called program-based respite care).  Respite services can be 
planned ahead of time or provided in a crisis. 
 
Family-Focused Services (TC23) 
No description of family-focused services was provided by the Texas Department 
of Mental Health and Mental Retardation website. 
 
Flexible Community Support (TC24) 
Supports provided to assist a family and their child to: 
• Identify and use non-clinical/non-professional community resources; 
• Reduce the symptoms of the child’s disorder(s); 
• Maintain the quality of life; and, 
• Promote family integration. 
 
These flexible community supports must be based on the preferences of the child 
and family and focus on the outcomes that you have chosen.  They must also be 
included as strategies in your individualized family plan of care for you and your 
child.  The supports must be unavailable through other Texas Department of 
Mental Health and Mental Retardation funding and not readily available through 
other social services resources, other agencies, natural community supports, 
volunteers or charitable contributions.  Flexible community supports may include: 
mentors; tutors; family aides; specialized camps; temporary child-care; initial job 
development and placement activities; and transportation services. 
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APPENDIX B 
Logistic Regression Analyses of Prevalence Data Regarding 
Antipsychotic Use 
CHILDREN AND ADOLESCENTS ENROLLED IN MEDI-CAL (CA) 
1. Prevalence of Total Antipsychotic Use (H1). 
2. Prevalence of Atypical Antipsychotic Use (H2). 
3. Prevalence of Typical Antipsychotic Use (H3). 
4. Age-Specific Prevalence of Total Antipsychotic Use (H5). 
5. Age-Specific Prevalence of Atypical Antipsychotic Use (H6). 
6. Age-Specific Prevalence of Typical Antipsychotic Use (H7). 
7. Gender-Specific Prevalence of Total Antipsychotic Use (H8). 
8. Gender-Specific Prevalence of Atypical Antipsychotic Use (H9). 
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CHILDREN AND ADOLESCENTS ENROLLED IN OHIO MEDICAID (OH) 
1. Prevalence of Total Antipsychotic Use (H1). 
2. Prevalence of Atypical Antipsychotic Use (H2). 
3. Prevalence of Typical Antipsychotic Use (H3). 
4. Age-Specific Prevalence of Total Antipsychotic Use (H5). 
5. Age-Specific Prevalence of Atypical Antipsychotic Use (H6). 
6. Age-Specific Prevalence of Typical Antipsychotic Use (H7). 
7. Gender-Specific Prevalence of Total Antipsychotic Use (H8). 
8. Gender-Specific Prevalence of Atypical Antipsychotic Use (H9). 
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CHILDREN AND ADOLESCENTS ENROLLED IN TEXAS MEDICAID (TX) 
1. Prevalence of Total Antipsychotic Use (H1). 
2. Prevalence of Atypical Antipsychotic Use (H2). 
3. Prevalence of Typical Antipsychotic Use (H3). 
4. Age-Specific Prevalence of Total Antipsychotic Use (H5). 
5. Age-Specific Prevalence of Atypical Antipsychotic Use (H6). 
6. Age-Specific Prevalence of Typical Antipsychotic Use (H7). 
7. Gender-Specific Prevalence of Total Antipsychotic Use (H8). 
8. Gender-Specific Prevalence of Atypical Antipsychotic Use (H9). 
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CHILDREN AND ADOLESCENTS ENROLLED IN A MANAGED CARE 
ORGANIZATION (MCO) 
1. Prevalence of Total Antipsychotic Use (H1). 
2. Prevalence of Atypical Antipsychotic Use (H2). 
3. Prevalence of Typical Antipsychotic Use (H3). 
4. Age-Specific Prevalence of Total Antipsychotic Use (H5). 
5. Age-Specific Prevalence of Atypical Antipsychotic Use (H6). 
6. Age-Specific Prevalence of Typical Antipsychotic Use (H7). 
7. Gender-Specific Prevalence of Total Antipsychotic Use (H8). 
8. Gender-Specific Prevalence of Atypical Antipsychotic Use (H9). 
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Analyses of Mean Daily Doses of Atypical Antipsychotics in Age 
Categories 
 
CHILDREN AND ADOLESCENTS ENROLLED IN MEDI-CAL (CA) 
Risperidone Dosing Analyses (H11) 
 
AGE <2 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 2 5.1250 1.59099 1.12500 -9.1695 19.4195 4.00 6.25 
1997 6 4.2604 1.64527 .67168 2.5338 5.9870 1.56 6.00 
1998 20 3.3188 2.19180 .49010 2.2930 4.3446 .52 8.00 
1999 17 2.5376 1.75972 .42680 1.6328 3.4424 .42 6.00 
2000 22 2.5723 2.35317 .50170 1.5290 3.6156 .40 8.00 
2001 15 1.7244 1.54308 .39842 .8699 2.5789 .26 5.60 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
1.110 5 76 .362 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 48.616 5 9.723 2.411 .044 
Within Groups 306.508 76 4.033   













AGE 2 – 4 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 8 4.1170 2.30497 .81493 2.1900 6.0441 .50 6.00 
1997 44 2.2220 1.65110 .24891 1.7200 2.7239 .50 6.16 
1998 117 1.9644 1.30577 .12072 1.7253 2.2035 .43 6.02 
1999 155 1.9232 1.32069 .10608 1.7136 2.1327 .25 7.50 
2000 216 1.5304 1.10243 .07501 1.3825 1.6782 .25 6.00 
2001 229 1.4689 1.09093 .07209 1.3268 1.6109 .25 6.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
5.997 5 763 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 92.634 5 18.527 12.255 .000 
Within Groups 1153.459 763 1.512   
Total 1246.093 768    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 .4955 .14061 .007 .0157 .9753 





















AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 90 2.4740 1.34743 .14203 2.1918 2.7563 .50 6.00 
1997 309 1.9597 1.17037 .06658 1.8287 2.0907 .48 6.00 
1998 1010 1.7910 1.06662 .03356 1.7251 1.8568 .30 6.00 
1999 1689 1.7803 1.12049 .02726 1.7268 1.8338 .25 6.00 
2000 2549 1.6177 1.09902 .02177 1.5750 1.6604 .25 6.00 
2001 3228 1.5343 1.11271 .01958 1.4960 1.5727 .25 6.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
3.073 5 8869 .009 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 184.684 5 36.937 29.989 .000 
Within Groups 10923.707 8869 1.232   
Total 11108.391 8874    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 1998 .6830 .14594 .000 .1777 1.1884 
 1999 .6937 .14463 .000 .1924 1.1950 
 2000 .8563 .14369 .000 .3579 1.3548 
 2001 .9397 .14338 .000 .4422 1.4372 
1997 2000 .3420 .07005 .000 .1046 .5794 
 2001 .4254 .06940 .000 .1901 .6607 
1998 2000 .1733 .04000 .000 .0385 .3081 
 2001 .2566 .03886 .000 .1257 .3876 
1999 2000 .1626 .03489 .000 .0452 .2801 













AGE 10 – 14 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 250 2.8783 1.55256 .09819 2.6849 3.0717 .50 6.67 
1997 722 2.5377 1.53274 .05704 2.4257 2.6496 .50 7.00 
1998 1819 2.2373 1.30812 .03067 2.1771 2.2974 .50 6.67 
1999 2806 2.1366 1.24132 .02343 2.0906 2.1825 .50 7.00 
2000 3901 2.0178 1.25752 .02013 1.9783 2.0573 .50 7.00 
2001 4822 1.9075 1.26683 .01824 1.8717 1.9432 .50 7.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
26.844 5 14314 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 522.472 5 104.494 63.294 .000 
Within Groups 23631.384 14314 1.651   
Total 24153.856 14319    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 1998 .6410 .10287 .000 .2917 .9904 
 1999 .7417 .10095 .000 .3987 1.0848 
 2000 .8605 .10024 .000 .5198 1.2013 
 2001 .9709 .09987 .000 .6313 1.3104 
1997 1998 .3004 .06477 .000 .0820 .5188 
 1999 .4011 .06167 .000 .1930 .6091 
 2000 .5199 .06049 .000 .3157 .7240 
 2001 .6302 .05989 .000 .4281 .8323 
1998 2000 .2195 .03669 .000 .0960 .3430 
 2001 .3298 .03569 .000 .2097 .4500 
1999 2000 .1188 .03090 .002 .0148 .2228 
 2001 .2291 .02970 .000 .1292 .3291 











AGE 15 – 19 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 491 4.1182 1.95707 .08832 3.9446 4.2917 .50 9.00 
1997 955 3.5045 1.99894 .06468 3.3776 3.6315 .50 9.00 
1998 1871 3.0337 1.79557 .04151 2.9523 3.1152 .50 9.00 
1999 2300 2.8357 1.74582 .03640 2.7643 2.9071 .50 9.00 
2000 2885 2.6696 1.66971 .03109 2.6086 2.7305 .50 9.00 
2001 3322 2.5730 1.67041 .02898 2.5162 2.6298 .50 9.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
25.272 5 11818 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 1610.057 5 322.011 105.616 .000 
Within Groups 36031.596 11818 3.049   
Total 37641.653 11823    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 1997 .6137 .10947 .000 .2444 .9829 
 1998 1.0844 .09759 .000 .7548 1.4140 
 1999 1.2825 .09553 .000 .9597 1.6052 
 2000 1.4486 .09363 .000 1.1322 1.7650 
 2001 1.5452 .09295 .000 1.2310 1.8593 
1997 1998 .4708 .07686 .000 .2118 .7297 
 1999 .6688 .07422 .000 .4187 .9189 
 2000 .8349 .07177 .000 .5931 1.0768 
 2001 .9315 .07088 .000 .6926 1.1704 
1998 1999 .1980 .05521 .005 .0122 .3839 
 2000 .3642 .05186 .000 .1896 .5388 
 2001 .4608 .05063 .000 .2903 .6312 
1999 2000 .1661 .04787 .007 .0050 .3273 






Olanzapine Dosing Analyses (H12) 
 
 
AGE <2 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 4 5.6250 3.14576 1.57288 .6194 10.6306 2.50 10.00 
1998 14 9.8903 6.79883 1.81706 5.9648 13.8159 2.50 24.06 
1999 25 11.2432 8.91052 1.78210 7.5652 14.9213 2.50 40.00 
2000 17 11.6490 8.11759 1.96880 7.4753 15.8227 2.50 30.30 
2001 14 11.7866 10.26226 2.74270 5.8613 17.7118 2.50 40.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.047 4 69 .389 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 149.030 4 37.258 .518 .722 
Within Groups 4959.542 69 71.877   



























AGE 2 – 4 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 1 10.0000 . . . . 10.00 10.00 
1997 11 8.7879 7.57705 2.28457 3.6976 13.8782 2.50 30.00 
1998 39 9.4614 5.76360 .92291 7.5931 11.3297 2.50 30.00 
1999 45 10.2474 7.28720 1.08631 8.0580 12.4367 2.50 30.00 
2000 50 7.7926 5.12179 .72433 6.3370 9.2482 2.50 20.00 
2001 56 7.5398 4.61473 .61667 6.3039 8.7756 2.50 20.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
2.026 5 196 .077 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 248.298 5 49.660 1.468 .202 
Within Groups 6629.654 196 33.825   






























AGE 5 – 9 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 4 7.9167 4.33013 2.16506 1.0265 14.8069 2.50 12.50 
1997 67 6.4815 4.04070 .49365 5.4959 7.4671 2.50 20.00 
1998 255 6.9350 4.07778 .25536 6.4321 7.4378 2.50 20.00 
1999 368 6.7522 4.16990 .21737 6.3247 7.1796 2.50 20.00 
2000 605 6.2769 3.90250 .15866 5.9653 6.5885 2.50 20.00 
2001 758 6.5085 3.98443 .14472 6.2244 6.7926 2.50 20.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
.722 5 196 .077 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 106.777 5 21.355 1.329 .249 
Within Groups 32955.369 2051 16.068   






























AGE 10 – 14 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 5 8.0000 2.73861 1.22474 4.5996 11.4004 5.00 10.00 
1997 181 8.9882 4.41030 .32781 8.3413 9.6350 2.50 20.15 
1998 804 8.0984 4.59853 .16218 7.7801 8.4168 2.50 20.61 
1999 1117 7.8025 4.56865 .13670 7.5343 8.0707 2.50 20.67 
2000 1485 7.6990 4.53391 .11765 7.4682 7.9298 2.50 20.39 
2001 1748 7.3776 4.40738 .10542 7.1709 7.5844 2.50 20.67 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
1.166 5 5334 .323 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 619.756 5 123.951 6.108 .000 
Within Groups 108246.575 5334 20.294   
Total 108866.332 5339    
 
Post Hoc Analysis 
Scheffe  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound






















AGE 15 – 19 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 24 11.1354 2.75782 .56294 9.9709 12.2999 7.75 20.00 
1997 510 10.8180 5.34780 .23680 10.3528 11.2833 2.50 30.00 
1998 1524 10.2364 5.50619 .14105 9.9598 10.5131 2.50 30.00 
1999 1958 10.0746 5.64991 .12768 9.8242 10.3250 2.50 30.00 
2000 2249 9.8226 5.91108 .12464 9.5781 10.0670 2.50 30.00 
2001 2414 10.0730 6.01269 .12238 9.8330 10.3130 2.50 30.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
6.870 5 8673 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 490.911 5 98.182 2.945 .012 
Within Groups 289159.161 8673 33.340   














Quetiapine Dosing Analyses (H13) 
 
AGE <2 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 3 143.0556 141.56451 81.73231 -208.6102 494.7213 25.00 300.00 
1999 2 35.4167 14.73139 10.41667 -96.9396 167.7730 25.00 45.83 
2000 3 179.5274 148.82956 85.92678 -190.1857 549.2405 25.00 321.92 
2001 3 186.1915 167.06856 96.45708 -228.8298 601.2128 25.00 358.57 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
1.019 3 7 .440 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 32694.570 3 10898.190 .543 .668 
Within Groups 140422.313 7 20060.330   




























AGE 2 – 4 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 2 125.0000 106.06602 75.00000 -827.9654 1077.9654 50.00 200.00 
1999 9 286.6021 317.64476 105.88159 42.4388 530.7655 45.83 800.00 
2000 18 163.7205 128.70145 30.33522 99.7188 227.7223 37.50 500.00 
2001 34 164.5088 161.01729 27.61424 108.3272 220.6904 25.00 782.61 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
5.304 3 59 .003 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 121241.704 3 40413.901 1.219 .311 
Within Groups 1955601.380 59 33145.786   































AGE 5 – 9 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 1 250.0000 . . . . 250.00 250.00 
1998 35 193.9234 141.86511 23.97958 145.1910 242.6558 25.00 600.00 
1999 111 133.9920 121.22049 11.50574 111.1903 156.7937 25.00 600.00 
2000 242 146.5170 117.09263 7.52700 131.6899 161.3441 25.00 600.00 
2001 430 165.5974 131.94724 6.36306 153.0907 178.1040 25.00 600.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
2.184 4 814 .069 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 173503.214 4 43375.804 2.701 .030 
Within Groups 13073856.014 814 16061.248   































AGE 10 – 14 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 109 207.7942 147.11982 14.09152 179.8624 235.7261 25.00 742.38 
1999 326 194.3966 165.23454 9.15149 176.3930 212.4002 25.00 800.07 
2000 573 225.9943 173.58261 7.25152 211.7515 240.2372 25.00 810.26 
2001 1070 222.6013 180.75307 5.52578 211.7587 233.4439 25.00 900.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
4.307 3 2074 .005 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 252014.674 3 84004.891 2.749 .041 
Within Groups 63371779.983 2074 30555.342   






























AGE 15 – 19 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 2 260.7143 196.97975 139.28571 -1509.0785 2030.5071 121.43 400.00 
1998 154 219.8745 163.82371 13.20129 193.7942 245.9549 25.00 800.00 
1999 481 241.9398 177.43389 8.09029 226.0430 257.8365 25.00 810.56 
2000 726 250.3473 189.71938 7.04115 236.5238 264.1707 25.00 836.73 
2001 1253 258.4873 195.73336 5.52954 247.6391 269.3355 25.00 900.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
4.836 4 2611 .001 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 259400.517 4 64850.129 1.814 .123 
Within Groups 93318088.544 2611 35740.363   















CHILDREN AND ADOLESCENTS ENROLLED IN OHIO MEDICAID (OH) 
Risperidone Dosing Analyses (H11) 
 
AGE <2 YEARS 
 
Descriptives 
  Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 1 6.0000 . . . . 6.00 6.00 
1997 2 2.4667 2.16846 1.53333 -17.0162 21.9495 .93 4.00 
1998 3 .3778 .21170 .12222 -.1481 .9037 .13 .50 
1999 15 2.7164 1.68992 .43634 1.7806 3.6523 .53 6.00 
2000 32 1.5048 1.58491 .28017 .9334 2.0762 .15 6.00 
2001 38 1.7411 1.33885 .21719 1.3010 2.1811 .26 4.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
1.347 5 85 .252 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 39.994 5 7.999 3.598 .005 
Within Groups 188.966 85 2.223   
Total 228.960 90    
 























AGE 2 – 4 YEARS 
 
Descriptives 
  Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 15 2.1800 .95758 .24725 1.6497 2.7103 .50 3.33 
1997 39 1.3821 .62674 .10036 1.1789 1.5852 .50 3.33 
1998 147 1.2526 .69540 .05736 1.1393 1.3660 .33 4.00 
1999 270 1.3337 .79622 .04846 1.2383 1.4291 .25 4.00 
2000 449 1.1905 .77653 .03665 1.1185 1.2625 .25 4.00 
2001 596 .9640 .63939 .02619 .9126 1.0154 .25 4.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
9.256 5 1510 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 50.017 5 10.003 19.309 .000 
Within Groups 782.293 1510 .518   
Total 832.311 1515    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 2001 1.2160 .24863 .002 .1871 2.2449 
1997 2001 .4180 .10372 .003 .0451 .7910 
1998 2001 .2886 .06305 .000 .0736 .5036 
1999 2001 .3697 .05508 .000 .1832 .5562 


















AGE 5 – 9 YEARS 
 
Descriptives 
  Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 455 1.3025 .73307 .03437 1.2349 1.3700 .27 4.00 
1997 1549 1.4213 .75523 .01919 1.3836 1.4589 .27 4.00 
1998 2944 1.5410 .87121 .01606 1.5095 1.5725 .27 4.00 
1999 4668 1.5399 .89568 .01311 1.5142 1.5656 .25 4.00 
2000 6803 1.3422 .86140 .01044 1.3217 1.3627 .25 4.00 
2001 8178 1.2544 .86244 .00954 1.2357 1.2731 .25 4.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
14.896 5 24591 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 339.701 5 67.940 91.626 .000 
Within Groups 18234.039 24591 .741   
Total 18573.740 24596    
 
Post Hoc Analysis 
Games-Howell 
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 1998 -.2385 .03793 .000 -.3667 -.1104 
 1999 -.2374 .03678 .000 -.3618 -.1131 
1997 1998 -.1197 .02502 .000 -.2040 -.0355 
 1999 -.1186 .02324 .000 -.1969 -.0404 
 2000 .0791 .02185 .004 .0055 .1527 
 2001 .1669 .02143 .000 .0947 .2390 
1998 2000 .1988 .01915 .000 .1344 .2633 
 2001 .2866 .01868 .000 .2237 .3494 
1999 2000 .1977 .01676 .000 .1413 .2541 
 2001 .2855 .01621 .000 .2309 .3400 












AGE 10 – 14 YEARS 
 
Descriptives 
  Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 1394 1.8734 1.19669 .03205 1.8105 1.9363 .27 6.00 
1997 3278 1.8535 1.19038 .02079 1.8127 1.8942 .27 6.00 
1998 5278 1.8558 1.19652 .01647 1.8235 1.8881 .27 6.00 
1999 7128 1.7912 1.15971 .01374 1.7642 1.8181 .25 6.00 
2000 10245 1.6423 1.09407 .01081 1.6211 1.6635 .25 6.00 
2001 12117 1.5392 1.08967 .00990 1.5198 1.5586 .25 6.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
5.439 5 39434 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 651.315 5 130.263 101.866 .000 
Within Groups 50426.796 39434 1.279   
Total 51078.111 39439    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 2000 .2311 .03383 .000 .1171 .3450 
 2001 .3342 .03355 .000 .2212 .4473 
1997 2000 .2111 .02343 .000 .1323 .2900 
 2001 .3143 .02303 .000 .2368 .3918 
1998 2000 .2134 .01970 .000 .1472 .2797 
 2001 .3166 .01922 .000 .2520 .3813 
1999 2000 .1488 .01748 .000 .0900 .2076 
 2001 .2520 .01693 .000 .1950 .3090 














AGE 15 – 19 YEARS 
 
Descriptives 
  Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 1700 2.2600 1.51694 .03679 2.1878 2.3321 .20 6.00 
1997 2835 2.2517 1.45700 .02736 2.1980 2.3053 .20 6.00 
1998 3965 2.2189 1.43473 .02278 2.1742 2.2636 .20 6.00 
1999 4527 2.1352 1.44962 .02155 2.0930 2.1774 .18 6.00 
2000 6012 1.9214 1.35642 .01749 1.8871 1.9557 .18 6.00 
2001 6834 1.8119 1.36321 .01649 1.7795 1.8442 .18 6.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
13.906 5 25867 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 816.514 5 163.303 82.256 .000 
Within Groups 51353.674 25867 1.985   
Total 52170.188 25872    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 2000 .3386 .04074 .000 .2014 .4758 
 2001 .4481 .04032 .000 .3123 .5839 
1997 2000 .3303 .03248 .000 .2210 .4396 
 2001 .4398 .03195 .000 .3323 .5474 
1998 2000 .2975 .02873 .000 .2008 .3942 
 2001 .4070 .02813 .000 .3124 .5017 
1999 2000 .2138 .02775 .000 .1204 .3072 
 2001 .3233 .02713 .000 .2321 .4146 







Olanzapine Dosing Analyses (H12) 
 
AGE <2 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 1 5.0000 . . . . 5.00 5.00 
1997 8 10.7500 5.07327 1.79367 6.5086 14.9914 2.33 20.00 
1998 24 5.8681 3.21792 .65686 4.5092 7.2269 .83 10.00 
1999 39 6.9487 3.31445 .53074 5.8743 8.0231 1.17 10.00 
2000 55 6.6167 4.17581 .56307 5.4878 7.7455 .83 18.67 
2001 27 11.3519 6.36620 1.22518 8.8335 13.8702 2.50 20.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
7.985 5 148 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 607.866 5 121.573 6.355 .000 
Within Groups 2831.145 148 19.129   
Total 3439.011 153    
 


























AGE 2 – 4 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 2 5.0000 .00000 .00000 5.0000 5.0000 5.00 5.00 
1998 14 9.3750 5.85789 1.56559 5.9928 12.7572 1.25 15.00 
1999 36 4.3981 2.63795 .43966 3.5056 5.2907 1.67 15.00 
2000 64 4.4987 2.76104 .34513 3.8090 5.1884 1.25 10.00 
2001 176 4.7259 2.71809 .20488 4.3216 5.1303 1.25 15.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
10.686 4 287 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 304.630 4 76.158 8.875 .000 
Within Groups 2462.820 287 8.581   
Total 2767.450 291    
 
Post Hoc Analysis 
Games-Howell 



























AGE 5 – 9 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 5 7.6000 2.37346 1.06145 4.6530 10.5470 5.00 9.33 
1997 134 5.0399 2.78331 .24044 4.5643 5.5154 1.25 10.00 
1998 587 5.3024 2.81890 .11635 5.0739 5.5309 1.25 15.00 
1999 715 5.2265 2.71495 .10153 5.0271 5.4258 1.25 15.00 
2000 1304 5.2181 2.74538 .07603 5.0689 5.3672 1.25 15.00 
2001 2522 5.4600 3.09667 .06166 5.3391 5.5809 1.25 15.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
9.228 5 5261 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 103.328 5 20.666 2.418 .034 
Within Groups 44967.851 5261 8.547   






























AGE 10 – 14 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 18 7.0556 2.65684 .62622 5.7343 8.3768 2.33 10.33 
1997 660 6.7462 3.54209 .13788 6.4755 7.0170 .83 20.00 
1998 1490 7.0535 4.30837 .11161 6.8346 7.2724 .83 20.00 
1999 1691 6.4124 4.03395 .09810 6.2199 6.6048 .83 20.00 
2000 3010 6.4980 4.09885 .07471 6.3515 6.6445 .83 20.00 
2001 4753 7.0757 4.53987 .06585 6.9466 7.2048 .83 20.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
25.975 5 11616 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 988.017 5 197.603 10.826 .000 
Within Groups 212021.363 11616 18.253   
Total 213009.380 11621    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 .6411 .14860 .000 .1408 1.1415 
 2000 .5555 .13431 .001 .1033 1.0077 
1999 2001 -.6633 .11815 .000 -1.0611 -.2656 



















AGE 15 – 19 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 70 8.0940 4.41602 .52781 7.0411 9.1470 1.67 20.00 
1997 1562 8.1253 4.67075 .11818 7.8935 8.3571 .75 20.00 
1998 2449 8.3021 5.23065 .10570 8.0948 8.5093 .75 20.00 
1999 2864 7.9703 5.12241 .09572 7.7826 8.1580 .75 20.00 
2000 3412 8.1386 5.06710 .08675 7.9685 8.3087 .83 20.00 
2001 4362 7.7383 5.02408 .07607 7.5891 7.8874 .75 20.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
6.532 5 14713 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 613.041 5 122.608 4.808 .000 
Within Groups 375156.138 14713 25.498   
Total 375769.179 14718    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 .5638 .13022 .000 .1255 1.0021 










Quetiapine Dosing Analyses (H13) 
 
AGE <2 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 2 50.0000 .00000 .00000 50.0000 50.0000 50.00 50.00 
1999 1 300.0000 . . . . 300.00 300.00 
2000 52 69.4551 41.76325 5.79152 57.8282 81.0821 5.83 200.00 
2001 6 100.0000 77.48118 31.63156 18.6885 181.3115 46.67 200.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
5.988 3 57 .001 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 57201.731 3 19067.244 9.135 .000 
Within Groups 118969.284 57 2087.180   
Total 176171.015 60    
 



























AGE 2 – 4 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 2 25.0000 .00000 .00000 25.0000 25.0000 25.00 25.00 
1999 13 63.7821 54.99854 15.25385 30.5468 97.0173 12.50 200.00 
2000 57 99.9896 100.05481 13.25258 73.4414 126.5377 20.00 400.00 
2001 125 73.7867 72.23297 6.46071 60.9991 86.5742 12.50 400.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
2.773 3 193 .043 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 37062.256 3 12354.085 1.917 .128 
Within Groups 1243894.760 193 6445.051   































AGE 5 – 9 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 124 78.2508 67.90725 6.09825 66.1797 90.3219 23.33 400.00 
1999 687 111.1303 95.90658 3.65906 103.9460 118.3146 23.33 400.00 
2000 1159 113.5517 95.62311 2.80880 108.0407 119.0626 20.83 400.00 
2001 1886 125.2368 100.41928 2.31231 120.7018 129.7717 20.83 400.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
13.837 3 3852 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 349701.220 3 116567.073 12.311 .000 
Within Groups 36473974.584 3852 9468.841   
Total 36823675.804 3855    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 -32.8795 7.11178 .000 -55.2741 -10.4849 
 2000 -35.3009 6.71402 .000 -56.5001 -14.1016 
 2001 -46.9860 6.52192 .000 -67.6135 -26.3585 
1999 2001 -14.1065 4.32846 .006 -27.6089 -.6041 




















AGE 10 – 14 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 4 185.4167 106.80005 53.40002 15.4740 355.3594 41.67 300.00 
1998 407 105.3403 90.73382 4.49751 96.4989 114.1816 13.33 500.00 
1999 1620 140.1814 126.01645 3.13090 134.0403 146.3224 13.33 600.00 
2000 3136 158.3942 136.48953 2.43731 153.6153 163.1731 13.33 600.00 
2001 4927 158.7384 140.60963 2.00320 154.8113 162.6656 13.33 600.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
40.829 4 10089 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 1445737.227 4 361434.307 19.723 .000 
Within Groups 184882053.136 10089 18325.112   
Total 186327790.363 10093    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 -34.8411 5.47998 .000 -52.7341 -16.9482 
 2000 -53.0539 5.11547 .000 -69.7705 -36.3374 
 2001 -53.3982 4.92345 .000 -69.4974 -37.2989 
1999 2000 -18.2128 3.96775 .000 -31.1366 -5.2890 



















AGE 15 – 19 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 10 142.9167 112.80052 35.67066 62.2240 223.6093 12.50 300.00 
1998 592 148.1929 141.19183 5.80295 136.7960 159.5898 12.50 666.67 
1999 1364 179.6938 168.82479 4.57119 170.7265 188.6611 12.50 666.67 
2000 2513 186.6646 161.78129 3.22725 180.3363 192.9929 12.50 666.67 
2001 3975 183.8045 160.01436 2.53799 178.8286 188.7804 12.50 666.67 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
8.776 4 8449 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 764197.288 4 191049.322 7.396 .000 
Within Groups 218243858.306 8449 25830.732   
Total 219008055.593 8453    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 -31.5009 7.38715 .000 -55.5928 -7.4090 
 2000 -38.4717 6.63998 .000 -60.1420 -16.8015 










CHILDREN AND ADOLESCENTS ENROLLED IN TEXAS MEDICAID (TX) 
Risperidone Dosing Analyses (H11) 
 
AGE <2 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 10 1.9237 1.39294 .44049 .9272 2.9201 .50 5.00 
1997 21 1.4080 .92813 .20254 .9855 1.8305 .33 4.00 
1998 21 1.6961 1.23113 .26865 1.1357 2.2565 .48 5.00 
1999 33 1.4604 1.17349 .20428 1.0443 1.8765 .25 5.00 
2000 42 1.2923 .89223 .13767 1.0143 1.5703 .25 3.69 
2001 57 1.1112 .97399 .12901 .8528 1.3696 .25 5.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
.940 5 178 .456 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 9.653 5 1.931 1.764 .123 
Within Groups 194.836 178 1.095   

























AGE 2 – 4 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 143 1.4120 .68532 .05731 1.2987 1.5253 .50 3.93 
1997 300 1.4378 .83010 .04793 1.3435 1.5321 .25 5.00 
1998 384 1.4423 .84048 .04289 1.3579 1.5266 .25 5.00 
1999 483 1.3221 .84348 .03838 1.2467 1.3975 .25 5.00 
2000 681 1.1552 .85059 .03259 1.0912 1.2192 .25 5.00 
2001 942 1.0274 .72841 .02373 .9808 1.0740 .25 5.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
5.738 5 2927 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 81.306 5 16.261 25.352 .000 
Within Groups 1877.462 2927 .641   
Total 1958.768 2932    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 2000 .2568 .06593 .002 .0324 .4812 
 2001 .3846 .06203 .000 .1728 .5963 
1997 2000 .2826 .05796 .000 .0867 .4786 
 2001 .4104 .05348 .000 .2294 .5914 
1998 2000 .2871 .05387 .000 .1052 .4689 
 2001 .4149 .04902 .000 .2492 .5805 
















AGE 5 – 9 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 919 1.7882 1.02703 .03388 1.7217 1.8547 .25 6.00 
1997 1712 1.7150 1.01538 .02454 1.6669 1.7631 .25 6.00 
1998 2371 1.6831 .99658 .02047 1.6429 1.7232 .25 6.00 
1999 2807 1.6134 .97369 .01838 1.5773 1.6494 .25 6.00 
2000 3733 1.4870 .99929 .01636 1.4549 1.5190 .25 6.00 
2001 4250 1.4275 .99747 .01530 1.3975 1.4575 .25 6.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
.768 5 15786 .573 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 226.994 5 45.399 45.646 .000 
Within Groups 15700.595 15786 .995   
Total 15927.588 15791    
 
Post Hoc Analysis 
Scheffe 
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 1999 .1749 .03790 .001 .0276 .3221 
 2000 .3012 .03672 .000 .1586 .4439 
 2001 .3607 .03628 .000 .2197 .5016 
1997 2000 .2280 .02911 .000 .1149 .3411 
 2001 .2875 .02855 .000 .1766 .3984 
1998 2000 .1961 .02619 .000 .0944 .2978 
 2001 .2556 .02556 .000 .1563 .3549 
1999 2000 .1264 .02491 .000 .0296 .2232 














AGE 10 – 14 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 1200 2.2386 1.26460 .03651 2.1670 2.3102 .50 6.00 
1997 2144 2.0404 1.22545 .02647 1.9885 2.0923 .50 6.00 
1998 2907 2.0344 1.20518 .02235 1.9905 2.0782 .50 6.00 
1999 3424 1.9451 1.15580 .01975 1.9064 1.9839 .50 6.00 
2000 4116 1.8573 1.17130 .01826 1.8215 1.8931 .50 6.00 
2001 5081 1.7981 1.18806 .01667 1.7654 1.8308 .50 6.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
3.391 5 18866 .005 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 283.040 5 56.608 39.932 .000 
Within Groups 26744.991 18866 1.418   
Total 27028.032 18871    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 1997 .1982 .04509 .000 .0463 .3500 
 1998 .2042 .04281 .000 .0600 .3484 
 1999 .2935 .04151 .000 .1537 .4333 
 2000 .3813 .04082 .000 .2438 .5188 
 2001 .4405 .04013 .000 .3053 .5757 
1997 2000 .1832 .03215 .000 .0749 .2914 
 2001 .2423 .03128 .000 .1370 .3476 
1998 2000 .1771 .02886 .000 .0800 .2742 
 2001 .2363 .02788 .000 .1424 .3301 













AGE 15 – 19 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 664 2.9811 1.70516 .06617 2.8512 3.1110 .50 8.00 
1997 982 2.7221 1.64737 .05257 2.6190 2.8253 .50 8.00 
1998 1220 2.5991 1.59002 .04552 2.5098 2.6884 .50 8.00 
1999 1475 2.4778 1.53527 .03998 2.3994 2.5563 .50 8.00 
2000 1723 2.3281 1.50481 .03625 2.2570 2.3992 .50 8.00 
2001 2024 2.3244 1.55258 .03451 2.2567 2.3921 .50 8.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
10.901 5 8082 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 328.100 5 65.620 26.621 .000 
Within Groups 19921.926 8082 2.465   
Total 20250.026 8087    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 1998 .3820 .08032 .000 .1112 .6528 
 1999 .5032 .07731 .000 .2426 .7639 
 2000 .6530 .07545 .000 .3985 .9075 
 2001 .6567 .07463 .000 .4050 .9084 
1997 1999 .2443 .06604 .003 .0218 .4667 
 2000 .3940 .06386 .000 .1789 .6092 
 2001 .3977 .06289 .000 .1859 .6096 
1998 2000 .2710 .05819 .000 .0751 .4670 







Olanzapine Dosing Analyses (H12) 
 
AGE <2 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 1 10.0000 . . . . 10.00 10.00 
1998 7 5.9821 2.88353 1.08987 3.3153 8.6490 2.50 10.00 
1999 6 7.2917 3.20319 1.30770 3.9301 10.6532 2.50 10.00 
2000 13 6.3365 4.03416 1.11887 3.8987 8.7744 2.00 15.00 
2001 7 5.0434 2.77490 1.04881 2.4770 7.6097 2.50 10.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
.983 4 29 .432 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 31.345 4 7.836 .663 .623 
Within Groups 342.684 29 11.817   




























AGE 2 – 4 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 2 3.7500 1.76777 1.25000 -12.1328 19.6328 2.50 5.00 
1997 15 7.3083 4.15569 1.07300 5.0070 9.6097 2.50 15.00 
1998 60 4.7101 2.77140 .35779 3.9942 5.4261 1.25 15.00 
1999 110 4.7875 2.59143 .24708 4.2978 5.2772 1.25 13.13 
2000 161 4.6328 2.94105 .23179 4.1750 5.0906 1.25 15.00 
2001 259 4.7558 2.82562 .17558 4.4100 5.1015 1.25 15.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
2.321 5 601 .042 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 101.938 5 20.388 2.514 .029 
Within Groups 4873.923 601 8.110   






























AGE 5 – 9 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 19 7.7030 3.97279 .91142 5.7882 9.6178 2.50 17.50 
1997 227 6.7292 3.37513 .22402 6.2878 7.1706 2.50 20.00 
1998 491 5.9699 3.17127 .14312 5.6887 6.2511 2.50 20.00 
1999 853 5.8416 3.57965 .12256 5.6010 6.0821 2.50 20.00 
2000 1241 5.7925 3.55209 .10083 5.5946 5.9903 2.50 20.00 
2001 1626 6.1302 3.64757 .09046 5.9528 6.3077 2.50 20.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
2.163 5 4451 .055 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 278.702 5 55.740 4.433 .000 
Within Groups 55969.708 4451 12.575   
Total 56248.410 4456    
 
Post Hoc Analysis 
Scheffe  



























AGE 10 – 14 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 36 9.7230 3.88693 .64782 8.4079 11.0382 2.50 20.00 
1997 464 8.1024 3.80016 .17642 7.7557 8.4490 2.50 25.00 
1998 941 7.5186 3.96894 .12938 7.2647 7.7725 2.50 25.00 
1999 1421 7.4402 4.30240 .11413 7.2163 7.6641 2.50 25.00 
2000 1770 7.3145 4.26774 .10144 7.1156 7.5135 2.50 25.00 
2001 2236 7.3456 4.31787 .09131 7.1665 7.5246 2.50 25.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
3.943 5 6862 .001 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 444.687 5 88.937 4.994 .000 
Within Groups 122196.729 6862 17.808   
Total 122641.416 6867    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 2000 2.4085 .65572 .009 .0216 4.7955 
 2001 2.3775 .65423 .010 -.0058 4.7607 
1997 2000 .7878 .20350 .002 .1008 1.4748 



















AGE 15 – 19 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 28 11.9459 5.58304 1.05510 9.7811 14.1108 5.00 22.50 
1997 369 9.8892 4.58924 .23891 9.4194 10.3590 2.50 24.52 
1998 634 9.8476 5.04746 .20046 9.4539 10.2412 2.50 30.00 
1999 801 9.5919 5.57623 .19703 9.2052 9.9787 2.50 30.00 
2000 994 9.6249 5.92935 .18807 9.2558 9.9939 2.50 30.00 
2001 1221 9.7141 6.09972 .17456 9.3716 10.0565 2.50 30.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
13.039 5 4041 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 181.802 5 36.360 1.131 .341 
Within Groups 129897.434 4041 32.145   














Quetiapine Dosing Analyses (H13) 
 
AGE <2 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1 25.0000 . . . . 25.00 25.00 
1999 2 50.0000 .00000 .00000 50.0000 50.0000 50.00 50.00 
2001 9 89.3807 90.14632 30.04877 20.0881 158.6733 14.58 307.14 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.268 2 9 .327 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 5539.077 2 2769.538 .383 .692 
Within Groups 65010.879 9 7223.431   






























AGE 2 – 4 YEARS 
 
Descriptives  
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 4 107.8125 44.88846 22.44423 36.3849 179.2401 50.00 156.25 
1998 15 58.3081 46.66359 12.04849 32.4666 84.1495 25.00 183.33 
1999 52 79.4056 55.46015 7.69094 63.9654 94.8458 25.00 300.00 
2000 61 101.4864 99.80197 12.77833 75.9260 127.0469 25.00 400.00 
2001 107 113.4307 77.92426 7.53322 98.4954 128.3661 25.00 400.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.154 4 234 .015 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 67729.121 4 16932.280 2.762 .028 
Within Groups 1434675.218 234 6131.091   






























AGE 5 – 9 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 20 80.9375 61.08514 13.65905 52.3488 109.5262 25.00 300.00 
1998 124 70.8748 73.81509 6.62879 57.7535 83.9960 25.00 500.00 
1999 366 98.0226 79.36483 4.14847 89.8647 106.1805 25.00 450.00 
2000 530 114.0851 91.85933 3.99011 106.2467 121.9235 25.00 500.00 
2001 894 125.4230 96.18279 3.21683 119.1096 131.7364 25.00 500.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
12.616 4 1929 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 461242.494 4 115310.624 14.109 .000 
Within Groups 15765167.461 1929 8172.715   
Total 16226409.955 1933    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 -27.1478 7.81989 .006 -52.9062 -1.3894 
 2000 -43.2103 7.73705 .000 -68.7028 -17.7179 
 2001 -54.5482 7.36810 .000 -78.8815 -30.2149 




















AGE 10 – 14 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 27 145.8854 106.55795 20.50709 103.7325 188.0384 25.00 357.14 
1998 227 129.2808 115.30663 7.65317 114.2001 144.3615 25.00 600.00 
1999 597 141.2365 112.84895 4.61860 132.1658 150.3073 25.00 600.00 
2000 910 157.8989 122.63987 4.06547 149.9201 165.8777 25.00 600.00 
2001 1567 162.1882 126.81847 3.20367 155.9042 168.4721 25.00 600.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
4.103 4 3323 .003 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 354056.204 4 88514.051 5.912 .000 
Within Groups 49747730.352 3323 14970.728   
Total 50101786.557 3327    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -28.6181 8.66597 .009 -57.0340 -.2022 
 2001 -32.9074 8.29666 .001 -60.1474 -5.6675 





















AGE 15 – 19 YEARS 
 
Descriptives  
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 10 104.4776 116.83283 36.94578 20.9004 188.0548 25.00 400.00 
1998 119 156.7365 129.52581 11.87361 133.2235 180.2495 25.00 500.00 
1999 304 188.2831 142.84165 8.19253 172.1617 204.4046 25.00 800.00 
2000 474 210.2616 169.05434 7.76492 195.0036 225.5197 25.00 800.00 
2001 789 217.3037 178.80541 6.36564 204.8081 229.7993 25.00 800.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
5.770 4 1691 .000 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 595677.099 4 148919.275 5.358 .000 
Within Groups 46996346.637 1691 27792.044   
Total 47592023.736 1695    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -53.5251 14.18720 .002 -100.2487 -6.8016 











CHILDREN AND ADOLESCENTS ENROLLED IN A MANAGED CARE 
ORGANIZATION (MCO) 
Risperidone Dosing Analyses (H11) 
 
AGE <2 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 2 2.1667 1.64992 1.16667 -12.6572 16.9906 1.00 3.33 
1997 5 1.5164 .99346 .44429 .2829 2.7500 .55 3.00 
1998 6 2.4583 1.53636 .62722 .8460 4.0706 1.00 5.00 
1999 3 1.5667 1.43643 .82932 -2.0016 5.1350 .50 3.20 
2000 7 2.7857 2.44706 .92490 .5226 5.0489 1.00 8.00 
2001 2 1.0000 .70711 .50000 -5.3531 7.3531 .50 1.50 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.512 5 19 .764 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 9.042 5 1.808 .582 .713 
Within Groups 59.027 19 3.107   
























AGE 2 – 4 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 6 1.1056 .51008 .20824 .5703 1.6409 .50 2.00 
1997 8 2.1302 1.66150 .58743 .7412 3.5193 .50 5.00 
1998 28 1.8641 1.35762 .25657 1.3377 2.3906 .50 6.00 
1999 53 1.4236 .99777 .13705 1.1485 1.6986 .25 4.67 
2000 41 1.1098 .86923 .13575 .8354 1.3842 .25 4.00 
2001 38 1.0165 .79123 .12835 .7564 1.2766 .25 3.70 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
5.613 5 168 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 19.508 5 3.902 3.734 .003 
Within Groups 175.544 168 1.045   
Total 195.052 173    
 
Post Hoc Analysis 
Games-Howell  


























AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 53 1.7398 .73563 .10105 1.5370 1.9425 .50 4.00 
1997 89 1.5829 .77782 .08245 1.4190 1.7467 .50 4.50 
1998 161 1.5400 .86895 .06848 1.4048 1.6753 .47 4.50 
1999 329 1.4074 .84245 .04645 1.3160 1.4987 .25 4.50 
2000 415 1.2865 .84489 .04147 1.2050 1.3681 .25 4.00 
2001 303 1.0917 .79396 .04561 1.0020 1.1815 .25 4.50 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.644 5 1344 .145 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 41.517 5 8.303 12.118 .000 
Within Groups 920.883 1344 .685   
Total 962.399 1349    
 
Post Hoc Analysis 
Scheffe 
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1996 2001 .6480 .12324 .000 .1683 1.1278 
1997 2001 .4911 .09980 .000 .1026 .8796 
1998 2001 .4483 .08073 .000 .1340 .7626 



















AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 130 1.8710 1.04447 .09161 1.6898 2.0523 .50 6.00 
1997 210 1.8236 1.12799 .07784 1.6701 1.9770 .50 6.00 
1998 283 1.7120 1.09757 .06524 1.5836 1.8405 .50 6.00 
1999 436 1.7998 1.18536 .05677 1.6883 1.9114 .50 6.00 
2000 601 1.7259 1.07516 .04386 1.6398 1.8120 .50 6.00 
2001 428 1.5831 1.08312 .05235 1.4802 1.6860 .50 6.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.795 5 2082 .553 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 15.891 5 3.178 2.593 .024 
Within Groups 2552.092 2082 1.226   






























AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 137 2.7620 1.82934 .15629 2.4529 3.0711 .50 8.00 
1997 190 2.3275 1.47160 .10676 2.1169 2.5381 .50 7.50 
1998 180 2.2371 1.55240 .11571 2.0088 2.4654 .50 8.00 
1999 278 2.2760 1.57766 .09462 2.0898 2.4623 .50 8.00 
2000 348 2.1845 1.55425 .08332 2.0206 2.3483 .50 8.00 
2001 260 2.0028 1.42912 .08863 1.8282 2.1773 .50 8.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.509 5 1387 .004 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 54.651 5 10.930 4.522 .000 
Within Groups 3352.479 1387 2.417   
Total 3407.130 1392    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound











Olanzapine Dosing Analyses (H12) 
 
AGE <2 YEARS 
 
Descriptives 
Year  N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 1 10.0000 . . . . 10.00 10.00 
1998 4 12.3651 7.38080 3.69040 .6206 24.1096 5.00 20.00 
1999 9 9.9861 5.94915 1.98305 5.4132 14.5590 5.00 20.00 
2000 6 6.2202 2.11414 .86310 4.0016 8.4389 4.82 10.00 
2001 2 3.7500 1.76777 1.25000 -12.1328 19.6328 2.50 5.00 
 
Test of Homogeneity of Variances 
Levene Statistic df1 df2 Sig. 
2.650 4 17 .069 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 155.862 4 38.966 1.403 .275 
Within Groups 472.041 17 27.767   




























AGE 2 – 4 YEARS 
  
Descriptives  
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 1 10.0000 . . . . 10.00 10.00 
1997 1 10.0000 . . . . 10.00 10.00 
1998 5 5.0000 3.14245 1.40535 1.0981 8.9019 2.50 10.00 
1999 15 6.4069 4.44122 1.14672 3.9474 8.8664 2.50 20.00 
2000 10 6.7348 5.99910 1.89708 2.4433 11.0263 2.50 20.00 
2001 12 4.9667 2.44358 .70540 3.4141 6.5192 1.46 10.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.421 5 38 .239 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 57.324 5 11.465 .618 .687 
Within Groups 705.227 38 18.559   






























AGE 5 – 9 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996         
1997 13 8.3974 4.67040 1.29534 5.5751 11.2197 5.00 20.00 
1998 31 6.8368 3.51828 .63190 5.5463 8.1273 2.50 15.00 
1999 72 6.1808 3.61689 .42625 5.3308 7.0307 2.50 20.00 
2000 111 6.7681 3.99260 .37896 6.0171 7.5191 2.50 20.00 
2001 76 6.0061 3.76702 .43211 5.1453 6.8669 2.50 20.00 
 
Test of Homogeneity of Variances 
 Levene Statistic df1 df2 Sig. 
.619 4 298 .649 
 
Analysis of Variance (ANOVA) 
Sum of Squares df Mean Square F Sig. 
Between Groups 84.114 4 21.028 1.431 .224 
Within Groups 4379.687 298 14.697   






























AGE 10 – 14 YEARS 
 
Descriptives 
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 2 8.4375 2.20971 1.56250 -11.4159 28.2909 6.88 10.00 
1997 39 8.0883 3.84878 .61630 6.8407 9.3360 2.50 20.00 
1998 83 7.4169 3.53386 .38789 6.6453 8.1885 2.50 20.00 
1999 138 6.7110 3.73016 .31753 6.0831 7.3389 2.50 17.50 
2000 184 6.7869 3.71908 .27417 6.2459 7.3278 2.50 20.00 
2001 141 6.3938 3.88069 .32681 5.7477 7.0400 2.50 20.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.523 5 581 .759 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 124.238 5 24.848 1.774 .116 
Within Groups 8137.585 581 14.006   






























AGE 15 – 19 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1996 10 8.3333 2.63523 .83333 6.4482 10.2185 2.50 10.00 
1997 59 8.3197 3.97810 .51790 7.2830 9.3564 2.50 20.00 
1998 113 8.3026 4.43034 .41677 7.4769 9.1284 2.50 20.00 
1999 154 8.7939 4.88171 .39338 8.0168 9.5711 2.50 20.00 
2000 208 9.0310 4.91705 .34094 8.3589 9.7032 2.50 20.00 
2001 166 8.5800 4.96555 .38540 7.8191 9.3410 2.50 20.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.150 5 704 .058 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 54.177 5 10.835 .480 .791 
Within Groups 15897.936 704 22.582   














Quetiapine Dosing Analyses (H13) 
 
AGE <2 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1 75.0000 . . . . 75.00 75.00 
2000 5 238.7500 220.53636 98.62686 -35.0821 512.5821 50.00 600.00 
2001 1 500.0000 . . . . 500.00 500.00 
 
Test of Homogeneity of Variances 
Test of homogeneity of variances cannot be performed because only one group has a computed variance. 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 93707.589 2 46853.795 .963 .456 
Within Groups 194545.139 4 48636.285   































AGE 2 – 4 YEARS 
 
Descriptives 
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 2 323.7809 245.76332 173.78091 -1884.3149 2531.8768 150.00 497.56 
1999 3 91.6667 62.91529 36.32416 -64.6236 247.9569 25.00 150.00 
2000 6 178.0116 217.10967 88.63465 -49.8310 405.8543 25.00 600.00 
2001 4 233.4375 196.37702 98.18851 -79.0422 545.9172 50.00 480.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.032 3 11 .416 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 72843.746 3 24281.249 .636 .607 
Within Groups 419691.120 11 38153.738   































AGE 5 – 9 YEARS 
 
Descriptives  
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 5 43.7500 20.72890 9.27025 18.0117 69.4883 25.00 75.00 
1999 26 111.3515 106.47474 20.88141 68.3454 154.3576 25.00 455.56 
2000 57 122.3357 84.43783 11.18406 99.9313 144.7401 25.00 400.00 
2001 65 123.0582 102.11998 12.66642 97.7541 148.3623 25.00 450.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.780 3 149 .153 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 31442.495 3 10480.832 1.155 .329 
Within Groups 1351829.678 149 9072.682   































AGE 10 – 14 YEARS 
 
Descriptives  
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 7 149.4048 127.34896 48.13338 31.6266 267.1829 50.00 400.00 
1999 42 160.9522 111.88387 17.26406 126.0867 195.8177 25.00 522.22 
2000 121 172.4037 157.60793 14.32799 144.0353 200.7721 25.00 800.00 
2001 144 170.2254 158.92226 13.24352 144.0470 196.4037 25.00 800.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.075 3 310 .360 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 6985.324 3 2328.441 .100 .960 
Within Groups 7203024.118 310 23235.562   































AGE 15 – 19 YEARS 
 
Descriptives  
Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1997 2 62.5000 17.67767 12.50000 -96.3276 221.3276 50.00 75.00 
1998 15 143.4306 106.05219 27.38256 84.7008 202.1603 25.00 300.00 
1999 42 209.3033 159.39394 24.59502 159.6327 258.9740 35.00 666.67 
2000 107 185.5980 171.09368 16.54025 152.8053 218.3907 25.00 800.00 
2001 140 177.5157 173.31509 14.64780 148.5544 206.4770 25.00 800.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.297 4 301 .271 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 86360.356 4 21590.089 .767 .548 
Within Groups 8477676.949 301 28165.040   
















Analyses of Inpatient Hospitalization Data for Texas Medicaid 
Children and Adolescents Receiving Antipsychotic Treatment and 
Mental Health Care Services from TDMHMR 
 
 
1. Parametric (ANOVA) and Nonparametric (Kruskal Wallis test) Analyses 
of Number of Hospitalizations Per Child or Adolescent (H26). 
2. Parametric (ANOVA) and Nonparametric (Kruskal Wallis test) Analyses 

















Parametric (ANOVA) and Nonparametric (Kruskal Wallis test) Analyses of 
Number of Hospitalizations Per Child or Adolescent (H26). 
ALL MATCHED CHILDREN AND ADOLESCENTS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 2413 .13 .439 .009 .12 .15 0 5 
1999 2957 .16 .530 .010 .14 .18 0 7 
2000 3394 .19 .535 .009 .17 .21 0 7 
2001 4124 .17 .491 .008 .16 .19 0 5 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
21.025 3 12884 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 4.707 3 1.569 6.203 .000 
Within Groups 3258.626 12884 .253   
Total 3263.333 12887    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -.05 .013 .000 -.09 -.02 
 2001 -.04 .012 .003 -.08 .00 
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 2413 6288.67 
 1999 2957 6364.77 
 2000 3394 6544.23 
 2001 4124 6510.77 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 27.763 
df 3 





HOSPITALIZED CHILDREN AND ADOLESCENTS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 251 1.28 .621 .039 1.20 1.36 1 5 
1999 341 1.38 .874 .047 1.28 1.47 1 7 
2000 487 1.31 .723 .033 1.25 1.37 1 7 
2001 573 1.25 .616 .026 1.20 1.31 1 5 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.305 3 1648 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 3.269 3 1.090 2.170 .090 
Within Groups 827.411 1648 .502   
Total 830.680 1651    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 251 825.26 
 1999 341 853.83 
 2000 487 834.08 
 2001 573 804.33 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 4.911 
df 3 



















AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 32 1.13 .336 .059 1.00 1.25 1 2 
1999 47 1.17 .433 .063 1.04 1.30 1 3 
2000 57 1.09 .285 .038 1.01 1.16 1 2 
2001 53 1.11 .423 .058 1.00 1.23 1 3 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.606 3 185 .190 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups .181 3 .060 .428 .733 
Within Groups 26.020 185 .141   
Total 26.201 188    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 32 96.63 
 1999 47 99.06 
 2000 57 93.16 
 2001 53 92.40 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 1.661 
df 3 



















AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 108 1.26 .632 .061 1.14 1.38 1 5 
1999 151 1.30 .632 .051 1.20 1.41 1 6 
2000 230 1.25 .566 .037 1.18 1.33 1 4 
2001 258 1.22 .580 .036 1.15 1.29 1 5 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.323 3 743 .266 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups .672 3 .224 .634 .593 
Within Groups 262.508 743 .353   
Total 263.181 746    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 108 371.31 
 1999 151 393.52 
 2000 230 375.50 
 2001 258 362.37 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 4.232 
df 3 



















AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 113 1.30 .639 .060 1.18 1.42 1 4 
1999 145 1.50 1.125 .093 1.31 1.68 1 7 
2000 212 1.36 .817 .056 1.25 1.47 1 7 
2001 269 1.27 .625 .038 1.19 1.34 1 4 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
8.550 3 735 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 5.197 3 1.732 2.689 .045 
Within Groups 473.502 735 .644   
Total 478.698 738    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 113 370.17 
 1999 145 386.06 
 2000 212 375.25 
 2001 269 357.13 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 3.638 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 167 1.29 .650 .050 1.19 1.39 1 5 
1999 203 1.29 .743 .052 1.18 1.39 1 7 
2000 294 1.24 .591 .034 1.18 1.31 1 5 
2001 357 1.23 .567 .030 1.17 1.29 1 4 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.553 3 1017 .199 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups .677 3 .226 .576 .631 
Within Groups 398.621 1017 .392   
Total 399.299 1020    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 167 524.53 
 1999 203 519.54 
 2000 294 511.37 
 2001 357 499.51 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 2.305 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 84 1.26 .562 .061 1.14 1.38 1 3 
1999 138 1.51 1.027 .087 1.33 1.68 1 7 
2000 193 1.41 .880 .063 1.28 1.53 1 7 
2001 214 1.30 .689 .047 1.21 1.40 1 5 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.466 3 625 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 4.802 3 1.601 2.378 .069 
Within Groups 420.651 625 .673   
Total 425.453 628    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 84 299.79 
 1999 138 331.94 
 2000 193 320.99 
 2001 214 304.65 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 4.708 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 4 1.00 .000 .000 1.00 1.00 1 1 
1999 2 1.00 .000 .000 1.00 1.00 1 1 
2000 3 1.00 .000 .000 1.00 1.00 1 1 
2001 7 1.29 .488 .184 .83 1.74 1 2 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
10.000 3 12 .001 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups .321 3 .107 .900 .470 
Within Groups 1.429 12 .119   
Total 1.750 15    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 4 7.50 
 1999 2 7.50 
 2000 3 7.50 
 2001 7 9.79 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 2.755 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 35 1.03 .169 .029 .97 1.09 1 2 
1999 45 1.36 .712 .106 1.14 1.57 1 4 
2000 72 1.38 .846 .100 1.18 1.57 1 6 
2001 75 1.25 .522 .060 1.13 1.37 1 3 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
10.288 3 223 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 3.171 3 1.057 2.499 .060 
Within Groups 94.344 223 .423   
Total 97.515 226    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 35 93.60 
 1999 45 119.07 
 2000 72 120.20 
 2001 75 114.53 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 8.634 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 37 1.22 .584 .096 1.02 1.41 1 4 
1999 59 1.22 .457 .060 1.10 1.34 1 3 
2000 78 1.24 .687 .078 1.09 1.40 1 5 
2001 72 1.26 .503 .059 1.15 1.38 1 3 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.324 3 242 .808 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups .086 3 .029 .088 .967 
Within Groups 78.764 242 .325   
Total 78.850 245    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 37 119.99 
 1999 59 124.58 
 2000 78 119.54 
 2001 72 128.71 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 1.565 
df 3 



















DISRUPTIVE BEHAVIORAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 41 1.27 .549 .086 1.10 1.44 1 3 
1999 55 1.13 .336 .045 1.04 1.22 1 2 
2000 58 1.14 .476 .062 1.01 1.26 1 4 
2001 51 1.12 .382 .053 1.01 1.23 1 3 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.649 3 201 .014 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups .656 3 .219 1.147 .331 
Within Groups 38.349 201 .191   
Total 39.005 204    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 41 112.20 
 1999 55 102.29 
 2000 58 100.16 
 2001 51 99.61 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 3.759 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 18 1.39 .608 .143 1.09 1.69 1 3 
1999 22 1.23 .429 .091 1.04 1.42 1 2 
2000 38 1.21 .413 .067 1.07 1.35 1 2 
2001 35 1.40 .736 .124 1.15 1.65 1 4 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
4.135 3 109 .008 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups .913 3 .304 .951 .419 
Within Groups 34.857 109 .320   
Total 35.770 112    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 18 61.44 
 1999 22 54.89 
 2000 38 53.97 
 2001 35 59.33 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 1.597 
df 3 



















MENTAL RETARDATION / DEVELOPMENTAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 14 1.14 .363 .097 .93 1.35 1 2 
1999 7 1.14 .378 .143 .79 1.49 1 2 
2000 14 1.64 1.151 .308 .98 2.31 1 5 
2001 14 1.36 .745 .199 .93 1.79 1 3 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.712 3 45 .018 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 2.102 3 .701 1.168 .333 
Within Groups 27.000 45 .600   
Total 29.102 48    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 14 22.71 
 1999 7 22.71 
 2000 14 28.39 
 2001 14 25.04 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 2.500 
df 3 



















OTHER PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 11 1.18 .405 .122 .91 1.45 1 2 
1999 11 1.18 .405 .122 .91 1.45 1 2 
2000 17 1.29 .588 .143 .99 1.60 1 3 
2001 25 1.08 .277 .055 .97 1.19 1 2 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.980 3 60 .012 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups .467 3 .156 .878 .458 
Within Groups 10.642 60 .177   
Total 11.109 63    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 11 33.23 
 1999 11 33.23 
 2000 17 35.21 
 2001 25 30.02 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 2.108 
df 3 



















COMORBID PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 81 1.48 .823 .091 1.30 1.66 1 5 
1999 126 1.67 1.246 .111 1.45 1.89 1 7 
2000 128 1.54 .904 .080 1.38 1.70 1 7 
2001 53 1.55 .992 .136 1.27 1.82 1 5 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.066 3 384 .104 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1.962 3 .654 .623 .601 
Within Groups 403.159 384 1.050   
Total 405.121 387    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 81 189.72 
 1999 126 196.90 
 2000 128 197.02 
 2001 53 190.02 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square .495 
df 3 



















NO PSYCHIATRIC DISORDER 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 3 1.00 .000 .000 1.00 1.00 1 1 
2000 1 1.00 . . . . 1 1 
2001 8 1.50 .756 .267 .87 2.13 1 3 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
8.766(a) 1 9 .016 
a  Groups with only one case are ignored in computing the test of homogeneity of variance for number of 
hospitalizations. 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups .667 2 .333 .750 .500 
Within Groups 4.000 9 .444   
Total 4.667 11    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospitalizations 1998 3 5.00 
 2000 1 5.00 
 2001 8 7.25 
 
Test Statistics 
 Number of Hospitalizations 
Chi-Square 1.800 
df 2 



















Parametric (ANOVA) and Nonparametric (Kruskal Wallis test) Analyses of 
Number of Hospital Days Per Hospitalized Child or Adolescent (H27). 
HOSPITALIZED CHILDREN AND ADOLESCENTS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 251 83.1952 80.41770 5.07592 73.1982 93.1922 1.00 366.00 
1999 341 82.6422 78.44842 4.24822 74.2861 90.9983 2.00 432.00 
2000 487 67.7988 66.28263 3.00355 61.8972 73.7003 1.00 362.00 
2001 573 56.9319 60.64228 2.53337 51.9561 61.9078 1.00 344.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
12.677 3 1648 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 197885.131 3 65961.710 13.677 .000 
Within Groups 7947872.411 1648 4822.738   
Total 8145757.542 1651    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 26.2633 5.67300 .000 8.4837 44.0428 
1999 2001 25.7103 4.94624 .000 10.2442 41.1763 
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 251 914.45 
 1999 341 911.73 
 2000 487 831.31 
 2001 573 733.17 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 41.405 
df 3 







AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 32 108.4688 90.28735 15.96070 75.9167 141.0208 10.00 336.00 
1999 47 79.2340 89.53702 13.06032 52.9450 105.5231 2.00 432.00 
2000 57 63.3684 49.68099 6.58041 50.1863 76.5506 3.00 198.00 
2001 53 70.7925 62.11632 8.53233 53.6711 87.9138 3.00 344.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
4.766 3 185 .003 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 44557.435 3 14852.478 2.861 .038 
Within Groups 960340.374 185 5191.029   
Total 1004897.810 188    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 32 117.72 
 1999 47 88.10 
 2000 57 87.96 
 2001 53 94.98 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 7.214 
df 3 



















AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 108 89.8796 85.53228 8.23035 73.5639 106.1953 1.00 366.00 
1999 151 91.1192 80.88098 6.58200 78.1138 104.1246 2.00 376.00 
2000 230 67.1478 67.94073 4.47988 58.3208 75.9749 2.00 362.00 
2001 258 58.9574 60.94823 3.79447 51.4851 66.4296 1.00 328.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
8.149 3 743 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 138874.172 3 46291.391 9.109 .000 
Within Groups 3775772.794 743 5081.794   
Total 3914646.967 746    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 30.9223 9.06293 .005 2.2396 59.6050 
1999 2001 32.1618 7.59742 .000 8.2684 56.0553 
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 108 421.64 
 1999 151 426.92 
 2000 230 362.05 
 2001 258 333.74 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 24.036 
df 3 










AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 113 66.1770 66.35137 6.24181 53.8096 78.5443 2.00 311.00 
1999 145 73.7793 70.17819 5.82798 62.2599 85.2988 2.00 340.00 
2000 212 65.8585 64.87735 4.45579 57.0749 74.6421 1.00 329.00 
2001 269 50.5353 55.06993 3.35767 43.9245 57.1461 1.00 321.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.539 3 735 .014 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 60593.925 3 20197.975 5.114 .002 
Within Groups 2903154.067 735 3949.869   
Total 2963747.992 738    
 
Post Hoc Analysis 
Scheffe  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1999 2001 23.2440 6.47488 .005 1.3583 45.1297 
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 113 384.46 
 1999 145 413.09 
 2000 212 390.04 
 2001 269 324.91 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 20.300 
df 3 














 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 167 89.4371 85.73731 6.63455 76.3381 102.5361 1.00 366.00 
1999 203 78.3547 75.91092 5.32790 67.8492 88.8601 2.00 432.00 
2000 294 65.2551 60.61358 3.53506 58.2978 72.2124 1.00 299.00 
2001 357 54.6807 60.83057 3.21950 48.3491 61.0123 1.00 344.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
11.324 3 1017 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 164044.879 3 54681.626 11.639 .000 
Within Groups 4778077.017 1017 4698.207   
Total 4942121.896 1020    
 
Post Hoc Analysis 
Games-Howell 
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 24.1820 7.51757 .008 .5503 47.8138 
 2001 34.7565 7.37444 .000 11.5613 57.9516 
1999 2001 23.6740 6.22509 .001 4.1531 43.1949 
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 167 588.85 
 1999 203 555.36 
 2000 294 517.19 
 2001 357 444.26 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 34.651 
df 3 












 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 84 70.7857 67.40117 7.35407 56.1588 85.4127 1.00 356.00 
1999 138 88.9493 81.91025 6.97266 75.1613 102.7372 2.00 340.00 
2000 193 71.6736 74.08829 5.33299 61.1548 82.1923 2.00 362.00 
2001 214 61.0981 60.38915 4.12812 52.9609 69.2353 1.00 328.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
4.896 3 625 .002 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 65182.645 3 21727.548 4.343 .005 
Within Groups 3126916.162 625 5003.066   
Total 3192098.808 628    
 
Post Hoc Analysis 
Games-Howell 
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1999 2001 27.8511 8.10305 .004 2.3468 53.3555 
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 84 320.26 
 1999 138 353.74 
 2000 193 313.21 
 2001 214 289.57 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 10.550 
df 3 














 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 4 171.7500 120.82046 60.41023 -20.5023 364.0023 50.00 295.00 
1999 2 56.5000 70.00357 49.50000 -572.4571 685.4571 7.00 106.00 
2000 3 104.0000 80.66598 46.57252 -96.3854 304.3854 11.00 155.00 
2001 7 65.8571 27.55255 10.41388 40.3753 91.3390 31.00 106.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
16.654 3 12 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 32539.330 3 10846.443 1.964 .173 
Within Groups 66262.107 12 5521.842   
Total 98801.438 15    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 4 11/75 
 1999 2 6.25 
 2000 3 9.67 
 2001 4 6.79 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 3.403 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 35 80.2286 61.24209 10.35180 59.1912 101.2660 7.00 245.00 
1999 45 85.4444 85.94516 12.81195 59.6237 111.2652 2.00 340.00 
2000 72 78.5417 77.33191 9.11365 60.3696 96.7138 6.00 333.00 
2001 75 57.1600 60.67526 7.00618 43.1999 71.1201 2.00 285.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.250 3 223 .023 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 29824.225 3 9941.408 1.929 .126 
Within Groups 1149555.238 223 5154.956   
Total 1179379.463 226    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 35 129.99 
 1999 45 120.11 
 2000 72 119.85 
 2001 75 97.25 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 7.914 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 37 59.4054 77.56233 12.75117 33.5448 85.2660 1.00 311.00 
1999 59 47.1356 54.48614 7.09349 32.9364 61.3348 2.00 325.00 
2000 78 48.4103 43.22050 4.89376 38.6655 58.1550 2.00 231.00 
2001 72 36.7083 36.73906 4.32974 28.0751 45.3416 2.00 167.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
4.680 3 242 .003 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 13367.086 3 4455.695 1.716 .164 
Within Groups 628429.581 242 2596.816   
Total 641796.667 245    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 37 121.92 
 1999 59 124.79 
 2000 78 133.88 
 2001 72 112.01 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 3.574 
df 3 



















DISRUPTIVE BEHAVIORAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 41 80.8780 66.87982 10.44487 59.7682 101.9879 3.00 312.00 
1999 55 92.2727 77.02151 10.38558 71.4509 113.0946 4.00 301.00 
2000 58 74.7241 66.66907 8.75408 57.1944 92.2539 3.00 299.00 
2001 51 69.4706 66.14419 9.26204 50.8672 88.0739 3.00 312.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.049 3 201 .372 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 15499.413 3 5166.471 1.069 .363 
Within Groups 971365.591 201 4832.665   
Total 986865.005 204    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 41 108.16 
 1999 55 113.12 
 2000 58 98.36 
 2001 51 93.22 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 3.652 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 18 69.3333 81.29757 19.16202 28.9050 109.7617 6.00 353.00 
1999 22 64.1818 53.77788 11.46548 40.3380 88.0256 7.00 212.00 
2000 38 55.8947 58.04602 9.41631 36.8155 74.9740 3.00 262.00 
2001 35 80.2857 80.27071 13.56823 52.7118 107.8597 9.00 321.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.124 3 109 .343 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 11132.324 3 3710.775 .783 .506 
Within Groups 516831.995 109 4741.578   
Total 527964.319 112    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 18 57.92 
 1999 22 59.36 
 2000 38 50.63 
 2001 35 61.96 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 2.366 
df 3 



















MENTAL RETARDATION / DEVELOPMENTAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 14 134.4286 122.94446 32.85829 63.4426 205.4146 15.00 366.00 
1999 7 93.8571 64.60761 24.41938 34.1051 153.6092 26.00 194.00 
2000 14 79.2857 77.47995 20.70739 34.5501 124.0213 5.00 267.00 
2001 14 49.3571 37.09988 9.91536 27.9363 70.7780 4.00 136.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
5.699 3 45 .002 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 52371.643 3 17457.214 2.474 .074 
Within Groups 317478.357 45 7055.075   
Total 369850.000 48    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 14 30.68 
 1999 7 28.86 
 2000 14 23.04 
 2001 14 19.36 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 5.170 
df 3 



















OTHER PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 11 48.5455 31.60495 9.52925 27.3130 69.7779 2.00 116.00 
1999 11 123.8182 127.34349 38.39551 38.2677 209.3687 14.00 432.00 
2000 17 81.9412 77.23460 18.73214 42.2308 121.6515 6.00 266.00 
2001 25 65.8000 70.75839 14.15168 36.5924 95.0076 2.00 270.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.722 3 60 .016 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 36568.133 3 12189.378 1.886 .142 
Within Groups 387757.305 60 6462.622   
Total 424325.438 63    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 11 28.45 
 1999 11 40.05 
 2000 17 34.53 
 2001 25 29.58 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 3.145 
df 3 



















COMORBID PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 81 96.3580 85.51569 9.50174 77.4490 115.2671 1.00 361.00 
1999 126 92.4524 80.04635 7.13110 78.3391 106.5657 2.00 376.00 
2000 128 80.3516 68.13622 6.02245 68.4342 92.2689 4.00 317.00 
2001 53 64.0755 66.39215 9.11966 45.7755 82.3754 2.00 290.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.147 3 384 .025 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 43356.371 3 14452.124 2.517 .058 
Within Groups 2204776.709 384 5741.606   
Total 2248133.080 387    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 81 206.20 
 1999 126 203.96 
 2000 128 192.54 
 2001 53 158.84 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square 7.178 
df 3 


















NO PSYCHIATRIC DISORDER 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 3 40.3333 21.38535 12.34684 -12.7908 93.4575 17.00 59.00 
2000 1 35.0000 . . . . 35.00 35.00 
2001 8 71.5000 99.62071 35.22124 -11.7850 154.7850 2.00 296.00 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.241(a) 1 9 .169 
a  Groups with only one case are ignored in computing the test of homogeneity of variance for number of 
hospital days. 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 2838.000 2 1419.000 .181 .837 
Within Groups 70384.667 9 7820.519   
Total 73222.667 11    
 
Ranks 
 RX YEAR N Mean Rank 
Number of Hospital Days 1998 3 7.00 
 2000 1 7.00 
 2001 8 6.25 
 
Test Statistics 
 Number of Hospital Days 
Chi-Square .115 
df 2 

















Analyses of Outpatient Mental Health Care Service Utilization 
Data for Texas Medicaid Children and Adolescents Receiving 
Antipsychotic Treatment and Mental Health Care Services from 
TDMHMR 
 
1. Parametric (ANOVA) and Nonparametric (Kruskal Wallis test) Analyses 
of Duration of Enrollment in Different Types of Outpatient Mental Health 
Care Services Per Child or Adolescent (H29). 
a. Assessment services 
b. Counseling and psychotherapy 
c. Crisis intervention 
d. Medication-related services 
e. Service coordination 
f. Skills training 













 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1557 5.01 13.987 .354 4.31 5.70 1 365 
1999 2013 3.39 7.253 .162 3.07 3.71 1 111 
2000 1825 2.35 5.432 .127 2.10 2.60 1 160 
2001 2322 2.29 4.201 .087 2.12 2.47 1 59 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
100.546 3 7713 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 8367.050 3 2789.017 42.596 .000 
Within Groups 505017.401 7713 65.476   
Total 513384.450 7716    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 1.62 .390 .000 .41 2.83 
 2000 2.66 .377 .000 1.49 3.83 
 2001 2.71 .365 .000 1.58 3.85 
1999 2000 1.04 .206 .000 .40 1.68 
 2001 1.09 .184 .000 .52 1.67 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 1557 4294.96 
 1999 2013 3913.14 
 2000 1825 3675.18 
 2001 2322 3664.22 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 245.347 
df 3 








ASSESSMENT SERVICES: AGE 2 – 4 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 23 5.30 6.560 1.368 2.47 8.14 1 15 
1999 25 2.12 3.876 .775 .52 3.72 1 15 
2000 30 2.90 4.831 .882 1.10 4.70 1 15 
2001 58 2.45 4.301 .565 1.32 3.58 1 15 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.824 3 132 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 159.328 3 53.109 2.307 .080 
Within Groups 3038.554 132 23.019   
Total 3197.882 135    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 23 81.54 
 1999 25 63.52 
 2000 30 69.15 
 2001 58 65.14 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 8.531 
df 3 




















ASSESSMENT SERVICES: AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 374 4.93 6.437 .333 4.27 5.58 1 30 
1999 477 3.96 7.272 .333 3.31 4.62 1 107 
2000 486 2.50 4.306 .195 2.11 2.88 1 15 
2001 567 2.50 4.400 .185 2.14 2.87 1 27 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
63.183 3 1900 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1871.436 3 623.812 19.566 .000 
Within Groups 60577.609 1900 31.883   
Total 62449.046 1903    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 2.43 .386 .000 1.23 3.64 
 2001 2.43 .381 .000 1.23 3.62 
1999 2000 1.47 .386 .001 .26 2.67 
 2001 1.46 .381 .001 .27 2.65 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 374 1064.56 
 1999 477 985.94 
 2000 486 899.44 
 2001 567 895.93 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 66.891 
df 3 









ASSESSMENT SERVICES: AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 773 5.25 14.383 .517 4.24 6.27 1 365 
1999 918 3.30 6.720 .222 2.87 3.74 1 111 
2000 781 2.50 6.940 .248 2.02 2.99 1 160 
2001 1045 2.25 4.270 .132 1.99 2.51 1 59 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
43.455 3 3513 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 4582.732 3 1527.577 20.824 .000 
Within Groups 257706.353 3513 73.358   
Total 262289.086 3516    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 1.95 .563 .003 .20 3.71 
 2000 2.75 .574 .000 .96 4.54 
 2001 3.00 .534 .000 1.34 4.67 
1999 2001 1.05 .258 .000 .24 1.85 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 773 1982.39 
 1999 918 1770.53 
 2000 781 1671.02 
 2001 1045 1649.38 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 142.337 
df 3 









ASSESSMENT SERVICES: AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 387 4.58 18.221 .926 2.76 6.40 1 328 
1999 593 3.12 8.080 .332 2.47 3.77 1 102 
2000 528 1.95 3.502 .152 1.65 2.25 1 15 
2001 652 2.17 3.897 .153 1.87 2.47 1 25 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
22.114 3 2156 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1926.923 3 642.308 7.561 .000 
Within Groups 183164.343 2156 84.956   
Total 185091.266 2159    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1999 2000 1.17 .365 .008 .03 2.31 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 387 1157.42 
 1999 593 1096.16 
 2000 528 1037.87 
 2001 652 1055.12 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 33.539 
df 3 












ASSESSMENT SERVICES: MALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1104 5.01 11.941 .359 4.30 5.71 1 328 
1999 1337 3.56 7.901 .216 3.14 3.99 1 111 
2000 1290 2.38 5.927 .165 2.06 2.70 1 160 
2001 1616 2.40 4.385 .109 2.18 2.61 1 59 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
75.764 3 5343 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 5686.016 3 1895.339 31.946 .000 
Within Groups 316992.467 5343 59.329   
Total 322678.483 5346    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 1.44 .419 .003 .13 2.75 
 2000 2.63 .395 .000 1.39 3.86 
 2001 2.61 .376 .000 1.44 3.78 
1999 2000 1.18 .272 .000 .34 2.03 
 2001 1.17 .242 .000 .41 1.92 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 1104 2983.13 
 1999 1337 2717.16 
 2000 1290 2528.69 
 2001 1616 2543.10 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 178.298 
df 3 








ASSESSMENT SERVICES: FEMALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 453 5.02 18.042 .848 3.35 6.68 1 365 
1999 676 3.04 5.749 .221 2.61 3.48 1 78 
2000 535 2.27 3.998 .173 1.93 2.61 1 15 
2001 706 2.06 3.741 .141 1.78 2.34 1 25 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
28.087 3 2366 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 2743.072 3 914.357 11.517 .000 
Within Groups 187842.730 2366 79.393   
Total 190585.801 2369    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 2.74 .865 .009 .04 5.45 
 2001 2.95 .859 .004 .27 5.64 
1999 2001 .98 .262 .001 .16 1.80 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 453 1310.49 
 1999 676 1199.12 
 2000 535 1147.18 
 2001 706 1121.30 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 68.108 
df 3 










ASSESSMENT SERVICES: ANXIETY DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 37 4.43 5.909 .971 2.46 6.40 1 15 
1999 32 4.19 5.671 1.002 2.14 6.23 1 15 
2000 34 4.35 6.004 1.030 2.26 6.45 1 15 
2001 46 4.35 6.038 .890 2.55 6.14 1 15 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.178 3 145 .911 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1.066 3 .355 .010 .999 
Within Groups 5084.156 145 35.063   
Total 5085.221 148    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 37 75.45 
 1999 32 75.48 
 2000 34 75.37 
 2001 46 74.03 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square .057 
df 3 




















ASSESSMENT SERVICES: BIPOLAR DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 89 9.57 34.766 3.685 2.25 16.90 1 328 
1999 116 4.09 5.782 .537 3.02 5.15 1 15 
2000 171 2.64 4.512 .345 1.96 3.32 1 15 
2001 299 1.54 2.651 .153 1.24 1.84 1 15 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
15.137 3 671 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 4576.675 3 1525.558 8.842 .000 
Within Groups 115766.741 671 172.529   
Total 120343.416 674    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1999 2001 2.55 .558 .000 .78 4.32 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 89 420.03 
 1999 116 369.44 
 2000 171 330.82 
 2001 299 305.49 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 75.807 
df 3 












ASSESSMENT SERVICES: DEPRESSIVE DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 287 5.36 22.251 1.313 2.78 7.95 1 365 
1999 394 3.80 7.615 .384 3.05 4.56 1 98 
2000 270 2.84 10.392 .632 1.60 4.09 1 160 
2001 397 2.68 5.177 .260 2.17 3.19 1 59 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
7.209 3 1344 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1399.623 3 466.541 3.073 .027 
Within Groups 204058.463 1344 151.829   
Total 205458.085 1347    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 287 723.33 
 1999 394 690.52 
 2000 270 636.74 
 2001 397 648.98 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 23.815 
df 3 




















ASSESSMENT SERVICES: DISRUPTIVE BEHAVIORAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 505 4.94 7.549 .336 4.28 5.60 1 99 
1999 647 3.55 7.829 .308 2.95 4.16 1 111 
2000 474 2.35 4.114 .189 1.98 2.73 1 15 
2001 471 2.69 4.632 .213 2.27 3.11 1 27 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
43.811 3 2093 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1971.630 3 657.210 15.918 .000 
Within Groups 86412.336 2093 41.286   
Total 88383.966 2096    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 2.59 .385 .000 1.38 3.79 
 2001 2.25 .398 .000 1.01 3.50 
1999 2000 1.20 .361 .005 .07 2.33 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 505 1163.60 
 1999 647 1046.29 
 2000 474 979.58 
 2001 471 999.71 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 65.017 
df 3 










ASSESSMENT SERVICES: PSYCHOTIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 113 4.48 6.410 .603 3.28 5.67 1 31 
1999 145 2.96 4.845 .402 2.16 3.75 1 15 
2000 99 2.53 4.322 .434 1.66 3.39 1 15 
2001 162 1.60 2.855 .224 1.16 2.05 1 15 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
37.242 3 515 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 560.481 3 186.827 8.648 .000 
Within Groups 11125.349 515 21.603   
Total 11685.830 518    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 2.87 .643 .000 .83 4.91 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 113 288.86 
 1999 145 264.07 
 2000 99 257.46 
 2001 162 237.78 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 23.326 
df 3 












ASSESSMENT SERVICES: MENTAL RETARDATION/DEVELOPMENTAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 45 3.16 5.081 .757 1.63 4.68 1 15 
1999 49 3.29 5.228 .747 1.78 4.79 1 15 
2000 46 3.46 5.357 .790 1.87 5.05 1 15 
2001 79 1.53 2.693 .303 .93 2.13 1 15 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
13.247 3 215 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 160.000 3 53.333 2.664 .049 
Within Groups 4304.995 215 20.023   
Total 4464.995 218    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 45 113.40 
 1999 49 114.54 
 2000 46 117.82 
 2001 79 100.70 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 8.576 
df 3 





















ASSESSMENT SERVICES: OTHER PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 74 5.35 7.208 .838 3.68 7.02 1 36 
1999 99 4.47 11.681 1.174 2.14 6.80 1 107 
2000 64 1.23 1.752 .219 .80 1.67 1 15 
2001 87 2.75 4.624 .496 1.76 3.73 1 15 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
12.852 3 320 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 723.894 3 241.298 4.022 .008 
Within Groups 19197.473 320 59.992   
Total 19921.367 323    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 4.12 .866 .000 1.34 6.90 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 74 184.30 
 1999 99 165.80 
 2000 64 140.66 
 2001 87 156.26 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 19.419 
df 3 












ASSESSMENT SERVICES: COMORBID PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 391 3.99 5.850 .296 3.41 4.57 1 35 
1999 513 2.60 6.181 .273 2.07 3.14 1 102 
2000 440 1.71 3.056 .146 1.42 1.99 1 15 
2001 153 2.28 4.050 .327 1.63 2.93 1 15 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
47.077 3 1493 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1114.598 3 371.533 14.041 .000 
Within Groups 39504.724 1493 26.460   
Total 40619.323 1496    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 1.39 .403 .003 .13 2.64 
 2000 2.28 .330 .000 1.25 3.31 
 2001 1.71 .441 .001 .33 3.09 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 391 823.49 
 1999 513 739.85 
 2000 440 700.13 
 2001 153 729.86 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 57.002 
df 3 










ASSESSMENT SERVICES: NO PSYCHIATRIC DISORDER 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 14 9.14 7.336 1.961 4.91 13.38 1 17 
1999 17 2.65 4.649 1.128 .26 5.04 1 15 
2000 10 1.00 .000 .000 1.00 1.00 1 1 
2001 44 1.93 3.487 .526 .87 2.99 1 15 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
16.395 3 81 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 618.620 3 206.207 10.650 .000 
Within Groups 1568.392 81 19.363   
Total 2187.012 84    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 8.14 1.961 .005 .65 15.63 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 14 61.21 
 1999 17 41.50 
 2000 10 36.50 
 2001 44 39.26 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 24.071 
df 3 












COUNSELING AND PSYCHOTHERAPY 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1294 58.57 78.480 2.182 54.29 62.85 1 365 
1999 1515 51.99 73.399 1.886 48.29 55.69 1 365 
2000 1377 52.70 68.387 1.843 49.08 56.31 1 366 
2001 1892 50.11 70.594 1.623 46.92 53.29 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.113 3 6074 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 57702.689 3 19234.230 3.653 .012 
Within Groups 31979415.916 6074 5264.968   
Total 32037118.605 6077    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 1294 3167.35 
 1999 1515 3024.75 
 2000 1377 3089.72 
 2001 1892 2927.31 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 16.282 
df 3 





















COUNSELING AND PSYCHOTHERAPY: AGE 2 – 4 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 22 58.64 82.760 17.644 21.94 95.33 1 287 
1999 21 78.52 104.978 22.908 30.74 126.31 1 314 
2000 22 46.73 46.809 9.980 25.97 67.48 1 165 
2001 55 45.51 60.996 8.225 29.02 62.00 1 309 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
5.302 3 116 .002 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 18230.729 3 6076.910 1.153 .331 
Within Groups 611160.438 116 5268.624   
Total 629391.167 119    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 22 59.05 
 1999 21 66.88 
 2000 22 64.11 
 2001 55 57.20 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 1.531 
df 3 




















COUNSELING AND PSYCHOTHERAPY: AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 363 72.30 89.853 4.716 63.03 81.57 1 365 
1999 364 55.10 81.596 4.277 46.69 63.51 1 365 
2000 340 54.07 71.348 3.869 46.46 61.68 1 366 
2001 467 54.47 77.953 3.607 47.38 61.56 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
7.973 3 1530 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 87500.062 3 29166.687 4.509 .004 
Within Groups 9896873.313 1530 6468.545   
Total 9984373.375 1533    
 
Post Hoc Analysis 
Games-Howell  




 RX YEAR N Mean Rank 
Duration of Enrollment 1998 363 832.25 
 1999 364 741.12 
 2000 340 766.35 
 2001 467 738.56 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 11.407 
df 3 















COUNSELING AND PSYCHOTHERAPY: AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 598 53.58 74.519 3.047 47.60 59.57 1 365 
1999 720 54.39 73.128 2.725 49.04 59.74 1 365 
2000 678 56.10 73.526 2.824 50.55 61.64 1 366 
2001 858 50.82 70.023 2.391 46.12 55.51 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.371 3 2850 .774 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 11320.853 3 3773.618 .716 .542 
Within Groups 15022101.076 2850 5270.913   
Total 15033421.929 2853    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 598 1429.58 
 1999 720 1456.02 
 2000 678 1457.74 
 2001 858 1378.22 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 4.985 
df 3 





















COUNSELING AND PSYCHOTHERAPY: AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 311 52.14 69.235 3.926 44.42 59.87 1 365 
1999 410 43.66 63.001 3.111 37.54 49.77 1 365 
2000 337 44.87 53.831 2.932 39.10 50.63 1 309 
2001 512 45.43 65.129 2.878 39.77 51.08 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.852 3 1566 .136 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 14537.074 3 4845.691 1.214 .303 
Within Groups 6250554.455 1566 3991.414   
Total 6265091.529 1569    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 311 844.03 
 1999 410 764.25 
 2000 337 802.40 
 2001 512 755.84 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 8.948 
df 3 





















COUNSELING AND PSYCHOTHERAPY: MALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 941 60.30 80.974 2.640 55.12 65.48 1 365 
1999 1055 52.13 74.988 2.309 47.60 56.66 1 365 
2000 934 51.83 66.868 2.188 47.54 56.13 1 366 
2001 1318 49.62 70.644 1.946 45.80 53.44 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
8.792 3 4244 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 67265.242 3 22421.747 4.167 .006 
Within Groups 22834631.572 4244 5380.450   
Total 22901896.814 4247    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 10.68 3.279 .006 .46 20.91 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 941 2222.95 
 1999 1055 2116.81 
 2000 934 2162.15 
 2001 1318 2033.69 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 14.642 
df 3 












COUNSELING AND PSYCHOTHERAPY: FEMALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 353 53.96 71.311 3.795 46.50 61.43 1 365 
1999 460 51.67 69.695 3.250 45.28 58.06 1 365 
2000 443 54.52 71.527 3.398 47.84 61.20 1 366 
2001 574 51.22 70.530 2.944 45.44 57.00 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.146 3 1826 .932 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 3770.163 3 1256.721 .251 .860 
Within Groups 9131209.783 1826 5000.663   
Total 9134979.945 1829    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 353 944.00 
 1999 460 908.88 
 2000 443 927.74 
 2001 574 893.83 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 2.356 
df 3 



















COUNSELING AND PSYCHOTHERAPY: ANXIETY DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 39 24.10 45.415 7.272 9.38 38.82 1 245 
1999 38 45.53 58.106 9.426 26.43 64.63 1 232 
2000 20 71.15 98.110 21.938 25.23 117.07 1 325 
2001 45 37.84 46.199 6.887 23.96 51.72 1 179 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.366 3 138 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 30537.715 3 10179.238 2.926 .036 
Within Groups 480095.525 138 3478.953   




 RX YEAR N Mean Rank 
Duration of Enrollment 1998 39 59.95 
 1999 38 75.59 
 2000 20 80.30 
 2001 45 74.14 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 4.868 
df 3 



















COUNSELING AND PSYCHOTHERAPY: BIPOLAR DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 105 54.03 77.431 7.556 39.04 69.01 1 365 
1999 114 44.75 74.756 7.002 30.88 58.63 1 365 
2000 138 61.84 71.124 6.054 49.87 73.81 1 366 
2001 255 50.65 69.866 4.375 42.03 59.26 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.424 3 608 .736 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 19985.797 3 6661.932 1.271 .284 
Within Groups 3187898.765 608 5243.255   
Total 3207884.562 611    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 105 306.00 
 1999 114 275.19 
 2000 138 342.59 
 2001 255 301.17 
 
Test Statistics  
 Duration of Enrollment 
Chi-Square 9.919 
df 3 





















COUNSELING AND PSYCHOTHERAPY: DEPRESSIVE DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 187 55.39 81.428 5.955 43.64 67.14 1 365 
1999 328 52.25 69.928 3.861 44.65 59.84 1 365 
2000 232 52.76 65.915 4.328 44.24 61.29 1 366 
2001 349 53.58 69.211 3.705 46.29 60.86 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.051 3 1092 .369 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1274.071 3 424.690 .084 .969 
Within Groups 5502912.699 1092 5039.297   
Total 5504186.770 1095    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 187 536.91 
 1999 328 547.99 
 2000 232 554.69 
 2001 349 551.07 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square .370 
df 3 




















COUNSELING AND PSYCHOTHERAPY: DISRUPTIVE BEHAVIORAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 433 63.05 77.316 3.716 55.75 70.35 1 365 
1999 440 59.60 84.922 4.049 51.65 67.56 1 365 
2000 422 56.78 73.056 3.556 49.79 63.77 1 366 
2001 526 54.63 80.767 3.522 47.71 61.55 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.623 3 1817 .600 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 18590.679 3 6196.893 .986 .398 
Within Groups 11419960.307 1817 6285.063   
Total 11438550.986 1820    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 433 971.71 
 1999 440 921.40 
 2000 422 917.71 
 2001 526 846.95 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 14.262 
df 3 





















COUNSELING AND PSYCHOTHERAPY: PSYCHOTIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 69 43.90 57.568 6.930 30.07 57.73 1 244 
1999 111 53.85 75.976 7.211 39.56 68.14 1 365 
2000 76 55.36 77.521 8.892 37.64 73.07 1 354 
2001 73 35.15 53.639 6.278 22.64 47.67 1 243 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.370 3 325 .071 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 21119.050 3 7039.683 1.507 .213 
Within Groups 1518169.437 325 4671.291   
Total 1539288.486 328    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 69 167.82 
 1999 111 177.80 
 2000 76 167.04 
 2001 73 140.75 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 7.073 
df 3 

























 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 44 49.89 64.660 9.748 30.23 69.54 1 274 
1999 34 47.38 55.730 9.558 27.94 66.83 1 243 
2000 24 21.21 26.870 5.485 9.86 32.55 1 99 
2001 72 67.65 90.729 10.692 46.33 88.97 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
5.607 3 170 .001 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 41207.813 3 13735.938 2.644 .051 
Within Groups 883324.739 170 5196.028   
Total 924532.552 173    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 44 90.14 
 1999 34 87.54 
 2000 24 64.96 
 2001 72 93.38 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 6.039 
df 3 




















COUNSELING AND PSYCHOTHERAPY: OTHER PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 60 71.58 89.348 11.535 48.50 94.66 1 365 
1999 54 50.57 76.071 10.352 29.81 71.34 1 365 
2000 50 78.64 95.944 13.569 51.37 105.91 1 366 
2001 70 40.13 55.942 6.686 26.79 53.47 1 332 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
4.560 3 230 .004 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 57543.350 3 19181.117 3.054 .029 
Within Groups 1444703.150 230 6281.318   
Total 1502246.500 233    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 60 128.25 
 1999 54 108.39 
 2000 50 133.52 
 2001 70 103.87 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 8.336 
df 3 





















COUNSELING AND PSYCHOTHERAPY: COMORBID PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 337 54.35 70.236 3.826 46.83 61.88 1 365 
1999 384 45.17 62.099 3.169 38.94 51.40 1 365 
2000 289 45.12 58.234 3.426 38.38 51.86 1 366 
2001 95 35.39 58.704 6.023 23.43 47.35 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.618 3 1101 .013 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 33319.715 3 11106.572 2.757 .041 
Within Groups 4435108.225 1101 4028.255   
Total 4468427.940 1104    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 337 587.95 
 1999 384 539.49 
 2000 289 559.79 
 2001 95 463.00 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 12.732 
df 3 





















COUNSELING AND PSYCHOTHERAPY: NO PSYCHIATRIC DISORDER 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 9 32.89 49.642 16.547 -5.27 71.05 1 135 
1999 8 45.13 41.602 14.708 10.35 79.90 1 92 
2000 5 41.60 46.934 20.990 -16.68 99.88 1 97 
2001 7 43.43 30.908 11.682 14.84 72.01 9 101 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.304 3 25 .295 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 757.529 3 252.510 .136 .938 
Within Groups 46372.678 25 1854.907   
Total 47130.207 28    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 9 12.83 
 1999 8 15.13 
 2000 5 15.00 
 2001 7 17.64 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 1.298 
df 3 























 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 532 37.93 63.669 2.760 32.51 43.35 1 365 
1999 543 35.71 65.591 2.815 30.18 41.24 1 365 
2000 387 49.06 78.385 3.985 41.23 56.89 1 366 
2001 420 50.20 79.267 3.868 42.60 57.80 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
12.214 3 1878 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 77635.164 3 25878.388 5.122 .002 
Within Groups 9488669.725 1878 5052.540   
Total 9566304.889 1881    
 
Post Hoc Analysis 
Games-Howell  




 RX YEAR N Mean Rank 
Duration of Enrollment 1998 532 931.62 
 1999 543 873.72 
 2000 387 1018.19 
 2001 420 970.98 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 17.592 
df 3 















CRISIS INTERVENTION: AGE 2 – 4 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 14 45.93 45.867 12.258 19.45 72.41 5 168 
1999 5 44.20 39.003 17.442 -4.23 92.63 4 104 
2000 6 102.33 127.624 52.102 -31.60 236.27 10 353 
2001 7 76.29 118.878 44.932 -33.66 186.23 4 337 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.926 3 28 .148 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 16365.010 3 5455.003 .765 .523 
Within Groups 199664.490 28 7130.875   
Total 216029.500 31    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 14 15.54 
 1999 5 15.30 
 2000 6 20.75 
 2001 7 15.64 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 1.523 
df 3 




















CRISIS INTERVENTION: AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 111 53.22 80.728 7.662 38.03 68.40 1 365 
1999 100 50.46 83.725 8.373 33.85 67.07 1 365 
2000 90 55.70 74.460 7.849 40.10 71.30 1 366 
2001 90 71.98 81.728 8.615 54.86 89.10 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.161 3 387 .324 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 26145.453 3 8715.151 1.350 .258 
Within Groups 2498764.506 387 6456.756   
Total 2524909.959 390    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 111 191.20 
 1999 100 175.45 
 2000 90 205.31 
 2001 90 215.45 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 6.788 
df 3 





















CRISIS INTERVENTION: AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 275 32.31 56.920 3.432 25.55 39.06 1 365 
1999 262 33.12 58.860 3.636 25.96 40.28 1 365 
2000 187 47.48 74.552 5.452 36.73 58.24 1 366 
2001 178 56.08 85.085 6.377 43.50 68.67 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
15.480 3 898 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 85074.474 3 28358.158 6.200 .000 
Within Groups 4107144.094 898 4573.657   
Total 4192218.569 901    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 -23.78 7.242 .006 -46.53 -1.03 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 275 429.44 
 1999 262 431.44 
 2000 187 489.14 
 2001 178 475.57 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 8.962 
df 3 












CRISIS INTERVENTION: AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 132 35.94 60.819 5.294 25.47 46.41 1 365 
1999 175 29.94 61.964 4.684 20.69 39.18 1 365 
2000 103 41.13 82.666 8.145 24.97 57.28 1 366 
2001 145 28.20 61.703 5.124 18.07 38.33 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.616 3 551 .050 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 12924.529 3 4308.176 .990 .397 
Within Groups 2397910.383 551 4351.924   
Total 2410834.912 554    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 132 292.01 
 1999 175 256.89 
 2000 103 296.03 
 2001 145 277.92 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 5.357 
df 3 





















CRISIS INTERVENTION: MALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 357 37.64 62.339 3.299 31.16 44.13 1 365 
1999 347 37.28 68.291 3.666 30.07 44.49 1 365 
2000 247 49.42 78.926 5.022 39.53 59.31 1 366 
2001 289 56.10 82.717 4.866 46.52 65.67 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
11.566 3 1236 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 79574.363 3 26524.788 5.044 .002 
Within Groups 6500049.479 1236 5258.940   
Total 6579623.842 1239    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 -18.45 5.879 .010 -36.84 -.06 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 357 602.80 
 1999 347 580.79 
 2000 247 662.28 
 2001 289 654.33 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 11.097 
df 3 












CRISIS INTERVENTION: FEMALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 175 38.51 66.479 5.025 28.59 48.43 1 365 
1999 196 32.93 60.587 4.328 24.39 41.46 1 365 
2000 140 48.43 77.699 6.567 35.44 61.41 1 366 
2001 131 37.19 69.609 6.082 25.16 49.22 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.107 3 638 .098 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 20083.728 3 6694.576 1.446 .228 
Within Groups 2953851.252 638 4629.861   
Total 2973934.980 641    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 175 329.27 
 1999 196 294.36 
 2000 140 356.81 
 2001 131 313.99 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 9.809 
df 3 



















CRISIS INTERVENTION: ANXIETY DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 10 42.80 48.529 15.346 8.08 77.52 1 149 
1999 9 20.78 19.999 6.666 5.41 36.15 4 55 
2000 3 35.00 20.809 12.014 -16.69 86.69 22 59 
2001 2 5.00 1.414 1.000 -7.71 17.71 4 6 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.130 3 20 .049 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 3724.678 3 1241.559 .983 .421 
Within Groups 25263.156 20 1263.158   
Total 28987.833 23    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 10 13.50 
 1999 9 11.56 
 2000 3 17.00 
 2001 2 5.00 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 3.836 
df 3 




















CRISIS INTERVENTION: BIPOLAR DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 49 60.12 100.938 14.420 31.13 89.12 1 365 
1999 44 51.55 83.624 12.607 26.12 76.97 1 365 
2000 38 55.24 93.277 15.131 24.58 85.90 2 366 
2001 46 65.65 96.016 14.157 37.14 94.17 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.672 3 173 .571 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 5012.161 3 1670.720 .189 .904 
Within Groups 1526525.478 173 8823.847   
Total 1531537.638 176    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 49 84.61 
 1999 44 88.78 
 2000 38 93.49 
 2001 46 90.17 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square .677 
df 3 





















CRISIS INTERVENTION: DEPRESSIVE DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 99 32.18 59.728 6.003 20.27 44.09 1 310 
1999 94 36.61 63.000 6.498 23.70 49.51 1 365 
2000 93 48.13 79.542 8.248 31.75 64.51 1 366 
2001 95 32.80 62.067 6.368 20.16 45.44 1 319 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.935 3 377 .033 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 15468.119 3 5156.040 1.169 .321 
Within Groups 1662926.815 377 4410.946   
Total 1678394.934 380    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 99 192.02 
 1999 94 178.63 
 2000 93 208.54 
 2001 95 185.01 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 3.844 
df 3 




















CRISIS INTERVENTION: DISRUPTIVE BEHAVIORAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 125 39.27 62.347 5.576 28.23 50.31 1 365 
1999 130 40.38 71.887 6.305 27.91 52.86 1 365 
2000 74 63.97 82.293 9.566 44.91 83.04 1 366 
2001 76 83.96 93.967 10.779 62.49 105.43 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
7.666 3 401 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 125916.575 3 41972.192 7.301 .000 
Within Groups 2305240.349 401 5748.729   
Total 2431156.923 404    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 -44.69 12.136 .002 -83.31 -6.07 
1999 2001 -43.58 12.487 .004 -83.24 -3.91 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 125 188.45 
 1999 130 178.00 
 2000 74 227.88 
 2001 76 245.47 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 21.234 
df 3 











CRISIS INTERVENTION: PSYCHOTIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 35 29.34 36.989 6.252 16.64 42.05 1 194 
1999 46 32.11 63.889 9.420 13.14 51.08 1 317 
2000 20 36.95 80.272 17.949 -.62 74.52 2 366 
2001 26 51.73 62.292 12.216 26.57 76.89 3 194 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.816 3 123 .148 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 8697.577 3 2899.192 .793 .500 
Within Groups 449636.408 123 3655.581   
Total 458333.984 126    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 35 65.13 
 1999 46 57.93 
 2000 20 66.65 
 2001 26 71.17 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 2.378 
df 3 





















CRISIS INTERVENTION: MENTAL RETARDATION/DEVELOPMENTAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 13 35.15 55.703 15.449 1.49 68.81 1 168 
1999 21 39.05 90.736 19.800 -2.25 80.35 1 365 
2000 13 29.23 65.344 18.123 -10.26 68.72 3 244 
2001 9 73.22 79.281 26.427 12.28 134.16 2 182 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.849 3 52 .474 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 11662.349 3 3887.450 .666 .577 
Within Groups 303416.508 52 5834.933   
Total 315078.857 55    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 13 28.31 
 1999 21 27.81 
 2000 13 26.46 
 2001 9 33.33 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 1.039 
df 3 





















CRISIS INTERVENTION: OTHER PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 28 39.04 49.167 9.292 19.97 58.10 1 190 
1999 14 37.36 47.999 12.828 9.64 65.07 1 157 
2000 10 37.90 69.267 21.904 -11.65 87.45 2 229 
2001 12 98.42 95.493 27.567 37.74 159.09 7 280 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
4.587 3 60 .006 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 35189.005 3 11729.668 2.948 .040 
Within Groups 238709.995 60 3978.500   
Total 273899.000 63    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 28 30.70 
 1999 14 28.75 
 2000 10 29.20 
 2001 12 43.83 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 5.600 
df 3 





















CRISIS INTERVENTION: COMORBID PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 169 33.89 55.600 4.277 25.45 42.34 1 365 
1999 179 29.47 57.136 4.271 21.05 37.90 1 365 
2000 87 54.90 82.860 8.883 37.24 72.56 1 366 
2001 45 22.00 59.623 8.888 4.09 39.91 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.595 3 476 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 47715.336 3 15905.112 4.098 .007 
Within Groups 1847312.789 476 3880.909   
Total 1895028.125 479    
 
Post Hoc Analysis 
Games-Howell  




 RX YEAR N Mean Rank 
Duration of Enrollment 1998 169 243.96 
 1999 179 225.65 
 2000 87 291.84 
 2001 45 187.32 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 20.732 
df 3 















CRISIS INTERVENTION: NO PSYCHIATRIC DISORDER 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 3 13.00 8.888 5.132 -9.08 35.08 6 23 
1999 5 23.20 45.180 20.205 -32.90 79.30 2 104 
2000 7 37.29 56.497 21.354 -14.97 89.54 3 152 
2001 4 8.00 4.899 2.449 .20 15.80 4 14 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.960 3 15 .066 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 2622.403 3 874.134 .476 .704 
Within Groups 27546.229 15 1836.415   
Total 30168.632 18    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 3 12.67 
 1999 5 6.40 
 2000 7 11.64 
 2001 4 9.63 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 3.373 
df 3 























 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 2314 148.42 118.613 2.466 143.58 153.25 1 365 
1999 3011 148.77 125.472 2.287 144.29 153.26 1 365 
2000 3609 137.26 115.679 1.926 133.48 141.03 1 366 
2001 4559 139.21 116.854 1.731 135.82 142.60 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
20.313 3 13489 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 347873.421 3 115957.807 8.213 .000 
Within Groups 190448299.842 13489 14118.786   
Total 190796173.264 13492    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 11.16 3.129 .002 1.41 20.90 
1999 2000 11.51 2.989 .001 2.20 20.82 
 2001 9.56 2.868 .005 .63 18.49 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 2314 6962.42 
 1999 3011 6833.03 
 2000 3609 6668.79 
 2001 4559 6642.75 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 13.284 
df 3 










MEDICATION-RELATED SERVICES: AGE 2 – 4 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 41 168.59 126.279 19.722 128.73 208.44 1 365 
1999 48 149.40 121.091 17.478 114.23 184.56 1 365 
2000 54 120.11 94.534 12.864 94.31 145.91 16 366 
2001 78 146.94 99.870 11.308 124.42 169.45 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.569 3 217 .015 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 57476.539 3 19158.846 1.619 .186 
Within Groups 2568677.443 217 11837.223   
Total 2626153.982 220    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 41 121.65 
 1999 48 110.31 
 2000 54 97.44 
 2001 78 115.21 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 3.910 
df 3 




















MEDICATION-RELATED SERVICES: AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 634 160.13 119.167 4.733 150.83 169.42 1 365 
1999 792 161.79 128.938 4.582 152.79 170.78 1 365 
2000 960 155.86 121.289 3.915 148.18 163.54 1 366 
2001 1211 152.24 119.949 3.447 145.47 159.00 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.125 3 3593 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 52736.504 3 17578.835 1.177 .317 
Within Groups 53656519.193 3593 14933.626   
Total 53709255.697 3596    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 634 1840.10 
 1999 792 1807.72 
 2000 960 1818.33 
 2001 1211 1756.46 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 3.419 
df 3 





















MEDICATION-RELATED SERVICES: AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1105 147.42 120.320 3.620 140.32 154.52 1 365 
1999 1423 152.91 127.450 3.379 146.28 159.54 1 365 
2000 1739 133.72 114.656 2.749 128.33 139.12 1 366 
2001 2115 143.66 117.328 2.551 138.66 148.67 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
15.436 3 6378 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 309039.763 3 103013.254 7.218 .000 
Within Groups 91029489.346 6378 14272.419   
Total 91338529.109 6381    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1999 2000 19.19 4.356 .000 5.61 32.76 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 1105 3238.03 
 1999 1423 3269.61 
 2000 1739 3079.53 
 2001 2115 3206.70 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 9.844 
df 3 












MEDICATION-RELATED SERVICES: AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 533 135.27 112.357 4.867 125.71 144.83 1 365 
1999 748 127.08 115.348 4.218 118.80 135.36 1 365 
2000 856 124.66 110.002 3.760 117.28 132.04 1 366 
2001 1155 116.87 110.663 3.256 110.49 123.26 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.452 3 3288 .226 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 133718.844 3 44572.948 3.563 .014 
Within Groups 41132995.603 3288 12510.035   
Total 41266714.447 3291    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 533 1760.07 
 1999 748 1654.76 
 2000 856 1673.98 
 2001 1155 1568.38 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 16.206 
df 3 





















MEDICATION-RELATED SERVICES: MALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1728 151.64 118.348 2.847 146.06 157.22 1 365 
1999 2152 151.15 126.426 2.725 145.81 156.50 1 365 
2000 2585 140.19 115.709 2.276 135.73 144.65 1 366 
2001 3338 138.49 116.144 2.010 134.55 142.43 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
20.237 3 9799 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 349850.105 3 116616.702 8.270 .000 
Within Groups 138179418.821 9799 14101.380   
Total 138529268.926 9802    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 11.45 3.645 .009 .09 22.81 
 2001 13.15 3.485 .001 2.29 24.01 
1999 2001 12.66 3.387 .001 2.11 23.21 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 1728 5103.26 
 1999 2152 4967.88 
 2000 2585 4885.89 
 2001 3338 4767.82 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 17.516 
df 3 










MEDICATION-RELATED SERVICES: FEMALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 586 138.92 118.986 4.915 129.26 148.57 1 365 
1999 859 142.81 122.921 4.194 134.57 151.04 1 365 
2000 1024 129.86 115.328 3.604 122.79 136.93 1 366 
2001 1221 141.17 118.798 3.400 134.50 147.84 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.153 3 3686 .091 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 100451.523 3 33483.841 2.370 .069 
Within Groups 52070578.753 3686 14126.581   
Total 52171030.275 3689    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 586 1848.49 
 1999 859 1869.98 
 2000 1024 1788.19 
 2001 1221 1874.91 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 4.359 
df 3 




















MEDICATION-RELATED SERVICES: ANXIETY DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 60 108.05 93.341 12.050 83.94 132.16 1 365 
1999 56 166.59 134.512 17.975 130.57 202.61 1 365 
2000 70 155.54 120.900 14.450 126.72 184.37 1 366 
2001 72 127.35 114.517 13.496 100.44 154.26 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
7.490 3 254 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 129032.716 3 43010.905 3.168 .025 
Within Groups 3448846.094 254 13578.134   
Total 3577878.810 257    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 60 114.07 
 1999 56 140.44 
 2000 70 141.36 
 2001 72 122.32 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 6.213 
df 3 




















MEDICATION-RELATED SERVICES: BIPOLAR DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 179 153.71 120.404 8.999 135.95 171.47 1 365 
1999 230 162.47 131.684 8.683 145.36 179.58 1 365 
2000 352 142.59 118.738 6.329 130.14 155.03 1 366 
2001 544 154.99 125.667 5.388 144.41 165.57 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.726 3 1301 .011 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 60987.794 3 20329.265 1.317 .267 
Within Groups 20075283.558 1301 15430.656   
Total 20136271.352 1304    
 
Post Hoc Analysis 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 179 661.97 
 1999 230 671.31 
 2000 352 635.49 
 2001 544 653.64 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 1.409 
df 3 




















MEDICATION-RELATED SERVICES: DEPRESSIVE DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 352 130.09 114.243 6.089 118.12 142.07 1 365 
1999 500 144.54 122.617 5.484 133.76 155.31 1 365 
2000 539 130.81 112.107 4.829 121.32 140.29 1 366 
2001 668 128.42 110.487 4.275 120.03 136.81 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
5.504 3 2055 .001 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 86017.107 3 28672.369 2.183 .088 
Within Groups 26987419.525 2055 13132.564   
Total 27073436.631 2058    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 352 1008.96 
 1999 500 1070.91 
 2000 539 1029.67 
 2001 668 1010.73 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 3.513 
df 3 




















MEDICATION-RELATED SERVICES: DISRUPTIVE BEHAVIORAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 761 154.22 121.080 4.389 145.60 162.84 1 365 
1999 965 155.58 124.524 4.009 147.71 163.45 1 365 
2000 1098 144.65 115.994 3.501 137.78 151.52 1 366 
2001 1167 151.67 120.720 3.534 144.73 158.60 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
4.171 3 3987 .006 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 72815.905 3 24271.968 1.673 .171 
Within Groups 57842070.255 3987 14507.667   
Total 57914886.159 3990    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 761 2017.14 
 1999 965 2016.92 
 2000 1098 1967.05 
 2001 1167 1992.15 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 1.282 
df 3 





















MEDICATION-RELATED SERVICES: PSYCHOTIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 164 166.30 122.244 9.546 147.46 185.15 1 365 
1999 229 154.88 128.100 8.465 138.20 171.56 1 365 
2000 230 146.50 117.292 7.734 131.26 161.73 1 366 
2001 272 150.47 131.006 7.943 134.83 166.11 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.960 3 891 .031 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 41104.732 3 13701.577 .873 .454 
Within Groups 13978678.593 891 15688.753   
Total 14019783.325 894    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 164 477.81 
 1999 229 448.28 
 2000 230 445.38 
 2001 272 432.00 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 3.256 
df 3 

























 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 122 160.14 110.024 9.961 140.42 179.86 1 365 
1999 136 158.38 130.382 11.180 136.27 180.49 1 365 
2000 168 147.91 111.514 8.603 130.93 164.90 1 366 
2001 161 178.34 125.854 9.919 158.75 197.92 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
5.554 3 583 .001 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 78159.467 3 26053.156 1.815 .143 
Within Groups 8370632.298 583 14357.860   
Total 8448791.765 586    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 122 298.40 
 1999 136 283.18 
 2000 168 279.95 
 2001 161 314.47 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 4.142 
df 3 




















MEDICATION-RELATED SERVICES: OTHER PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 99 137.54 126.422 12.706 112.32 162.75 1 365 
1999 128 144.61 126.238 11.158 122.53 166.69 1 365 
2000 151 134.74 113.516 9.238 116.48 152.99 1 366 
2001 136 144.79 116.301 9.973 125.06 164.51 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.279 3 510 .281 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 10543.300 3 3514.433 .244 .866 
Within Groups 7349061.315 510 14409.924   
Total 7359604.615 513    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 99 246.55 
 1999 128 258.02 
 2000 151 256.76 
 2001 136 265.80 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square .969 
df 3 





















MEDICATION-RELATED SERVICES: COMORBID PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 518 142.81 111.635 4.905 133.17 152.44 1 365 
1999 716 130.48 120.390 4.499 121.65 139.32 1 365 
2000 665 142.07 117.854 4.570 133.09 151.04 1 366 
2001 191 124.64 120.253 8.701 107.48 141.81 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.278 3 2086 .078 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 93901.095 3 31300.365 2.269 .079 
Within Groups 28776166.373 2086 13794.902   
Total 28870067.468 2089    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 518 1099.59 
 1999 716 995.34 
 2000 665 1080.36 
 2001 191 965.46 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 14.718 
df 3 





















MEDICATION-RELATED SERVICES: NO PSYCHIATRIC DISORDER 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 14 69.21 64.393 17.210 32.03 106.39 1 226 
1999 13 103.08 109.550 30.384 36.88 169.28 1 340 
2000 14 118.50 91.093 24.346 65.90 171.10 5 284 
2001 20 92.40 71.982 16.096 58.71 126.09 1 258 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.511 3 57 .221 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 18016.190 3 6005.397 .847 .474 
Within Groups 404239.580 57 7091.922   
Total 422255.770 60    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 14 25.68 
 1999 13 30.00 
 2000 14 35.96 
 2001 20 31.90 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 2.448 
df 3 























 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 2355 82.23 97.353 2.006 78.29 86.16 1 365 
1999 3300 90.49 97.413 1.696 87.17 93.82 1 365 
2000 3073 116.69 109.414 1.974 112.82 120.56 1 366 
2001 3964 118.43 111.837 1.776 114.95 121.91 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
48.469 3 12688 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 3039084.469 3 1013028.156 91.836 .000 
Within Groups 139959082.602 12688 11030.823   
Total 142998167.071 12691    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 -8.27 2.627 .009 -16.45 -.09 
 2000 -34.47 2.814 .000 -43.24 -25.70 
 2001 -36.20 2.680 .000 -44.55 -27.86 
1999 2000 -26.20 2.602 .000 -34.31 -18.10 
 2001 -27.94 2.456 .000 -35.58 -20.29 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 2355 5446.31 
 1999 3300 5864.22 
 2000 3073 6880.05 
 2001 3964 6869.17 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 346.205 
df 3 








SERVICE COORDINATION: AGE 2 – 4 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 53 91.57 98.599 13.544 64.39 118.74 1 365 
1999 58 94.31 91.914 12.069 70.14 118.48 1 365 
2000 47 142.23 111.670 16.289 109.45 175.02 1 366 
2001 78 124.54 108.473 12.282 100.08 149.00 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.337 3 232 .263 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 95148.401 3 31716.134 2.983 .032 
Within Groups 2466733.243 232 10632.471   
Total 2561881.644 235    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 53 101.33 
 1999 58 106.82 
 2000 47 138.87 
 2001 78 126.58 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 10.350 
df 3 




















SERVICE COORDINATION: AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 670 85.58 99.293 3.836 78.05 93.12 1 365 
1999 861 97.94 101.921 3.473 91.12 104.76 1 365 
2000 866 122.26 113.882 3.870 114.67 129.86 1 366 
2001 1074 127.80 112.764 3.441 121.05 134.55 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
12.618 3 3467 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 992663.589 3 330887.863 28.402 .000 
Within Groups 40391508.408 3467 11650.276   
Total 41384171.997 3470    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -36.68 5.449 .000 -53.67 -19.69 
 2001 -42.22 5.153 .000 -58.29 -26.15 
1999 2000 -24.32 5.200 .000 -40.54 -8.11 
 2001 -29.86 4.889 .000 -45.10 -14.62 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 670 1463.20 
 1999 861 1605.66 
 2000 866 1851.54 
 2001 1074 1917.51 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 111.259 
df 3 









SERVICE COORDINATION: AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1159 76.99 94.617 2.779 71.54 82.44 1 365 
1999 1604 90.39 98.798 2.467 85.55 95.23 1 365 
2000 1432 120.03 112.000 2.960 114.23 125.84 1 366 
2001 1909 118.45 112.815 2.582 113.38 123.51 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
37.031 3 6100 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1908302.557 3 636100.852 56.855 .000 
Within Groups 68247650.415 6100 11188.139   
Total 70155952.972 6103    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 1999 -13.40 3.716 .002 -24.98 -1.82 
 2000 -43.05 4.060 .000 -55.70 -30.39 
 2001 -41.46 3.794 .000 -53.28 -29.64 
1999 2000 -29.65 3.853 .000 -41.65 -17.64 
 2001 -28.06 3.571 .000 -39.18 -16.93 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 1159 2556.12 
 1999 1604 2831.36 
 2000 1432 3363.77 
 2001 1909 3306.19 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 202.204 
df 3 








SERVICE COORDINATION: AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 473 89.25 100.581 4.625 80.17 98.34 1 365 
1999 777 82.18 88.955 3.191 75.91 88.44 1 365 
2000 728 101.85 96.713 3.584 94.81 108.89 1 366 
2001 903 106.72 107.960 3.593 99.67 113.77 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
9.903 3 2877 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 298670.354 3 99556.785 10.147 .000 
Within Groups 28228507.634 2877 9811.786   
Total 28527177.988 2880    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1999 2000 -19.67 4.799 .000 -34.64 -4.71 
 2001 -24.54 4.805 .000 -39.53 -9.56 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 473 1338.48 
 1999 777 1327.06 
 2000 728 1535.82 
 2001 903 1516.29 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 38.715 
df 3 











SERVICE COORDINATION: MALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1734 83.19 97.260 2.336 78.61 87.77 1 365 
1999 2358 91.88 98.133 2.021 87.92 95.85 1 365 
2000 2149 119.71 111.287 2.401 115.01 124.42 1 366 
2001 2824 120.20 113.189 2.130 116.03 124.38 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
41.678 3 9061 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 2344551.100 3 781517.033 69.519 .000 
Within Groups 101861858.834 9061 11241.790   
Total 104206409.934 9064    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -36.52 3.349 .000 -46.96 -26.09 
 2001 -37.01 3.161 .000 -46.86 -27.16 
1999 2000 -27.83 3.138 .000 -37.60 -18.05 
 2001 -28.32 2.936 .000 -37.46 -19.17 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 1734 3902.15 
 1999 2358 4193.11 
 2000 2149 4933.86 
 2001 2824 4899.11 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 246.996 
df 3 









SERVICE COORDINATION: FEMALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 621 79.53 97.639 3.918 71.83 87.22 1 365 
1999 942 87.01 95.547 3.113 80.90 93.12 1 365 
2000 924 109.67 104.650 3.443 102.92 116.43 1 366 
2001 1140 114.03 108.340 3.209 107.74 120.33 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
8.428 3 3623 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 730166.524 3 243388.841 23.218 .000 
Within Groups 37979052.429 3623 10482.764   
Total 38709218.953 3626    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -30.15 5.216 .000 -46.42 -13.88 
 2001 -34.51 5.064 .000 -50.30 -18.71 
1999 2000 -22.66 4.642 .000 -37.13 -8.19 
 2001 -27.02 4.471 .000 -40.96 -13.09 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 621 1537.59 
 1999 942 1671.21 
 2000 924 1950.81 
 2001 1140 1971.67 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 102.699 
df 3 









SERVICE COORDINATION: ANXIETY DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 87 49.41 65.012 6.970 35.56 63.27 1 365 
1999 65 91.68 101.749 12.620 66.46 116.89 1 365 
2000 78 110.74 109.655 12.416 86.02 135.47 1 366 
2001 100 76.69 95.573 9.557 57.73 95.65 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.091 3 326 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 164988.919 3 54996.306 6.277 .000 
Within Groups 2856223.581 326 8761.422   
Total 3021212.500 329    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -61.33 14.239 .000 -106.59 -16.07 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 87 136.30 
 1999 65 178.88 
 2000 78 196.74 
 2001 100 157.85 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 18.583 
df 3 












SERVICE COORDINATION: BIPOLAR DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 167 87.47 93.557 7.240 73.18 101.77 1 365 
1999 270 89.49 100.707 6.129 77.43 101.56 1 365 
2000 297 121.66 115.224 6.686 108.50 134.81 1 366 
2001 538 121.42 116.222 5.011 111.58 131.27 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
8.675 3 1268 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 308786.477 3 102928.826 8.494 .000 
Within Groups 15364543.459 1268 12117.148   
Total 15673329.936 1271    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -34.18 9.855 .003 -65.06 -3.31 
 2001 -33.95 8.805 .001 -61.57 -6.33 
1999 2000 -32.16 9.070 .002 -60.53 -3.80 
 2001 -31.93 7.916 .000 -56.68 -7.18 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 167 573.31 
 1999 270 559.00 
 2000 297 678.32 
 2001 538 671.92 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 25.927 
df 3 









SERVICE COORDINATION: DEPRESSIVE DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 338 77.77 93.698 5.097 67.74 87.79 1 365 
1999 540 91.70 96.035 4.133 83.58 99.81 1 365 
2000 477 119.05 106.668 4.884 109.46 128.65 1 366 
2001 593 114.80 109.325 4.489 105.98 123.62 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
7.548 3 1944 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 489638.749 3 163212.916 15.537 .000 
Within Groups 20421219.002 1944 10504.742   
Total 20910857.752 1947    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -41.28 7.059 .000 -63.33 -19.24 
 2001 -37.03 6.792 .000 -58.24 -15.82 
1999 2000 -27.36 6.398 .000 -47.33 -7.39 
 2001 -23.10 6.102 .001 -42.14 -4.06 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 338 809.85 
 1999 540 910.65 
 2000 477 1081.64 
 2001 593 1040.31 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 61.465 
df 3 









SERVICE COORDINATION: DISRUPTIVE BEHAVIORAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 887 80.52 98.096 3.294 74.06 86.99 1 365 
1999 1115 92.31 99.110 2.968 86.49 98.14 1 365 
2000 968 123.54 111.275 3.577 116.52 130.55 1 366 
2001 1029 136.06 119.723 3.732 128.73 143.38 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
34.981 3 3995 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1986682.094 3 662227.365 57.293 .000 
Within Groups 46176915.018 3995 11558.677   
Total 48163597.112 3998    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -43.01 4.862 .000 -58.17 -27.86 
 2001 -55.54 4.978 .000 -71.05 -40.02 
1999 2000 -31.22 4.648 .000 -45.71 -16.73 
 2001 -43.74 4.769 .000 -58.61 -28.88 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 887 1653.58 
 1999 1115 1830.98 
 2000 968 2208.37 
 2001 1029 2285.74 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 198.953 
df 3 









SERVICE COORDINATION: PSYCHOTIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 159 94.23 99.122 7.861 78.70 109.75 1 365 
1999 225 95.07 105.046 7.003 81.27 108.87 1 365 
2000 204 109.20 110.967 7.769 93.88 124.52 1 366 
2001 259 119.64 116.814 7.258 105.34 133.93 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.624 3 843 .049 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 99145.478 3 33048.493 2.774 .040 
Within Groups 10044393.355 843 11915.057   
Total 10143538.834 846    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 159 401.38 
 1999 225 396.34 
 2000 204 434.77 
 2001 259 453.43 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 8.419 
df 3 





















SERVICE COORDINATION: MENTAL RETARDATION/DEVELOPMENTAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 62 78.35 96.608 12.269 53.82 102.89 1 365 
1999 76 85.71 102.227 11.726 62.35 109.07 1 365 
2000 69 133.30 119.643 14.403 104.56 162.05 1 366 
2001 100 138.43 120.763 12.076 114.47 162.39 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
4.327 3 303 .005 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 223879.317 3 74626.439 5.997 .001 
Within Groups 3770262.944 303 12443.112   
Total 3994142.261 306    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 -60.08 17.215 .004 -114.59 -5.56 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 62 124.10 
 1999 76 134.53 
 2000 69 172.33 
 2001 100 174.69 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 19.151 
df 3 












SERVICE COORDINATION: OTHER PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 104 100.28 104.011 10.199 80.05 120.51 1 365 
1999 168 95.54 98.060 7.566 80.60 110.47 1 365 
2000 142 104.42 106.620 8.947 86.73 122.10 1 366 
2001 140 118.57 112.969 9.548 99.69 137.45 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.202 3 550 .308 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 43074.724 3 14358.241 1.295 .275 
Within Groups 6096911.471 550 11085.294   
Total 6139986.195 553    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 104 265.78 
 1999 168 266.17 
 2000 142 276.19 
 2001 140 301.13 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 4.473 
df 3 





















SERVICE COORDINATION: COMORBID PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 521 78.81 93.481 4.095 70.76 86.85 1 365 
1999 798 81.20 86.495 3.062 75.19 87.21 1 365 
2000 617 112.99 104.036 4.188 104.76 121.21 1 366 
2001 196 105.74 104.685 7.477 91.00 120.49 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
9.988 3 2128 .000 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 492565.565 3 164188.522 18.093 .000 
Within Groups 19311141.881 2128 9074.785   
Total 19803707.447 2131    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2000 -34.18 5.858 .000 -52.46 -15.90 
 2001 -26.94 8.526 .009 -53.69 -.18 
1999 2000 -31.79 5.188 .000 -47.97 -15.60 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 521 957.26 
 1999 798 1005.04 
 2000 617 1210.29 
 2001 196 1154.47 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 62.272 
df 3 










SERVICE COORDINATION: NO PSYCHIATRIC DISORDER 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 5 179.80 164.418 73.530 -24.35 383.95 32 360 
1999 18 85.33 76.670 18.071 47.21 123.46 1 255 
2000 9 102.33 103.977 34.659 22.41 182.26 1 284 
2001 16 87.81 90.330 22.582 39.68 135.95 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.236 3 44 .031 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 38106.075 3 12702.025 1.340 .273 
Within Groups 416947.238 44 9476.074   
Total 455053.313 47    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 5 30.90 
 1999 18 23.47 
 2000 9 24.89 
 2001 16 23.44 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 1.244 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1885 66.55 78.647 1.811 63.00 70.10 1 365 
1999 2587 66.52 82.636 1.625 63.33 69.70 1 365 
2000 3294 65.03 79.514 1.385 62.32 67.75 1 366 
2001 4180 59.44 78.131 1.208 57.07 61.81 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
2.580 3 11942 .052 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 117451.769 3 39150.590 6.181 .000 
Within Groups 75642815.934 11942 6334.183   
Total 75760267.703 11945    
 
Post Hoc Analysis 
Scheffe 
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1999 2001 7.08 1.991 .006 .37 13.78 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 1885 6229.07 
 1999 2587 6134.60 
 2000 3294 6051.93 
 2001 4180 5696.73 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 45.291 
df 3 












SKILLS TRAINING: AGE 2 – 4 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 40 52.23 64.653 10.222 31.55 72.90 1 294 
1999 42 54.12 62.361 9.623 34.69 73.55 1 306 
2000 46 74.48 84.417 12.447 49.41 99.55 1 366 
2001 85 56.52 81.534 8.844 38.93 74.10 1 333 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.822 3 209 .144 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 14377.984 3 4792.661 .834 .477 
Within Groups 1201556.082 209 5749.072   
Total 1215934.066 212    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 40 104.38 
 1999 42 112.10 
 2000 46 122.28 
 2001 85 97.45 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 5.377 
df 3 




















SKILLS TRAINING: AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 551 73.34 82.925 3.533 66.40 80.28 1 365 
1999 687 67.58 84.666 3.230 61.23 73.92 1 365 
2000 903 67.69 84.176 2.801 62.20 73.19 1 366 
2001 1079 66.63 84.569 2.575 61.57 71.68 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.052 3 3216 .984 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 17684.872 3 5894.957 .831 .476 
Within Groups 22800531.134 3216 7089.717   
Total 22818216.006 3219    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 551 1720.47 
 1999 687 1613.65 
 2000 903 1598.52 
 2001 1079 1562.36 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 10.912 
df 3 




















SKILLS TRAINING: AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 940 65.19 78.022 2.545 60.19 70.18 1 365 
1999 1264 68.48 83.376 2.345 63.88 73.08 1 365 
2000 1605 67.51 80.408 2.007 63.57 71.45 1 366 
2001 2099 58.67 76.989 1.680 55.38 61.97 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.612 3 5904 .013 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 105799.938 3 35266.646 5.582 .001 
Within Groups 37301871.735 5904 6318.068   
Total 37407671.673 5907    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1999 2001 9.81 2.830 .007 .27 19.34 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 940 3017.34 
 1999 1264 3053.85 
 2000 1605 3044.00 
 2001 2099 2798.10 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 28.034 
df 3 












SKILLS TRAINING: AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 354 61.23 74.263 3.947 53.47 68.99 1 365 
1999 594 62.00 79.822 3.275 55.57 68.43 1 365 
2000 740 55.82 70.320 2.585 50.74 60.89 1 366 
2001 917 53.02 71.717 2.368 48.37 57.67 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.769 3 2601 .151 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 36734.898 3 12244.966 2.260 .079 
Within Groups 14090640.941 2601 5417.394   
Total 14127375.839 2604    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 354 1379.12 
 1999 594 1359.73 
 2000 740 1293.21 
 2001 917 1244.76 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 12.834 
df 3 





















SKILLS TRAINING: MALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 1409 67.25 78.465 2.090 63.15 71.35 1 365 
1999 1901 65.21 82.769 1.898 61.48 68.93 1 365 
2000 2373 64.86 78.673 1.615 61.69 68.02 1 366 
2001 3072 58.00 76.729 1.384 55.29 60.72 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.274 3 8751 .020 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 119540.527 3 39846.842 6.404 .000 
Within Groups 54446389.628 8751 6221.733   
Total 54565930.155 8754    
 
Post Hoc Analysis 
Games-Howell  
(I) RX YEAR (J) RX YEAR Mean 
Difference (I-
J) 
Std. Error Sig. 99% Confidence Interval 
 
     Lower Bound Upper Bound
1998 2001 9.25 2.538 .004 .70 17.80 
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 1409 4627.76 
 1999 1901 4446.56 
 2000 2373 4464.26 
 2001 3072 4154.39 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 42.627 
df 3 












SKILLS TRAINING: FEMALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 476 64.48 79.232 3.632 57.34 71.61 1 365 
1999 686 70.16 82.217 3.139 63.99 76.32 1 365 
2000 921 65.49 81.684 2.692 60.20 70.77 1 366 
2001 1108 63.43 81.795 2.457 58.61 68.26 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.147 3 3187 .931 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 20053.937 3 6684.646 1.007 .389 
Within Groups 21157048.030 3187 6638.547   
Total 21177101.966 3190    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 476 1599.22 
 1999 686 1688.66 
 2000 921 1588.39 
 2001 1108 1543.57 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 10.734 
df 3 



















SKILLS TRAINING: ANXIETY DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 54 71.78 78.232 10.646 50.42 93.13 1 313 
1999 44 49.48 61.998 9.346 30.63 68.33 1 241 
2000 81 53.15 82.873 9.208 34.82 71.47 1 366 
2001 81 60.26 85.726 9.525 41.30 79.21 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.828 3 256 .480 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 15669.677 3 5223.226 .822 .483 
Within Groups 1627006.088 256 6355.493   
Total 1642675.765 259    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 54 152.28 
 1999 44 127.11 
 2000 81 120.05 
 2001 81 128.27 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 6.449 
df 3 




















SKILLS TRAINING: BIPOLAR DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 158 66.74 78.609 6.254 54.39 79.09 1 365 
1999 239 65.70 82.779 5.355 55.15 76.25 1 365 
2000 339 67.12 81.565 4.430 58.41 75.84 1 366 
2001 615 59.17 78.492 3.165 52.96 65.39 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.353 3 1347 .256 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 18665.688 3 6221.896 .971 .406 
Within Groups 8632545.449 1347 6408.720   
Total 8651211.137 1350    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 158 729.24 
 1999 239 696.22 
 2000 339 688.26 
 2001 615 647.70 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 7.267 
df 3 





















SKILLS TRAINING: DEPRESSIVE DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 263 60.38 74.744 4.609 51.30 69.46 1 365 
1999 440 62.36 79.215 3.776 54.94 69.79 1 365 
2000 437 69.65 82.249 3.935 61.92 77.39 1 366 
2001 573 56.57 76.789 3.208 50.27 62.87 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.767 3 1709 .152 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 43227.051 3 14409.017 2.336 .072 
Within Groups 10540799.313 1709 6167.817   
Total 10584026.364 1712    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 263 859.10 
 1999 440 871.64 
 2000 437 907.23 
 2001 573 806.49 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 11.058 
df 3 




















SKILLS TRAINING: DISRUPTIVE BEHAVIORAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 686 67.68 80.625 3.078 61.64 73.73 1 365 
1999 904 67.10 81.673 2.716 61.77 72.44 1 365 
2000 1149 68.07 81.005 2.390 63.38 72.75 1 366 
2001 1311 62.16 78.770 2.176 57.89 66.42 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.396 3 4046 .756 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 27246.769 3 9082.256 1.406 .239 
Within Groups 26137317.997 4046 6460.039   
Total 26164564.766 4049    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 686 2091.96 
 1999 904 2056.75 
 2000 1149 2061.64 
 2001 1311 1937.50 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 11.544 
df 3 





















SKILLS TRAINING: PSYCHOTIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 146 55.83 69.414 5.745 44.47 67.18 1 320 
1999 166 66.98 88.291 6.853 53.45 80.51 1 365 
2000 182 61.76 73.796 5.470 50.97 72.56 1 366 
2001 289 55.28 79.862 4.698 46.04 64.53 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.290 3 779 .276 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 17302.396 3 5767.465 .935 .423 
Within Groups 4807442.197 779 6171.299   
Total 4824744.593 782    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 146 393.99 
 1999 166 414.44 
 2000 182 412.20 
 2001 289 365.39 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 7.256 
df 3 





















SKILLS TRAINING: MENTAL RETARDATION/DEVELOPMENTAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 42 51.33 73.895 11.402 28.31 74.36 1 352 
1999 54 82.67 89.778 12.217 58.16 107.17 1 365 
2000 85 64.35 88.971 9.650 45.16 83.54 1 366 
2001 99 66.98 96.230 9.671 47.79 86.17 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.268 3 276 .286 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 24152.863 3 8050.954 .999 .394 
Within Groups 2223498.705 276 8056.155   
Total 2247651.568 279    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 42 127.38 
 1999 54 161.50 
 2000 85 138.85 
 2001 99 136.03 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 5.146 
df 3 





















SKILLS TRAINING: OTHER PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 68 72.99 75.567 9.164 54.69 91.28 1 365 
1999 119 78.95 88.276 8.092 62.92 94.97 1 365 
2000 138 65.53 91.306 7.772 50.16 80.90 1 366 
2001 145 73.77 80.751 6.706 60.51 87.02 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.074 3 466 .360 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 11903.376 3 3967.792 .547 .651 
Within Groups 3383249.094 466 7260.191   
Total 3395152.470 469    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 68 253.46 
 1999 119 252.73 
 2000 138 208.84 
 2001 145 238.31 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 8.556 
df 3 





















SKILLS TRAINING: COMORBID PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 452 69.39 78.481 3.691 62.14 76.65 1 365 
1999 598 64.78 83.108 3.399 58.10 71.45 1 365 
2000 686 61.25 73.118 2.792 55.77 66.73 1 366 
2001 233 49.73 73.279 4.801 40.27 59.19 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.426 3 1965 .017 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 63423.443 3 21141.148 3.518 .015 
Within Groups 11809224.502 1965 6009.783   
Total 11872647.944 1968    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 452 1045.04 
 1999 598 989.09 
 2000 686 986.67 
 2001 233 853.12 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 17.874 
df 3 





















SKILLS TRAINING: NO PSYCHIATRIC DISORDER 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 7 31.00 44.057 16.652 -9.75 71.75 2 113 
1999 16 100.50 109.905 27.476 41.94 159.06 2 365 
2000 15 48.80 47.847 12.354 22.30 75.30 1 152 
2001 12 46.83 102.072 29.466 -18.02 111.69 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.422 3 46 .248 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 35809.713 3 11936.571 1.617 .198 
Within Groups 339490.067 46 7380.219   
Total 375299.780 49    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 7 21.14 
 1999 16 33.25 
 2000 15 24.83 
 2001 12 18.54 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 7.952 
df 3 






















 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 217 44.77 68.815 4.671 35.56 53.98 1 365 
1999 196 27.36 51.721 3.694 20.08 34.65 1 324 
2000 72 34.10 53.576 6.314 21.51 46.69 1 230 
2001 72 47.56 85.136 10.033 27.55 67.56 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
4.312 3 553 .005 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 39716.721 3 13238.907 3.235 .022 
Within Groups 2262925.857 553 4092.090   
Total 2302642.578 556    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 217 295.95 
 1999 196 250.67 
 2000 72 272.66 
 2001 72 311.37 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 11.886 
df 3 





















SUPPORTIVE SERVICES: AGE 2 – 4 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 2 63.50 9.192 6.500 -19.09 146.09 57 70 
1999 4 25.50 29.682 14.841 -21.73 72.73 1 61 
2001 2 24.50 9.192 6.500 -58.09 107.09 18 31 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.694 2 5 .039 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 2205.500 2 1102.750 1.961 .235 
Within Groups 2812.000 5 562.400   
Total 5017.500 7    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 2 7.00 
 1999 4 3.75 
 2001 2 3.50 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 2.825 
df 2 






















SUPPORTIVE SERVICES: AGE 5 – 9 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 52 54.50 82.225 11.403 31.61 77.39 1 339 
1999 37 27.43 49.965 8.214 10.77 44.09 1 243 
2000 18 27.33 44.971 10.600 4.97 49.70 1 153 
2001 22 34.05 75.233 16.040 .69 67.40 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.135 3 125 .028 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 20406.980 3 6802.327 1.446 .233 
Within Groups 587919.036 125 4703.352   
Total 608326.016 128    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 52 71.05 
 1999 37 60.64 
 2000 18 55.08 
 2001 22 66.16 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 3.246 
df 3 





















SUPPORTIVE SERVICES: AGE 10 – 14 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 119 39.60 62.141 5.696 28.32 50.88 1 334 
1999 102 30.97 58.895 5.831 19.40 42.54 1 324 
2000 45 33.80 50.811 7.575 18.53 49.07 1 230 
2001 34 50.59 87.618 15.026 20.02 81.16 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.852 3 296 .138 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 11248.534 3 3749.511 .946 .419 
Within Groups 1172924.986 296 3962.584   
Total 1184173.520 299    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 119 150.07 
 1999 102 139.52 
 2000 45 157.69 
 2001 34 175.43 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 4.916 
df 3 





















SUPPORTIVE SERVICES: AGE 15 – 19 YEARS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 44 46.41 70.446 10.620 24.99 67.83 1 365 
1999 53 20.51 37.968 5.215 10.04 30.97 1 232 
2000 9 49.11 81.363 27.121 -13.43 111.65 1 195 
2001 14 64.71 101.082 27.015 6.35 123.08 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.965 3 116 .010 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 30369.964 3 10123.321 2.477 .065 
Within Groups 474141.628 116 4087.428   
Total 504511.592 119    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 44 70.92 
 1999 53 50.04 
 2000 9 54.56 
 2001 14 71.18 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 10.708 
df 3 





















SUPPORTIVE SERVICES: MALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 165 40.87 61.996 4.826 31.34 50.40 1 365 
1999 134 28.87 55.641 4.807 19.36 38.37 1 324 
2000 47 31.43 51.649 7.534 16.26 46.59 1 195 
2001 50 49.20 87.789 12.415 24.25 74.15 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.720 3 392 .162 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 20216.811 3 6738.937 1.713 .164 
Within Groups 1542453.399 392 3934.830   
Total 1562670.210 395    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 165 210.28 
 1999 134 177.73 
 2000 47 186.20 
 2001 50 226.87 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 10.138 
df 3 





















SUPPORTIVE SERVICES: FEMALE 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 52 57.13 86.555 12.003 33.04 81.23 1 339 
1999 62 24.11 42.256 5.367 13.38 34.84 1 273 
2000 25 39.12 57.777 11.555 15.27 62.97 1 230 
2001 22 43.82 80.634 17.191 8.07 79.57 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
5.703 3 157 .001 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 31249.460 3 10416.487 2.311 .078 
Within Groups 707650.180 157 4507.326   
Total 738899.640 160    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 52 86.44 
 1999 62 73.28 
 2000 25 85.28 
 2001 22 85.02 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 2.850 
df 3 




















SUPPORTIVE SERVICES: ANXIETY DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 3 53.33 38.423 22.184 -42.11 148.78 9 77 
2000 4 23.00 31.230 15.615 -26.69 72.69 3 69 
2001 2 24.00 9.899 7.000 -64.94 112.94 17 31 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.639 2 6 .270 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1801.333 2 900.667 .904 .454 
Within Groups 5976.667 6 996.111   
Total 7778.000 8    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 3 6.67 
 2000 4 3.50 
 2001 2 5.50 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 2.378 
df 2 






















SUPPORTIVE SERVICES: BIPOLAR DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 13 59.77 75.082 20.824 14.40 105.14 6 253 
1999 7 67.86 87.154 32.941 -12.75 148.46 1 232 
2000 4 48.00 50.033 25.017 -31.61 127.61 2 119 
2001 14 81.57 124.491 33.272 9.69 153.45 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.991 3 34 .409 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 5059.301 3 1686.434 .178 .911 
Within Groups 322206.593 34 9476.665   
Total 327265.895 37    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 13 19.85 
 1999 7 19.36 
 2000 4 19.38 
 2001 14 19.29 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square .020 
df 3 





















SUPPORTIVE SERVICES: DEPRESSIVE DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 26 59.73 83.001 16.278 26.21 93.26 1 282 
1999 29 19.17 29.940 5.560 7.78 30.56 1 102 
2000 6 84.33 96.742 39.495 -17.19 185.86 1 230 
2001 13 40.38 44.595 12.369 13.44 67.33 1 134 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
6.128 3 70 .001 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 34058.499 3 11352.833 2.965 .038 
Within Groups 267987.664 70 3828.395   
Total 302046.162 73    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 26 42.85 
 1999 29 28.83 
 2000 6 45.33 
 2001 13 42.54 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 8.024 
df 3 




















SUPPORTIVE SERVICES: DISRUPTIVE BEHAVIORAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 76 36.17 54.358 6.235 23.75 48.59 1 312 
1999 67 31.45 61.684 7.536 16.40 46.49 1 324 
2000 29 24.10 44.308 8.228 7.25 40.96 1 188 
2001 17 35.88 88.225 21.398 -9.48 81.24 1 365 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
.775 3 185 .509 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 3334.774 3 1111.591 .315 .814 
Within Groups 652241.798 185 3525.631   
Total 655576.571 188    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 76 103.38 
 1999 67 89.45 
 2000 29 88.07 
 2001 17 91.24 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 3.231 
df 3 





















SUPPORTIVE SERVICES: PSYCHOTIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 16 55.56 95.462 23.866 4.69 106.43 1 365 
1999 18 22.89 58.739 13.845 -6.32 52.10 1 243 
2000 4 103.00 102.823 51.412 -60.62 266.62 1 195 
2001 9 23.22 10.438 3.479 15.20 31.25 1 31 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
3.095 3 43 .037 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 27517.197 3 9172.399 1.730 .175 
Within Groups 227939.271 43 5300.913   
Total 255456.468 46    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 16 26.81 
 1999 18 17.42 
 2000 4 32.13 
 2001 9 28.56 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 7.596 
df 3 





















SUPPORTIVE SERVICES: MENTAL RETARDATION/DEVELOPMENTAL DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 7 74.43 91.360 34.531 -10.07 158.92 1 229 
1999 2 124.00 168.291 119.000 -1388.04 1636.04 5 243 
2000 5 37.20 12.133 5.426 22.14 52.26 22 56 
2001 2 38.00 49.497 35.000 -406.72 482.72 3 73 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
8.285 3 12 .003 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 12901.423 3 4300.474 .634 .607 
Within Groups 81440.514 12 6786.710   
Total 94341.938 15    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 7 7.86 
 1999 2 9.50 
 2000 5 9.40 
 2001 2 7.50 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square .486 
df 3 





















SUPPORTIVE SERVICES: OTHER PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 5 30.80 41.246 18.446 -20.41 82.01 1 91 
1999 7 36.29 29.815 11.269 8.71 63.86 4 91 
2000 3 29.67 29.535 17.052 -43.70 103.04 1 60 
2001 1 1.00 . . . . 1 1 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
1.076(a) 2 12 .372 
a  Groups with only one case are ignored in computing the test of homogeneity of variance for Duration of 
Enrollment. 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 1100.855 3 366.952 .317 .813 
Within Groups 13882.895 12 1156.908   
Total 14983.750 15    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 5 7.80 
 1999 7 9.71 
 2000 3 8.83 
 2001 1 2.50 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 2.205 
df 3 

















SUPPORTIVE SERVICES: COMORBID PSYCHIATRIC DISORDERS 
 
Descriptives  
 Year N Mean Std. 
Deviation
Std. Error 95% Confidence 
Interval for Mean 
 
Minimum Maximum





1998 71 41.01 69.721 8.274 24.51 57.52 1 339 
1999 66 19.86 32.742 4.030 11.81 27.91 1 229 
2000 17 16.41 29.392 7.129 1.30 31.52 1 114 
2001 5 19.40 15.900 7.111 -.34 39.14 1 31 
 
Test of Homogeneity of Variances  
Levene Statistic df1 df2 Sig. 
5.848 3 155 .001 
 
Analysis of Variance (ANOVA)  
Sum of Squares df Mean Square F Sig. 
Between Groups 18911.018 3 6303.673 2.300 .080 
Within Groups 424788.076 155 2740.568   
Total 443699.094 158    
 
Ranks 
 RX YEAR N Mean Rank 
Duration of Enrollment 1998 71 82.62 
 1999 66 80.05 
 2000 17 66.91 
 2001 5 86.60 
 
Test Statistics 
 Duration of Enrollment 
Chi-Square 1.778 
df 3 





















SUPPORTIVE SERVICES: NO PSYCHIATRIC DISORDER 
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